nct_id,title,official_title,overall_status,phase,sponsor,start_date,primary_completion_date,completion_date,first_posted_date,last_update_date,planned_primary_outcomes,planned_secondary_outcomes,results_outcome_measures,results_participant_flow,results_baseline,results_adverse_events,site_count,site_countries,sites_compact,start_year,Pathologic_Complete_Response,Event_Free_Survival,Disease_Free_Survival,Overall_Survival,Best_Overall_Response,Duration_of_Response,Progression_Free_Survival,Overall_Response,Target_Response,Non_target_Response,Symptomatic_Deterioration,Disease_Recurrence,Pathologic_Complete_Response_pCR,Objective_Response_Rate,Time_to_Progression,detected_endpoint_names,planned_endpoint_count,reporting_gap_flag,consort_participant_flow,consort_recruitment,consort_baseline,consort_numbers_analyzed,consort_outcomes_estimation,consort_ancillary_analyses,consort_harms,consort_results_score,HER2_flag,BRCAm_flag,NM_new_medicine,EI_extension_of_indication,nm_ei_explanation,sponsor_class,has_results,completion_year,years_since_completion,multi_country_flag,phase_bucket
NCT01009437,Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer,A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer,COMPLETED,PHASE1,"Masonic Cancer Center, University of Minnesota",2010-05-26,2014-07,2014-07,2009-11-06,2017-12-05,['Inhibition of breast cancer by targeting Hsp90-Akt pathway'],"['Activation of apoptosis markers', 'Modulation of autophagy markers', 'Alteration of plasma levels of eicosanoids', 'Induction of Hsp70 in peripheral blood mononuclear cells', 'Reduction of ERα in ERα+ tumors', 'Changes in TNF-α and IL-6 levels as well as reduction in intratumoral nuclear NF-kB and phospho-Stat3', 'Alteration of urine eicosanoid levels', 'Alteration of plasma and urine eicosanoid levels resulting from tumor resection.', 'Induction of the unfolded protein response (UPR) assayed by grp78 or related markers (phospho-PERK, ATF-4, and CHOP)', 'inhibition of tumor growth markers (Ki67 LI, Hsp90, phosphorylated AKT)']",,,,,2,United States,"Masonic Cancer Center, University of Minnesota [Minneapolis, United States] | The Kimmel Cancer Center at Jefferson University [Philadelphia, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2014.0,11.0,0,Phase 1
NCT01084057,Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer,Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer,COMPLETED,PHASE1,City of Hope Medical Center,2010-05-17,2012-11-12,2019-09-27,2010-03-10,2019-11-05,"['Dose limiting toxicity defined as any treatment-related grade 3 or greater non-hematologic toxicity, grade 4 febrile neutropenia, thrombocytopenia or grade 4 neutropenia as a result of unresolved toxicity']","['Objective response rate and/or clinical benefit rate', 'Toxicity profile']",,,,,2,United States,"City of Hope [Duarte, United States] | South Pasadena Cancer Center [South Pasadena, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT01138085,"Safety, Pharmacokinetics (PK) of AKT and MEK Combination","A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795",COMPLETED,PHASE1,GlaxoSmithKline,2010-05-04,2014-11-19,2014-11-19,2010-06-07,2017-11-13,"['Part 1A: To determine the safety, tolerability and recommended Phase II dose of GSK1120212 and GSK2141795 administered in combination orally, once daily continuously', 'Part 1B:To determine the safety, tolerability and recommended Phase II dose of GSK1120212 and GSK2141795 administered in combination with an alternate schedule (i.e., at least one agent is dosed intermittently)', 'Parts 2A/2B: To evaluate the clinical activity of GSK1120212 and GSK2141795 administered in combination in subjects with solid tumors that are predicted to be sensitive to the inhibition of MEK and/or AKT, including TNBC and BRAF-wild type melanoma']","['To characterize the PK of GSK1120212 and GSK2141795 for a once daily continuous dosing schedule (Part 1A) and/or an intermittent dosing schedule (Part 1B).', 'Part 1A, Part 1B: To evaluate the clinical activity of GSK1120212 and GSK2141795 in subjects with solid tumors.', 'Parts 1 and 2: To characterize the durability of response with GSK1120212 and GSK2141795 dosed orally in combination', 'To evaluate the pharmacodynamic (PD) response in tumors after treatment with the combination of GSK1120212 and GSK2141795.', 'To explore relationships between study drug PK, PD and clinical activity']",,,,,10,United States,"GSK Investigational Site [Aurora, United States] | GSK Investigational Site [New Haven, United States] | GSK Investigational Site [Boston, United States] | GSK Investigational Site [Boston, United States] | GSK Investigational Site [New Brunswick, United States] | GSK Investigational Site [Nashville, United States] | GSK Investigational Site [Dallas, United States] | GSK Investigational Site [Houston, United States] | GSK Investigational Site [San Antonio, United States] | GSK Investigational Site [Salt Lake City, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2014.0,11.0,0,Phase 1
NCT01138384,Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer,A Phase I/II Study of Foretinib in Combination With Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer,COMPLETED,PHASE1; PHASE2,NCIC Clinical Trials Group,2010-10-27,2014-05-14,2015-02-13,2010-06-07,2023-08-04,"['Toxicity, maximum administered dose and the recommended phase II dose']","['Pharmacokinetic evaluation of lapatinib', 'Preliminary evidence of efficacy']",,,,,5,Canada,"BCCA - Cancer Centre for the Southern Interior [Kelowna, Canada] | BCCA - Vancouver Cancer Centre [Vancouver, Canada] | Cancer Centre of Southeastern Ontario at Kingston [Kingston, Canada] | London Regional Cancer Program [London, Canada] | McGill University - Dept. Oncology [Montreal, Canada]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,NETWORK,False,2015.0,10.0,0,Phase 2
NCT01145430,"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer","Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer",COMPLETED,PHASE1,National Cancer Institute (NCI),2010-06-01,2017-05-23,,2010-06-16,2017-12-22,"['Recommended Phase II dose of veliparib, based on incidence of dose limiting toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0']","['Frequency of subjects experiencing toxicities in each stratum, assessed and graded according to terminology in the Cancer Therapy Evaluation Program (CTEP) version 4.0 of the CTCAE', 'Overall survival', 'Progression-free survival']",,,,,6,United States,"Laura and Isaac Perlmutter Cancer Center at NYU Langone [New York, United States] | Mount Sinai Hospital [New York, United States] | Columbia University/Herbert Irving Cancer Center [New York, United States] | Weill Medical College of Cornell University [New York, United States] | Montefiore Medical Center-Einstein Campus [The Bronx, United States] | Montefiore Medical Center - Moses Campus [The Bronx, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,NIH,False,,,0,Phase 1
NCT01162200,Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer,A Phase I Study of Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer,COMPLETED,PHASE1,University of Texas Southwestern Medical Center,2010-10-04,2015-07-25,2015-12-28,2010-07-14,2020-08-20,['The maximum tolerated dose to the lumpectomy cavity in patients with early stage breast cancer'],"['Dose-limiting toxicity', 'The cosmesis of breast']",,,,,2,United States,"University of Texas Southwestern Medical Center [Dallas, United States] | UT Southwestern Medical Center [Dallas, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2015.0,10.0,0,Phase 1
NCT01219699,"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene","A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",COMPLETED,PHASE1,Novartis Pharmaceuticals,2010-10-05,2015-02-05,2020-04-16,2010-10-13,2020-09-22,['Incidence rate of dose limiting toxicities (DLT).'],"['Overall safety and tolerability of BYL719 as single agent and in combination with fulvestrant', 'PK parameters of BYL719 as single agent and in combination with fulvestrant - AUC-tlast and AUC0-inf.', 'PK parameters of BYL719 as single agent and in combination with fulvestrant - Cmax.', 'Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant - Tmax.', 'Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant - CL/F.', 'Pharmaconkinetics of BYL719 as single agent and in combination with fulvestrant - Vz/F.', 'Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant - Terminal half-life (t1/2)', 'Preliminary efficacy of BYL719 as single agent and in combination with fulvestrant by measuring ORR.', 'Progression-free survival at maximum tolerated dose']",,,,,11,Germany; Netherlands; Spain; United Kingdom; United States,"UCSF Medical Center [San Francisco, United States] | Massachusetts General Hospital [Boston, United States] | Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4) [Nashville, United States] | Vanderbilt Univeristy SC [Nashville, United States] | MD Anderson Cancer Center/University of Texas MD Anderson [Houston, United States] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Würzburg, Germany] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain] | Novartis Investigative Site [Oxford, United Kingdom]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on BYL719, which is being tested as a new treatment for advanced solid malignancies, indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT01226316,"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules","A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies",COMPLETED,PHASE1,AstraZeneca,2010-12-01,2019-04-26,2024-12-03,2010-10-22,2025-06-29,"['Parts A,B,C,D,E & F : Safety and tolerability of AZD5363 in terms of adverse events and serious adverse events', 'Parts A,B,C,D,E & F : Safety and tolerability of AZD5363 in terms of death', 'Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing changes from baseline of laboratory data (clinical chemistry, haematology, urinalysis)', 'Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 in terms of changes from baseline in vital signs and in electrocardiogram (ECG) parameters', 'Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing changes from baseline in electrocardiogram (ECG) parameters', 'Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing changes from baseline of glucose laboratory parameters (Urine, serum and plasma glucose, glycosylated haemoglobin).', 'Parts A,B,C,D,E & F: Safety and tolerability of AZD5363 by assessing left ventricular ejection fraction (LVEF).']","['To characterise AZD5363 PK following single & multiple dosing by assessment of maximum plasma concentration,time to Cmax, terminal rate constant, terminal half life,area under the plasma concentration-time curve,plasma clearance & volume of distribution.', 'Parts A,B,C,D,E&F: To obtain a preliminary assessment of anti-tumour activity of AZD5363 via use of Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1']",,,,,34,Canada; Denmark; France; Italy; Japan; Netherlands; Singapore; Spain; United Kingdom; United States,"Research Site [Los Angeles, United States] | Research Site [Stanford, United States] | Research Site [West Hollywood, United States] | Research Site [Aurora, United States] | Research Site [Boston, United States] | Research Site [New York, United States] | Research Site [Oklahoma City, United States] | Research Site [Portland, United States] | Research Site [Charleston, United States] | Research Site [Nashville, United States] | Research Site [Nashville, United States] | Research Site [Houston, United States] | Research Site [Edmonton, Canada] | Research Site [Vancouver, Canada] | Research Site [Toronto, Canada] | Research Site [Montreal, Canada] | Research Site [København Ø, Denmark] | Research Site [Paris, France] | Research Site [Pierre-Bénite, France] | Research Site [Villejuif, France] | Research Site [Milan, Italy] | Research Site [Napoli, Italy] | Research Site [Prato, Italy] | Research Site [Chūōku, Japan] | Research Site [Kashiwa, Japan] | Research Site [Kōtoku, Japan] | Research Site [Sapporo, Japan] | Research Site [Amsterdam, Netherlands] | Research Site [Singapore, Singapore] | Research Site [Madrid, Spain] | Research Site [Madrid, Spain] | Research Site [Valencia, Spain] | Research Site [Manchester, United Kingdom] | Research Site [Sutton, United Kingdom]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT01234857,A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3),"A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients",COMPLETED,PHASE2,Merck Sharp & Dohme LLC,2010-09-17,2013-10-15,2013-10-15,2010-11-04,2017-05-31,['Progression free survival (PFS)'],"['Objective response rate (ORR)', 'Overall survival (OS)']",,,,,0,,,2010.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Ridaforolimus and Dalotuzumab, which are being tested in combination for a specific cancer type, indicating a new medicine approach rather than an extension of indication for existing treatments.",INDUSTRY,False,2013.0,12.0,0,Phase 2
NCT01263145,MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer,Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer,COMPLETED,PHASE1,National Cancer Institute (NCI),2011-01-05,2012-10-19,2012-10-19,2010-12-20,2017-08-25,"['Antitumor activity of the combination in metastatic breast cancer (Expansion phase)', 'MTD of the combination of MK-2206 and paclitaxel defined as the dose level in which less than or equal to 1 out of 6 patients develop dose limiting toxicity assessed using Common Terminology Criteria for Adverse Events version 4 (Phase I)']","['Change in average number of circulating tumor cells (CTCs)', 'Change in multiplex proteomics', 'Change in percentage of biomarkers assessed using immunohistochemistry', 'Change in percentage of marker of proliferation Ki-67 (Ki-67) positive cells', 'Change in reverse phase proteomic arrays (RPPA)', 'Pharmacokinetic parameters of Akt inhibitor MK2206', 'Pharmacokinetic parameters of paclitaxel']",,,,,3,United States,"Dana-Farber Cancer Institute [Boston, United States] | Vanderbilt University/Ingram Cancer Center [Nashville, United States] | M D Anderson Cancer Center [Houston, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,1,"The trial involves MK2206, which is a new medicine being tested in combination with paclitaxel for treating advanced solid tumors and metastatic breast cancer, indicating both a new medicine and an extension of indication for the existing treatment.",NIH,False,2012.0,13.0,0,Phase 1
NCT01324479,Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,COMPLETED,PHASE1,Novartis Pharmaceuticals,2012-02-29,2017-07-04,2017-07-04,2011-03-29,2020-12-19,['Incidence rate of dose-limiting toxicities and adverse events'],['Objective response by local investigator assessment'],,,,,47,Australia; Canada; France; Germany; Hong Kong; Israel; Italy; Netherlands; Norway; Singapore; South Korea; Spain; Taiwan; Thailand; United States,"Highlands Oncology Group [Fayetteville, United States] | University of Chicago SC [Chicago, United States] | Karmanos Cancer Institute Wayne St Karmanos [Detroit, United States] | Sarah Cannon Research Institute Dept of Onc [Nashville, United States] | University of Texas/MD Anderson Cancer Center Dept of Onc [Houston, United States] | Novartis Investigative Site [Westmead, Australia] | Novartis Investigative Site [Woolloongabba, Australia] | Novartis Investigative Site [Ottawa, Canada] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [La Tronche, France] | Novartis Investigative Site [Lille Cédex, France] | Novartis Investigative Site [Strasbourg, France] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Frankfurt, Germany] | Novartis Investigative Site [Freiburg im Breisgau, Germany] | Novartis Investigative Site [Göttingen, Germany] | Novartis Investigative Site [Hanover, Germany] | Novartis Investigative Site [Oldenburg, Germany] | Novartis Investigative Site [Shatin, New Territories, Hong Kong] | Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Haifa, Israel] | Novartis Investigative Site [Kfar Saba, Israel] | Novartis Investigative Site [Ramat Gan, Israel] | Novartis Investigative Site [Tel Aviv, Israel] | Novartis Investigative Site [Ancona, Italy] | Novartis Investigative Site [Meldola, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Reggio Emilia, Italy] | Novartis Investigative Site [Utrecht, Netherlands] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Rotterdam, Netherlands] | Novartis Investigative Site [Oslo, Norway] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Gyeonggi-do, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Granada, Spain] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Oviedo, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Zaragoza, Spain] | Novartis Investigative Site [Tainan City, Taiwan] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Songkhla, Thailand]",2012.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on assessing the safety and tolerability of INC280, which indicates it is a study of a new medicine.",INDUSTRY,False,2017.0,8.0,1,Phase 1
NCT01339442,BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer,"A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer",COMPLETED,PHASE1,Washington University School of Medicine,2011-11-14,2016-12-21,2016-12-28,2011-04-20,2017-01-25,"['MTD of BKM120 in combination with fulvestrant', 'Number of participants with adverse events after treatment with BKM120 in combination with fulvestrant']","['Anti-tumor effect (PR, CR, SD and PD) of BKM120 in combination with fulvestrant', 'Steady state blood concentration of BKM120', 'Tumor PI3K pathway abnormalities in tissue from previous biopsy or collected at baseline', 'Effects of study therapy on blood levels of fasting C-peptide', 'Effects of study therapy on blood levels of glucose', 'Samples will be analyzed for markers of PI3K signaling (including pAKT, pS6, Cyclin D1, subcellular localization of FOXO3a, phosphoproteomics), tumor cell proliferation (Ki67) and apoptosis (cleaved caspase 3 or TUNEL staining).', 'Examine the PIK3CA mutation status in circulating DNA at baseline thru last treatment']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2016.0,9.0,0,Phase 1
NCT01339650,"Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE1,"AbbVie (prior sponsor, Abbott)",2011-05-06,2017-11-30,2017-11-30,2011-04-21,2018-01-02,['Pharmacokinetic profile'],['Safety (number of subjects with adverse events and/or dose limiting toxicities)'],,,,,3,Netherlands,"Univ Med Center Groningen [Groningen, Netherlands] | Univ Med Ctr, St. Radboud [Nijmegen, Netherlands] | Erasmus Medisch Centrum [Rotterdam, Netherlands]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,1,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT01344031,"MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer","A Phase 1 Trial of MK-2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer",COMPLETED,PHASE1,National Cancer Institute (NCI),2011-04-21,2011-07-01,,2011-04-28,2018-07-23,"['MTD of Akt inhibitor MK-2206 in combination with anastrozole determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) (Phase IA)', 'RPTD of Akt inhibitor MK-2206 in combination with anastrozole evaluated by the tolerability of prolonged administration at the MTD assessed by CTCAE v4.0 (Phase IB)', 'RPTD of fulvestrant in combination with Akt inhibitor MK-2206 assessed by CTCAE v4.0 (ARM C)', 'RPTD of anastrozole plus fulvestrant in combination with Akt inhibitor MK-2206 assessed by CTCAE v4.0 (ARM D)']","['Incidence of toxicity, assessed by CTCAE v4.0', 'Clinical benefit rate (CR+PR+SD for more than 6 months)', 'Serum levels of estradiol prior to and following 1 course of Akt inhibitor MK-2206 therapy']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,NIH,False,,,0,Phase 1
NCT01351103,A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,"A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands",COMPLETED,PHASE1,Novartis Pharmaceuticals,2011-12-01,2021-06-01,2024-06-17,2011-05-10,2025-06-13,['Incidence of dose limiting toxicities (DLTs) during the first cycle of LGK974 treatment and during the first 2 cycles of LGK974 in combination with PDR001'],"['Type and category of study drug related adverse events (AE)', 'Absorption and plasma concentrations of LGK974', 'PD related to the Wnt pathway', 'Overall response rate of tumor', 'Absorportion and plasma concentrations of PDR001']",,,,,20,Canada; France; Germany; Italy; Netherlands; Spain; United States,"UCLA School of Medicine [Los Angeles, United States] | Sidney Kimmel Comprehensive Cancer Center Johns Hopkins [Baltimore, United States] | Dana Farber Cancer Institute SC-7 [Boston, United States] | University of Michigan Comprehensive Cancer Center Onc Dept. [Ann Arbor, United States] | Karmanos Cancer Institute Wayne St [Detroit, United States] | University of Texas/MD Anderson Cancer Center MD Anderson 2 [Houston, United States] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Villejuif, France] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Napoli, Italy] | Novartis Investigative Site [Rotterdam, Netherlands] | Novartis Investigative Site [Utrecht, Netherlands] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain] | Novartis Investigative Site [Valencia, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Madrid, Spain]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT01373710,Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis,Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis,COMPLETED,PHASE1; PHASE2,Institut Curie,2011-05-19,2018-04,2018-04-09,2011-06-15,2019-07-10,['Phase I : To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route.'],"['Phase I : Recommended dose (RD will be used in Phase II)', 'Phase I&II : Toxicity during treatment', 'Time to neurologic progression', 'Biological response: CSF cellularity and protein concentration', 'Radiological response: cerebrospinal meningitis and neuraxis MRI', 'Impact on quality of life', 'Impact on survival (overall survival, survival without neurological progression, progression-free survival)', 'Pharmacokinetics: dose of trastuzumab in CSF and plasma', 'FCGR3A Genetic status influence on efficacy trastuzumab in metastatic breast cancer', 'Phase II : Determination of antitumor activity trastuzumab when administrated by IT or intra-ventricular in terms of neurological progression free survival at 2 months']",,,,,10,France,"François Baclesse Center [Caen, France] | Rene Huguenin Hospital [Saint-Cloud, France] | Oscar Lambret Center [Lille, France] | Léon Bérard Center [Lyon, France] | Institut Bergonié [Bordeaux, France] | CHU Grenoble [Grenoble, France] | Institut du Cancer de Montpellier [Montpellier, France] | Institut Univesitaire du Cancer de Toulouse [Toulouse, France] | Institut Curie - Claudius Regaud Hospital [Paris, France] | Pitie Salpetriere Hospital [Paris, France]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 2
NCT01407562,"Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors,TERMINATED,PHASE1,"Rutgers, The State University of New Jersey",2010-09-17,2016-03-29,2016-03-29,2011-08-02,2022-09-28,['Establish the maximum tolerated dose (MTD) of pazopanib with weekly paclitaxel and carboplatin on a 28- day cycle'],"['Determine the drug-drug interactions with paclitaxel, carboplatin, and pazopanib']",,,,,1,United States,"Rutgers Cancer Institute of New Jersey [New Brunswick, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2016.0,9.0,0,Phase 1
NCT01434303,"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only","Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed",COMPLETED,PHASE1,National Cancer Institute (NCI),2012-01-10,2016-02-16,2016-02-16,2011-09-14,2019-05-20,['RP2D for entinostat in combination with lapatinib ditosylate defined as the highest dose level in which 6 patients have been treated with at most 1 patient experiencing dose limiting toxicity'],"['Incidence of grade III or IV toxicities, graded according to Common Terminology Criteria for Adverse Events version 4']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,NIH,False,2016.0,9.0,0,Phase 1
NCT01495247,"Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer","A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer",TERMINATED,PHASE1; PHASE2,Novartis Pharmaceuticals,2012-01-30,2014-05-19,2014-05-19,2011-12-19,2020-12-08,['Phase lb: Dose Limiting Toxicities (DLTs) the first cycle of treatment'],"['Phase lb: Frequency and severity of adverse events', 'Phase lb: Progression free survival (PFS)', 'Phase lb: Overall Response Rate (ORR)', 'Phase lb: Clinical Benefit Rate (CBR)']",,,,,3,France; Spain,"Novartis Investigative Site [Dijon, France] | Novartis Investigative Site [Saint-Herblain Cédex, France] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain]",2012.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating BEZ235, which is a new drug being tested in combination with Paclitaxel for a specific patient population with HER2 negative breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2014.0,11.0,1,Phase 2
NCT01602406,Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,"A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer",COMPLETED,PHASE1,Novartis Pharmaceuticals,2012-09-21,2017-08-02,2017-08-02,2012-05-21,2020-12-19,['Incidence rate of Dose Limiting Toxicities'],"['Number of adverse events', 'Number of serious adverse events', 'Pharmacodynamic response to LJM716 in tumor tissue', 'Progression-free survival', 'Duration of response', 'Serum concentration of anti-LJM716 antibodies', 'Serum concentration of LJM716 when administered in combination with trastuzumab', 'Frequency of partial responses according to Response Evaluation Criteria In Solid Tumors (RECIST)', 'Frequency of complete responses according to RECIST', 'Frequency of stable disease according to RECIST']",,,,,11,Belgium; France; Italy; Netherlands; South Korea; Spain; Taiwan; United Kingdom; United States,"Novartis Investigative Site [Boston, United States] | Novartis Investigative Site [Chapel Hill, United States] | Novartis Investigative Site [Philadelphia, United States] | Novartis Investigative Site [Wilrijk, Belgium] | Novartis Investigative Site [Saint-Herblain, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Valencia, Spain] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Oxford, United Kingdom]",2012.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2017.0,8.0,1,Phase 1
NCT01606241,"Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer,COMPLETED,PHASE1,Mayo Clinic,2012-07-24,2014-09-25,2018-03-09,2012-05-25,2024-08-21,"[""Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)""]","['Disease-free survival', 'FRa expression', 'Overall survival time', 'Percentage change in plasma concentration of cytokines and chemokines']",,,,,1,United States,"Mayo Clinic [Rochester, United States]",2012.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[""Disease-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT01624441,Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer,A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,National Cancer Institute (NCI),2012-08-21,2013-09-10,2013-09-10,2012-06-20,2018-03-30,"['MTD of dinaciclib given in combination with epirubicin hydrochloride, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4']","['Predictive value of MCL-1, LMW-E, and tumor grade as predictors of biologic response (i.e. induction of apoptosis) in tumors treated with therapy', 'Clinical benefit rate (complete response [CR] + partial response [PR] + stable disease [SD]), assessed using Response Evaluation Criteria in Solid Tumors (RECIST)', 'Changes in proliferation as measured by Ki67 and apoptosis as measured by TUNEL']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Dinaciclib, which is being tested in combination with Epirubicin for a specific patient population (metastatic triple-negative breast cancer), indicating it is a new medicine being evaluated for efficacy in this context.",NIH,False,2013.0,12.0,0,Phase 1
NCT01632332,Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer,A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer,COMPLETED,PHASE1,Mayo Clinic,2012-07-09,2014-03-24,2018-07-09,2012-07-02,2018-10-09,"[""Proportion of patients who experience toxicities of attribution during the course of treatment (grades 3-5 of the NCI's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0) for 2 years."", 'To determine the ability of this vaccination protocol to elicit an immune response as measured by activated HER-2/neu-specific T lymphocytes or high-affinity antibodies']",['Disease-free survival'],,,,,1,United States,"Mayo Clinic [Rochester, United States]",2012.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[""Disease-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction",COMPLETED,PHASE1,National Cancer Institute (NCI),2012-08-03,2018-11-29,2020-09-01,2012-07-11,2025-02-07,"['Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0', 'Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0', 'Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method']","['Child-Pugh classification of hepatic dysfunction', 'Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria']",,,,,12,Canada; United States,"City of Hope Comprehensive Cancer Center [Duarte, United States] | University of California Davis Comprehensive Cancer Center [Sacramento, United States] | Emory University Hospital/Winship Cancer Institute [Atlanta, United States] | University of Chicago Comprehensive Cancer Center [Chicago, United States] | Johns Hopkins University/Sidney Kimmel Cancer Center [Baltimore, United States] | National Cancer Institute Developmental Therapeutics Clinic [Bethesda, United States] | Wayne State University/Karmanos Cancer Institute [Detroit, United States] | Mayo Clinic in Rochester [Rochester, United States] | Case Western Reserve University [Cleveland, United States] | Penn State Milton S Hershey Medical Center [Hershey, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | University Health Network-Princess Margaret Hospital [Toronto, Canada]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,NIH,False,2020.0,5.0,1,Phase 1
NCT01639911,Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors,STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors,COMPLETED,PHASE1,University of Illinois at Chicago,2013-08-14,2016-07-28,2016-07-28,2012-07-13,2019-07-22,['Optimally Tolerated Dose'],['Toxicity Profile'],,,,,1,United States,"University of Illinois Cancer Center [Chicago, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2016.0,9.0,0,Phase 1
NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer,A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer,COMPLETED,PHASE1,Eli Lilly and Company,2012-07-31,2019-04-04,2022-02-02,2012-08-01,2022-04-08,['Recommended Phase 2 dose'],"['Pharmacokinetics: Maximum concentration (Cmax)', 'Pharmacokinetics: Time of maximal concentration', 'Number of participants with tumor response', 'Potential of LY3023414 to inhibit CYP3A4-mediated metabolism']",,,,,8,Italy; Puerto Rico; United States,"UCLA Medical Center [Los Angeles, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Peggy and Charles Stephenson Oklahoma Cancer Center [Oklahoma City, United States] | Penn Presbyterian Medical Center [Philadelphia, United States] | Sarah Cannon Cancer Center [Nashville, United States] | Tennessee Oncology PLLC [Nashville, United States] | Azienda Ospedaliero - Universitaria S. Luigi Gonzaga [Orbassano, Italy] | Fundacion de Investigacion de Diego [San Juan, Puerto Rico]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT01676753,Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,A Phase 1b Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression,COMPLETED,PHASE1,Jo Chien,2016-12-28,2020-06-30,2022-02-28,2012-08-31,2022-09-21,"['Maximum tolerated dose (MTD)', 'Proportion of participants with reported dose-limiting toxicities (DLTs)']",['Overall Response Rate'],,,,,1,United States,"University of California, San Francisco [San Francisco, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Dinaciclib, which is a cyclin-dependent kinase inhibitor being tested in combination with Pembrolizumab for a specific indication (advanced breast cancer), indicating it is a new medicine.",OTHER,False,2022.0,3.0,0,Phase 1
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study,COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2012-11-05,2022-03-01,2022-03-01,2012-11-12,2022-03-07,"['Maximum Tolerated Dose', 'assessing toxicity by the number of adverse events']",['CNS progression-free survival'],,,,,6,United States,"Memoral Sloan Kettering Cancer Center [Basking Ridge, United States] | Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Cancer Center @ Suffolk [Commack, United States] | Memorial Sloan Kettering Westchester [Harrison, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Memorial Sloan Kettering Nassau [Uniondale, United States]",2012.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT01740336,A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer,"A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer",COMPLETED,PHASE2,"Genentech, Inc.",2013-02-06,2015-10-20,2015-12-10,2012-12-04,2017-04-24,['Progression-Free Survival (PFS) Assessed as per Modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)'],"['Percentage of Participants With Adverse Events', 'Percentage of Participants With Objective Tumor Response Assessed as per Modified RECIST v1.1', 'Percentage of Participants Acheiving Clinical Benefit (Partial Response, Complete Response or Stable Disease Lasting for at Least 6 Months) Assessed as per Modified RECIST v1.1', 'Duration of Confirmed Objective Response Assessed as per Modified RECIST v1.1', 'Population Pharmacokinetics (PK) for GDC-0941', 'Population PK for Paclitaxel']",,,,,97,Australia; Austria; Belgium; Czechia; South Korea; Spain; United Kingdom; United States,"Arizona Oncology Associates, PC - NAHOA [Sedona, United States] | Pacific Cancer Medical Center [Anaheim, United States] | California Cancer Associates for Research & Excellence, Inc. [Encinitas, United States] | Kaiser Permanente - Hayward [Hayward, United States] | Kaiser Permanente - Oakland [Oakland, United States] | Bay Area Cancer Research Group, LLC [Pleasant Hill, United States] | Kaiser Permanente Medical Center - Roseville [Roseville, United States] | Kaiser Permanente Sacramento Medical Center [Sacramento, United States] | Kaiser Permanente - San Francisco (2238 Geary) [San Francisco, United States] | University of California at San Francisco [San Francisco, United States] | Kaiser Permanente - San Jose [San Jose, United States] | Kaiser Permanente - Santa Clara [Santa Clara, United States] | Kaiser Permanente - South San Francisco [South San Francisco, United States] | Kaiser Permanente - Vallejo [Vallejo, United States] | Kaiser Permanente - Walnut Creek [Walnut Creek, United States] | Helen & Harry Gray Cancer Center-Hartford Hospital-CCD PRIME; Research [Hartford, United States] | Clinical Research of South Florida [Coral Gables, United States] | Cancer Specialists of North Florida [Orange Park, United States] | Hematology - Oncology Associates of Treasure Coast [Port Saint Lucie, United States] | Phoebe Putney Memorial Hospital [Albany, United States] | Joliet Oncology-Hematology; Associates, Ltd. [Joliet, United States] | Oncology Specialists, S.C. [Park Ridge, United States] | Illinois Cancer Care [Peoria, United States] | Cotton-O'Neil Clinical Research Center, Hematology and Oncology; Cotton O'Neil Cancer Center [Topeka, United States] | Hematology Oncology Clinic [Baton Rouge, United States] | Metairie Oncologist, LLC [Metairie, United States] | Maine Research Associates [Auburn, United States] | Dana Farber Cancer Institute [Boston, United States] | Beth Israel Deaconess Med Ctr [Brookline, United States] | Henry Ford Health System [Detroit, United States] | Billings Clinic Cancer Center-CCD PRIME [Billings, United States] | Nebraska Cancer Specialists; Oncology Hematology West, PC [Omaha, United States] | ProHEALTH Care Associates LLP [Lake Success, United States] | Summa Health System [Akron, United States] | Aultman Hospital; Aultman Hospital Cancer Center [Canton, United States] | TriHealth Oncology Institute [Cincinnati, United States] | Abington Memorial Hospital [Abington, United States] | Hematology and Oncology Associates of Sc [Greenville, United States] | Shivers Cancer Center at University Medical Center Brackenridge [Austin, United States] | Texas Oncology [Bedford, United States] | Texas Oncology, P.A. - El Paso; West [El Paso, United States] | Texas Oncology - Memorial City [Houston, United States] | Texas Oncology, P.A. ;Sherman Cancer Center [Sherman, United States] | Northern Utah Associates [Ogden, United States] | Shenandoah Oncology Associates [Winchester, United States] | Puget Sound Cancer Centers [Edmonds, United States] | Swedish Health Services [Seattle, United States] | Royal Prince Alfred Hospital [Camperdown, Australia] | Concord Repatriation General Hospital [Concord, Australia] | Port Macquarie Base Hospital;North Coast Cancer Institute [Port Macquarie, Australia] | Sydney Haematology & Oncology Clinic [Wahroonga, Australia] | Calvary Mater Newcastle; Medical Oncology [Waratah, Australia] | Border Medical Oncology [Wodonga, Australia] | Royal Brisbane and Women's Hospital [Herston, Australia] | Mater Adult Hospital [Mackay, Australia] | Ashford Cancer Center Research [Kurralta Park, Australia] | Royal Hobart Hospital [Hobart, Australia] | Bendigo Hospital; Oncology [Bendigo, Australia] | Peninsula and South Eastern Haematology and Oncology Grou [Frankston, Australia] | Royal Perth Hospital; Medical Oncology [Perth, Australia] | Lkh-Univ. Klinikum Graz [Graz, Austria] | LKH - Universitätsklinikum der PMU Salzburg [Salzburg, Austria] | Krankenhaus Hietzing m.Neurolog. Zentrum Rosenhuegel [Vienna, Austria] | Klinikum Wels-Grieskirchen [Wels, Austria] | Institut Jules Bordet [Brussels, Belgium] | UZ Antwerpen [Edegem, Belgium] | UZ Leuven Gasthuisberg [Leuven, Belgium] | CHU Ambroise Paré [Mons, Belgium] | Clinique Ste-Elisabeth [Namur, Belgium] | Sint Augustinus Wilrijk [Wilrijk, Belgium] | Fakultni nemocnice Brno [Brno, Czechia] | Masarykuv onkologicky ustav [Brno, Czechia] | Krajska nemocnice Liberec a.s. [Liberec, Czechia] | Multiscan s.r.o. [Pardubice, Czechia] | Vseobecna fakultni nemocnice v Praze [Prague, Czechia] | Nemocnice Na Bulovce [Prague, Czechia] | Thomayerova nemocnice [Praha 4 - Krc, Czechia] | Chungbuk National University Hospital [Cheongju-si, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | Institut Catala d´Oncologia Hospital Germans Trias i Pujol [Badalona, Spain] | Institut Catala d Oncologia Hospital Duran i Reynals [Barcelona, Spain] | Complejo Hospitalario de Jaen [Jaén, Spain] | Hospital General Univ. Gregorio Maranon [Madrid, Spain] | START Madrid. Centro Integral Oncologico Clara Campal; CIOCC [Madrid, Spain] | Royal Sussex County Hospital [Brighton, United Kingdom] | Royal Surrey County Hospital [Guildford, United Kingdom] | Leicester Royal Infirmary [Leicester, United Kingdom] | Barts Hospital [London, United Kingdom] | The Christie [Manchester, United Kingdom] | Freeman Hospital [Newcastle upon Tyne, United Kingdom] | Nottingham University Hospitals City Campus [Nottingham, United Kingdom] | Royal Stoke University Hospital [Stoke-on-Trent, United Kingdom] | Royal Cornwall Hospital [Truro, United Kingdom] | New Cross Hospital [Wolverhampton, United Kingdom]",2013.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Progression-Free Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves GDC-0941, which is being tested in combination with Paclitaxel for a specific cancer indication, indicating it is a new medicine being evaluated.",INDUSTRY,False,2015.0,10.0,1,Phase 2
NCT01795586,A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients,A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer,COMPLETED,PHASE1,H. Lee Moffitt Cancer Center and Research Institute,2013-02-06,2015-02-24,2022-05-11,2013-02-20,2022-10-31,['Maximum Tolerated Dose (MTD)'],['Response Rate (RR)'],,,,,1,United States,"H. Lee Moffitt Cancer Center and Research Institute [Tampa, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT01846091,Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer,Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer,COMPLETED,PHASE1,Mayo Clinic,2013-04-09,2019-09-18,2019-11-26,2013-05-03,2023-02-14,"['MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) as assessed by the National Cancer (NCI) CTCAE v. 4.0', 'Number of toxicity incidents defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment']","['Number of responses using Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1', 'Time to tumor progression']",,,,,1,United States,"Mayo Clinic [Rochester, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,"[""Overall Survival"",""Time to Progression""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT01853306,"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors","A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors",COMPLETED,PHASE1,AbbVie,2013-03-18,2017-05-03,2017-06-29,2013-05-15,2017-11-21,"['Part 2 - Dose Escalation Cohort: Pharmacokinetic testing', 'Part 1 - Pharmacokinetic profile', 'Part 3 - Safety Expanded Cohort: Number of subjects with adverse events', 'Part 3 - Safety Expanded Cohort: Vital signs', 'Part 3 - Safety Expanded Cohort: Laboratory tests']",['The number of participants with adverse events who receive the extended release formulations of veliparib.'],,,,,0,,,2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT01861509,BP-C1 in Metastatic Breast Cancer Patients,"Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer. A Phase ID Study",COMPLETED,PHASE1,Meabco A/S,2014-01-19,2016-01-20,2016-01-20,2013-05-23,2019-10-07,"['Single-dose PK: Maximum Observed Serum Concentration (Cmax) for Platinum', 'Single-dose PK: Time to Reach Maximum Observed Serum Concentration (Tmax) for Platinum', 'Single-dose PK: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC(0-t)) for Platinum', 'Single-dose PK: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC(0-∞))', 'Single-dose PK: Serum Decay Half-Life (T1/2) for Platinum', 'Multiple-dose PK: Maximum Observed Serum Concentration at Steady State (Css,max) for Platinum', 'Multiple-dose PK: Time to Reach Maximum Observed Serum Concentration at steady state (Tss,max) for Platinum', 'Multiple-dose PK: Minimum Observed Serum Concentration at Steady State (Css,min) for Platinum', 'Multiple-dose PK: Average Serum concentration at steady state (Css,av) for Platinum', 'Multiple-dose PK: Area Under the Curve within a dosing interval of tau (=24 hr) at steady state (AUCss,tau) for Platinum', 'Multiple-dose PK: Serum Decay Half-Life (T1/2) for Platinum']","['Interleukin Serum levels (Interferon γ and β, Tumour Necrosis Factor (TNF-α), IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-21 and IL-25)', 'Change (%) in the sum of diameters of target lesions', 'Number of target lesions', 'Treatment response']",,,,,2,Israel; Thailand,"Oncology Unit. Sheba Medical Centre [Ramat Gan, Israel] | Lampang Cancer Center [Lampang, Thailand]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a study of BP-C1 in metastatic breast cancer patients, indicating that BP-C1 is being tested as a new treatment for this condition, which classifies it as a New Medicine.",INDUSTRY,False,2016.0,9.0,1,Phase 1
NCT01862081,"A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer",,COMPLETED,PHASE1,"Genentech, Inc.",2013-07-16,2017-06-09,2017-06-09,2013-05-24,2017-11-28,"['Safety: Incidence of adverse events', 'Safety: Incidence of dose limiting toxicities']","['Area under the curve from time 0 to the last measurable concentration (AUC0-last)', 'Time to maximum observed plasma concentration (Tmax)', 'Maximum observed plasma concentration (Cmax)', 'Minimum observed plasma concentration (Cmin)', 'Objective response according to RECIST v1.1', 'Duration of response according to RECIST v1.1', 'Progression-free survival (PFS) according to RECIST v1.1']",,,,,14,Belgium; Canada; Spain; United States,"Florida Cancer Specialists - Tampa (Dr. MLK Blvd) [Tampa, United States] | Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Barbara Ann Karmanos Cancer Institute [Detroit, United States] | Sarah Cannon Research Institute [Nashville, United States] | Vanderbilt University Medical Center [Nashville, United States] | Texas Oncology, P.A; Baylor Sammons Cancer Center [Dallas, United States] | Texas Oncology, P.A. - Fort Worth [Fort Worth, United States] | Virginia Oncology Associates [Norfolk, United States] | Yakima Valley Memorial Hospital/North Star Lodge [Yakima, United States] | UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy [Leuven, Belgium] | Princess Margaret Hospital [Toronto, Canada] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain]",2013.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves GDC-0032, which is being assessed for safety and pharmacokinetics in combination with other treatments for specific types of cancer, indicating it is a new medicine.",INDUSTRY,False,2017.0,8.0,1,Phase 1
NCT01862900,Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.,COMPLETED,PHASE1,Providence Health & Services,2012-04-27,2016-05-17,2018-08-15,2013-05-27,2019-03-21,['Determine the maximum tolerated dose and safety profile of radiation administered in combination with anti-OX40 in patients with metastatic breast cancer.'],['Estimate the response rate of combined modality treatment in both irradiated and non-irradiated tumors.'],,,,,1,United States,"Portland Providence Medical Center [Portland, United States]",2012.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT01884285,AZD8186 First Time In Patient Ascending Dose Study,"A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014",COMPLETED,PHASE1,AstraZeneca,2013-07-09,2019-03-31,2020-02-07,2013-06-24,2020-05-29,['Safety and tolerability'],"['Part A: The number of evaluable patients with dose limiting toxicities (DLTs).', 'Part A, B, C + D: Antitumor activity of AZD8186 monotherapy or in combination', 'Part A, B, C and D: Anti-tumour activity of AZD8186 monotherapy or in combination', 'Part A + B: Plasma concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean resistance time)', 'Part A + B: 4 beta-hydroxy cholesterol concentration in blood samples.', 'Part B: Obtaining a preliminary assessment of the antitumour activity of AZD8186 as monotherapy', 'Part B: Obtaining a preliminary assessment of AZD8186 drug effect in the tumour', 'Part A: Urine concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean residence time)', 'Part C: safety and tolerability assessed by dose limiting toxicity of AZD8186 with abiraterone acetate (and prednisone)', 'Part C: pharmacokinetics of and exposure to AZD8186, its major metabolite M1, and abiraterone', 'Part C: steady state exposure to abiraterone', 'Part C: steady state exposure of AZD8186 in combination with abiraterone acetate', 'Part D: Measure the dose limiting toxicity of AZD8186 in combination with AZD2014.', 'Part D: Single dose and multiple dose pharmacokinetics of and assess exposure to AZD8186, its major metabolite M1, and AZD2014 when co-administered', 'Part D: Measure the exposure to AZD2014 following the last weekly dose of AZD2014 in the absence and presence of multiple dose AZD8186.', 'Part D: Measure the exposure on the 4th administred dose of AZD8186 in the absence and presence of multiple dose AZD2014']",,,,,13,Canada; Spain; United Kingdom; United States,"Research Site [Boston, United States] | Research Site [Detroit, United States] | Research Site [New York, United States] | Research Site [Seattle, United States] | Research Site [Madison, United States] | Research Site [Toronto, Canada] | Research Site [Barcelona, Spain] | Research Site [Barcelona, Spain] | Research Site [Pozuelo de Alarcón, Spain] | Research Site [Cambridge, United Kingdom] | Research Site [London, United Kingdom] | Research Site [Manchester, United Kingdom] | Research Site [Sutton, United Kingdom]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT01969643,A Safety Study of SGN-LIV1A in Breast Cancer Patients,"A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,Seagen Inc.,2013-10-22,2023-02-04,2023-02-04,2013-10-25,2023-03-07,"['Incidence of adverse events', 'Incidence of laboratory abnormalities', 'Incidence of dose-limiting toxicity (DLT)']","['Blood concentrations of LV and metabolites', 'Incidence of antitherapeutic antibodies', 'Objective response rate (ORR)', 'Duration of response (DOR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'PFS relative to prior therapy']",,,,,38,United States,"University of Alabama at Birmingham [Birmingham, United States] | Pinnacle Oncology Hematology [Scottsdale, United States] | UC San Diego / Moores Cancer Center [La Jolla, United States] | Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute [Los Angeles, United States] | University of California at San Francisco [San Francisco, United States] | UCLA Medical Center / David Geffen School of Medicine [Santa Monica, United States] | Rocky Mountain Cancer Centers - Aurora [Aurora, United States] | Poudre Valley Health System (PVHS) [Fort Collins, United States] | Yale Cancer Center [New Haven, United States] | The Whittingham Cancer Center / Norwalk Hospital [Norwalk, United States] | H. Lee Moffitt Cancer Center and Research Institute [Tampa, United States] | Piedmont Cancer Institute [Atlanta, United States] | University of Chicago Medical Center [Chicago, United States] | Indiana University Simon Cancer Center [Indianapolis, United States] | Louisiana State University Health Sciences Center [New Orleans, United States] | University of Maryland [Baltimore, United States] | Dana Farber Cancer Institute [Boston, United States] | Karmanos Cancer Institute / Wayne State University [Detroit, United States] | Allina Health Cancer Institute [Minneapolis, United States] | University of Minnesota [Minneapolis, United States] | Mayo Clinic Rochester [Rochester, United States] | Washington University in St Louis [St Louis, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | University of New Mexico Cancer Center [Albuquerque, United States] | Columbia University Medical Center [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Weill Cornell Medicine [New York, United States] | Wake Forest Baptist Medical Center / Wake Forest University [Winston-Salem, United States] | Case Western Reserve University / University Hospitals Cleveland Medical Center [Cleveland, United States] | The Cleveland Clinic [Cleveland, United States] | Oregon Health and Science University [Portland, United States] | Tennessee Oncology-Nashville/Sarah Cannon Research Institute [Nashville, United States] | Texas Oncology - Baylor Sammons Cancer Center [Dallas, United States] | Cancer Care Centers of South Texas - HOAST/Texas Oncology [New Braunfels, United States] | Northwest Medical Specialties [Puyallup, United States] | Swedish Cancer Institute [Seattle, United States] | Seattle Cancer Care Alliance / University of Washington [Seattle, United States] | West Virginia University [Morgantown, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT01971515,First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,"A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies",COMPLETED,PHASE1,EMD Serono,2013-12-13,2018-08-09,2018-08-09,2013-10-29,2018-09-19,"['Number of dose limiting toxicities (DLTs) in Dose Escalation and Trastuzumab or Tamoxifen combination arms', 'Number of subjects with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs), and deaths in cohort for subjects with PAM pathway alterations']","['Observed Maximum Plasma Concentration (Cmax)', 'Time To Reach Maximum Plasma Concentration (Tmax)', 'Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t)', 'Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf)', 'Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau)', 'Apparent Terminal Half-life ( t1/2)', 'Apparent Oral Clearance (CL/F)', 'Apparent Oral Clearance Steady State (CLss/F)', 'Apparent Volume of Distribution (Vz/F)', 'Apparent Volume of Distribution at Steady State (Vss/F)', 'Factor to Assess the Increase of Drug Concentration in Plasma Until Steady State is Reached [Racc(AUC)]', 'Factor to Assess the Maximal Increase of Drug Concentration in Plasma [Racc (Cmax)]', 'Number of subjects with best overall response according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) or Cheson 2007', 'Percentage of subjects with clinical benefit', 'Disease control rate (DCR) for Cohort 2 only', 'Progression-free survival (PFS) rate for Cohorts 2 and 3 only']",,,,,15,United States,"University of Alabama at Birmingham [Birmingham, United States] | Cedars Sinai Medical Center [Los Angeles, United States] | University of California at San Diego, Moores Cancer Center [San Diego, United States] | Sylvester Comprehensive Cancer Center [Miami, United States] | Metairie Oncology [Metairie, United States] | Massachusetts General Hospital [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Henry Ford Hospital [Detroit, United States] | Washington University School of Medicine [St Louis, United States] | Mount Sinai [New York, United States] | Medical University of South Carolina [Charleston, United States] | Mary Crowley Cancer Research Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States] | University of Texas Health Science Center at San Antonio [San Antonio, United States] | Fletcher Allen Health Care, Inc. [Burlington, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT01989546,"Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations","Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",COMPLETED,PHASE1; PHASE2,National Cancer Institute (NCI),2014-02-04,2020-03-26,2020-03-26,2013-11-21,2021-02-23,"['Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy']",['Response Rate (Complete Response (CR) + Partial Response (PR) of Treatment With Talazoparib (BMN 673) in Participants With Deleterious Breast Cancer (BRCA) Mutations'],"[{""type"":""PRIMARY"",""title"":""Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy"",""timeFrame"":""Cycle 1, day 8"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""44.4"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Response Rate (Complete Response (CR) + Partial Response (PR) of Treatment With Talazoparib (BMN 673) in Participants With Deleterious Breast Cancer (BRCA) Mutations"",""timeFrame"":""Restaging scans will be carried out every 2 cycles (8 weeks) until the end of treatment (average, 7 months)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""5"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)"",""timeFrame"":""Date treatment consent signed to date off study, approximately 28 months and 24 days."",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""9"",""spread"":null,""lower"":null,""upper"":null}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Talazoparib (BMN 673)"",""n"":""9""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Talazoparib (BMN 673)"",""n"":""0""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Talazoparib (BMN 673)"",""n"":""9""}]}],""dropWithdraws"":[{""type"":""Clinical Progression"",""reasons"":[{""group"":""Talazoparib (BMN 673)"",""n"":""1""}]},{""type"":""Disease progression on study"",""reasons"":[{""group"":""Talazoparib (BMN 673)"",""n"":""8""}]}]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""5"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""4"",""spread"":null}]},{""title"":""Age, Continuous"",""unit"":""years"",""paramType"":""MEAN"",""dispersionType"":""STANDARD_DEVIATION"",""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""61.23"",""spread"":""12.33""}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""5"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""4"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""9"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""1"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""8"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""9"",""spread"":null}]}]","[{""group"":""Talazoparib (BMN 673)"",""serious_affected"":3,""serious_at_risk"":9,""other_affected"":9,""other_at_risk"":9}]",1,United States,"National Institutes of Health Clinical Center, 9000 Rockville Pike [Bethesda, United States]",2014.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,1,1,1,0,0,0,1,4,0,0,1,0,"The trial is testing BMN 673, which is identified as a new oral PARP inhibitor for patients with advanced solid tumors and BRCA mutations, indicating it is a new medicine.",NIH,True,2020.0,5.0,0,Phase 2
NCT02009449,A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors,"A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,Eli Lilly and Company,2013-11-15,2019-02-19,2023-07-22,2013-12-12,2024-11-15,"['Safety and tolerability as measured by incidence of adverse events', 'Pharmacokinetic (PK) parameters']","['Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)', 'Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for participants with metastatic castration resistant prostate cancer (CRPC)', 'Anti-Pegilodecakin antibody formation']",,,,,10,United States,"UCLA Medical Hematology & Oncology [Los Angeles, United States] | UCSF [San Francisco, United States] | Sarah Cannon Research Institute at HealthONE [Denver, United States] | Florida Cancer Specialists & Research Institute [Sarasota, United States] | Dana Farber Cancer Institute [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program [Oklahoma City, United States] | Sarah Cannon Research Institute [Nashville, United States] | The University of Texas M.D. Anderson Cancer Center [Houston, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT02019524,Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,COMPLETED,PHASE1,"COL George Peoples, MD, FACS",2013-09-30,2016-12-06,2016-12-06,2013-12-24,2020-03-18,['Primary vaccination strategy'],"['Short-term immunity', 'Optimal booster inoculation strategy', 'Delayed Type Hypersensitivity evaluation']",,,,,1,United States,"University of Texas M.D. Anderson Cancer Center [Houston, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves two new peptide vaccines (E39 and J65) targeting folate binding protein in breast and ovarian cancer patients, indicating the development of new medicines.",FED,False,2016.0,9.0,0,Phase 1
NCT02025192,A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,"A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer",COMPLETED,PHASE1,Seagen Inc.,2013-12-31,2017-10-03,2020-03-16,2013-12-31,2020-06-04,"['Incidence of adverse events', 'Severity of adverse events']","['Incidence of clinical lab abnormalities (hematology, chemistry, liver function tests, coagulation, urinalysis)', 'Severity of clinical lab abnormalities (hematology, chemistry, liver function tests, coagulation, urinalysis)', 'Frequency of dose reductions in tucatinib (ONT-380', 'Frequency of dose reductions in capecitabine', 'Plasma concentrations of tucatinib (ONT-380) and metabolite', 'Plasma concentrations of capecitabine and metabolites', 'Objective response rate (ORR)', 'Duration of response', 'Disease control rate', 'Clinical benefit rate (CBR)', 'Progression-free survival (PFS)']",,,,,5,United States,"University of Colorado [Aurora, United States] | Providence Cancer Center [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | MD Anderson Cancer Center [Houston, United States] | Northwest Medical Specialties [Tacoma, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating Tucatinib (ONT-380), which is a new medicine being tested in combination with other treatments for HER2+ metastatic breast cancer.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT02045368,Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R,STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R),COMPLETED,PHASE1,"IGF Oncology, LLC",2014-01-28,2016-09-30,2016-09-30,2014-01-24,2019-08-22,['Maximum Tolerated Dose (MTD)'],"['Adverse Effects', 'Disease Response based on RECIST Criteria']",,,,,1,United States,"University of Illinois at Chicago [Chicago, United States]",2014.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2016.0,9.0,0,Phase 1
NCT02076620,L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours,Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours,COMPLETED,PHASE1,Philogen S.p.A.,2013-01-16,2018-01-25,2018-01-25,2014-03-03,2022-04-04,['Dose limiting toxicity (DLT)'],"['Pharmacokinetics assessment of L19TNFα', 'Human anti-fusion protein antibodies (HAFA) levels', 'Objective response rate (ORR)', 'Median progression free survival (mPFS)', 'Median overall survival (OS)']",,,,,2,Germany; Italy,"Universitätsklinikum Münster [Münster, Germany] | Fondazione IRCCS Istituto Nazionale dei Tumori [Milan, Italy]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,"A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer",COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-05-19,2018-04-17,2018-04-17,2014-03-17,2020-12-17,"['Incidence of Dose limiting toxicities (DLTs) - Phase lb only', 'Progression free survival (PFS) - Phase ll only']","['Safety and Tolerability of the combinations of LEE011 with fulvestrant, LEE011 + BKM120 with fulvestrant and LEE011 + BYL719 with fulvestrant', 'Plasma concentration-time profiles of LEE011, BKM120, BYL719 and fulvestrant.', 'Overall Response Rate (ORR)', 'Duration of Response (DOR)', 'Progression Free Survival (PFS) (phase l only)', 'Overall Survival (OS) - Phase II only']",,,,,11,France; Italy; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,"University of Alabama at Birmingham/ Kirklin Clinic Dept Onc [Birmingham, United States] | Dana Farber Cancer Institute Onc. Dept. [Boston, United States] | Sarah Cannon Research Institute Onc Dept [Nashville, United States] | Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Modena, Italy] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Leicester, United Kingdom]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"LEE011 is being studied in combination with other agents for a specific patient population, indicating it is a new medicine being evaluated for its efficacy in treating advanced breast cancer.",INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02138812,Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,"An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",TERMINATED,PHASE1,Bayer,2014-05-09,2017-04-28,2017-10-02,2014-05-15,2018-10-12,"['Maximum tolerated dose (MTD)', 'Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.', 'Plasma concentration of Paclitaxel characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax']",[],,,,,6,United States," [Santa Monica, United States] |  [New Haven, United States] |  [Boston, United States] |  [Detroit, United States] |  [Nashville, United States] |  [San Antonio, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT02154776,"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.","A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.",COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-06-27,2016-10-26,2016-10-26,2014-06-03,2020-12-19,"['Incidence of dose-limiting toxicities (DLTs)', 'Safety and tolerability of the combination of LEE011, buparlisib, and letrozole']","['Safety and tolerabiity of the combination of LEE011, buparlisib, and letrozole', 'Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles', 'Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles', 'Disease control rate', 'PFS (progression free survival)']",,,,,6,Spain; United States,"University of California at Los Angeles UCLA SC [Los Angeles, United States] | Horizon Oncology Center SC [Lafayette, United States] | Medical University of South Carolina SC [Charleston, United States] | South Texas Accelerated Research Therapeutics SC [San Antonio, United States] | University of Utah / Huntsman Cancer Institute SC-3 [Salt Lake City, United States] | Novartis Investigative Site [Madrid, Spain]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2016.0,9.0,1,Phase 1
NCT02167854,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer","A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2014-06-16,2021-07-07,2021-07-07,2014-06-19,2021-07-09,"['maximum tolerated dose (MTD) of BYL719', 'recommended dose for expansion (RDE)']","['Toxicity will be assessed using the NCI Common Toxicity Criteria, version 4.0, unless otherwise specified. The type, severity, timing and relationship of each adverse event will be documented.']",,,,,6,United States,"Memorial Sloan Kettering at Basking Ridge [Basking Ridge, United States] | Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Commack [Commack, United States] | Memoral Sloan Kettering Westchester [Harrison, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Memorial Sloan Kettering Rockville Centre [Rockville Centre, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves LJM716 and BYL719, which are new investigational drugs being evaluated for safety and tolerability in a specific patient population, indicating a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT02187822,Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases,A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer,TERMINATED,PHASE1,H. Lee Moffitt Cancer Center and Research Institute,2014-10-09,2018-02-20,2018-03-31,2014-07-11,2021-02-04,['Maximum Tolerated Dose (MTD) of TPI 287'],"['Disease Control Rate (DCR)', 'Progression Free Survival (PFS) Rate']",,,,,1,United States,"H. Lee Moffitt Cancer Center and Research Institute [Tampa, United States]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02189174,Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,"A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies",TERMINATED,PHASE1,Novartis Pharmaceuticals,2014-08-07,2015-11-12,2015-11-12,2014-07-14,2021-12-03,"['Incidence of DLT', 'Objective response rate (ORR) as per RECIST v1.1']","['Incidence of Adverse Events (AEs) and Serious Advers Events (SAEs)', 'Severity of AEs and SAEs and dose reductions and interruptions', 'Duration of response (DOR)', 'Progression free survival (PFS)', 'Best overall response (BOR)', 'Plasma concentration and Pharmacokinetics (PK) parameters of CLR457', 'Changes from baseline in glucose metabolism markers (fasting glucose and insulin)', 'Pre- and post- treatment immunohistochemistry of PI3K pathway molecules in newly obtained paired tumor samples']",,,,,7,Canada; Japan; Singapore; Spain; United States,"Massachusetts General Hospital SC-9 [Boston, United States] | Memorial Sloan Kettering SC-4 [New York, United States] | Tennessee Oncology SC [Nashville, United States] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Barcelona, Spain]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2015.0,10.0,1,Phase 1
NCT02216786,A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer,A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Queen Mary University of London,2014-01-16,2021-12-31,2021-12-31,2014-08-15,2024-12-02,['Progression-free survival'],"['Progression-free survival', 'Objective response', 'Average change (%) in tumour size', 'Clinical Benefit (CB)']",,,,,79,France; Georgia; Germany; Hungary; Portugal; Romania; South Korea; Spain; United Kingdom,"ICO Paul Papin [Angers, France] | Institut Sainte Catherine [Avignon, France] | Antoine Lacassagne Centre De Lutte Contre Le Cancer De Nice [Nice, France] | Hospital Center Private Saint-Grégoire [Saint-Grégoire, France] | Centre Paul Strauss [Strasbourg, France] | Clinic Health House [Tbilisi, Georgia] | Institute of Clinical Oncology [Tbilisi, Georgia] | S. Khechinashvili University Clinic [Tbilisi, Georgia] | Tbilisi Cancer Center [Tbilisi, Georgia] | Frauenärztliche Gemeinschaftspraxis - Onkologie [Braunschweig, Germany] | Kliniken Essen-Mitte Senologie [Essen, Germany] | Klinik für Gynäkologie & Geburtshilfe/Brustzentrum [Frankfurt, Germany] | Praxis für interdisziplinäre Onkologie & Hämatologie [Freiburg im Breisgau, Germany] | MediProjekt GbR Hannover [Hannover, Germany] | SLK-Kliniken Heilbronn GmbH [Heilbronn, Germany] | Dokusan GmbH [Herne, Germany] | St. Vincentius Kliniken [Karlsruhe, Germany] | Schwerpunktpraxis Hämatologie / Onkologie MVZ Lahr [Lahr, Germany] | Klinikum Neumarkt [Neumarkt, Germany] | Onkologische Praxis [Oldenburg, Germany] | Praxis für Innere Medizin [Singen, Germany] | MVZ Klinik Dr. Hancken GmbH [Stade, Germany] | Mutterhaus der Borromäerinnen [Trier, Germany] | Schwarzwald Baar Klinikum, Villingen-Schwenningen [Villingen-Schwenningen, Germany] | Uzsoki Street Hospital [Budapest, Hungary] | Bacs-Kiskun County Hospital [Kalocsa, Hungary] | University of Pecs, Institute of Oncology [Pécs, Hungary] | Zala County Szent Rafael Hospital [Zalaegerszeg, Hungary] | Hospital da Luz [Lisbon, Portugal] | Ipo Porto [Porto, Portugal] | Center of Oncology Euroclinic [Bucharest, Romania] | Oncology Center Sf Nectarie [Caracal, Romania] | Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology [Cluj-Napoca, Romania] | Oncology Institute ""Prof. Dr. Ion Chiricuta"" [Cluj-Napoca, Romania] | Oncology Center Oncolab Craiova [Craiova, Romania] | National Cancer Center South Korea [Goyang, South Korea] | Korea University Medical Center Guro Hospital [Seoul, South Korea] | Yonsei University Health System [Seoul, South Korea] | Hospital Universitari Vall D'Hebron [Barcelona, Spain] | Instituto Oncologico Dr. Rosell [Barcelona, Spain] | Consorcio Hospitalario Provincial de Castellon [Castelló, Spain] | Cafeteria Hospital San Pedro de Alcantara [Cáceres, Spain] | Hospital Ico Josep Trueta [Girona, Spain] | University Hospital Arnau de Vilanova [Lleida, Spain] | Hospital Clinico Universitario San Carlos [Madrid, Spain] | Hospital Son Llàtzer [Palma, Spain] | Hospital Son Espases [Palma de Mallorca, Spain] | Hospital Universitario de Canarias [San Cristóbal de La Laguna, Spain] | Hospital Universitari Sant Joan de Reus [Tarragona, Spain] | Wansbeck General Hospital [Ashington, United Kingdom] | Princess of Wales Hospital [Bridgend, United Kingdom] | Royal Sussex County Hospital [Brighton, United Kingdom] | Kent and Canterbury Hospital [Canterbury, United Kingdom] | Cumberland Infirmary [Carlisle, United Kingdom] | Broomfield Hospital [Chelmsford, United Kingdom] | University Hospital of North Durham [Durham, United Kingdom] | Calderdale Royal Hospital [Halifax, United Kingdom] | Huddersfield Royal Infirmary [Huddersfield, United Kingdom] | Kidderminster Hospital [Kidderminster, United Kingdom] | Royal Glamorgan Hospital [Llantrisant, United Kingdom] | Queen Mary University of London [London, United Kingdom] | Charring Cross Hospital [London, United Kingdom] | King's College Hospital [London, United Kingdom] | Mount Vernon Hospital [London, United Kingdom] | Queen Elizabeth Hospital, Woolwich [London, United Kingdom] | Saint Bartholomew's Hospital [London, United Kingdom] | The Royal Free Hospital [London, United Kingdom] | The Kent Oncology Centre [Maidstone, United Kingdom] | North Tyneside General Hospital [North Shields, United Kingdom] | Nottingham City Hospital [Nottingham, United Kingdom] | Derriford Hospital [Plymouth, United Kingdom] | Weston Park Hospital [Sheffield, United Kingdom] | Solihull Hospital [Solihull, United Kingdom] | Southend University Hospital [Southend-on-Sea, United Kingdom] | Royal Stoke University Hospital [Stoke-on-Trent, United Kingdom] | King's Mill Hospital [Sutton in Ashfield, United Kingdom] | Great Western Hospital [Swindon, United Kingdom] | Wrexham Maelor [Wrexham, United Kingdom] | Yeovil District Hospital [Yeovil, United Kingdom]",2014.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves AZD2014, which is a dual mTOR inhibitor being tested in combination with Fulvestrant for the treatment of metastatic or advanced breast cancer, indicating it is a new medicine.",OTHER,False,2021.0,4.0,1,Phase 2
NCT02219789,Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer,COMPLETED,PHASE1,Mayo Clinic,2014-12-05,2016-03-28,2018-10-01,2014-08-19,2018-10-03,['Maximum tolerated dose (MTD) of alisertib in combination with fulvestrant graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0'],['Tumor response (complete or partial response) using Response Evaluation Criteria in Solid Tumors version 1.1'],,,,,1,United States,"Mayo Clinic [Rochester, United States]",2014.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02248090,AZD9496 First Time in Patients Ascending Dose Study,"Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer",COMPLETED,PHASE1,AstraZeneca,2014-10-22,2017-01-31,2019-04-03,2014-09-25,2019-06-24,['Safety and tolerability'],"['Single and multiple dose pharmacokinetics of AZD9496', '4β-hydroxycholesterol concentration in blood', 'Antitumour activity']",,,,,6,South Korea; United Kingdom; United States,"Florida Cancer Specialists [Sarasota, United States] | Research Site [New York, United States] | Sarah Cannon [Nashville, United States] | Seoul National Univ. Hospital [Seoul, South Korea] | Research Site [Cambridge, United Kingdom] | Christie [Manchester, United Kingdom]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02250118,Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer,Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer,TERMINATED,PHASE1,Institut Curie,2014-12-09,2017-04-12,2017-10-17,2014-09-26,2017-11-06,['To determine the maximum tolerated dose (MTD)'],"['Study of the pleural and serum pharmacokinetics', 'Study of pleural and serum Vascular Endothelial Growth Factor (VEGF) levels', 'Determination of time until new punction or death', 'Total number of pleural drainage procedures', 'Drainage-free survival and overall survival', 'Evaluation of dyspnoea', 'Evaluation of quality of life']",,,,,1,France,"Institut Curie - Hôpital René Huguenin [Saint-Cloud, France]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2017.0,8.0,0,Phase 1
NCT02309177,"Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer","A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-pacitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-paclitaxel/Carboplatin in Stage Iiib/iv Non-small Cell Lung Cancer or Nab-paclitaxel in Metastastic Breast Cancer",COMPLETED,PHASE1,Celgene,2015-01-12,2018-09-12,2018-09-12,2014-12-05,2019-05-31,"['Evaluate Dose Limiting Toxicity (DLT) of each combination regimen', 'Evaluate the safety of the nab-paclitaxel/nivolumab combination regimens', 'Grade 3 or 4 TEAE']","['Treatment Emergent Adverse Events', 'Progression-free survival', 'Overall Survival', 'Disease Control Rate', 'Overall Response Rate', 'Duration of Response']",,,,,15,United States,"UC Davis Cancer Center [Sacramento, United States] | University of California Los Angeles [Santa Monica, United States] | Yale Cancer Center [New Haven, United States] | H. Lee Moffitt Cancer Center and Research Institute University of South Florida [Tampa, United States] | Northwestern University-NMDTI [Chicago, United States] | Dana-Farber / Harvard Cancer Institute [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | John Theurer Cancer Center at Hackensack University Medical Center [Hackensack, United States] | Regional Care Cancer Centers NJ [Morristown, United States] | Levine Cancer Institute [Charlotte, United States] | Oncology Hematology Care, Inc. [Cincinnati, United States] | Ohio State Medical Center [Columbus, United States] | University of Pennslyvania [Philadelphia, United States] | Seattle Cancer Center Alliance [Seattle, United States] | Medical College of Wisconsin [Milwaukee, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT02316509,A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,"An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",COMPLETED,PHASE1,"Genentech, Inc.",2015-03-17,2020-01-10,2020-01-10,2014-12-15,2020-10-05,"['Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of GDC-0927', 'Percentage of Participants With Adverse Events (AEs)']","['Percentage of Participants With Objective Response Assessed by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)', 'Percentage of Participants With Clinical Benefit Assessed by RECIST v1.1', 'Part I: Maximum Observed Plasma Concentration (Cmax) of GDC-0927', 'Part II: Cmax of GDC-0927', 'Part I: Time to Reach Cmax (Tmax) of GDC-0927', 'Part II: Tmax of GDC-0927', 'Part I: Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0927', 'Part II: AUC of GDC-0927', 'Plasma Half-Life (t1/2) of GDC-0927', 'Part II: t1/2 of GDC-0927', ""Part I: Change From Baseline in Corrected QT (QTc) Interval Using Fridericia's Formula, as Assessed by Electrocardiogram (ECG)"", ""Part II: Change From Baseline in QTc Interval Using Fridericia's Formula, as Assessed by ECG"", 'Part I: Change From Baseline in RR Interval, as Assessed by ECG', 'Part II: Change From Baseline in RR Interval, as Assessed by ECG']",,,,,13,Spain; United States,"Massachusetts General Hospital. [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Sarah Cannon Cancer Center [Germantown, United States] | Vanderbilt Ingram Cancer Ctr [Nashville, United States] | ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO [L'Hospitalet de Llobregat, Spain] | Onkologikoa - Kutxaren Institutu Onkologikoa [Donostia / San Sebastian, Spain] | Hospital Univ Vall d'Hebron; Servicio de Oncologia [Barcelona, Spain] | MD Anderson Cancer Center Madrid - España; Servicio de Farmacia [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital General Universitario Gregorio Maranon [Madrid, Spain] | HM Sanchinarro - CIOCC [Madrid, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT02338245,Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab,Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy,COMPLETED,PHASE2,ASLAN Pharmaceuticals,2014-12-29,2016-05-19,2016-08-25,2015-01-14,2017-10-17,"['To compare the efficacy of ASLAN001 in combination with capecitabine, to lapatinib in combination with capecitabine in the percentage change from baseline tumor size at Week 12']","['Safety for all metastatic breast cancer (MBC) subjects (Physical examination, body weight, vital signs, ECG parameter, hematology, clinical laboratory tests and Adverse Events)', 'To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by PFS and tumor volume', 'To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by the Objective Response Rate (ORR), Duration of Response (DoR), and Overall Survival (OS)']",,,,,19,Australia; Hong Kong; New Zealand; Philippines; Singapore; South Korea; Taiwan,"Australia [Western Australia, Australia] | Hong Kong [Hong Kong, Hong Kong] | New Zealand [Christchurch, New Zealand] | New Zealand [Tauranga, New Zealand] | Philippines [Bacolod City, Philippines] | Philippines [Dasmariñas, Philippines] | Singapore [Singapore, Singapore] | Singapore [Singapore, Singapore] | South Korea [Seoul, South Korea] | South Korea [Seoul, South Korea] | South Korea [Seoul, South Korea] | South Korea [Seoul, South Korea] | Taiwan [Linkou District, Taiwan] | Taiwan [Kaohsiung City, Taiwan] | Taiwan [Taichung, Taiwan] | Taiwan [Taipei, Taiwan] | Taiwan [Taipei, Taiwan] | Taiwan [Taipei, Taiwan] | Taiwan [Taipei, Taiwan]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"ASLAN001 is being studied as a new treatment option in combination with capecitabine for metastatic breast cancer (MBC), indicating it is a new medicine.",OTHER,False,2016.0,9.0,1,Phase 2
NCT02348320,Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,COMPLETED,PHASE1,Washington University School of Medicine,2015-06-17,2020-03-12,2020-03-12,2015-01-28,2020-07-01,"['Safety of the personalized polyepitope DNA vaccine strategy, measured by both clinical observation and laboratory evaluation']","['Immunogenicity of the personalized polyepitope DNA vaccine strategy, measured by ELISPOT analysis, a surrogate for CD8 T cell function, and multiparametric flow cytometry']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2015.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a personalized polyepitope DNA vaccine strategy, which indicates the development of a new therapeutic approach for breast cancer patients.",OTHER,False,2020.0,5.0,0,Phase 1
NCT02358200,Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,"Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer",TERMINATED,PHASE1,Pamela Munster,2015-02-23,2019-01-08,2019-01-08,2015-02-06,2020-01-10,['Overall Response Rate (ORR)'],['Intolerable Toxicity'],,,,,1,United States,"University of California San Francisco [San Francisco, United States]",2015.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT02365662,A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,TERMINATED,PHASE1,AbbVie,2015-01-09,2018-03-15,2018-03-15,2015-02-19,2018-03-30,"['Number of participants with adverse events', 'Maximum Plasma Concentration (Cmax) of ABBV-221', 'Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221', 'Maximum tolerated dose of ABBV-221', 'Area Under the Plasma Concentration-time Curve of ABBV-221', 'Recommended Phase 2 dose of ABBV-221']","['Assess the effect of systemic ABBV-221 administration on QT prolongation', 'Objective Response Rate (ORR)']",,,,,5,Spain; United States,"Massachusetts General Hospital [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Fundacion Jimenez Diaz [Madrid, Spain] | Hosp Univ Madrid Sanchinarro [Madrid, Spain]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02366949,Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,"An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",COMPLETED,PHASE1,Bayer,2015-02-27,2018-03-30,2019-04-18,2015-02-19,2020-04-07,"['Maximum tolerated dose (MTD)', 'Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.', 'Maximum observed drug concentration (Cmax) of BAY1217389 in plasma', 'Area under the concentration versus time curve from zero to 12 hours (AUC [0-12]) of BAY1217389 in plasma', 'Area under the concentration versus time curve from zero to 96 hours (AUC [0-96]) of BAY1217389 in plasma', 'Maximum observed drug concentration (Cmax) of paclitaxel in plasma', 'Area under the concentration versus time curve from zero to infinity (AUC) of paclitaxel in plasma']",[],,,,,7,Netherlands; United States," [Santa Monica, United States] |  [Denver, United States] |  [New Haven, United States] |  [Hackensack, United States] |  [Houston, United States] |  [San Antonio, United States] |  [Rotterdam, Netherlands]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02375958,PCA062 in pCAD-positive Tumors.,"A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors",COMPLETED,PHASE1,Novartis Pharmaceuticals,2015-04-15,2018-07-17,2018-07-17,2015-03-03,2020-12-19,['Incidence rate of dose limiting toxicities'],"['Incidence and severity of serious/adverse events', 'Pharmacokinetic parameter Cmax', 'Presence of PCA062 anti-bodies', 'Overall response rate', 'Duration of response', 'Progression free survival', 'Disease control rate', 'Best overall response', 'Pharmacokinetic paramater Tmax']",,,,,7,France; Italy; Japan; Singapore; Spain; United States,"Novartis Investigative Site [Houston, United States] | Novartis Investigative Site [San Antonio, United States] | Novartis Investigative Site [Villejuif, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Koto Ku, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Madrid, Spain]",2015.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on PCA062, which is being tested in a new patient population (p-CAD positive tumors), indicating it is a new medicine.",INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02384746,Phase I Study of the Combination of MLN9708 and Fulvestrant,Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer,TERMINATED,PHASE1,Dartmouth-Hitchcock Medical Center,2015-06-02,2018-04-12,2018-06-10,2015-03-10,2019-04-29,['Number of participants with adverse events prior to commencing a second cycle of treatment.'],['Time to Disease Progression'],,,,,1,United States,"Dartmouth-Hitchcock Medical Center [Lebanon, United States]",2015.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"[""Time to Progression""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02390427,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,COMPLETED,PHASE1,"Otto Metzger, MD",2015-04-20,2022-12,2024-07,2015-03-17,2024-10-02,['Maximum Tolerated Dose (MTD) of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.'],"['Clinical Benefit Rate (CBR) for efficacy of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.', 'Progression Free Survival (PFS) for efficacy of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.', 'Overall Survival for efficacy of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.', 'Occurrence of AEs and SAEs during treatment with Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.', 'Occurrence of dose delays or holds', 'Occurrence of dose reductions', 'Dose Limiting Toxicity of Taselisib in combination with anti-HER2 therapy(ies) and/or paclitaxel.']",,,,,3,United States,"Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Sarah Cannon Research Institute [Nashville, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating Taselisib (GDC-0032), which is a new medicine being tested in combination with existing therapies for advanced HER2+ breast cancer.",OTHER,False,2024.0,1.0,0,Phase 1
NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer,COMPLETED,PHASE1,AbbVie,2015-04-14,2019-07-05,2019-07-05,2015-03-18,2019-11-29,"['Maximum Tolerated Dose of ABBV-075', 'Time to Cmax (peak time, Tmax) for ABBV-075', 'Number of participants with adverse events', 'Maximum observed plasma concentration (Cmax) of ABBV-075', 'Area under the curve (AUC)']","['Duration of overall response (DOR)', 'Objective Response Rate (ORR)', 'Progression Free Survival (PFS)']",,,,,10,United States,"Scottsdale Healthcare /ID# 132963 [Scottsdale, United States] | City of Hope /ID# 154053 [Duarte, United States] | UC Davis Comp Cancer Ctr /ID# 154644 [Sacramento, United States] | Yale University /ID# 136982 [New Haven, United States] | University of Chicago /ID# 155453 [Chicago, United States] | Indiana Univ School Medicine /ID# 132946 [Indianapolis, United States] | Duke Univ Med Ctr /ID# 154647 [Durham, United States] | Mary Crowley Cancer Research /ID# 154059 [Dallas, United States] | Univ TX, MD Anderson /ID# 132276 [Houston, United States] | UT MD Anderson Cancer Center /ID# 164122 [Houston, United States]",2015.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02419495,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies,TERMINATED,PHASE1,M.D. Anderson Cancer Center,2015-06-26,2024-09-16,2024-09-16,2015-04-17,2025-06-04,['Incidence of adverse events'],"['Disease control rate (complete response, partial response + stable disease for at least 6 months', 'Objective tumor response rate (complete response + partial response)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Incidence of adverse events']",,,,,5,United States,"MD Anderson in The Woodlands [Conroe, United States] | M D Anderson Cancer Center [Houston, United States] | MD Anderson West Houston [Houston, United States] | MD Anderson League City [League City, United States] | MD Anderson in Sugar Land [Sugar Land, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating Selinexor (KPT-330), which is a new medicine being tested in combination with standard treatments for advanced malignancies.",OTHER,False,2024.0,1.0,0,Phase 1
NCT02423603,PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer,"A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (PAKT).",COMPLETED,PHASE2,Queen Mary University of London,2014-05-14,2017-06-30,2024-06-30,2015-04-22,2025-03-10,['Progression-free survival'],[],,,,,46,France; Georgia; Hungary; Romania; South Korea; United Kingdom,"ICO René Gauducheau [Nantes, France] | Centre André-lacassagne [Nice, France] | Centre Hospitalier Prive Saint-Gregoire [Saint-Grégoire, France] | Institute of Clinical Oncology [Tbilisi, Georgia] | Országos Onkológiai Intézet [Budapest, Hungary] | University of Pécs - Clinical Center Institute of Oncotherapy [Pécs, Hungary] | Zala County Hospital Szent Rafael [Zalaegerszeg, Hungary] | Prof. Dr. I. Chiricuta Oncology Institute [Cluj-Napoca, Romania] | Sf. Nectarie SRL Oncologie Medical Center [Craiova, Romania] | Center of Oncology Euroclinic [Iași, Romania] | Chungbuk National University Hospital [Cheongju-si, South Korea] | National Cancer Center [Goyang-si, South Korea] | Asan Medical Center [Seoul, South Korea] | Korea University Guro Hospital [Seoul, South Korea] | Samsung Medical Centre [Seoul, South Korea] | Yonsei University Health System [Seoul, South Korea] | Betsi Cadwaladr University Health Board [Bangor, United Kingdom] | Belfast Health and Social Care Trust [Belfast, United Kingdom] | Glan Clwyd Hospital BCU Health Board NHS Wales [Bodelwyddan, United Kingdom] | Brighton and Sussex University Hospitals NHS Trust [Brighton, United Kingdom] | Cambridge University Hospitals NHS Foundation Trust [Cambridge, United Kingdom] | East Kent Hospitals University NHS Foundation Trust [Canterbury, United Kingdom] | Velindre Cancer Centre [Cardiff, United Kingdom] | University Hospitals Coventry and Warwickshire NHs Trust [Coventry, United Kingdom] | NHS Lothian [Edinburgh, United Kingdom] | Medway NHS Foundation Trust [Gillingham, United Kingdom] | Beatson West of Scotland Cancer Centre [Glasgow, United Kingdom] | Leeds Teaching Hospitals NHs Trust [Leeds, United Kingdom] | Barts Health NHS Trust [London, United Kingdom] | University College London Hospitals [London, United Kingdom] | Barking, Havering and Redbridge University Hospitals NHS Trust [London, United Kingdom] | Guys and St Thomas' NHS Foundation Trust [London, United Kingdom] | Lewisham and Greenwich NHS Trust [London, United Kingdom] | Royal Marsden NHS Foundation Trust-Fulham [London, United Kingdom] | Imperial College Healthcare NHS Trust [London, United Kingdom] | Maidstone and Tunbridge Wells NHS Trust [Maidstone, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom] | Nottingham University Hospitals NHS Trust [Nottingham, United Kingdom] | Southampton University Hospitals NHS Trust [Southampton, United Kingdom] | Southend University Hospital NHS Foundation Trust [Southend, United Kingdom] | University Hospital of North Staffordshire NHS Trust [Stoke-on-Trent, United Kingdom] | Royal Marsden - Sutton [Sutton, United Kingdom] | Abertawe Bro Margannwg University Health Board [Swansea, United Kingdom] | Royal Cornwall Hospitals NHS Trust [Truro, United Kingdom] | Ysbyty Wrexham Maelor Hospital [Wrexham, United Kingdom] | Yeovil District Hospital NHS Foundation Trust [Yeovil, United Kingdom]",2014.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves AZD5363, an AKT inhibitor, which is being tested in combination with Paclitaxel for a specific type of cancer (triple-negative advanced or metastatic breast cancer). This indicates the investigation of a new medicine.",OTHER,False,2024.0,1.0,1,Phase 2
NCT02432950,Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer,PANCREATIC NUTRITIONAL PROGRAM (PNP): A Novel Weight Reduction Program in Overweight/Obese Breast Cancer Survivors,COMPLETED,,City of Hope Medical Center,2016-01-07,2018-01-15,2022-12-19,2015-05-04,2023-03-21,['Change in body weight'],"['Change in body chemistry (lipid panel; comprehensive metabolic panel; complete blood count; fasting blood glucose; insulin resistance)', 'Change in body composition (BMI)', 'Change in physical fitness (measured using a handgrip dynamometer)', 'Change in quality of life score (FACT-B+4)', 'Change in serum inflammatory markers (C-reactive protein; cytokines)', 'Compliance metrics (days glucometer sensor not utilized; days body weight not recorded; days journal entries not made; days meal cards not created; weekly counseling sessions missed)', ""DNA repair capacity (comet assay's mean olive tail moment; number of gamma-H2A histone family, member X foci)"", 'Incidence of adverse events reported as possibly or definitely related to wearing the glucometer sensor following the PNP diet']",,,,,1,United States,"City of Hope Medical Center [Duarte, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT02462200,Shave Margins in Breast Conservation Therapy,Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial,TERMINATED,PHASE2,Washington University School of Medicine,2016-06-13,2019-11-27,2019-11-27,2015-06-03,2020-06-25,"['Proportion of patients with positive margins on pathological specimen analysis', 'Patient perceptions of the surgery as measured by BREAST-Q questionnaire and novel 3-dimensional breast imaging', 'Compare intraoperative NIR fluorescence from goggle system with pathologic tissue exam results']","['Relationship between CSM and volume of tissue excised in association iwth post-operative aesthetic outcomes', 'Cost-effectiveness of routine CSM in BCS as measured by operative time, specimen processing, and resource usage', 'Disease status associated with cancer biomarkers', 'Tumor characteristics associated with cancer biomarkers']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT02474173,Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,"Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer",TERMINATED,PHASE1,National Cancer Institute (NCI),2016-01-15,2022-10-26,2022-10-26,2015-06-17,2022-11-04,"['Recommended phase 2 dose (R2PD)', 'Toxicity profile of onalespib in combination with paclitaxel']","['Pharmacokinetic (PK) parameters of onalespib', 'Pharmacokinetic (PK) parameters of paclitaxel', 'Overall response rate (partial response [PR]+ complete response [CR])', 'Response duration', 'Progression-free survival']",,,,,4,United States,"University of Kentucky/Markey Cancer Center [Lexington, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | University of Pittsburgh Cancer Institute (UPCI) [Pittsburgh, United States]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Onalespib, which is identified as a new HSP90 inhibitor being tested in combination with Paclitaxel for a specific cancer type, indicating it is a new medicine.",NIH,False,2022.0,3.0,0,Phase 1
NCT02476539,Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer,"An Ascending Single and Multiple Dose Study of the Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022 in Patients With HER2-Positive Advanced Breast Cancer",COMPLETED,PHASE1,"Tianjin Hemay Pharmaceutical Co., Ltd",2015-10-14,2023-09-30,2023-09-30,2015-06-19,2024-03-01,"['Number of participants with adverse events', 'Observed maximum concentration of Hemay022', 'Time of maximum concentration of Hemay022', 'Area under the plasma concentration versus time curve of Hemay022', 'Trough Plasma Concentrations of Hemay022', 'Predose plasma concentration']","['Disease control rate (complete response rate + partial response rate + stable disease rate) according to RECIST v1.1', 'Objective response rate (complete response rate + partial response rate) according to RECIST v1.1']",,,,,1,China,"Cancer Hospital, Chinese Academy of Medical Sciences [Beijing, China]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The study evaluates Hemay022, an irreversible epidermal growth factor receptor inhibitor, in patients with HER2-positive advanced breast cancer, indicating it is a new medicine being tested for this specific indication.",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT02476955,Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole,An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors,TERMINATED,PHASE1,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",2015-06-09,2019-05-07,2019-05-07,2015-06-22,2020-09-30,"['Number of treatment emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03', 'Overall Response Rate (ORR) based on central review of tumor measurement using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1', 'Progression Free Survival (PFS) based on central review of tumor measurement using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1', 'Duration of Response (DoR) based on central review of tumor measurement']","['Peak plasma concentration (Cmax)', 'Area under the plasma concentration vs. time curve (AUC)', 'Half-life of ARQ 092']",,,,,5,United States," [Grand Rapids, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University of Oklahoma Health Sciences Center [Oklahoma City, United States] | MD Anderson Cancer Center [Houston, United States] |  [San Antonio, United States]",2015.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[""Duration of Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves ARQ 092, which is being tested in combination with other agents for selected solid tumors, indicating it is a new medicine being evaluated for efficacy and safety.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02482311,"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours",COMPLETED,PHASE1,AstraZeneca,2015-07-01,2018-01-25,2019-08-22,2015-06-26,2023-07-03,"['Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) as a measure of safety and tolerability.']","['Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Response (DoR)', 'Progression Free Survival (PFS)', 'PK profile: Plasma concentrations of AZD1775 and PK parameters (Cmax, C8hr, tmax, AUC, tlast, t½λz)', 'QTc prolongation']",,,,,16,Canada; United States,"Research Site [Fayetteville, United States] | Research Site [San Francisco, United States] | Research Site [West Hollywood, United States] | Research Site [Fort Myers, United States] | Research Site [Indianapolis, United States] | Research Site [Detroit, United States] | Research Site [Charlotte, United States] | Research Site [Oklahoma City, United States] | Research Site [Philadelphia, United States] | Research Site [Greenville, United States] | Research Site [Nashville, United States] | Research Site [Houston, United States] | Research Site [Milwaukee, United States] | Research Site [Edmonton, Canada] | Research Site [Vancouver, Canada] | Research Site [Toronto, Canada]",2015.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing AZD1775 monotherapy in patients with advanced solid tumours, indicating it is a new medicine being evaluated for its safety and efficacy.",INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02485119,Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies,"An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies",COMPLETED,PHASE1,Bayer,2015-08-14,2017-04-28,2017-07-04,2015-06-30,2018-06-04,"['Number of Treatment-emergent Adverse Events (TEAEs) as a measure of safety and tolerability', 'Intensity of TEAEs acc. to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.03', 'Cmax (maximum drug concentration in plasma after single dose administration ) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'Cmax,norm (Cmax divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'Cmax/D (Cmax divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'AUC(0-tlast) (area under the plasma concentration vs time curve from time 0 to the last data point) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'AUC(0-tlast)norm (AUC(0-tlast) divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'AUC(0-tlast)/D (AUC(0-tlast) divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me']","['Tumor response based on RECIST (Response Evaluation Criteria in Solid Tumors)', 'Level of mesothelin expression using IHC (Immunohistochemistry) staining for the tumor tissue obtained from fresh or archival tumor tissue', 'Plasma levels of soluble mesothelin', 'Immunogenicity evaluation based on anti-BAY94-9343 antibody count']",,,,,2,Japan,"National Cancer Center Hospital East [Kashiwa, Japan] | National Cancer Center Hospital [Tyuo, Japan]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT02506556,Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer,"A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.",COMPLETED,PHASE2,"Peter MacCallum Cancer Centre, Australia",2015-09-07,2021-10-26,2021-10-26,2015-07-23,2022-08-16,['Objective response rate'],"['Clinical Benefit Rate', 'Progression free survival', 'Safety and tolerability of BYL719']",,,,,1,Australia,"Peter MacCallum Cancer Centre [East Melbourne, Australia]",2015.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing BYL719, a selective PI3K Alpha inhibitor, in a new patient population (advanced breast cancer) and does not indicate it is an extension of an existing indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02521441,"A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.","A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiving Myelotoxic Chemotherapy.",COMPLETED,PHASE2,EVIVE Biotechnology,2014-07-03,2015-09-20,2015-12-22,2015-08-13,2018-02-23,"['The duration of moderate or severe (grade 3 and 4, respectively) neutropenia']","['The incidence rates of Grade 3 and Grade 4 neutropenia', 'The duration in days of Grade 3 and Grade 4 neutropenia for cycle 2 to 4.', 'The incidence rates of febrile neutropenia', 'The depth of the ANC nadir', 'Number of participants with adverse events, changes from baseline of laboratory']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2014.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a new medicine (F-627) in patients with breast cancer, indicating it is a new treatment being tested.",INDUSTRY,False,2015.0,10.0,0,Phase 2
NCT02522234,A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,"A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of F-627 as Prophylaxis Therapy to TAC Chemotherapy in Women With Breast Cancer",COMPLETED,PHASE1; PHASE2,EVIVE Biotechnology,2014-02-25,2015-08-19,2015-08-19,2015-08-13,2019-11-21,['Number of participants with adverse events/abnormal laboratory value as measure of safety'],"['Parameter of Peak Plasma Concentration', 'Parameter of Area Under Plasma Concentration versus Time Curve', 'Parameter of Clearance', 'Absolute Neutrophil Count changes over time']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2014.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing a new drug (F-627) in a specific patient population (women with breast cancer) and is focused on its safety and pharmacokinetics, indicating it is a new medicine.",INDUSTRY,False,2015.0,10.0,0,Phase 2
NCT02565758,"ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors","A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,AbbVie,2015-09-18,2019-03-25,2019-03-25,2015-10-01,2019-04-05,"['Terminal elimination half life of ABBV-085.', 'Maximum observed plasma concentration (Cmax) of ABBV-085.', 'Number of participants with Adverse Events', 'Area under the curve (AUC) from time zero to the last measurable concentration AUC(0-t) of ABBV-085.']","['Objective response rate (ORR)', 'Progression free survival (PFS)', 'Duration of overall response (DOR)']",,,,,20,France; Spain; United States,"Mayo Clinic Arizona /ID# 148582 [Phoenix, United States] | Scottsdale Healthcare /ID# 151349 [Scottsdale, United States] | University of California, Los Angeles /ID# 148586 [Los Angeles, United States] | Univ of Colorado Cancer Center /ID# 148581 [Aurora, United States] | University of Chicago /ID# 148579 [Chicago, United States] | Dana-Farber Cancer Institute /ID# 143782 [Boston, United States] | Washington University-School of Medicine /ID# 151348 [St Louis, United States] | NYU Langone Medical Center /ID# 150786 [New York, United States] | Duke Univ Med Ctr /ID# 148200 [Durham, United States] | Carolina BioOncology Institute /ID# 148583 [Huntersville, United States] | University of Pennsylvania /ID# 148576 [Philadelphia, United States] | Greenville Hospital System /ID# 148652 [Greenville, United States] | Mary Crowley Cancer Research /ID# 148580 [Dallas, United States] | Univ TX, MD Anderson /ID# 147681 [Houston, United States] | South Texas Accelerated Research Therapeutics /ID# 141715 [San Antonio, United States] | Virginia Cancer Specialists /ID# 148584 [Fairfax, United States] | Gustave Roussy /ID# 150300 [Villejuif, France] | Hospital Univ Ramon y Cajal /ID# 150799 [Madrid, Spain] | Fundacion Jimenez Diaz /ID# 148564 [Madrid, Spain] | Hosp Univ Madrid Sanchinarro /ID# 146039 [Madrid, Spain]",2015.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[""Duration of Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02576548,A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.,"A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors",COMPLETED,PHASE1,MedImmune LLC,2015-09-23,2018-05-23,2018-05-23,2015-10-15,2019-06-18,"['Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).']","['Objective Response Rate (ORR)', 'Peak Plasma Concentration (Cmax)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Area under the plasma concentration versus time curve (AUC)']",,,,,5,United States,"Research Site [Stanford, United States] | Research Site [Sarasota, United States] | Research Site [Indianapolis, United States] | Research Site [Charlotte, United States] | Research Site [Nashville, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating MEDI4276, which appears to be a new drug being tested in a specific patient population (adults with HER2-expressing advanced solid tumors), indicating it is a New Medicine.",INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT02586987,"A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours","A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",COMPLETED,PHASE1,AstraZeneca,2015-12-28,2018-07-25,2019-09-20,2015-10-27,2019-11-18,"['Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of safety laboratory tests', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of blood pressure (BP)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Electrocardiogram (ECG)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of physical examinations', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Echocardiogram (ECHO)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of pulse', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of body temperature', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of respiratory rate', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Multigated Acquisition (MUGA)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (best corrected visual acuity)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (Intraocular pressure)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)']","['Long-term tolerated dose and exposure predicted to result in biological activity (including but not limited to Response Evaluation Criteria in Solid Tumours (RECIST)', 'Objective response rate (ORR)', 'Change in tumour size', 'Best Objective Response (BoR)', 'Duration of Response (DoR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma']",,,,,6,United States,"Research Site [Chicago, United States] | Research Site [Boston, United States] | Research Site [Las Vegas, United States] | Research Site [New Brunswick, United States] | Research Site [Charlotte, United States] | Research Site [Pittsburgh, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02594371,"Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer","An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer",COMPLETED,PHASE3,"Athenex, Inc.",2015-12-02,2019-07-25,2022-06-30,2015-11-03,2022-08-03,"['Tumor response as determined by response criteria', 'Safety and tolerability assessments of Oraxol compared with IV paclitaxel, as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information']","['Progression-free survival (PFS)', 'Overall survival (OS)']",,,,,45,Argentina; Chile; Colombia; Dominican Republic; Ecuador; El Salvador; Guatemala; Honduras; Panama; Peru,"Centro de Investigacion Pergamino SA [Pergamino, Argentina] | Clinica Universitaria Privada Reina Fabiola [Córdoba, Argentina] | IONC [Córdoba, Argentina] | Centro Oncologico Infinito [Santa Rosa, Argentina] | Fundación Koriza [Santa Rosa, Argentina] | Clinica Viedma [Viedma, Argentina] | CEMEDIC [Buenos Aires, Argentina] | COIBA [Buenos Aires, Argentina] | Fundación Investigar [Buenos Aires, Argentina] | Fundación Centro Oncológico Riojano Integral (CORI) [La Rioja, Argentina] | CAIPO [San Miguel de Tucumán, Argentina] | Centro Medico San Roque [San Miguel de Tucumán, Argentina] | Hospital Provincial del Centenario [Santa Fe, Argentina] | Instituto de Oncologia de Rosario [Santa Fe, Argentina] | Sanatorio Britanico [Santa Fe, Argentina] | Fundación Arturo López Pérez [Santiago, Chile] | Hospital de Referencia de Salud Cordillera Unidad de Patología Mamaria [Santiago, Chile] | Hospital San Borja Arriarán [Santiago, Chile] | IRAM [Santiago, Chile] | Clínica Alemana Temuco [Temuco, Chile] | Instituto Nacional de Cancerología E.S.E. [Bogotá, Colombia] | Fundación Colombiana de Cancerología Clinica Vida [Medellín, Colombia] | Fundación Hospitalaria San Vicente de Paúl [Medellín, Colombia] | Hemato Oncologos S.A. [Valle, Colombia] | Hospital Metropolitano de Santiago (HOMS) [Santiago de los Caballeros, Dominican Republic] | Clinical Research [Santo Domingo, Dominican Republic] | Hospital General de la Plaza de la Salud [Santo Domingo, Dominican Republic] | Hospital SOLCA [Guayaquil, Ecuador] | Hospital Carlos Andrade Martín [Quito, Ecuador] | Hospital SOLCA [Quito, Ecuador] | Espemedic [San Salvador, El Salvador] | Hospital Diagnotico Clinica Oncologica & Cancer Research [San Salvador, El Salvador] | American Cancer Center [Guatemala City, Guatemala] | CELAN Clínica Médica [Guatemala City, Guatemala] | Clinica Privada [Guatemala City, Guatemala] | Clínica Privada [Guatemala City, Guatemala] | Grupo Angeles, S.A. [Guatemala City, Guatemala] | Oncomedica en Guatemala [Guatemala City, Guatemala] | CRESEM [Quetzaltenango, Guatemala] | Excel Medica [Cortés, Honduras] | Tecnología en Investigación [Cortés, Honduras] | Centro Hemato Oncológico Panamá [Panama City, Panama] | Clínica Oncológica Miraflores [Lima, Peru] | Hospital Cayetano Heredia [Lima, Peru] | Hospital Nacional del Arzobispo Loayza [Lima, Peru]",2015.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating Oraxol, which is a new formulation of a drug (Paclitaxel) for the treatment of metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT02598427,Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis,TERMINATED,PHASE1,Kimberly Blackwell,2017-05-01,2018-02-22,2018-02-22,2015-11-05,2018-02-28,"['Safety as measured by adverse events', 'Maximum tolerated dose as measure by dose limiting toxicity']","['Response rate as measured by brain MRI', 'Changes in cell-free circulating tumor DNA (ctDNA) in response to treatment']",,,,,1,United States,"Duke University Medical Center [Durham, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02605083,A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,TERMINATED,PHASE1; PHASE2,Effector Therapeutics,2015-12-03,2019-01-11,2019-03-22,2015-11-16,2020-11-02,"['Maximum tolerated dose (MTD)/Recommended dose (RD)', 'Overall response rate (ORR)']","['Safety (Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v. 4.03))', 'Plasma concentration of eFT508 as characterized by maximum serum concentration (Cmax)', 'Plasma concentration of eFT508 as characterized by Area Under the Curve (AUC)', 'Changes in eIF4E phosphorylation in peripheral blood cells (PBMCs)', 'Tumor control evaluated by modified RECIST criteria v 1.1']",,,,,4,United States,"SCRI at HealthONE [Denver, United States] | Florida Cancer Specialists [Sarasota, United States] | Tennessee Oncology, PLLC [Nashville, United States] | MD Anderson Cancer Center [Houston, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on a new drug (eFT508) being tested in subjects with advanced solid tumors, indicating it is a New Medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 2
NCT02627274,"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)",COMPLETED,PHASE1,Hoffmann-La Roche,2015-12-07,2022-11-10,2022-11-10,2015-12-10,2022-11-22,"['Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'Maximum Tolerated Dose (MTD) of RO6874281', 'Optimal Biological Dose (OBD) of RO6874281', 'Recommended Dose for Further Development of RO6874281', 'Systemic Clearance (CL) of RO6874281', 'Volume of Distribution at Steady State (Vss) of RO6874281', 'Area Under the Concentration-Time Curve (AUC) of RO6874281', 'Maximum Observed Serum Concentration (Cmax) of RO6874281']","['Number of T Cells in the Peripheral Blood', 'Number of Natural Killer (NK) Cells in the Peripheral Blood', 'Density of Cluster of Differentiation (CD)8+ Cells in Tumor Samples', 'Density of CD3-/Perforin+ Cells in Tumor Samples', 'Density of CD20 Cells in Tumor Samples', 'Percentage of Participants With Overall Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)', 'Percentage of Participants With Disease Control According to RECIST v1.1', 'Progression-Free Survival (PFS) According to RECIST v1.1', 'Percentage of Participants With Overall Response According to Modified RECIST', 'Percentage of Participants With Disease Control According to Modified RECIST', 'PFS According to Modified RECIST', 'Percentage of Participants With Overall Response According to iRECIST', 'Percentage of Participants With Disease Control According to iRECIST', 'PFS According to iRECIST']",,,,,26,Belgium; Canada; Denmark; France; Italy; Netherlands; Spain; United Kingdom; United States,"University of Arizona Cancer Center [Tucson, United States] | UCSD - Moores Cancer Center [La Jolla, United States] | Banner MD Anderson Cancer Center [Greeley, United States] | Washington University; Division of Oncology [St Louis, United States] | The Ohio State University [Columbus, United States] | UZ Antwerpen [Edegem, Belgium] | Juravinski Cancer Clinic; Department of Oncology [Hamilton, Canada] | Princess Margaret Cancer Center [Toronto, Canada] | Rigshospitalet; Onkologisk Klinik [København Ø, Denmark] | Institut Bergonie; Oncologie [Bordeaux, France] | Centre Georges Francois Leclerc [Dijon, France] | Centre Leon Berard [Lyon, France] | Institut Claudius Regaud; Departement Oncologie Medicale [Toulouse, France] | Institut Gustave Roussy; Sitep [Villejuif, France] | IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica [Meldola, Italy] | Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo [Milan, Italy] | Istituto Europeo di Oncologia; Svil. Nuovi Farmaci per Terapie Innovative [Milan, Italy] | Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck [Milan, Italy] | Ospedale Policlinico S. Matteo; Phase I Clinical Trial Unit and Experimental Therapy [Pavia, Italy] | Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie [Amsterdam, Netherlands] | Erasmus MC [Rotterdam, Netherlands] | Clinica Universitaria de Navarra [Pamplona, Spain] | Hospital Univ Vall d'Hebron; Servicio de Oncologia [Barcelona, Spain] | Leicester Royal Infirmary [Leicester, United Kingdom] | Guys and St Thomas NHS Foundation Trust, Guys Hospital [London, United Kingdom] | Christie Hospital [Manchester, United Kingdom]",2015.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial evaluates RO6874281, which is described as an immunocytokine targeting Fibroblast Activation Protein-α (FAP), indicating it is a new medicine being tested for safety and efficacy.",INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT02632071,ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer,Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer,COMPLETED,PHASE1,Columbia University,2016-03-01,2020-09-30,2020-09-30,2015-12-16,2021-01-07,['Maximum tolerated dose (MTD) of ACY-1215 (Ricolinostat)'],['Number of adverse events related to ACY-1215 (Ricolinostat)'],,,,,1,United States,"Columbia Irving University Medical Center [New York, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves ACY-1215 (Ricolinostat), which is being tested in combination with Nab-paclitaxel for a specific cancer indication, indicating it is a new medicine being evaluated for efficacy and safety in a new context.",OTHER,False,2020.0,5.0,0,Phase 1
NCT02632448,A Study of LY2880070 in Participants With Advanced or Metastatic Cancer,A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer,COMPLETED,PHASE1; PHASE2,Esperas Pharma Inc.,2016-05-16,2025-04-14,2025-04-14,2015-12-16,2025-05-02,['Maximum Tolerated Dose(s)'],"['Number of dose limiting toxicities (DLTs)', 'Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24)', 'Peak plasma concentration (Cmax)', 'Time to reach maximum plasma concentration (tmax)', 'Change from baseline in white blood cell count', 'Change from baseline in neutrophil count', 'Change from baseline in lymphocyte count', 'Number of participants with tumor response (objective response rate) as measured by the Response Evaluable Criteria in Solid Tumors (RECIST v.1.1)', 'Duration of objective response', 'Best response', 'Progression free survival', 'Overall survival']",,,,,16,Canada; Croatia; Poland; United States,"Dana Farber Cancer Institute [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Tom Baker Cancer Centre [Calgary, Canada] | Cross Cancer Institute [Edmonton, Canada] | BC Cancer Agency [Vancouver, Canada] | Ottawa Hospital Cancer Centre [Ottawa, Canada] | University Health Network - Princess Margaret Hospital [Toronto, Canada] | Centre Hospitalier de l'Université de Montréal [Montreal, Canada] | Jewish General Hospital [Montreal, Canada] | McGill University Health Centre [Montreal, Canada] | General Hospital Zadar [Zadar, Croatia] | University Hospital Centre Zagreb [Zagreb, Croatia] | Centrum Onkologii im. prof. F. Łukaszczyka [Bydgoszcz, Poland] | Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz [Gdansk, Poland] | Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o. [Krakow, Poland] | Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o. [Krakow, Poland]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a study evaluating LY2880070, which indicates it is a new medicine being tested for safety and efficacy in patients with advanced or metastatic cancer.",OTHER,False,2025.0,0.0,1,Phase 2
NCT02635672,Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer,"An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.",COMPLETED,PHASE1,"Vincerx Pharma, Inc.",2016-02-10,2024-11-11,2024-11-11,2015-12-21,2024-11-15,"['Incidence of DLT (Dose limit toxicity) of VIP152 (BAY1251152)', 'Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP152 (BAY1251152)', 'Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP152 (BAY1251152)', 'AUC from time 0 to the last data point > Lower limit of quantitation (LLOQ) [AUC(0-tlast)] of VIP152 (BAY1251152)', 'Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval (Cmax,md) of VIP152 (BAY1251152)', 'AUC from time 0 to the last data point > LLOQ after multiple dosing [AUC(0-tlast)md] of VIP152 (BAY1251152)', 'Recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152)', 'Incidence of DLT (Dose limit toxicity) of VIP152 (BAY1251152) in combination with Keytruda® (pembrolizumab)', 'Recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab)', 'Number of participants with adverse events as a measure safety and tolarability']",['Tumor response evaluation based on the response criteria as applicable (RECIST v1.1 criteria for solid tumors and revised Lugano Classification for aggressive NHL)'],,,,,16,Chile; Spain; United States,"Highlands Oncology Group [Springdale, United States] | Norton Cancer Institute [Louisville, United States] | Maryland Oncology Hematology [Silver Spring, United States] | John Theurer Cancer Center [Hackensack, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University of Cincinnati Medical Center [Cincinnati, United States] | Willamette Valley Cancer Institute [Eugene, United States] | Oregon Health and Science University [Portland, United States] | Avera Health [Sioux Falls, United States] | Sarah Cannon Research Institute [Nashville, United States] | NEXT Oncology [Austin, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States] | Centro de Investigaciones Clínicas Viña del Mar [Viña del Mar, Chile] | Oncocentro [Viña del Mar, Chile] | START Madrid- Fundación Jiménez Diaz [Madrid, Spain]",2016.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT02646748,Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,"A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors",COMPLETED,PHASE1,Incyte Corporation,2016-01-25,2019-11-07,2020-11-20,2016-01-06,2022-03-31,"['Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events']","['Part 1 and 2: Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria', 'Part 1 and 2: Change in the number of Tumor Infiltrating Lymphocytes(TILs) and the ratio of CD8+ lymphocytes to FOXP3+ cells infiltrating tumor post-treatment versus pretreatment by IHC']",,,,,17,United States,"University of California San Francisco Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | John Wayne Cancer Institute at Providence Saint John's Health Center [Santa Monica, United States] | Georgetown University Medical Center Lombardi CCC [Washington D.C., United States] | Hematology-Oncology Associates of Treasure Coast [Port Saint Lucie, United States] | Emory University, Winship Cancer Institute [Atlanta, United States] | University of Kentucky, Markey Cancer Center [Lexington, United States] | The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision) [Bethesda, United States] | Beth Israel Medical Deaconess Medical Center [Boston, United States] | Dana Farber Cancer institute [Boston, United States] | Karmanos Cancer Center [Detroit, United States] | Henry Ford Hospital System [Detroit, United States] | St. Luke's Hospital of Kansas City [Kansas City, United States] | NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone [New York, United States] | Duke Cancer Institute [Durham, United States] | UPMC CancerCenters, Hilman Cancer Center [Pittsburgh, United States] | HOPE Cancer Center of East Texas [Tyler, United States] | Utah Cancer Specialists [Salt Lake City, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a combination of Pembrolizumab with new agents (Itacitinib and INCB050465) in advanced solid tumors, indicating the exploration of a new treatment regimen rather than an extension of indication for an existing medicine.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT02650635,"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors",TERMINATED,PHASE1,Mayo Clinic,2016-02-05,2016-09-26,2017-06-01,2016-01-08,2018-09-05,['Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide'],"[""Duration of response, assessed by irDOR, defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented"", 'Incidence of adverse events of cyclophosphamide and TLR8 agonist VTX-2337, using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0', 'Overall response rate assessed by irBORR', 'Overall survival (OS)', 'PFS as measured by serial imaging studies and assessed by irRECIST']",,,,,1,United States,"Mayo Clinic in Arizona [Scottsdale, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2017.0,8.0,0,Phase 1
NCT02650752,Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2016-01-06,2021-01-22,2021-01-22,2016-01-08,2021-01-26,['maximum tolerated dose (MTD)'],[],,,,,9,United States,"University of Michigan Health System [Ann Arbor, United States] | Memoral Sloan Kettering Cancer Center [Basking Ridge, United States] | Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Cancer Center @ Suffolk [Commack, United States] | Memorial Sloan Kettering Westchester [Harrison, United States] | Queens Cancer Center of Queens Hospital [Jamaica, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Memorial Sloan Kettering at Mercy Medical Center [Rockville Centre, United States] | Memorial Sloan Kettering Nassau [Uniondale, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT02650817,Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer,A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging,COMPLETED,PHASE1,"Stemline Therapeutics, Inc.",2016-04-01,2018-08-30,2019-10-18,2016-01-08,2022-08-18,['Effect of ER Binding after RAD1901 treatment'],"['Correlation of FES uptake after RAD1901 treatment to clinical response', 'Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines', 'Safety and Tolerability assessed in terms of adverse events, serious adverse events, ECG, physical examination, ECOG performance status, vital signs, and laboratory values', 'Plasma concentrations of RAD1901 will be assessed at predefined intervals']",,,,,5,Belgium; Netherlands,"Institut Jules Bordet [Brussels, Belgium] | UZ Leuven Campus Gasthuisberg [Leuven, Belgium] | Vrije Universiteit Medisch Centrum (VUMC) [Amsterdam, Netherlands] | Universitair Medisch Centrum Groningen (UMCG) [Groningen, Netherlands] | Erasmus Medical Center [Rotterdam, Netherlands]",2016.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a Phase IB study evaluating RAD1901, indicating it is a new medicine being tested for its effects on metastatic breast cancer.",INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02718144,Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,A Phase I/II Clinical Trial Assessing Safety and Efficacy of Estetrol (E4) in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,COMPLETED,PHASE1; PHASE2,Pantarhei Oncology B.V.,2017-06-01,2019-12-31,2019-12-31,2016-03-24,2021-06-18,['The number of patients with a dose limiting toxicity (DLT)'],"['Questionnaire on estrogen deficiency symptoms', 'Pharmacokinetics: estetrol trough levels', 'Preliminary anti-tumour response according to RECIST 1.1']",,,,,2,Germany,"Katholisches Klinikum Mainz [Mainz, Germany] | Universitatsmedizin Mainz [Mainz, Germany]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT02723877,PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO),"An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR309 and Eribulin Combination in Patients With Locally Advanced or Metastatic HER2 Negative and Triple-Negative Breast Cancer",COMPLETED,PHASE1; PHASE2,PIQUR Therapeutics AG,2016-03-28,2018-10-03,2018-10-03,2016-03-31,2019-03-22,"['Number of patients with treatment related Adverse Events and Serious Adverse Events as assessed by NCI CTCAEV4.03', 'RECIST the Response criteria for solid tumors will be used to identify clinical benefit rate (CBR) including complete Response (CR), partial Response (PR) and stable disease (SD)']","['Number of patients with Adverse Events and Serious Adverse Events and number of anormal laboratory values that constitute an Adverse Events on their own', 'Number and percent of patients having each ECOG (Eastern Oncology Cooperative Group) performance status level will be presented for baseline and each post-baseline measurement.', 'Assessment of PQR309 and Eribulin blood concentration', 'Physical examination, Body weight in kg', 'Physical examination, ECG', 'Vital signs like heart rate', 'Vital signs like blood pressure', 'Vital signs like body temperature', 'Objective Response Rate (ORR), is defined as the best overall response (confirmed CR or PR) recorded for each patient since baseline.', 'Time to Response (TTR) is defined, for patients with tumor response, as the time from the date of study entry to the first documentation of response (complete or partial)', 'Duration of response (DOR) is defined, for the patients with tumor response, as the time from the date of the first confirmed response to disease progression.', 'Progression- free survival (PFS) is defined as the time from study entry to progression or death due to any cause', 'Time to treatment failure (TTF) is defined as the time from study entry to any treatment failure including disease progression or discontinuation of treatment', '1-year survival, defined as the time from study entry to death as a result of any cause at 1-year cut-off date', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-∞', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC(Racemate)', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24', 'PK parameters of PQR309 and eribulin will include: AUC0-∞', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-∞', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: t1/2', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC (Racemate)', 'Changes in glucose levels', 'Changes in Insulin levels', 'Changes of Routine laboratory -Haematology', 'Changes of Routine laboratory -blood chemistry', 'Changes of Routine laboratory -urinanalysis']",,,,,5,Spain; United Kingdom,"Hospital Universitarsi Vall d'Hebron [Barcelona, Spain] | Insitut Català d´Oncologia [Barcelona, Spain] | Fundación Instituto Valenciano de Oncología [Valencia, Spain] | Barts Cancer Institute [London, United Kingdom] | Churchill hospital [Oxford, United Kingdom]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 2
NCT02734615,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,"A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy",TERMINATED,PHASE1,Novartis Pharmaceuticals,2016-06-14,2021-09-13,2021-09-13,2016-04-12,2022-08-01,"['Incidence of dose limiting toxicities (DLTs)', 'Safety and tolerability of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719']","['Overall response rate (ORR)', 'Duration of Response (DOR)', 'Progression Free Survival (PFS)', 'Disease control rate (DCR)', 'Plasma concentration of study medications', 'Plasma concentration under fasted condition and fed condition', 'Levels of Pharmacodynamic marker Estrogen receptor (ER)', 'Levels of Pharmacodynamic marker Progesterone receptor (PgR)', 'Levels of Pharmacodynamic marker pS6', 'Pharmacokinetics (PK) parameter AUC', 'PK parameter Cmax', 'PK parameter Tmax', 'PK parameter Cmin']",,,,,10,Belgium; France; Germany; Italy; Japan; Singapore; United States,"Massachusetts General Hospital Massachusetts General Hospital [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | MD Anderson Cancer Center SC - LSZ102X2101 [Houston, United States] | Novartis Investigative Site [Brussels, Belgium] | Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Ulm, Germany] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Koto Ku, Japan] | Novartis Investigative Site [Singapore, Singapore]",2016.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT02735746,Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis,Novel High Fidelity Functional Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis,COMPLETED,,Cedars-Sinai Medical Center,2016-08-21,2025-06-06,2025-06-06,2016-04-13,2025-08-22,"['A Pearson correlation of >0.579 between peak expiratory flow as measured by HFFLI analysis of cinefluorograph compared with 4D planning CT', 'A Pearson correlation of >0.579 between peak inspiratory flow as measured by HFFLI analysis of cinefluorograph compared with 4D planning CT', 'A Pearson correlation of >0.579 between ventilation/local time constant as measured by HFFLI analysis of cinefluorograph compared with 4D planning CT', 'A Pearson correlation of >0.579 between expiratory time constant as measured by HFFLI analysis of cinefluorograph compared with 4D planning CT', 'A Pearson correlation of >0.579 between inspiratory time constant as measured by HFFLI analysis of cinefluorograph compared with 4D planning CT', 'A Pearson correlation of >0.579 between tissue shear as measured by HFFLI analysis of cinefluorograph compared with 4D planning CT', 'A Pearson correlation of >0.579 between peak expiratory flow as measured by HFFLI analysis of cinefluorograph compared with cone beam CT', 'A Pearson correlation of >0.579 between peak inspiratory flow as measured by HFFLI analysis of cinefluorograph compared with cone beam CT', 'A Pearson correlation of >0.579 between ventilation/local time constant as measured by HFFLI analysis of cinefluorograph compared with cone beam CT', 'A Pearson correlation of >0.579 between expiratory time constant as measured by HFFLI analysis of cinefluorograph compared with cone beam CT', 'A Pearson correlation of >0.579 between inspiratory time constant as measured by HFFLI analysis of cinefluorograph compared with cone beam CT', 'A Pearson correlation of >0.579 between tissue shear as measured by HFFLI analysis of cinefluorograph compared with cone beam CT']","['Forced expiratory volume 1 (FEV1)', 'FEV1/Forced vital capacity', 'Total lung capacity', 'Diffusing capacity for carbon monoxide']",,,,,1,United States,"Cedars-Sinai Medical Center [Los Angeles, United States]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2025.0,0.0,0,NA/Other
NCT02754011,Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative,"Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes",COMPLETED,PHASE1,UNICANCER,2017-02-02,2022-02-28,2022-12-23,2016-04-28,2023-12-07,['Determination of the maximum tolerated dose (MTD) and the recommended dose for phase 2 (RP2D) of ribociclib and capecitabine combination'],"['Evaluate safety of ribociclib and capecitabine combination', 'Characterize the pharmacokinetic (PK) profile of ribociclib and capecitabine combination', 'Evaluate the anti-tumor activity of ribociclib and capecitabine combination', 'Evaluate anti-tumor activity and safety of the ribociclib and capecitabine combination RP2D according to RH status', 'Evaluate the anti-tumor activity of ribociclib and capecitabine depending on Rb status']",,,,,2,France,"Centre Leon Berard [Lyon, France] | Institut de Cancérologie de l'Ouest [Saint-Herblain, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT02757651,KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response,Phase I 'Run in' Study Followed by Randomised Phase II Trial Testing Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Women With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response,COMPLETED,PHASE1; PHASE2,"Institute of Cancer Research, United Kingdom",2017-01-19,2020-11-12,2020-11-12,2016-05-02,2020-11-27,"['Phase I: Patient reported maximum intra-tumoural pain intensity over duration of treatment', 'Phase II: Tumour response 3 months post-radiotherapy according to RECIST 1.1 criteria']","['Phase I: Proportion of patients with severe pain at any time before and up to 24 hours after any of the KORTUC injections. Server Sever pain is defined as scoring a max grade ≥5 above baseline', 'Phase II: Proportion of patients with severe pain at any time before and up to 24 hours after any of the KORTUC injections. Server pain is defined as scoring a max grade ≥5 above baseline Frequency and duration of pain score ≥1 at each time point', 'Phase I: Tumour response 3 months post- radiotherapy according to RECIST 1.1 criteria', 'Phase II: Local progression-free survival at 24 months']",,,,,1,United Kingdom,"The Royal Marsden NHS Foundation Trust [London, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 2
NCT02783794,BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer,"A Randomized, Double Blind and Placebo Controlled Multicenter Study Comparing BP-C1 and Equal Looking Placebo in Metastatic Breast Cancer Patients. A Phase IIB Study",COMPLETED,PHASE2,Meabco A/S,2012-12-24,2014-02-28,2014-02-28,2016-05-26,2019-10-10,['Change (%) in the sum of diameters of target lesions'],"['Number of target lesions', 'Number of non-target lesions', 'Treatment response', 'Karnofsky Performance Status (KPS) score', 'Changes in the scores of the general questionnaire EORTC QLQ-C30 (""Physical activity problem last week"", ""Discomfort last week"", ""Health and quality of life"")', 'Changes in three separate scores of the specific questionnaire EORTC QLQ-BR23 (""Breast cancer treatment problem last week"", ""Sexual interest and activity last four weeks"", ""Breast cancer related pain and discomfort last week"")', 'Change in Maximum Common Toxicity Criteria (CTC) score', 'Sum CTC score', 'Number of registered adverse events']",,,,,6,Russia; Thailand,"Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS) [Moscow, Russia] | State Budgetary Institution of Nizhniy Novgorod Region ""Oncology Dispensary of Nizhniy Novgorod"" (Branch nr.1) [Nizhny Novgorod, Russia] | Leningrad Regional Oncological Centre [Saint Petersburg, Russia] | St. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary [Saint Petersburg, Russia] | Siriraj Hospital, Mahidol University [Bangkok, Thailand] | Udon Thani Cancer Hospital [Udon Thani, Thailand]",2012.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[""Target Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating BP-C1, which indicates it is a new medicine being tested for the treatment of metastatic breast cancer.",INDUSTRY,False,2014.0,11.0,1,Phase 2
NCT02791334,A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors,A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT),COMPLETED,PHASE1,Eli Lilly and Company,2016-06-29,2020-05-22,2024-06-27,2016-06-06,2024-09-27,['Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs)'],"['Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3300054', 'PK: Cmax of Ramucirumab', 'PK: Cmax of Abemaciclib', 'PK: Cmax of Merestinib', 'PK: Cmax of LY3321367', 'Objective Response Rate (ORR): Proportion of Participants With a Complete Response (CR) or Partial Response (PR)', 'Progression Free Survival (PFS)', 'Duration of Response (DoR)', 'Time to Response (TTR)', 'Disease Control Rate (DCR): Proportion of Participants who Exhibit Stable Disease (SD), CR or PR']",,,,,14,Belgium; Canada; France; South Korea; Spain; Taiwan; United States,"Tennessee Oncology PLLC [Nashville, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | The START Center for Cancer Care [San Antonio, United States] | Cliniques Universitaires Saint-Luc [Brussels, Belgium] | Universitair Ziekenhuis Antwerpen [Edegem, Belgium] | Princess Margaret Hospital [Toronto, Canada] | Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest [Bordeaux, France] | Gustave Roussy [Villejuif, France] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital Yonsei University Health System [Seoul, South Korea] | Hospital Universitario Fundación Jiménez Díaz [Madrid, Spain] | Hospital Madrid Norte Sanchinarro [Madrid, Spain] | National Cheng Kung University Hospital [Tainan City, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan]",2016.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT02794493,Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer,"A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of Traditional Chinese Medicine Formula LC09 for Treatment of Capecitabine-Induced Hand and Foot Syndrome",COMPLETED,PHASE3,China-Japan Friendship Hospital,2015-04-01,2017-12-31,2018-04-25,2016-06-09,2019-07-25,"['Grade of hand foot syndrome over time as measured by NCI CTCAE version 4.03 PPE syndrome criteria', 'Assessment of patient reported pain using a 1-10 score.']","['Instrumental Activities of Daily Living Scale', 'Dermatology Life Quality Index (DLQI) Total Score', 'Chemotherapy completion rate', 'Incidence of reduced dosage of capecitabine thereby', 'Incidence of cessation of capecitabine thereby']",,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing a Traditional Chinese Medicine formula (LC09) for the treatment of a specific condition (Hand and Foot Syndrome) induced by a chemotherapy drug (Capecitabine), indicating it is a new medicine.",OTHER,False,2018.0,7.0,0,Phase 3
NCT02820961,Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,"A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer",COMPLETED,PHASE1,Syndax Pharmaceuticals,2016-06-29,2018-09-10,2021-07-12,2016-07-01,2021-12-15,"['Cmax, maximum plasma concentration', 'Tmax, time at which maximum plasma concentration was observed', 'AUC0-t, area under the plasma concentration-time curve from time zero to the last measurable concentration', 'AUC0-inf, area under the plasma concentration-time curve from time zero extrapolated to infinity', 'T1/2, elimination half-life', 'lambda z , apparent terminal phase elimination constant (λz)', 'AUC0-τ where τ=168 hours for entinostat and τ=24 hours for exemestane', 'Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs resulting in the permanent discontinuation of study drug, and deaths occurring within 30-days of the last dose of study drug', 'Changes from baseline in laboratory, vital signs, and electrocardiogram (ECG) values']","['Best overall tumor response', 'Overall survival']",,,,,3,United States,"Sarah Cannon Research Institute HealthONE [Denver, United States] | Florida Cancer Specialists [Sarasota, United States] | Sarah Cannon Research Institute [Nashville, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT02833155,Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer,"A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer",COMPLETED,PHASE1,"Taizhou EOC Pharma Co., Ltd.",2016-08-29,2018-07-18,2018-07-18,2016-07-14,2019-05-07,"['Adverse events, 12-lead ECG, blood pressure/pulse, temperature, laboratory parameters and physical examination.']","['Cmax,maximum plasma concentration', 'tmax,time at which maximum plasma concentration was observed', 'AUC 0-168h area under the plasma concentration-time curve from time zero to 168h', 'AUC 0-inf,area under the plasma concentration-time curve from time zero to infinity', 'T1/2, elimination half-life', 'lambda z , apparent terminal phase elimination constant (λz)', 'MRT，mean residence time']",,,,,4,China,"Cancer Hospital Chinese Academy Medical Sciences [Beijing, China] | Hunan Cancer Hospital [Changsha, China] | West China Hospital [Chengdu, China] | Tianjin Medical University Cancer Institute & Hospital [Tianjin, China]",2016.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT02833766,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial,TERMINATED,PHASE2,Swiss Cancer Institute,2016-10-28,2020-10-31,2021-08-03,2016-07-14,2021-09-29,['Progression-free survival (PFS)'],"['Objective response rate (ORR)', 'Duration of response (DOR)', 'Time to Progression (TTP)', 'PFS', 'Overall survival (OS)', 'Adverse events (AEs)']",,,,,15,Switzerland,"Kantonsspital Aarau [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitaetsspital-Basel [Basel, Switzerland] | Inselspital, Bern [Bern, Switzerland] | Kantonsspital Graubuenden [Chur, Switzerland] | Hopitaux Universitaires de Geneve [Geneva, Switzerland] | Centre Hospitalier Universitaire Vaudois [Lausanne, Switzerland] | Kantonsspital Luzern [Lucerne, Switzerland] | Kantonsspital Olten [Olten, Switzerland] | Kantonsspital St. Gallen [Sankt Gallen, Switzerland] | Hôpital de Sion [Sion, Switzerland] | Spital STS AG [Thun, Switzerland] | Kantonsspital Winterthur [Winterthur, Switzerland] | Onkozentrum - Klinik im Park [Zurich, Switzerland] | Universitätsspital Zürich [Zurich, Switzerland]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing a new formulation (anti-EGFR-immunoliposomes loaded with doxorubicin) in a specific patient population (advanced triple negative EGFR positive breast cancer), indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02890069,"A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat","Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)",COMPLETED,PHASE1,Novartis Pharmaceuticals,2016-10-14,2022-02-22,2022-02-22,2016-09-07,2023-01-11,"['Phase 1: Incidence of dose limiting toxicities (DLTs)', 'Frequency of dose interruptions and reductions', 'Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)', 'Changes between baseline and post-baseline laboratory parameters and vital signs', 'Dose intensities']","['Changes from baseline in ECG parameters in patients recieving PDR001 in combination with Panobinostat', 'Best overall response (BOR)', 'Time to reach max concentration (Tmax) for PDR001', 'Presence of anti-PDR001 antibodies', 'Progression free survival (PFS)', 'Treatment Free Survival (TFS)', 'Maximum and minimum plasma concentrations of LCL161 (Cmax and Cmin)', 'Maximum and minimum Plasma concentrations of everolimus (Cmax and Cmin)', 'Maximum and minimum plasma concentrations of panobinostat (Cmax and Cmin)', 'Concentration of anti-PDR001 antibodies', 'Maximum and minimum serum concentration of PDR001 (Cmax and Cmin)', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for PDR001, as applicable', 'Progression free survival (PFS) per irRC', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for LCL161, as applicable', 'Time to reach max concentration (Tmax) for LCL161', 'Time to reach max concentration (Tmax) for Everolimus', 'Time to reach max concentration (Tmax) for Panobinostat', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for Everolimus, as applicable', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for Panobinostat, as applicable', 'Maximum and minimum Plasma concentrations of QBM076 (Cmax and Cmin)', 'Maximum and minimum Plasma concentrations of HDM201 (Cmax and Cmin)', 'Time to reach max concentration (Tmax) for QBM076', 'Time to reach max concentration (Tmax) for HDM201', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for QBM076, as applicable', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for HDM201, as applicable']",,,,,25,Germany; Netherlands; South Korea; Spain; Taiwan; United Kingdom; United States,"UCLA Santa Monica Hematology / Oncology SC [Santa Monica, United States] | Sidney Kimmel Comprehensive Cancer Center [Baltimore, United States] | Massachusetts General Hospital [Boston, United States] | The Regents of the University of Michigan [Ann Arbor, United States] | Washington University Medical School SC [St Louis, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | UT Health San Antonio Mays Cancer Center [San Antonio, United States] | Huntsman Cancer Institute [Salt Lake City, United States] | Seattle Cancer Care Alliance [Seattle, United States] | Novartis Investigative Site [Jena, Germany] | Novartis Investigative Site [Ulm, Germany] | Novartis Investigative Site [Würzburg, Germany] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Leiden, Netherlands] | Novartis Investigative Site [Rotterdam, Netherlands] | Novartis Investigative Site [Utrecht, Netherlands] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Pamplona, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Sutton, United Kingdom] | Novartis Investigative Site [Manchester, United Kingdom] | Novartis Investigative Site [Oxford, United Kingdom]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT02892123,Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers,Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers,COMPLETED,PHASE1,Jazz Pharmaceuticals,2016-09-30,2024-10-31,2024-10-31,2016-09-08,2024-11-27,"['The proportion of patients who experience dose-limiting toxicities (DLTs) (Part 1)', 'The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Parts 2 and 3)']","['Serum concentrations of ZW25', 'The proportion of patients who develop detectable anti-drug antibodies', 'The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria', 'Progression free survival as defined by RECIST 1.1 criteria', 'The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Part 1)']",,,,,17,Canada; South Korea; United States,"University of Alabama [Birmingham, United States] | USC/Norris Cancer Center [Los Angeles, United States] | Hoag Family Cancer Institute [Newport Beach, United States] | University of Colorado Cancer Center [Aurora, United States] | Rush University Medical Center [Chicago, United States] | Sarah Cannon - Tennessee Oncology [Nashville, United States] | MD Anderson Cancer Center [Houston, United States] | South Texas Accelerated Research Therapeutics (START) [San Antonio, United States] | Northwest Medical Specialties [Tacoma, United States] | University of Ottawa [Ottawa, Canada] | Princess Margaret Cancer Centre [Toronto, Canada] | Jewish General Hospital [Montreal, Canada] | Seoul National University Bundang Hospital [Seongnam-si, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies,COMPLETED,PHASE1,Emory University,2016-10-24,2021-10-15,2021-10-15,2016-09-13,2023-10-10,"['Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0', 'Incidence of dose limiting toxicities defined as grade 3 or higher toxicity', 'Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin']","['Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria', 'Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax)', 'Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)']",,,,,1,United States,"Emory University/Winship Cancer Institute [Atlanta, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT02897778,Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,COMPLETED,PHASE1,Syndax Pharmaceuticals,2016-08-24,2017-03-13,2017-03-13,2016-09-13,2022-04-28,"['Change from Baseline in Heart Rate (HR)', 'Change from Baseline in Electrocardiogram Procedures', 'Change from Baseline in T-Cell Morphology']","['Number of Participants with Treatment-emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)', 'Number of Participants with Clinically Significant Abnormalities in Laboratory Values Reported as a TEAE', 'Change from Baseline in Vital Signs', 'Change from Baseline in ECG Values', 'Change from Baseline in QTc', 'Cmax (Maximum Plasma Concentration) of Entinostat when given as a Single Supratherapeutic Dose', 'Tmax (Time of Maximum Plasma Concentration) of Entinostat when given as a Single Supratherapeutic Dose', 'AUC0-24 (Area under the Plasma Concentration-time Curve from Time Zero to 24 hours) of Entinostat when given as a Single Supratherapeutic Dose', 'AUC0-t (Area under the Plasma Concentration-time Curve from Time Zero to the Last Measurable Concentration) of Entinostat when given as a Single Supratherapeutic Dose', 'AUC0-inf (Area under the Plasma Concentration-time Curve from 0-time Extrapolated to Infinity) of Entinostat when given as a Single Supratherapeutic Dose', 't1/2 (Elimination Half-life and Apparent Plasma Terminal Phase Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose', 'λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose']",,,,,1,United States,"The START Center for Cancer Care [San Antonio, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT02900664,"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",COMPLETED,PHASE1,Novartis Pharmaceuticals,2016-08-23,2021-03-17,2021-03-17,2016-09-14,2022-03-29,"['Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety', 'Changes between baseline and post-baseline laboratory parameters and vital signs.', 'Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)', 'Frequency of dose interruptions', 'Dose intensities', 'Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety', 'Frequency of dose reductions']","['Key secondary: Histopathology of tumor infiltrating lymphocytes (TILs)', 'Changes from baseline in electrocardiogram (ECG) parameters', 'Best overall response (BOR)', 'Progression free survival (PFS) per irRC and RECIST v1.1', 'Treatment Free Survival (TFS)', 'Presence and/or concentration of anti-PDR001 antibodies.', 'Serum concentration of PDR001, canakinumab, CJM112', 'Plasma concentrations of trametinib and EGF816', 'Key secondary: Histopathology of myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate).', 'PK parameters (Eg. TMax) of EGF816', 'PK parameters (Eg. TMax) of trametinib', 'PK parameter (Eg. TMax) of PDR001', 'PK parameters (Eg. TMax) of canakinumab', 'PK parameters (Eg. TMax) of CJM112', 'Presence and/or concentration of anti-canakinumab antibodies.', 'Presence and/or concentration of anti-CJM112 antibodies.']",,,,,23,Belgium; Canada; France; Israel; Italy; Singapore; Spain; Taiwan; United States,"Sidney Kimmel Comprehensive Cancer Center SC-3 [Baltimore, United States] | Dana Farber Cancer Center [Boston, United States] | Sarah Cannon Research Institute [Nashville, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | Novartis Investigative Site [Brussels, Belgium] | Novartis Investigative Site [Wilrijk, Belgium] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Paris, France] | Novartis Investigative Site [Toulouse, France] | Novartis Investigative Site [Villejuif, France] | Novartis Investigative Site [Tel Aviv, Israel] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Rozzano, Italy] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Tainan City, Taiwan] | Novartis Investigative Site [Taoyuan District, Taiwan]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves PDR001, which is being studied in combination with other drugs, indicating it is a new medicine being evaluated for safety and efficacy.",INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT02909452,Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,"A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)",COMPLETED,PHASE1,Syndax Pharmaceuticals,2016-09-20,2019-07-17,2021-02-09,2016-09-21,2022-01-25,"['Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) resulting in the permanent discontinuation of study drug, and deaths occurring within the reporting period required for the study', 'Changes from baseline in laboratory results', 'Changes from baseline in vital signs', 'Changes from baseline in ECG results']","['AUC0-t (area under the curve to last observed concentration time) of entinostat when given in combination with pembrolizumab', 'AUC0-inf (area under the curve extrapolated to infinity) of entinostat when given in combination with pembrolizumab', 'Cmax (maximum plasma concentration) of entinostat when given in combination with pembrolizumab', 'Tmax (time to maximum plasma concentration) of entinostat when given in combination with pembrolizumab', 'T1/2 (elimination half life) of entinostat when given in combination with pembrolizumab', 'Vd (clearance and volume of distribution) of entinostat when given in combination with pembrolizumab']",,,,,1,United States,"The START Center for Cancer Care [San Antonio, United States]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT02936102,A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,"A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies",TERMINATED,PHASE1,Novartis Pharmaceuticals,2016-10-20,2024-11-22,2024-11-22,2016-10-18,2025-01-13,"['Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'Incidence of Dose Limiting Toxicities (DLTs)', 'Dose interruptions and reductions', 'Dose intensity']","['Serum concentration-time profiles of FAZ053 as single agent and FAZ053 in combination with PDR001.', 'Presence of anti-FAZ053 and anti-PDR001.', 'Concentration of anti-FAZ053 and anti-PDR001.', 'Receptor Occupancy (RO) profiles when FAZ053 is given as single agent.', 'Total soluble/shed PD-L1 concentration-time profiles when FAZ053 is given as single agent and for FAZ053 in combination with PDR001.', 'Histopathology of tumor infiltrating lymphocytes (TILs) by hematoxylin.', 'Histopathology of tumor infiltrating lymphocytes (TILs) by eosin (H&E) stain.', 'Overall response rate (ORR) per RECIST v1.1', 'Best overall response per RECIST v1.1', 'Disease control rate per RECIST 1.1', 'Progression free survival (PFS) per RECIST 1.1', 'Duration of response per RECIST 1.1', 'Overall response rate (ORR) per immune related Response Criteria (irRC).', 'Progression free survival (PFS) per immune related Response Criteria (irRC).', 'Characterization of Tumor Infiltrating Lymphocytes (TILs) by Immunohistochemistry (IHC)', 'Characterization of myeloid cell infiltrate by IHC.', 'Area under the curve (AUC) for FAZ053 as single agent and FAZ053 in combination with PDR001.', 'Cmax for FAZ053 as single agent and FAZ053 in combination with PDR001.', 'Tmax for FAZ053 as single agent and FAZ053 in combination with PDR001.', 'Half-life for FAZ053 as single agent and FAZ053 in combination with PDR001.', 'Clast for FAZ053 as single agent and FAZ053 in combination with PDR001.', 'Tlast for FAZ053 as single agent and FAZ053 in combination with PDR001.']",,,,,12,Canada; France; Israel; Italy; Japan; Singapore; Spain; Taiwan; United States,"Memorial Sloan Kettering Cancer Ctr [New York, United States] | UT MD Anderson Cancer Center [Houston, United States] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Toulouse, France] | Novartis Investigative Site [Tel Aviv, Israel] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Modena, Italy] | Novartis Investigative Site [Koto Ku, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Seville, Spain] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Taipei, Taiwan]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT02941835,Preoperative Breast Irradiation,"Preoperative Breast Irradiation, the PROBI Trial. A Phase I/II Feasibility Trial",TERMINATED,,The Netherlands Cancer Institute,2018-03-12,2018-08-09,2018-08-09,2016-10-21,2019-10-22,['Postoperative surgical complications'],"['Radiological response', 'Pathological response', 'cosmetic outcome']",,,,,1,Netherlands,"Netherlands Cancer Institute [Amsterdam, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,NA/Other
NCT02947165,Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,"A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies",COMPLETED,PHASE1,Novartis Pharmaceuticals,2017-04-25,2021-06-18,2021-06-18,2016-10-27,2022-01-31,"['Incidence of DLTs, AEs, SAEs and dose reductions / interruptions for NIS793', 'Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001']","['Best overall response (BOR)', 'Disease control rate (DCR)', 'Overall response rate (ORR)', 'Progression free survival (PFS)', 'Duration of response (DOR)', 'Serum concentration-time profiles of NIS793 single agent and NIS793 in combination with PDR001', 'Presence of anti-NIS793 and anti-PDR001 antibodies', 'Concentration of anti-NIS793 and anti-PDR001 antibodies', 'Area under the curve (AUC) for NIS793 single agent and NIS793 in combination with PDR001.', 'Cmax for NIS793 single agent and NIS793 in combination with PDR001.', 'Tmax for NIS793 single agent and NIS793 in combination with PDR001.', 'Half life of NIS793 as single agent and in combination with PDR001.', 'Characterization of tumor infiltrating lymphocytes (TILs) by H&E', 'Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1']",,,,,12,Austria; Canada; Germany; Hong Kong; Italy; Japan; Switzerland; Taiwan; United States,"Sarah Cannon Research Institute SC [Nashville, United States] | Huntsman Cancer Institute SC [Salt Lake City, United States] | Novartis Investigative Site [Salzburg, Austria] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Ulm, Germany] | Novartis Investigative Site [Würzburg, Germany] | Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Rozzano, Italy] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Sankt Gallen, Switzerland] | Novartis Investigative Site [Taipei, Taiwan]",2017.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT02952729,Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,"A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2",COMPLETED,PHASE1,Mersana Therapeutics,2016-11-21,2019-01-28,2019-01-28,2016-11-02,2021-02-24,['Maximum tolerated dose or recommended Phase 2 dose'],"['Time of maximum observed concentration of XMT-1522', 'Maximum concentration of XMT-1522', 'Area under the concentration curve of the last measurable concentration of XMT-1522', 'Antineoplastic effects of XMT-1522', 'Anti-drug antibody']",,,,,5,United States,"Moffitt Cancer Center [Tampa, United States] | Massachusetts General Hospital [Boston, United States] | Sarah Cannon Research Institute [Nashville, United States] | Mary Crowley Cancer Research Center [Dallas, United States] | South Texas Accelerated Research Therapeutics (START) [San Antonio, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a Phase 1b study of XMT-1522, which is a new drug being tested in humans for the treatment of advanced breast cancer and other tumors, indicating it is a new medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02952989,A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,"A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors",TERMINATED,PHASE1,Seagen Inc.,2017-02-23,2019-06-24,2019-06-24,2016-11-02,2019-07-19,"['The number of participants with adverse events that are related to treatment', 'The number of participants with laboratory abnormalities that are related to treatment', 'Incidence of dose-limiting toxicities (DLTs)']","['Pharmacokinetic assessments', 'Markers of fucosylation status', 'Objective response rate', 'Disease control rate', 'Duration of response', 'Clinical benefit rate', 'Progression-free survival', 'Overall survival']",,,,,11,United States,"University of Alabama at Birmingham [Birmingham, United States] | City of Hope National Medical Center [Duarte, United States] | University of Colorado Hospital / University of Colorado [Aurora, United States] | Winship Cancer Institute / Emory University School of Medicine [Atlanta, United States] | Dana Farber Cancer Institute [Boston, United States] | Karmanos Cancer Institute / Wayne State University [Detroit, United States] | Duke University Medical Center [Durham, United States] | Providence Portland Medical Center [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | MD Anderson Cancer Center / University of Texas [Houston, United States] | Seattle Cancer Care Alliance / University of Washington [Seattle, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02993094,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,TERMINATED,PHASE1; PHASE2,Arbeitsgemeinschaft medikamentoese Tumortherapie,2016-11-21,2020-08-15,2020-08-15,2016-12-15,2020-11-30,['Maximum tolerated dose (MTD)'],"['Safety profile based on adverse events evaluation', 'Overall response rate', 'Clinical benefit rate', 'Progression-free survival (PFS)', 'Quality of Life of MBC patients']",,,,,12,Austria,"Universitätsklinik für Innere Medizin Graz [Graz, Austria] | Universitätsklinik für Frauenheilkunde Innsbruck [Innsbruck, Austria] | Klinikum Kreuzschwestern Wels GmbH [Wels, Austria] | Landeskrankenhaus Feldkirch, Innere Med. II, Interne E [Feldkirch, Austria] | UK Graz: Universitätsklinik für Frauenheilkunde und Geburtshilfe, Klinische Abteilung für Gynäkologie [Graz, Austria] | LKH Hochsteiermark: Department für Hämato-Onkologie [Leoben, Austria] | BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie [Linz, Austria] | KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie [Linz, Austria] | PMU Salzburg: Universitätsklinik für Innere Medizin III [Salzburg, Austria] | Landeskrankenhaus Steyr, Innere Medizin II Onkologie [Steyr, Austria] | AKH Wien Universitätsklinik für Frauenheilkunde: Klin. Abt. f. Allg. Gynäkologie und gynäkologische Onkologie [Vienna, Austria] | LK Wiener Neustadt: Innere Medizin, Hämatologie und internistische Onkologie [Wiener Neustadt, Austria]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Ixazomib (MLN9708), which is being tested in combination with Carboplatin for a specific patient population (pretreated women with advanced triple negative breast cancer), indicating it is a new medicine being evaluated for a new use.",OTHER,False,2020.0,5.0,0,Phase 2
NCT02996825,"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer","A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)",COMPLETED,PHASE1,City of Hope Medical Center,2017-03-22,2024-02-09,2024-02-09,2016-12-19,2024-04-02,['Recommended phase II dose assessed by Common Terminology Criteria for Adverse Events version 4'],"['Incidence of treatment-emergent adverse events and clinically significant >= grade 3 changes assessed by Common Terminology Criteria for Adverse Events version 4.0', 'Response', 'Progression free survival', 'Assessment of biological correlatives assessed by biopsy']",,,,,2,United States,"City of Hope Medical Center [Duarte, United States] | City of Hope Upland [Upland, United States]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2024.0,1.0,0,Phase 1
NCT03000257,A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors,"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,AbbVie,2016-12-14,2022-03-29,2022-03-29,2016-12-22,2022-04-14,"['Part 1: Recommended Phase 2 Dose (RPTD) for Budigalimab', 'Part 1: Maximum tolerated dose (MTD) of Budigalimab', 'Part 1 and Part 3: Terminal Half-life (t1/2) of Budigalimab', 'Part 1 and Part 3: Maximum Observed Serum Concentration (Cmax) of Budigalimab', 'Part 1 and Part 3: Time to Cmax (Tmax) of Budigalimab', 'Part 1 and Part 3: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Budigalimab', 'Part 2: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Rovalpituzumab Tesirine Combination', 'Part 3: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Venetoclax Combination.', 'Part 3: Maximum Observed Serum Concentration (Cmax) for Venetoclax', 'Part 3: Area Under the Serum Concentration Time Curve from Time 0 to 24 Hours Post-dose (AUC(0-24)) of Venetoclax', 'Part 3: Time to Cmax (Tmax) of Venetoclax', 'Part 1, Part 2, Part 3: Number of Participants with Adverse Events']","['Part 2: Terminal Half-life (t1/2) of Budigalimab', 'Part 2: Terminal Half-life (t1/2) of Rovalpituzumab Tesirine', 'Part 2: Maximum Observed Serum Concentration (Cmax) of Rovalpituzumab Tesirine', 'Part 2: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Rovalpituzumab Tesirine', 'Part 2: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Budigalimab', 'Part 2: Time to Cmax (Tmax) of Budigalimab', 'Part 2: Time to Cmax (Tmax) of Rovalpituzumab Tesirine', 'Part 1 and Part 3: Objective response rate (ORR)', 'Part 1 and Part 3: Clinical benefit rate (CBR, defined as CR, PR or SD)', 'Part 1 and Part 3: Progression-free survival (PFS)', 'Part 1, Part 2 and Part 3: Duration of objective response (DOR)']",,,,,26,Australia; Austria; Belgium; Canada; Finland; France; Japan; Spain; Taiwan; United States,"Moores Cancer Center at UC San Diego /ID# 157374 [La Jolla, United States] | The University of Chicago Medical Center /ID# 157375 [Chicago, United States] | Carolina BioOncology Institute /ID# 157376 [Huntersville, United States] | South Texas Accelerated Research Therapeutics /ID# 157378 [San Antonio, United States] | Virginia Cancer Specialists - Fairfax /ID# 157377 [Fairfax, United States] | Blacktown Hospital /ID# 167386 [Blacktown, Australia] | St Vincent's Hospital Melbourne /ID# 167552 [Fitzroy Melbourne, Australia] | Linear Clinical Research /ID# 170797 [Nedlands, Australia] | Medizinische Universitaet Graz /ID# 168752 [Graz, Austria] | Universitair Ziekenhuis Antwerpen /ID# 170702 [Edegem, Belgium] | UZ Gent /ID# 170881 [Ghent, Belgium] | Cross Cancer Institute /ID# 167603 [Edmonton, Canada] | Tampere University Hospital /ID# 166839 [Tampere, Finland] | Docrates Cancer Center /ID# 166838 [Helsinki, Finland] | Institut Bergonie /ID# 162662 [Bordeaux, France] | Institut du Cancer de Montpellier - Val d'Aurelle /ID# 163999 [Montpellier, France] | Centre Leon Berard /ID# 162660 [Lyon, France] | Institut Gustave Roussy /ID# 162753 [Villejuif, France] | National Cancer Center Hospital East /ID# 166433 [Kashiwa-shi, Japan] | National Hospital Organization Kyushu Cancer Center /ID# 206229 [Fukuoka, Japan] | National Cancer Center Hospital /ID# 166279 [Chuo-ku, Japan] | Hospital Universitario Fundacion Jimenez Diaz /ID# 163862 [Madrid, Spain] | Hospital Universitario HM Sanchinarro /ID# 163861 [Madrid, Spain] | Hospital Clinico Universitario de Valencia /ID# 163925 [Valencia, Spain] | National Taiwan University Hospital /ID# 163997 [Taipei, Taiwan] | Taipei Medical University Hospital /ID# 163998 [Taipei, Taiwan]",2016.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03000920,Evaluation of the Short Message Service Effectiveness in the Screening Invitation Strategy for Breast Cancer (USIMaPI),Multicenter Randomized Controlled Trial Evaluating the Effectiveness and Cost-effectiveness of the Use of Short Message Service (SMS) in the Screening Invitation Strategy for Breast Cancer.,COMPLETED,,"University Hospital, Tours",2017-05-02,2018-12-01,2019-06-30,2016-12-22,2019-07-18,"['Phase 1: Compare the participation rates in organized breast cancer screening (and the cost by screened woman) in response to a strategy of sending an SMS before the invitation letter (vs sending the invitation letter alone = usual strategy).', 'Phase 2: Compare participation rates in organized breast cancer screening (and the cost by screened woman) in response to a strategy of replacing the reminder 1 by mail with a reminder 1 by SMS ( reminder 1 mail = usual strategy).']",[],,,,,4,France,"ADOC41 [Blois, France] | ADOC28 [Chartres, France] | CREDEP [Châteauroux, France] | CCDC [Tours, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03012230,Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer,COMPLETED,PHASE1,Mayo Clinic,2017-12-06,2023-01-06,2023-03-08,2017-01-06,2024-01-31,"['Maximum tolerated dose', 'Incidence of adverse events']",['Best response'],,,,,1,United States,"Mayo Clinic in Arizona [Scottsdale, United States]",2017.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2023.0,2.0,0,Phase 1
NCT03052634,A Study of RC48-ADC in Subjects With Advanced Breast Cancer,"A Phase Ib Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Breast Cancer With HER2 Positive or HER2 Low Expression",COMPLETED,PHASE1; PHASE2,"RemeGen Co., Ltd.",2016-12-23,2022-07-31,2023-04-07,2017-02-14,2023-12-18,['RP2D'],"['Cmax', 'AUC', 'Tmax', 'Overall response Rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Progression Free Survival (PFS)']",,,,,7,China,"Cancer Hospital Chinese Academy of Medical Sciences [Beijing, China] | The first bethune hospital of jilin unversity [Changchun, China] | Liaoning cancer hospital & institute [Shenyang, China] | Zhejiang cancer hospital [Hangzhou, China] | Affiliated cancer hospital of Harbin medical university [Harbin, China] | The fourth hospital of Hebei medical university [Hebei, China] | Jiangsu Cancer Hospital [Nanjing, China]",2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating a new drug (RC48-ADC) for advanced breast cancer, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT03060356,Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET),Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma,TERMINATED,EARLY_PHASE1,University of Pennsylvania,2016-12-21,2020-03-27,2020-03-27,2017-02-23,2023-06-22,['Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 in melanoma and breast cancer subjects'],"['Objective overall response rate by clinical exam for visible cutaneous tumors', 'Objective overall response rate by radiologic imaging using RECIST 1.1', 'Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using RECIST 1.1 criteria', 'Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using pathological evaluation of resected or biopsied tissue']",,,,,1,United States,"University of Pennsylvania [Philadelphia, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a new treatment using autologous T cells expressing a specific CAR (chimeric antigen receptor) targeting cMET, indicating it is a new medicine.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03071757,"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors","A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,AbbVie,2017-03-21,2022-04-13,2022-04-13,2017-03-07,2022-04-28,"['Terminal half-life (t1/2) of ABBV-368', 'Area under the serum concentration-time curve (AUC) of ABBV-368', 'Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181', 'Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181', 'Time to Cmax (Tmax) of ABBV-368', 'Terminal phase elimination rate constant (β) of ABBV-368', 'Number of Participants With Adverse Events', 'Maximum observed serum concentration (Cmax) of ABBV-368']","['Objective Response Rate (ORR)', 'Clinical benefit rate (CBR)', 'Duration of Objective Response (DOR)', 'Progression-Free Survival (PFS)']",,,,,27,France; Japan; Puerto Rico; Spain; Taiwan; United States,"Moores Cancer Center at UC San Diego /ID# 201334 [La Jolla, United States] | University of California, Davis Comprehensive Cancer Center /ID# 201342 [Sacramento, United States] | Stanford University /ID# 206949 [Stanford, United States] | Yale University /ID# 207895 [New Haven, United States] | Carolina BioOncology Institute /ID# 160786 [Huntersville, United States] | Greenville Hospital System /ID# 160785 [Greenville, United States] | University of Texas Southwestern Medical Center /ID# 201934 [Dallas, United States] | South Texas Accelerated Research Therapeutics /ID# 160788 [San Antonio, United States] | University of Virginia /ID# 212895 [Charlottesville, United States] | Virginia Cancer Specialists - Fairfax /ID# 160787 [Fairfax, United States] | AP-HM - Hopital de la Timone /ID# 165036 [Marseille, France] | Centre Leon Berard /ID# 165037 [Lyon, France] | Institut Gustave Roussy /ID# 165035 [Villejuif, France] | Institut Curie /ID# 165038 [Paris, France] | National Cancer Center Hospital East /ID# 214530 [Kashiwa-shi, Japan] | National Cancer Center Hospital /ID# 214531 [Chuo-ku, Japan] | Pan American Center for Oncology Trials, LLC /ID# 213809 [Rio Piedras, Puerto Rico] | Hospital Duran i Reynals /ID# 205997 [L'Hospitalet de Llobregat, Spain] | Hospital Universitario Puerta de Hierro, Majadahonda /ID# 206973 [Majadahonda, Spain] | CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 208879 [Pamplona, Spain] | Hospital General Universitario Gregorio Maranon /ID# 205999 [Madrid, Spain] | CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 205996 [Madrid, Spain] | Hospital Universitario Fundacion Jimenez Diaz /ID# 211500 [Madrid, Spain] | Hospital Clinico Universitario de Valencia /ID# 211499 [Valencia, Spain] | National Cheng Kung University Hospital /ID# 164002 [Tainan City, Taiwan] | National Taiwan University Hospital /ID# 164000 [Taipei, Taiwan] | Taipei Medical University Hospital /ID# 164001 [Taipei, Taiwan]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03075462,A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients,"An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer",COMPLETED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2017-03-09,2021-08-22,2021-12-13,2017-03-09,2022-07-01,['The type and incidence of adverse events [safety and tolerability]'],"['Objective Response Rate (ORR)', 'Disease Control Rate (DOR)', 'Time to Progression (TTP)', 'Overall Survival (OS)', 'Cmax', 'T1/2 (Half-life)', 'Area under curve (AUC)', 'V/F', 'CL/F']",,,,,1,China,"Beijing Cancer Hosptial [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03083782,Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus,"A Phase I, Open-Label, Crossover, Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus in Healthy Volunteers",COMPLETED,PHASE1,Thomas Jefferson University,2017-04-18,2017-06-05,2017-06-30,2017-03-20,2017-10-11,"['Apixaban area under the plasma concentration curve between 0 and 72 hours (AUC(0-72)).', 'Apixaban peak plasma concentration (Cmax)']","['Safety and tolerability of apixaban when co-administered with cyclosporine assessed by capturing adverse events and laboratory safety tests', 'Safety and tolerability of apixaban when co-administered with tacrolimus assessed by capturing adverse events and laboratory safety tests']",,,,,1,United States,"Thomas Jefferson University [Philadelphia, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2017.0,8.0,0,Phase 1
NCT03085888,The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types,The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection,COMPLETED,,"GRAIL, Inc.",2017-02-28,2022-06-30,2024-04-01,2017-03-21,2024-09-20,"['To evaluate the performance of the pre-specified GRAIL Test to detect invasive cancers (including hematologic malignancies).', 'To refine the predictive algorithms and cut points of the GRAIL test to detect breast and other invasive cancers (including hematologic malignancies).']","['Diagnosis of invasive cancers, including hematologic malignancies, diagnosed in To evaluate the performance of the GRAIL Test to detect invasive cancers in clinically meaningful subgroups.', 'Diagnosis of invasive cancers, including hematologic malignancies, diagnosed in 6-month time windows (e.g. 0-6 months, >6-12 months, >12-18 months, >18-24 months).']",,,,,35,United States,"Mayo Clinic [Phoenix, United States] | Scottsdale Medical Imaging Research [Scottsdale, United States] | Sutter Health [Elk Grove, United States] | Sutter Health [Folsom, United States] | Sutter Health [Mountain View, United States] | Sutter Health [Oakland, United States] | Sutter Health [Palo Alto, United States] | Sutter Health [Roseville, United States] | Sutter Health [Sacramento, United States] | Sutter Health [San Francisco, United States] | Sutter Health [San Mateo, United States] | Sutter Health [Santa Cruz, United States] | Sutter Health [Santa Rosa, United States] | Mayo Clinic [Jacksonville, United States] | Sarah Cannon Research Institute [Snellville, United States] | Sarah Cannon Research Institute [Overland Park, United States] | Henry Ford Health System [Dearborn, United States] | Henry Ford Health System [Detroit, United States] | Henry Ford Health System [Grosse Pointe Farms, United States] | Henry Ford Health System [Livonia, United States] | Mayo Clinic [Rochester, United States] | Sarah Cannon Research Institute [Independence, United States] | Cleveland Clinic [Avon, United States] | Cleveland Clinic [Beachwood, United States] | Cleveland Clinic [Cleveland, United States] | Sarah Cannon Research Institute [Charleston, United States] | Sarah Cannon Research Institute [Hermitage, United States] | Sarah Cannon Research Institute [Nashville, United States] | Sarah Cannon Research Institute [McKinney, United States] | Sarah Cannon Research Institute [Salt Lake City, United States] | Sarah Cannon Research Institute [Richmond, United States] | Sarah Cannon Research Institute [Richmond, United States] | Sarah Cannon Research Institute [Salem, United States] | Mayo Clinic [Eau Claire, United States] | Mayo Clinic [La Crosse, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes the development of a new blood test (GRAIL Test) for the early detection of multiple cancer types, indicating it is a New Medicine.",INDUSTRY,False,2024.0,1.0,0,NA/Other
NCT03088527,"Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer","A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",COMPLETED,PHASE1,"Stemline Therapeutics, Inc.",2017-10-23,2020-08-28,2020-09-24,2017-03-23,2022-08-18,"['Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment', 'Number of adverse events related to study treatment', 'Number participants with dose interruptions and dose adjustments']","['Maximum plasma concentration (Cmax)', 'Time to maximum plasma concentration (Tmax)', 'Area under the plasma concentration versus time curve (AUC)', 'Tumor response']",,,,,5,United States,"Yale Cancer Center [New Haven, United States] | Cancer Center Protocol Office [Boston, United States] | Barbara Ann Karmanos Cancer Center [Detroit, United States] | Washington University School of Medicine [St Louis, United States] | Sarah Cannon Research Institute [Nashville, United States]",2017.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03089918,A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,An Open-Label Microdosing Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,COMPLETED,PHASE1,"Janssen Research & Development, LLC",2017-05-17,2018-08-24,2018-08-24,2017-03-24,2025-04-27,"['Effective Radiation Dose Following Injection of 11C-JNJ-63779586 (Part A)', 'Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 11C-JNJ-63779586 (Part B)', 'Percent Intact Tracer of 11C-JNJ-63779586 in Blood Samples (Part B)', 'Radiometabolite Fraction of 11C-JNJ-63779586 in Blood Samples (Part B)']",['Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Part A and Part B)'],,,,,2,Belgium,"UZ Leuven [Leuven, Belgium] | University of Antwerpen [Wilrijk, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,The text describes a study involving a specific drug (11C-JNJ-63779586) which indicates it is a new medicine being investigated for its effects on brain drug transporters.,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03093350,TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer,Tumor Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Breast Cancer,COMPLETED,PHASE2,Baylor College of Medicine,2017-10-10,2019-05-30,2024-08-23,2017-03-28,2025-08-29,['The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion) According to the RECIST Criteria'],"['Median Progression-free Survival', 'Median Overall Survival']","[{""type"":""PRIMARY"",""title"":""The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion) According to the RECIST Criteria"",""timeFrame"":""12 weeks"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Median Progression-free Survival"",""timeFrame"":""1 year"",""unit"":""days"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""69.5"",""spread"":null,""lower"":""13"",""upper"":""72""}]},{""type"":""SECONDARY"",""title"":""Median Overall Survival"",""timeFrame"":""1 year"",""unit"":""days"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""116"",""spread"":null,""lower"":""37"",""upper"":""NA""}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""TAA-Specific CTLs"",""n"":""12""}]},{""type"":""Started Treatment"",""achievements"":[{""group"":""TAA-Specific CTLs"",""n"":""10""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""TAA-Specific CTLs"",""n"":""10""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""TAA-Specific CTLs"",""n"":""2""}]}],""dropWithdraws"":[{""type"":""Death"",""reasons"":[{""group"":""TAA-Specific CTLs"",""n"":""1""}]},{""type"":""Signed consent, never began treartment"",""reasons"":[{""group"":""TAA-Specific CTLs"",""n"":""1""}]}]}]}","[{""title"":""Age, Continuous"",""unit"":""years"",""paramType"":""MEAN"",""dispersionType"":""STANDARD_DEVIATION"",""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""58.80"",""spread"":""11.91""}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""10"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""1"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""9"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""10"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null},{""group"":""TAA-Specific CTLs"",""value"":""0"",""spread"":null}]}]","[{""group"":""TAA-Specific CTLs"",""serious_affected"":1,""serious_at_risk"":10,""other_affected"":7,""other_at_risk"":10}]",2,United States,"Houston Methodist Hospital [Houston, United States] | Smith Clinic - Harris Health System [Houston, United States]",2017.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response"",""Overall Survival""]",2,1,1,1,1,0,1,0,1,5,0,0,1,0,"The trial involves the administration of TAA Specific Cytotoxic T Lymphocytes, which indicates a new treatment approach for breast cancer, suggesting it is a New Medicine.",OTHER,True,2024.0,1.0,0,Phase 2
NCT03107663,⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma,"A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Selected Solid Malignancies (Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Squamous Cell Carcinoma Head and Neck (SqCCHN), Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma",COMPLETED,PHASE1,"ImaginAb, Inc.",2017-06-19,2018-08-16,2018-08-16,2017-04-11,2018-09-18,"['Safety and tolerability of ⁸⁹Zr-Df-IAB22M2C assessed by local and systemic signs and symptoms of infusion reactions,incidence of adverse events,changes in laboratory test results,dose limiting toxicities,vital signs and 12-lead electrocardiogram findings']","['Evaluate imaging time window with ⁸⁹Zr-Df-IAB22M2C', 'Evaluate protein dose for imaging with ⁸⁹Zr-Df-IAB22M2C', 'Evaluate the radioactive pharmacokinetics of ⁸⁹Zr-Df-IAB22M2C by determining the time-activity curves for serum (% injected dose/liter), AUC, clearance, volume of distribution, Tmax and Cmax.', 'Evaluate the dosimetry of a single dose of ⁸⁹Zr-Df-IAB22M2C']",,,,,3,United States,"Honor Health and Imaging Endpoints [Scottsdale, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University of Pennsylvania [Philadelphia, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03109080,Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC),"A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease",COMPLETED,PHASE1,Institut Curie,2017-07-24,2020-02-17,2021-11-29,2017-04-12,2024-01-31,['Determination of the Maximal Tolerated Dose of Olaparib administered with concurrent loco regional radiotherapy'],"['Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence and severity of laboratory abnormalities, graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence of acute toxicity 2 weeks and 6 weeks after the end of radiotherapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence of late toxicity at 1 year and at 2 years as of initiation of radiation therapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence of treatment discontinuations and treatment modifications due to AEs to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Evaluation of the Objective Response Rate (ORR) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of the Complete Response Rate to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of Pathological Response Rate (pRR) after salvage surgery to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of the loco-regional Progression Free Survival (l-PFS) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of the Progression Free Survival (PFS) or Disease Free survival (DFS) according to stage of disease to evaluate patient outcome', 'Evaluation of the distant relapse rate to evaluate patient outcome', 'Evaluation of patient outcome by evaluation of the Overall Survival (OS).', 'Evaluation of patient outcome by evaluate disease specific survival rate.', 'Explore biomarkers of Olaparib activity in combination with concurrent radiotherapy.']",,,,,1,France,"Institut Curie [Paris, France]",2017.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT03113825,"Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery","An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery",COMPLETED,PHASE2,"Avelas Biosciences, Inc.",2017-07-05,2020-04-08,2020-11-18,2017-04-14,2021-06-11,['Determine the accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.'],"['Safety of AVB-620 as assessed by incidence of adverse events and abnormal laboratory values.', 'Identify malignant tissue types that provide the most robust fluorescence response compared to non-malignant tissue.', 'Evaluate timing of AVB-620 administration on optical fluorescence characteristics']",,,,,13,United States,"UCSD [San Diego, United States] | Medstar Washington Hospital [Washington D.C., United States] | Mayo Clinic Jacksonville -- Center for Breast Health [Jacksonville, United States] | Moffitt Cancer Center [Tampa, United States] | Advocate Good Shepherd Hospital [Barrington, United States] | William Beaumont Hospital [Royal Oak, United States] | UNLV School of Medicine [Las Vegas, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Montefiore Einstein Center for Cancer Care [The Bronx, United States] | University Hospitals Cleveland Medical Center [Cleveland, United States] | Ohio State University, James Cancer Center [Columbus, United States] | Roper St. Francis Hospital [Charleston, United States] | Swedish Cancer Institute [Seattle, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is studying AVB-620, which appears to be a new treatment or imaging agent for breast cancer, indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,0,Phase 2
NCT03134638,A Study of SY-1365 in Adult Patients With Advanced Solid Tumors,"A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors",TERMINATED,PHASE1,Syros Pharmaceuticals,2017-05-12,2020-05-15,2020-06-24,2017-05-01,2021-03-09,"['(Part 1) First-cycle dose-limiting toxicities (DLTs)', '(Part 1) ECG QTc Interval', '(Part 1 and 2) Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]']","['Peak Plasma Concentration (Cmax) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only)', 'Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-last) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only)', 'Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-INF) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only)', '(Part 1 and 2) Terminal elimination half life (t1/2)', '(Part 1 and 2) Evaluate the PD effects of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin or fulvestrant (Part 2 only)', '(Part 2) Evaluation of Objective Response Rate (ORR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1', '(Part 2) Evaluation of Duration of Response (DoR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1', '(Part 2) Evaluation of Disease Control Rate (DCR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1']",,,,,20,Canada; France; United States,"University of Alabama at Birmingham [Birmingham, United States] | Honor Health Research Institute [Scottsdale, United States] | Palo Alto Medical Foundation Group [San Francisco, United States] | University of Chicago Medical Center [Chicago, United States] | Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Columbia University Medical Center [New York, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Willamette Valley Cancer Institute and Research Center [Eugene, United States] | Women and Infants Hospital of Rhode Island [Providence, United States] | Tennessee Oncology [Nashville, United States] | Texas Oncology [Austin, United States] | University of Texas Southwestern Medical Center [Dallas, United States] | Texas Oncology [Fort Worth, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Hamilton Health Sciences [Hamilton, Canada] | McGill University Health Center [Montreal, Canada] | Centre Léon Bérard [Lyon, France] | Institut de Cancérologie de l'Ouest [Saint-Herblain, France] | Institut Gustave Roussy [Villejuif, France]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03135171,Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,COMPLETED,PHASE1,University of Michigan Rogel Cancer Center,2017-07-26,2020-03-16,2020-03-20,2017-05-01,2021-09-10,['Recommended Phase II Dose of Tocilizumab'],['The Frequency of Adverse Events at Each Dose Level'],,,,,3,United States,"University of Chicago [Chicago, United States] | University of Michigan Comprehensive Cancer Center [Ann Arbor, United States] | Yale University [New Haven, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT03145909,"A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)","A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)",TERMINATED,PHASE1,AbbVie,2017-07-03,2018-11-27,2018-11-27,2017-05-09,2018-11-29,"['Dose Escalation Cohort: Tmax of ABBV-176', 'Dose Escalation Cohort: AUC∞ for ABBV-176', 'Dose Escalation Cohort: Terminal phase elimination rate constant (β) for ABBV-176', 'Dose Escalation Cohort: Recommended Phase 2 dose (RPTD) for ABBV-176', 'Dose Escalation Cohort: Cmax of ABBV-176', 'Dose Escalation Cohort: Maximum tolerated dose (MTD) of ABBV-176', 'Expanded Recommended Phase Two Dose (RPTD) Cohort: Objective Response Rate (ORR)', 'Dose Escalation Cohort: AUCt for ABBV-176', 'Dose Escalation Cohort: t1/2 for ABBV-176']","['Expanded RPTD Cohort: AUCt for ABBV-176', 'Expanded RPTD Cohort: Tmax of ABBV-176', 'Expanded RPTD Cohort: Overall Survival (OS)', 'Expanded RPTD Cohort: Cmax of ABBV-176', 'Expanded RPTD Cohort: Duration of Response (DOR)', 'Expanded RPTD Cohort: Terminal phase elimination rate constant (β) for ABBV-176', 'Expanded Recommended Phase Two Dose (RPTD) Cohort: Progression-Free Survival (PFS)', 'Expanded RPTD Cohort: Change in ECOG Performance Status', 'Expanded RPTD Cohort: AUC∞ for ABBV-176', 'Expanded RPTD Cohort: t1/2 for ABBV-176', 'Dose Escalation Cohort: Change from Baseline in QTcF']",,,,,11,Australia; Denmark; Spain; United States,"HonorHealth Research Institute - Pima /ID# 161078 [Scottsdale, United States] | City of Hope /ID# 161079 [Duarte, United States] | Yale University /ID# 201357 [New Haven, United States] | St. Lukes Cancer Institute /ID# 201353 [Kansas City, United States] | Washington University-School of Medicine /ID# 162745 [St Louis, United States] | Rutgers Cancer Institute of NJ /ID# 161080 [New Brunswick, United States] | University of Utah /ID# 161606 [Salt Lake City, United States] | Sydney Children's Hospital /ID# 162917 [Randwick, Australia] | Mater Misericordiae /ID# 162918 [South Brisbane, Australia] | Rigshospitalet /ID# 159707 [Copenhagen Ø, Denmark] | Hosp Univ Madrid Sanchinarro /ID# 161644 [Madrid, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT03153163,Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer,A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy,COMPLETED,PHASE1,Hoffmann-La Roche,2017-06-20,2018-09-27,2018-09-27,2017-05-15,2018-11-23,"[""Area Under the Concentration-Time Curve [AUC] of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Maximum Serum Concentration (Cmax) Immediately After Dosing of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Minimum (Trough) Concentration (Cmin) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Clearance (CL) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Volume of Distribution at Steady-State (Vss) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Half-Life (t1/2) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1""]","['Percentage of Participants with Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.03 (NCI CTCAE V4.03)']",,,,,1,China,"Fudan University Shanghai Cancer Center; Medical Oncology [Shanghai, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03154281,Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast,A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Gynecologic Malignancies and Breast Cancer,COMPLETED,PHASE1,Avera McKennan Hospital & University Health Center,2017-07-26,2021-04-21,2023-05-01,2017-05-16,2024-08-01,['Number of Patients Who Developed Does-limiting Toxicity (DLT)'],"['Number of Patients With Beneficial Clinical Response', 'Number of Patients With Tumor Objective Response']","[{""type"":""PRIMARY"",""title"":""Number of Patients Who Developed Does-limiting Toxicity (DLT)"",""timeFrame"":""From the start of treatment to 30 days after the first dose of study drug"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Cohort 1"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 2"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 3"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 4"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Number of Patients With Beneficial Clinical Response"",""timeFrame"":""From beginning of study to the end of the 2nd cycle, and then at 16 weeks if the patient has stable disease or better."",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Cohort 1"",""value"":""5"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 2"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 3"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 4"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Number of Patients With Tumor Objective Response"",""timeFrame"":""From beginning of study to the end of the 2nd cycle, and then at 16 weeks if the patient has stable disease or better."",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Cohort 1"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 2"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 3"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Cohort 4"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Progression Free Survival (in Months)"",""timeFrame"":""From beginning of study to the end of the 2nd cycle, and then at 16 weeks if the patient has stable disease or better"",""unit"":""months"",""paramType"":""MEDIAN"",""dispersionType"":""Full Range"",""groups"":[{""group"":""Cohort 1"",""value"":""3.7"",""spread"":null,""lower"":""1.2"",""upper"":""7.3""},{""group"":""Cohort 2"",""value"":""2.4"",""spread"":null,""lower"":""1.8"",""upper"":""6.8""}]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Overall Survival"",""timeFrame"":""From the end of treatment till 2 years following the last dose"",""unit"":""months"",""paramType"":""MEDIAN"",""dispersionType"":""Full Range"",""groups"":[{""group"":""Cohort 1"",""value"":""16.1"",""spread"":null,""lower"":""1.9"",""upper"":""36.4""},{""group"":""Cohort 2"",""value"":""16.6"",""spread"":null,""lower"":""4.3"",""upper"":""32.5""}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Cohort 1"",""n"":""8""},{""group"":""Cohort 2"",""n"":""6""},{""group"":""Cohort 3"",""n"":""0""},{""group"":""Cohort 4"",""n"":""0""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Cohort 1"",""n"":""7""},{""group"":""Cohort 2"",""n"":""4""},{""group"":""Cohort 3"",""n"":""0""},{""group"":""Cohort 4"",""n"":""0""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Cohort 1"",""n"":""1""},{""group"":""Cohort 2"",""n"":""2""},{""group"":""Cohort 3"",""n"":""0""},{""group"":""Cohort 4"",""n"":""0""}]}],""dropWithdraws"":[]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Cohort 1"",""value"":""0"",""spread"":null},{""group"":""Cohort 2"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Cohort 1"",""value"":""3"",""spread"":null},{""group"":""Cohort 2"",""value"":""4"",""spread"":null},{""group"":""Total"",""value"":""7"",""spread"":null},{""group"":""Cohort 1"",""value"":""5"",""spread"":null},{""group"":""Cohort 2"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""7"",""spread"":null}]},{""title"":""Age, Continuous"",""unit"":""years"",""paramType"":""MEDIAN"",""dispersionType"":""FULL_RANGE"",""groups"":[{""group"":""Cohort 1"",""value"":""67.5"",""spread"":null},{""group"":""Cohort 2"",""value"":""62"",""spread"":null},{""group"":""Total"",""value"":""64.5"",""spread"":null}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Cohort 1"",""value"":""8"",""spread"":null},{""group"":""Cohort 2"",""value"":""6"",""spread"":null},{""group"":""Total"",""value"":""14"",""spread"":null},{""group"":""Cohort 1"",""value"":""0"",""spread"":null},{""group"":""Cohort 2"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null}]},{""title"":""Race and Ethnicity Not Collected"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Total"",""value"":""0"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Cohort 1"",""value"":""8"",""spread"":null},{""group"":""Cohort 2"",""value"":""6"",""spread"":null},{""group"":""Total"",""value"":""14"",""spread"":null}]}]","[{""group"":""Cohort 1"",""serious_affected"":3,""serious_at_risk"":8,""other_affected"":8,""other_at_risk"":8},{""group"":""Cohort 2"",""serious_affected"":5,""serious_at_risk"":6,""other_affected"":6,""other_at_risk"":6},{""group"":""Cohort 3"",""serious_affected"":0,""serious_at_risk"":0,""other_affected"":0,""other_at_risk"":0},{""group"":""Cohort 4"",""serious_affected"":0,""serious_at_risk"":0,""other_affected"":0,""other_at_risk"":0}]",1,United States,"Avera Cancer Institute [Sioux Falls, United States]",2017.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response""]",1,1,1,1,1,0,1,0,1,5,0,0,1,0,,OTHER,True,2023.0,2.0,0,Phase 1
NCT03166085,PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer,COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2017-05-23,2021-12-14,2021-12-14,2017-05-24,2021-12-20,['Maximum Tolerated Dose (MTD)'],[],,,,,1,United States,"Memorial Sloan Kettering Cancer Center [New York, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves PU-H71, which is a new medicine being tested in combination with an existing treatment (Nab-paclitaxel) for a specific type of cancer.",OTHER,False,2021.0,4.0,0,Phase 1
NCT03183206,Safety and Efficiency of γδ T Cell Against Breast Cancer,γδ T Cell Immunotherapy for Treatment of Breast Cancer,COMPLETED,PHASE1; PHASE2,"Fuda Cancer Hospital, Guangzhou",2017-06-15,2018-06-15,2019-06-15,2017-06-12,2020-07-13,"['Relief degree of tumors', 'Progress free survival（PFS）', 'Overall survival（OS）']",[],,,,,1,China,"Biotherapy center in Fuda cancer hospital [Guangzhou, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text discusses a new immunotherapy approach using γδ T cells specifically for the treatment of breast cancer, indicating it is a new medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03195699,"Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers","Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients with Advanced Cancers",COMPLETED,PHASE1,"Tvardi Therapeutics, Incorporated",2017-11-15,2024-06-24,2024-06-24,2017-06-22,2025-03-21,"['Maximum Tolerated Dose of TTI-101', 'Pharmacokinetics - Cmax', 'Pharmacokinetics - Tmax', 'Pharmacokinetics - AUC(0-t)']","['Pharmacodynamics of TTI-101 in patients', 'Complete Response (CR) - Target Lesions', 'Partial Response (PR) - Target Lesions', 'Progressive Disease (PD) - Target Lesions', 'Stable Disease (SD) - Target Lesions', 'Complete Response (CR) - Non-target Lesions', 'Non-CR/Non-PD - Non-target Lesions', 'Progressive Disease (PD) - Non-target Lesions', 'Best Overall Response']",,,,,2,United States,"The University of Texas MD Anderson Cancer Center [Houston, United States] | Mays Cancer Center at University of Texas Health Science Center SA [San Antonio, United States]",2017.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT03199586,Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies,"First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies",COMPLETED,PHASE1,"Novita Pharmaceuticals, Inc.",2017-12-21,2020-05-07,2020-05-07,2017-06-27,2025-07-20,['Establish the safe recommended phase 2 dose'],"['Identify and characterize preliminary anti tumor activity', 'Characterize the pharmacokinetics of NP-G2-044', 'Tmax', 'Cmax']",,,,,3,United States,"HonorHealth Research Institute [Scottsdale, United States] | City of Hope National Medical Center [Duarte, United States] | Memorial Sloan Kettering Hospital [New York, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03201913,Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,Phase 1 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,COMPLETED,PHASE1,"TTC Oncology, LLC",2017-12-11,2019-12-31,2020-04-30,2017-06-28,2020-08-11,['MTD'],"['Best response to treatment', 'PFS', 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'Maximum Plasma Concentration (Cmax)', 'Half life', 'Area Under the Curve (AUC)']",,,,,4,United States,"HonorHealth Research Institute [Scottsdale, United States] | HealthPartners Institute, Regions Cancer Care Center [Saint Paul, United States] | Sanford Health [Sioux Falls, United States] | University of Wisconsin, Carbone Cancer Center [Madison, United States]",2017.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03202446,Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer,Phase 3 Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT) System in Advanced Breast Cancer,TERMINATED,PHASE3,Eske Corporation S.A.C,2016-06-13,2018-01,2018-01,2017-06-28,2018-02-23,['Overall Response Rate'],"['Overall Survival', 'Relative change in overall tumor burden', 'Health Related Quality of Life (HRQOL)']",,,,,4,Peru,"Clinica Ricardo Palma [Lima, Peru] | Hospital Maria Auxiliadora [Lima, Peru] | Hospital Nacional Arzobispo Loayza [Lima, Peru] | Hospital Nacional Guillermo Almenara Irigoyen [Lima, Peru]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial evaluates a new treatment method (Laser-Assisted Immunotherapy) for advanced breast cancer, indicating it is a new medicine.",INDUSTRY,False,2018.0,7.0,0,Phase 3
NCT03205176,"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas",COMPLETED,PHASE1,AstraZeneca,2017-06-30,2021-03-01,2021-04-08,2017-07-02,2021-05-06,['Incidence of dose-limiting toxicity (DLT).'],"['Peak plasma concentration (Cmax)', 'The urine concentration of AZD5153 and its co-former (if appropriate).', 'The effect of AZD 5153 on QTc interval.', 'Antitumor activity of AZD5153 in patients by assessing the disease control rate (DCR).', 'Antitumor activity of AZD5153 in patients by assessing progression free survival (PFS).', 'Antitumor activity of AZD5153 in patients by assessing overall response rate (ORR).', 'Antitumor activity of AZD5153 in patients by assessing duration of response (DoR).', 'Area under the plasma concentration versus time curve (AUC).', 'Time to reach peak plasma concentration (tmax).', 'Elimination half-lfe (t1/2).', 'Volume of distribution (Vd).', 'Clearance (CL).']",,,,,4,Canada; United States,"Research Site [Sarasota, United States] | Research Site [Oklahoma City, United States] | Research Site [Nashville, United States] | Research Site [Toronto, Canada]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03207529,Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer,Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,COMPLETED,PHASE1,M.D. Anderson Cancer Center,2019-06-07,2023-12-31,2023-12-31,2017-07-02,2024-10-10,['Maximum tolerated dose (MTD) of alpelisib in combination with enzalutamide'],"['Incidence of adverse events', 'Profession-free survival (PFS)', 'Clinical benefit rate (CBR) (complete response or partial response + prolonged stable disease)']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Alpelisib, which is being tested in combination with Enzalutamide for a specific patient population, indicating it is a new medicine approach rather than an extension of indication for an existing treatment.",OTHER,False,2023.0,2.0,0,Phase 1
NCT03219268,A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms,"A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms",COMPLETED,PHASE1,MacroGenics,2017-08-18,2023-02-08,2023-02-08,2017-07-17,2023-12-21,"['Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)', 'Number of participants with Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab)']","['Area Under the Plasma Concentration versus Time Curve (AUC) of tebotelimab', 'Maximum Plasma Concentration (Cmax) of tebotelimab and tebotelimab plus margetuximab', 'Time to reach maximum (peak) plasma concentration (Tmax) of tebotelimab and tebotelimab plus margetuximab', 'Trough plasma concentration (Ctrough) of tebotelimab', 'Total body clearance of the drug from plasma (CL) of tebotelimab', 'Apparent volume of distribution at steady state (Vss) of tebotelimab', 'Terminal half-life (t1/2) of tebotelimab', 'Number of patients with anti-drug antibody', 'Objective response rate (ORR)', 'Median Duration of response (DoR)', 'Progression-free survival (PFS)', 'Median Overall survival (OS)']",,,,,40,Australia; Bulgaria; Hong Kong; Poland; Spain; Thailand; Ukraine; United States,"Banner MD Anderson Cancer Center [Gilbert, United States] | USC/Norris Comprehensive Cancer Center [Los Angeles, United States] | UCLA Hematology & Oncology Clinic [Los Angeles, United States] | Hoag Memorial Hospital Presbyterian [Newport Beach, United States] | Florida Cancer Specialists & Research Institute [Sarasota, United States] | University of Chicago Medicine [Chicago, United States] | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins [Baltimore, United States] | Massachusetts General Hospital and Dana-Farber Cancer Institute [Boston, United States] | Duke University Medical Center [Durham, United States] | Cincinnati Children's Hospital Medical Center [Cincinnati, United States] | Stephenson Cancer Center, The University of Oklahoma [Oklahoma City, United States] | University of Pennsylvania, Abramson Cancer Center [Philadelphia, United States] | UPMC Hillman Cancer Center [Pittsburgh, United States] | Sarah Cannon Research Institute [Nashville, United States] | The University of Texas M.D. Anderson Cancer Center [Houston, United States] | St Vincent's Hospital Sydney [Darlinghurst, Australia] | Calvary Mater Newcastle [Waratah, Australia] | Southern Medical Day Care Centre [Wollongong, Australia] | Austin Health Melbourne [Heidelberg, Australia] | ""Complex Oncology Center - Burgas"" EOOD [Burgas, Bulgaria] | ""Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda"" EAD, Sofia [Sofia, Bulgaria] | Multiprofile Hospital for Active Treatment ""Serdika"" EOOD, Sofia [Sofia, Bulgaria] | Prince of Wales Hospital [Shatin, Hong Kong] | Pratia MCM Kraków [Krakow, Poland] | BioVirtus Research Site Sp. Z o.o. / Biovirtus Centrum Medyczne [Józefów, Poland] | Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy [Warsaw, Poland] | Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy [Warsaw, Poland] | Med-Polonia Sp. z o.o. [Poznan, Poland] | Vall d'Hebron Institute of Oncology [Barcelona, Spain] | Hospital Ruber Internacional [Madrid, Spain] | START Madrid-CIOCC, Hospital HM Sanchinarro [Madrid, Spain] | King Chulalongkorn Memorial Hospital [Bangkok, Thailand] | Maharaj Nakorn Chiang Mai Hospital [Chiang Mai, Thailand] | Songklanagarind Hospital [Songkhla, Thailand] | Communal Nonprofit Enterprise ""Cherkassy Regional Oncology Dispensary"" of Cherkassy Regional Council [Cherkassy, Ukraine] | Communal Nonprofit Enterprise Podillia Regional Center of Oncology of Vinnytsia Regional Council [Vinnytsia, Ukraine] | Communal Non-profit Enterprise ""City Clinical Hospital #4"" of Dnipro City Council [Dnipro, Ukraine] | Communal Nonprofit Enterprise ""Prykarpatsky Clinical Oncological Centre of Ivano-Frankivska Regional Council"" [Ivano-Frankivsk, Ukraine] | Municipal Non-Profit Enterprise of Sumy Regional Council ""Sumy Regional Clinical Oncology Dispensary"" [Sumy, Ukraine] | Communal Nonprofit Enterprise ""Central City Clinical Hospital of Uzhhorod City Council"", City Oncology Center, State Higher Educational Institution <<Uzhhorod National University>> [Uzhhorod, Ukraine]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT03238196,"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)",COMPLETED,PHASE1,Vanderbilt-Ingram Cancer Center,2017-08-18,2021-04-30,2024-03-20,2017-08-03,2024-11-14,['Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)'],"['Progression-free Survival', 'Overall Response Rate', 'Clinical Benefit Rate (CBR; Complete Response + Partial Response + Stable Disease Without Disease Progression at 6 Months)', 'Pharmacokinetic Assessment of Erdafitinib - Area Under the Curve (AUC)', 'Pharmacokinetic Assessment of Erdafitinib - Cmax (Maximum Plasma Concentration)', 'Pharmacokinetic Assessment of Erdafitinib - Tmax', 'Pharmacokinetic Assessment of Erdafitinib - CL/F', 'Incidence of Treatment-Emergent Adverse Events [Tolerability]']","[{""type"":""PRIMARY"",""title"":""Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)"",""timeFrame"":""From the time of randomization up to 4 weeks of treatment (cycle 1), for each patient"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Progression-free Survival"",""timeFrame"":""Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months"",""unit"":""weeks"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Escalation and Expansion"",""value"":""12.4"",""spread"":null,""lower"":""8.1"",""upper"":""22.0""}]},{""type"":""SECONDARY"",""title"":""Overall Response Rate"",""timeFrame"":""Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Escalation and Expansion"",""value"":""9.7"",""spread"":null,""lower"":""3.3"",""upper"":""24.9""}]},{""type"":""SECONDARY"",""title"":""Clinical Benefit Rate (CBR; Complete Response + Partial Response + Stable Disease Without Disease Progression at 6 Months)"",""timeFrame"":""From the time of randomization up to 6 months for each patient"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Escalation and Expansion"",""value"":""64.5"",""spread"":null,""lower"":""46.9"",""upper"":""78.9""}]},{""type"":""SECONDARY"",""title"":""Pharmacokinetic Assessment of Erdafitinib - Area Under the Curve (AUC)"",""timeFrame"":""From the time of randomization up to 4 weeks of treatment for each patient"",""unit"":""ng/ml.hr"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""1128"",""spread"":""608"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""718"",""spread"":""521"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""1268"",""spread"":""827"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Pharmacokinetic Assessment of Erdafitinib - Cmax (Maximum Plasma Concentration)"",""timeFrame"":""From the time of randomization up to 4 weeks of treatment for each patient"",""unit"":""ng/ml"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""875"",""spread"":""625"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""668"",""spread"":""528"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""737"",""spread"":""348"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Pharmacokinetic Assessment of Erdafitinib - Tmax"",""timeFrame"":""From the time of randomization up to 4 weeks of treatment for each patient"",""unit"":""hour"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""2.8"",""spread"":""2.5"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""2.5"",""spread"":""1.8"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""2.8"",""spread"":""2.5"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Pharmacokinetic Assessment of Erdafitinib - CL/F"",""timeFrame"":""From the time of randomization up to 4 weeks of treatment for each patient"",""unit"":""l/hr"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""5.5"",""spread"":""2.6"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""11.3"",""spread"":""5.5"",""lower"":null,""upper"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""8.6"",""spread"":""4.6"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Incidence of Treatment-Emergent Adverse Events [Tolerability]"",""timeFrame"":""From date of randomization until 28 days post treatment discontinuation from any cause, assessed up to 48 months"",""unit"":""patients"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""27"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""29"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""18"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""14"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""19"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""19"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""18"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""13"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""8"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""13"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""12"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""7"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""9"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""10"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""6"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""5"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""3"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""5"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""3"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""3"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""25"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""15"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""12"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""15"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""6"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Escalation (6mg-8mg) and Expansion"",""value"":""6"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Serial Measurements of Serum Phosphate, Calcium, Vitamin D, Parathyroid Hormone (PTH), FGF23, sFGFR2, sFGFR3, and sFGFR4"",""timeFrame"":""During the first 8 weeks of treatment (days 1, 8, 15, 22 of cycle 1 and days 1 and 15 of cycle 2)"",""unit"":null,""paramType"":null,""dispersionType"":null,""groups"":[]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""FGFR1 Amplification Levels by FISH and cfDNA"",""timeFrame"":""At study entry (baseline)"",""unit"":null,""paramType"":null,""dispersionType"":null,""groups"":[]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Next Generation Sequencing"",""timeFrame"":""At study entry (baseline)"",""unit"":null,""paramType"":null,""dispersionType"":null,""groups"":[]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Plasma Cell-free Deoxyribonucleic Acid (cfDNA)"",""timeFrame"":""At study entry (baseline), at 4 weeks, and at study discontinuation from disease progression (for each patient), assessed up to 48 months."",""unit"":null,""paramType"":null,""dispersionType"":null,""groups"":[]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Expansion"",""n"":""22""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""3""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""6""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""4""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Expansion"",""n"":""0""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""0""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""0""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""0""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Expansion"",""n"":""22""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""3""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""6""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""4""}]}],""dropWithdraws"":[{""type"":""Adverse Event"",""reasons"":[{""group"":""Expansion"",""n"":""3""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""0""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""2""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""2""}]},{""type"":""Withdrawal by Subject"",""reasons"":[{""group"":""Expansion"",""n"":""4""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""1""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""1""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""0""}]},{""type"":""Disease progression"",""reasons"":[{""group"":""Expansion"",""n"":""14""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""2""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""3""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""2""}]},{""type"":""Still on treatment"",""reasons"":[{""group"":""Expansion"",""n"":""1""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""n"":""0""},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""n"":""0""},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""n"":""0""}]}]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Expansion"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Expansion"",""value"":""18"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""2"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""5"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Total"",""value"":""28"",""spread"":null},{""group"":""Expansion"",""value"":""4"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""1"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""1"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""1"",""spread"":null},{""group"":""Total"",""value"":""7"",""spread"":null}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Expansion"",""value"":""22"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""6"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""4"",""spread"":null},{""group"":""Total"",""value"":""35"",""spread"":null},{""group"":""Expansion"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Expansion"",""value"":""1"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""1"",""spread"":null},{""group"":""Expansion"",""value"":""14"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""1"",""spread"":null},{""group"":""Total"",""value"":""21"",""spread"":null},{""group"":""Expansion"",""value"":""7"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Total"",""value"":""13"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Expansion"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Expansion"",""value"":""2"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""1"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null},{""group"":""Expansion"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Expansion"",""value"":""1"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""1"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""2"",""spread"":null},{""group"":""Expansion"",""value"":""17"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""2"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""24"",""spread"":null},{""group"":""Expansion"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Expansion"",""value"":""2"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""0"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""2"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""6"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Expansion"",""value"":""22"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg (Escalation)"",""value"":""3"",""spread"":null},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg (Escalation)"",""value"":""6"",""spread"":null},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg (Escalation)"",""value"":""4"",""spread"":null},{""group"":""Total"",""value"":""35"",""spread"":null}]}]","[{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 5mg"",""serious_affected"":1,""serious_at_risk"":3,""other_affected"":3,""other_at_risk"":3},{""group"":""Expansion"",""serious_affected"":5,""serious_at_risk"":22,""other_affected"":22,""other_at_risk"":22},{""group"":""Fulvestrant 500mg/Palbociclib 125mg/Erdafitinib 6mg"",""serious_affected"":1,""serious_at_risk"":6,""other_affected"":6,""other_at_risk"":6},{""group"":""Fulvestrant 500mg, Palbociclib 125mg and Erdafitinib 8mg"",""serious_affected"":1,""serious_at_risk"":4,""other_affected"":4,""other_at_risk"":4}]",6,United States,"University of Alabama [Birmingham, United States] | Memorial Sloan-Kettering Cancer Center [New York, United States] | University of Pittsburgh Medical Center [Pittsburgh, United States] | Baptist Memorial Hospital MEMPHIS [Memphis, United States] | Vanderbilt-Ingram Cancer Center [Nashville, United States] | University of Texas Southwestern Simmons Comprehensive Cancer Center [Dallas, United States]",2017.0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival"",""Overall Response""]",3,1,1,1,1,0,1,0,1,5,1,0,1,0,"The trial involves Erdafitinib, which is identified as a new pan-FGFR tyrosine kinase inhibitor being tested in combination with other agents for a specific cancer indication, indicating it is a new medicine.",OTHER,True,2024.0,1.0,0,Phase 1
NCT03240224,Bioinformation Therapy for Breast Cancer,Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Breast Cancer,COMPLETED,PHASE2; PHASE3,"Fuda Cancer Hospital, Guangzhou",2017-09-02,2018-09-02,2018-09-02,2017-08-07,2019-01-25,['Relief degree of tumors'],"['Progress free survival（PFS）', 'Overall survival（OS）']",,,,,1,China,"Fuda cancer institute of Fuda cancer hospital [Guangzhou, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a new therapy approach (Bioinformation Therapy) for treating breast cancer, indicating it is a new medicine rather than an extension of an existing indication.",OTHER,False,2018.0,7.0,0,Phase 3
NCT03242239,A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects,"A Randomized, Double-Blind, Parallel, Phase I Pharmacokinetic Trial Comparing The Potential Biosimilar ALT02(Trastuzumab) With Herceptin in Healthy Volunteers",COMPLETED,PHASE1,"Alteogen, Inc.",2016-02-09,2016-08-04,2016-09-30,2017-08-08,2017-08-21,['AUC0-inf: area under the concentration-time curve from time zero to infinity'],"['AUC0-t: area under the concentration-time curve from time zero to the last non-zero concentration', 'Cmax: maximum observed concentration', 'Tmax: time of observed Cmax', 'Kel: apparent terminal elimination rate constant', 'T½ el: apparent terminal half-life', 'CL: apparent body clearance, calculated as Dose/AUC0-inf', 'Vd: apparent volume of distribution, calculated as Dose/(kel x AUC0-inf)']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2016.0,9.0,0,Phase 1
NCT03243331,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,COMPLETED,PHASE1,Kathy Miller,2018-01-19,2020-05-27,2020-05-27,2017-08-09,2021-01-07,['Safety of Gedatolisb + PTK7-ADC using NCI CTCAE v4.0'],"['Efficacy in all enrolled subjects', 'Overall response rate in all enrolled subjects', 'Progression free survival in all enrolled subjects', 'Pharmacodynamic determination of inhibition of PI3k signaling', 'Pharmacodynamic determination modulation of Wnt pathway', 'Pharmacodynamic determination modulation of Wnt pathway']",,,,,1,United States,"IU Simon Cancer Center [Indianapolis, United States]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Gedatolisib, which is being tested in combination with PTK7-ADC for a specific cancer type, indicating it is a new medicine being evaluated for safety and efficacy.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03255070,"A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)","A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression",COMPLETED,PHASE1,"Ambrx, Inc.",2018-03-20,2023-09-13,2023-10-18,2017-08-21,2024-02-01,"['Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)', 'Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.']","['Number of subjects with tumor response per imaging assessment based on RECIST version 1.1.', 'Area under the concentration-time curve (AUC) from first infusion to subject end of study.', 'Half-life of ARX788 from first infusion to end of study.', 'Immunogenicity profile of ARX788']",,,,,12,Australia; United States,"USC Norris Cancer Hospital [Los Angeles, United States] | UCLA Hematology-Oncology [Santa Monica, United States] | Washington University School of Medicine [St Louis, United States] | Cleveland Clinic [Cleveland, United States] | Baylor Sammons Cancer Center [Dallas, United States] | Research Site [East Albury, Australia] | Research Site [North Sydney, Australia] | Mater Misericordiae Limited [South Brisbane, Australia] | Princess Alexandria Hospital [Woolloongabba, Australia] | Monash Health [Clayton, Australia] | Research Site [Frankston, Australia] | Research Site [Nedlands, Australia]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is focused on ARX788, which is being studied as a new treatment for advanced solid tumors with HER2 expression, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT03284957,Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,"A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer",TERMINATED,PHASE1; PHASE2,Sanofi,2017-09-20,2024-11-08,2024-11-08,2017-09-15,2024-12-06,"['Dose Limiting Toxicities (DLTs)', 'Objective Response Rate (ORR)', 'Adverse Events']","['Adverse Events', 'ORR', 'Time to First Response (TTR)', 'Clinical Benefit Rate (CBR)', 'Duration of response', 'tlag of amcenestrant after single dose', 'tmax of amcenestrant after single dose', 'Cmax of amcenestrant after single dose', 'AUC0-24 of amcenestrant after single dose', 'tmax of amcenestrant after repeated dose administration', 'Cmax of amcenestrant after repeated dose administration', 'AUC0-24 of amcenestrant after repeated dose administration', 'Ctrough of amcenestrant during repeated dose administration', 'tmax of palbociclib after single dose', 'Cmax of palbociclib after single dose', 'AUC0-24 of palbociclib after single dose', 'tmax of palbociclib after repeated dose administration', 'Cmax of palbociclib after repeated dose administration', 'AUC0-24 of palbociclib after repeated dose administration', 'Urine excretion of amcenestrant', 'Cholesterol concentration ratios', 'ER occupancy at 18F-FES-PET imaging', 'Progression free survival', 'Observation of tumor changes by FES PET and FDG PET scans', 'tmax of alpelisib after third dose', 'Cmax of alpelisib after third dose', 'AUC0-24 of alpelisib after third dose', 'tmax of alpelisib after repeated dose administration', 'Cmax of alpelisib after repeated dose administration', 'AUC0-24 of alpelisib after repeated dose administration', 'tmax of everolimus after single dose', 'Cmax of everolimus after single dose', 'AUC0-24 of everolimus after single dose', 'tmax of everolimus after repeated dose administration', 'Cmax of everolimus after repeated dose administration', 'AUC0-24 of everolimus after repeated dose administration', 'tmax of abemaciclib after single dose', 'Cmax of abemaciclib after single dose', 'AUC0-24 of abemaciclib after single dose', 'tmax of abemaciclib after repeated dose administration', 'Cmax of abemaciclib after repeated dose administration', 'AUC0-24 of abemaciclib after repeated dose administration']",,,,,25,Belgium; Canada; Czechia; France; Italy; Poland; Portugal; Spain; United Kingdom; United States,"University of Colorado- Site Number : 8400005 [Denver, United States] | Massachusetts General Hospital Site Number : 8400002 [Boston, United States] | Memorial Sloan Kettering Cancer Center- Site Number : 8400003 [New York, United States] | Seattle Cancer Care Alliance- Site Number : 8400001 [Seattle, United States] | Investigational Site Number : 0560001 [Leuven, Belgium] | Investigational Site Number : 1240004 [Edmonton, Canada] | Investigational Site Number : 1240003 [Vancouver, Canada] | Investigational Site Number : 1240002 [Toronto, Canada] | Investigational Site Number : 2030002 [Brno, Czechia] | Investigational Site Number : 2030001 [Prague, Czechia] | Investigational Site Number : 2030003 [Prague, Czechia] | Investigational Site Number : 2500002 [Bordeaux, France] | Investigational Site Number : 2500005 [Lille, France] | Investigational Site Number : 2500003 [Lyon, France] | Investigational Site Number : 2500001 [Saint-Herblain, France] | Investigational Site Number : 2500004 [Villejuif, France] | Investigational Site Number : 3800003 [Milan, Italy] | Investigational Site Number : 6160004 [Gdynia, Poland] | Investigational Site Number : 6200001 [Lisbon, Portugal] | Investigational Site Number : 6200002 [Lisbon, Portugal] | Investigational Site Number : 7240007 [Madrid, Spain] | Investigational Site Number : 7240002 [Madrid, Spain] | Investigational Site Number : 7240001 [Madrid, Spain] | Investigational Site Number : 8260003 [Oxford, United Kingdom] | Investigational Site Number : 8260002 [Cardiff, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT03291886,Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer,Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer,COMPLETED,PHASE2,"Kyowa Kirin Co., Ltd.",2017-09-22,2019-04-04,2021-03-26,2017-09-25,2022-06-21,['Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)'],"['Overall survival (OS)', 'Antitumor effect']",,,,,28,Japan,"Aichi Cancer Center Hospital [Nagoya, Japan] | Nagoya City University Hospital [Nagoya, Japan] | Shikoku Cancer Center [Matsuyama, Japan] | Kitakyushu Municipal Medical Center [Kitakyushu, Japan] | Gunma Cancer Center [Ōta, Japan] | Hokkaido Cancer Center [Sapporo, Japan] | Hokkaido University Hospital [Sapporo, Japan] | The Hospital of Hyogo College of Medicine [Nishinomiya, Japan] | Tsukuba University Hospital [Tsukuba, Japan] | Tokai University Hospital [Isehara, Japan] | Kanagawa Cancer Center [Yokohama, Japan] | Nahanishi Clinic [Naha, Japan] | Kindai University Hospital [Sayama, Japan] | Osaka University Hospital [Suita, Japan] | Saitama Medical University International Medical Center [Hidaka, Japan] | Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital [Bunkyo, Japan] | National Cancer Center Hospital [Chūō, Japan] | The Cancer Institute Hospital of JFCR [Koto, Japan] | Toranomon Hospital [Minato, Japan] | Showa University Hospital [Shinagawa, Japan] | Chiba Cancer Center [Chiba, Japan] | Kyushu Cancer Center [Fukuoka, Japan] | Sagara Hospital [Kagoshima, Japan] | Kumamoto University Hospital [Kumamoto, Japan] | Kyoto University Hospital [Kyoto, Japan] | Niigata Cancer Center Hospital [Niigata, Japan] | Okayama University Hospital [Okayama, Japan] | Osaka National Hospital [Osaka, Japan]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on KHK2375, which is being studied in a specific patient population (advanced or recurrent breast cancer), indicating it is a new medicine being evaluated for efficacy in this context.",INDUSTRY,False,2021.0,4.0,0,Phase 2
NCT03291938,IACS-010759 in Advanced Cancers,A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,COMPLETED,PHASE1,M.D. Anderson Cancer Center,2017-11-13,2020-11-23,2020-11-23,2017-09-25,2020-11-24,"['Incidence of adverse events', 'Maximum tolerated dose']","['Maximum Plasma concentration of IACS-010759 [Cmax]', 'Overall response rate', 'Duration of response']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT03294694,Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer,TERMINATED,PHASE1,Dana-Farber Cancer Institute,2017-11-08,2020-10-14,2020-10-14,2017-09-27,2025-05-31,"['Cohort A: MTD/RP2D of the Combination of Ribociclib + PDR001', 'Cohort B: MTD/RP2D of the Combination of Ribociclib + PDR001 + Fulvestrant']","['Number of Participants with Adverse Events', 'Objective Response Rate']",,,,,3,United States,"Massachusetts General Hospital [Boston, United States] | Brigham and Women's Hospital [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT03308201,Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer,Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer,COMPLETED,PHASE1,"Tianjin Hemay Pharmaceutical Co., Ltd",2017-10-16,2022-06-30,2023-03-01,2017-10-12,2024-03-06,['Number of participants with adverse events'],"['Objective response rate (complete response rate + partial response rate) according to RECIST v1.1', 'Clinical benefit rate defined as percentage of patients with stable disease (SD) ≥ 6 months/partial response (PR)/complete response (CR). according to RECIST v1.1', 'Progression Free Survival defined as the proportion of patients alive and without progression (according to RECIST v1.1 criteria)', 'Observed maximum concentration of Hemay022 and exemestane', 'Time of maximum concentration of Hemay022 and exemestane', 'Area under the plasma concentration versus time curve of Hemay022 and exemestane', 'Trough Plasma Concentrations of Hemay022 and exemestane']",,,,,1,China,"Beijing Cancer Hospital [Beijing, China]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The study evaluates Hemay022, which is a new medicine being tested in combination with existing endocrine therapy for a specific type of breast cancer.",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT03310541,AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations,"A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3",COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2017-10-11,2023-05-03,2023-05-03,2017-10-16,2023-05-06,['number of patients with an objective response rate (ORR) of AZD5363'],[],,,,,3,United States,"Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Westchester [Harrison, United States] | Memorial Sloan Kettering Cancer Center [New York, United States]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a study of AZD5363, which is a new medicine being tested in patients with advanced solid tumors harboring specific mutations, suggesting it is not yet approved for this indication.",OTHER,False,2023.0,2.0,0,Phase 1
NCT03310957,Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer,"Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer",COMPLETED,PHASE1; PHASE2,Seagen Inc.,2018-02-27,2024-09-30,2024-09-30,2017-10-16,2024-12-20,"['Confirmed objective response rate', 'Incidence of adverse events', 'Incidence of laboratory abnormalities', 'Incidence of dose-limiting toxicities']","['Duration of response', 'Disease control rate', 'Progression-free survival', 'Overall survival']",,,,,50,Germany; South Korea; Spain; United States,"University of Alabama at Birmingham [Birmingham, United States] | Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute [Los Angeles, United States] | Chao Family Comprehensive Cancer Center University of California Irvine [Orange, United States] | University of California Irvine - Newport [Orange, United States] | Rocky Mountain Cancer Centers - Aurora [Aurora, United States] | The Whittingham Cancer Center / Norwalk Hospital [Norwalk, United States] | Helen F. Graham Cancer Center / Christiana Care Health Systems [Newark, United States] | Miami Cancer Institute at Baptist Health, Inc. [Miami, United States] | AdventHealth Cancer Institute [Orlando, United States] | H. Lee Moffitt Cancer Center and Research Institute [Tampa, United States] | Piedmont Cancer Institute [Atlanta, United States] | Winship Cancer Institute / Emory University School of Medicine [Atlanta, United States] | Ingalls Cancer Care / Ingalls Memorial Hospital [Harvey, United States] | Cardinal Bernardin Cancer Center / Loyola University Medical Center [Maywood, United States] | University of Maryland [Baltimore, United States] | Allina Health Cancer Institute [Minneapolis, United States] | Saint Luke's Cancer Institute LLC [Kansas City, United States] | Summit Medical Group [Florham Park, United States] | New Mexico Cancer Center [Albuquerque, United States] | Weill Cornell Medicine [New York, United States] | University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center [Pittsburgh, United States] | Texas Oncology - DFW [Dallas, United States] | Texas Oncology - Houston Memorial City [Houston, United States] | Texas Oncology - San Antonio Medical Center Northeast [San Antonio, United States] | University of Virginia [Charlottesville, United States] | Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington [Seattle, United States] | Gynakologisches Zentrum Bonn Friedensplatz [Bonn, Germany] | Marien Hospital Bottrop [Bottrop, Germany] | Stadtisches Klinikum Dessau [Dessau, Germany] | Universitatsklinikum Erlangen [Erlangen, Germany] | Kliniken Essen-Mitte - Evang. Huyssens-Stiftung [Essen, Germany] | Rotkreuzklinikum Munich [Munich, Germany] | Klinikum der Universitat Munchen [München, Germany] | Klinikum Rechts der Isar der Technischen Universitaet Muenchen [München, Germany] | Pusan National University Hospital [Busan, South Korea] | CHA Bundang Medical Center [Seongnam, South Korea] | Korea Cancer Center Hospital [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | Complejo Hospitalario Universitario La Coruna [A Coruña, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Complejo Hospitalario de Jaen [Jaén, Spain] | L'Institut Catala d'Oncologia [L'Hospitalet de Llobregat, Spain] | MD Anderson Cancer Center - Madrid [Madrid, Spain] | Hospital Ruber Internacional [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | HM Centro Integral Oncologico Clara Campal [Madrid, Spain] | Hospital Universitario Quironsalud Madrid [Pozuelo de Alarcón, Spain]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is investigating SGN-LIV1A, which is a new treatment being tested in combination with Pembrolizumab for a specific type of cancer, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT03316794,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),TERMINATED,PHASE1,AbbVie,2018-01-04,2018-10-05,2018-10-05,2017-10-20,2018-12-17,['Number of Participants with Dose-limiting Toxicities (DLTs)'],"['QTcF Change from Baseline', 'Area Under the Plasma Concentration-time Curve (AUC)', 'Clinical benefit rate (CBR)', 'Maximum plasma concentration observed (Cmax)', 'Overall Survival (OS)', 'Observed Plasma Concentrations at Trough', 'Duration of Clinical Benefit (DOCB)', 'Objective Response Rate (ORR)Up to approximately 4 years', 'Time of Cmax (Tmax)', 'Progression Free Survival (PFS)', 'Duration of Response (DOR)']",,,,,8,United States,"University of Chicago /ID# 169231 [Chicago, United States] | Washington University School /ID# 169177 [St Louis, United States] | Memorial Sloan Kettering /ID# 201016 [New York, United States] | Gabrail Cancer Center Research /ID# 168756 [Canton, United States] | Oklahoma University /ID# 200937 [Oklahoma City, United States] | Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233 [Nashville, United States] | Baylor University /ID# 169860 [Houston, United States] | MD Anderson Cancer Center /ID# 169232 [Houston, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The study involves SC-005, which is being tested in subjects with Triple Negative Breast Cancer (TNBC), indicating it is a new medicine being evaluated for this specific condition.",INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03318562,A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC,A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma,TERMINATED,PHASE2,Effector Therapeutics,2017-11-21,2018-07-05,2019-01-22,2017-10-24,2019-07-18,['Level of biomarkers of antitumor activation'],"['Molecular profiling of circulating lymphocytes and tumor-infiltrating lymphocytes (TILs)', 'Levels of eIF4E and phospho-eIF4E', 'Number of mutations', 'Objective tumor response', 'Progression Free Survival', 'Proportion of subjects with TEAEs and SAEs', 'PK plasma concentrations']",,,,,2,United States,"City of Hope [Duarte, United States] | Kansas City Research Institute [Kansas City, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a pharmacodynamic study of oral eFT508, which suggests it is a new medicine being tested for advanced triple negative breast cancer and hepatocellular carcinoma.",INDUSTRY,False,2019.0,6.0,0,Phase 2
NCT03319459,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Fate Therapeutics,2018-01-18,2020-05-29,2020-12-15,2017-10-24,2021-11-22,['Incidence of dose-limiting toxicity (DLT)'],"['Objective-response rate (ORR)', 'Pharmacokinetics (PK) of FATE-NK100']",,,,,4,United States,"UCSD Moores Cancer Center [San Diego, United States] | University of Minnesota [Minneapolis, United States] | The Ohio State University James Cancer Hospital [Columbus, United States] | Baylor Scott & White Research Institute [Dallas, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing FATE-NK100, which is a new medicine being evaluated for its efficacy and safety in subjects with advanced solid tumors.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03322215,HR+/HER2- Advanced Breast Cancer and Endocrine Resistance,"A Phase 2, International, Multicenter, Open-labeled, Randomized Trial of PAlbociclib and Fulvestrant vs. Standard Oral Capecitabine In Patients With Hormone Receptor (HR)+ / HER2- Advanced Breast Cancer and Documented Endocrine Resistance",TERMINATED,PHASE2,Theodoros Foukakis,2017-10-24,2021-04-30,2023-10-31,2017-10-26,2024-03-08,"['Progression free survival (PFS), as assessed locally by the investigator.']","['Health related quality of life score EuroQol (EQ-5D)', 'Health related quality of life score EORTC QLQ-C30', 'Health related quality of life score EORTC QLQ-BR23', 'Correlation of efficacy measures with tumor Biomarkers', 'Correlation of efficacy measures with tumor Biomarkers', 'Correlation of efficacy measures with tumor Biomarkers', 'Correlation of efficacy measures with tumor Biomarkers', 'Correlation of efficacy measures with tumor Biomarkers', 'Overall survival (OS)', '1-year survival', '2-year survival', 'Objective response', 'Duration of response', 'Clinical Benefit Rate', 'Frequency of adverse events (AE)']",,,,,9,Sweden; United Kingdom,"Sahlgrenska University Hospital [Gothenburg, Sweden] | Skåne University Hospital [Malmo, Sweden] | S:t Görans Hospital [Stockholm, Sweden] | Karolinska University Hospital [Stockholm, Sweden] | Uppsala University Hospital [Uppsala, Sweden] | NHS Grampian [Aberdeen, United Kingdom] | Western General Hospital [Edinburgh, United Kingdom] | Beatson [Glasgow, United Kingdom] | NHS Ayshire and Arran [Kilmarnock, United Kingdom]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves a new combination of PAlbociclib and Fulvestrant for treating HR+/HER2- advanced breast cancer, indicating it is testing a new medicine approach.",OTHER,False,2023.0,2.0,1,Phase 2
NCT03328494,Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies,"A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies",COMPLETED,PHASE1,Boston Pharmaceuticals,2017-10-13,2021-03-16,2021-03-16,2017-11-01,2021-04-15,"['Incidence of adverse events (AEs)', 'Number of participants with a dose-limiting toxicity (DLT)']","['Part A Monotherapy: Plasma concentration of BOS172722 measured over 24 hours when administered alone', 'Part A Combination: Plasma concentration of BOS172722 and paclitaxel measured over 24 hours when administered either individually or in combination', 'Part B Expansion: Plasma concentration of BOS172722 and paclitaxel measured over 24 hours when administered in combination', 'Objective response rate (ORR)', 'Duration of response (DOR)', 'Time to response (TTR)', 'Time to progression on study']",,,,,3,United Kingdom,"Addenbrooks Hospital [Cambridge, United Kingdom] | Edinburgh Cancer Centre - Western General Hospital [Edinburgh, United Kingdom] | Royal Marsden [London, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves BOS172722, a new drug being tested in combination with Paclitaxel for advanced nonhaematologic malignancies, indicating it is a new medicine.",INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03328884,Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients,"Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)",COMPLETED,PHASE2,MedSIR,2017-05-02,2018-08-31,2025-04-02,2017-11-01,2025-04-23,['CNS Overall Response Rate (ORR)'],"['CNS disease stabilization on week 12', 'ORR, according to a volumetric parameter, and to the RECIST v.1.1 criteria', 'CBR', 'Safety profile of nal-IRI in this population by Common Terminology Criteria for Adverse Events version 4 (CTCAE v.4) criteria', 'Progression-Free Survival (PFS)', 'Overall Survival (OS)', 'Disease Control Rate', 'TTR', 'DoR', 'MTS']",,,,,16,Spain,"ICO [Badalona, Spain] | IOB Institute of Oncology - Quirón Barcelona [Barcelona, Spain] | Hospital Universitario Virgen de Las Nieves [Granada, Spain] | Hospital Universitario Clinico San Cecilio [Granada, Spain] | H. Ruber Juan Bravo [Madrid, Spain] | Hospital Clínico San Carlos [Madrid, Spain] | Hospital Doce de Octubre [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | MD Anderson Madrid [Madrid, Spain] | Hospital Clínico Virgen de la Victoria [Málaga, Spain] | Hospital Universitari Son Espases [Palma de Mallorca, Spain] | Son Llatzer [Palma de Mallorca, Spain] | Sant Joan de Reus [Reus, Spain] | Hospital Universitario Virgen del Rocío [Seville, Spain] | IVO [Valencia, Spain] | H. Miguel Servet [Zaragoza, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial evaluates Nal-IRI, which is a new formulation or application of an existing drug for a specific condition (brain metastases in breast cancer), indicating it is a new medicine.",OTHER,False,2025.0,0.0,0,Phase 2
NCT03329950,A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies,A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies,COMPLETED,PHASE1,Celldex Therapeutics,2017-12-01,2022-09-13,2022-09-13,2017-11-06,2024-03-28,['Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0'],"['Objective Response Rate', 'Clinical benefit rate', 'Duration of Response', 'Progression-free survival', 'Overall survival', 'Immunogenicity evaluation', 'Pharmacokinetic evaluation']",,,,,11,United States,"HonorHealth Research Insititute [Scottsdale, United States] | Northside Hospital, Inc. [Atlanta, United States] | Georgia Cancer Center at Augusta University [Augusta, United States] | Oncology Hematology West, PC dba Nebraska Cancer Specialists [Omaha, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Gabrail Cancer Center Research LLC [Canton, United States] | Providence Portland Medical Center [Portland, United States] | Abramson Cancer Center at the University of Pennsylvania [Philadelphia, United States] | Rhode Island Hospital (RIH) The Miriam Hospital (TMH) [Providence, United States] | Houston Methodist [Houston, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03330561,PRS-343 in HER2-Positive Solid Tumors,"A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,"Pieris Pharmaceuticals, Inc.",2017-09-13,2023-12-01,2023-12-01,2017-11-06,2024-04-22,['Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03'],"['Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC)', 'Time to maximum dose concentration (Tmax)', 'Terminal half life (t1/2)', 'Tumor responses as defined by the Response Evaluation in Solid Tumors (RECIST) v.1.1', 'Duration of response', 'Disease control rate', 'Presence of PRS-343 anti-drug antibodies', 'Biomarkers (CD137, soluable HER2, cell surface antigens for immunotyping) in tumor tissues and blood samples']",,,,,10,United States,"University of Arizona Cancer Center [Tucson, United States] | University of California Los Angeles (UCLA) [Santa Monica, United States] | Georgetown University, Lombardi Comprehensive Cancer Center [Washington D.C., United States] | Johns Hopkins University School of Medicine [Baltimore, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University of Pittsburgh Medical Center (UPMC) [Pittsburgh, United States] | Sarah Cannon Research Institute [Nashville, United States] | M.D. Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States] | START - South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT03343613,A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors,A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors,TERMINATED,PHASE1,Eli Lilly and Company,2017-11-17,2020-02-07,2020-05-04,2017-11-17,2020-06-09,['Number of Participants with Dose Limiting Toxicities (DLTs)'],"['Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916', 'PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916', 'PK: Cmax of LY3381916 Administered in Combination with LY3300054', 'PK: AUC of LY3381916 Administered in Combination with LY3300054', 'PK: Cmax of LY3300054 Administered in Combination with LY3381916', 'PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916', 'Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)', 'Time to Response (TTR)', 'Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR', 'Duration of Response (DOR)', 'Progression Free Survival (PFS)']",,,,,12,Belgium; Denmark; France; Italy; Spain; United States,"IU Simon Cancer Center [Indianapolis, United States] | Sarah Cannon Research Institute SCRI [Nashville, United States] | Tennessee Oncology PLLC [Nashville, United States] | Institut Jules Bordet [Brussels, Belgium] | Universitair Ziekenhuis Antwerpen [Edegem, Belgium] | Universitair Ziekenhuis Gent [Ghent, Belgium] | Finsen Institute [Copenhagen, Denmark] | Gustave Roussy [Villejuif, France] | Azienda Ospedaliera San Gerardo [Monza, Italy] | Azienda Ospedaliera Umberto I [Ancona, Italy] | Hospital Clinico Universitario Virgen de la Victoria [Málaga, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves LY3381916, which is identified as a new anti-IDO-1 agent being tested for the first time in combination with another agent (LY3300054) in participants with solid tumors, indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03348293,Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction,Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction,COMPLETED,PHASE1,Xijing Hospital,2018-07-30,2024-12-30,2024-12-30,2017-11-20,2025-08-03,['adverse events'],"['Cosmetic outcome', 'Satisfaction of patients', 'Recurrence rate', '5-Year disease free survival']",,,,,1,China,"Xijing hospital [Xi'an, China]",2018.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[""Disease-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a new approach to breast reconstruction using a personalized biodegradable implant, indicating it is a new medicine.",OTHER,False,2024.0,1.0,0,Phase 1
NCT03361800,"Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC","A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)",TERMINATED,EARLY_PHASE1,UNC Lineberger Comprehensive Cancer Center,2018-11-28,2019-09-18,2019-10-11,2017-12-05,2024-03-25,['Decrease in Ki-67 mRNA following treatment with entinostat across TNBC breast cancers'],"['mRNA gene expression changes following treatment with entinostat, across TNBC', 'Changes in the proliferation signature by mRNA expression following treatment with entinostat across TNBC', 'Differential kinome activation before and after treatment with entinostat across TNBC', 'Correlation of mutation and/or copy number variations by whole exome sequencing (WES) with mRNA gene expression changes and reduction of proliferation signature following treatment with entinostat across TNBC.', 'Correlation of protein lysine hyperacetylation in peripheral blood and tumor from pre- and post-entinostat treated TNBCs', 'Percentage of participants with treatment related adverse events']",,,,,1,United States,"Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill [Chapel Hill, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is investigating the use of Entinostat, which is not previously approved for the specific patient population of newly diagnosed Stage I-IIIC TNBC, indicating it is a new medicine trial.",OTHER,False,2019.0,6.0,0,Phase 1
NCT03381417,Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.,"A Randomized, Double-blind, Parallel Study Comparing Efficacy and Safety of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Prevention of Chemotherapy (Accelerated AC Regimen)Induced Neutropenia in Breast-cancer Patients.",COMPLETED,PHASE3,Nanogen Pharmaceutical Biotechnology Joint Stock Company,2016-10-06,2017-11-06,2017-11-06,2017-12-22,2018-01-02,"['Percentage of patients who developed Febrile neutropenia in cycle 1,2 and 3']","['Incidence of grade 4 severe neutropenia', 'Incidence of antibiotics use', 'Incidence of adverse events', 'Changes in laboratory safety parameters', 'Presence of antibodies against Pegfilgrastim']",,,,,1,Vietnam,"Vietnam National Cancer Institute (Hospital K) [Hanoi, Vietnam]",2016.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating Pegcyte, which is a new medicine being compared to an existing reference product (Neulastim) for a specific indication (prevention of chemotherapy-induced neutropenia in breast cancer patients).",INDUSTRY,False,2017.0,8.0,0,Phase 3
NCT03394287,A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC,"A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer",COMPLETED,PHASE2,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2018-01-10,2019-12-30,2020-09-30,2018-01-09,2020-10-23,['ORR'],"['Incidence of Treatment-Emergent Adverse Events', 'DCR', 'DoR', 'PFS', 'One year-OS', 'CBR', 'TTR', 'Frequencies Of Biomarkers']",,,,,1,China,"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University [Guangzhou, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves SHR-1210, which is an Anti-PD-1 antibody being tested in combination with Apatinib for a specific patient population (advanced TNBC), indicating it is a new medicine.",OTHER,False,2020.0,5.0,0,Phase 2
NCT03396445,Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001),A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors,COMPLETED,PHASE1,Merck Sharp & Dohme LLC,2018-02-18,2024-09-27,2024-09-27,2018-01-11,2025-07-02,"['Arms 1 and 2: Dose-limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 or Later', 'Arms 1 and 2: Number of Participants with Adverse Events (AEs)', 'Arms 1 and 2: Number of Study Treatment Discontinuations Due to an Adverse Event (AE)']","['All Arms: Area Under the Concentration-Time Curve (AUC) of boserolimab', 'All Arms: Minimum Serum Concentration (Cmin) of boserolimab', 'All Arms: Maximum Serum Concentration (Cmax) of boserolimab', 'Arms 1, 2, and 4: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)', 'Arm 3: Dose-limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 or Later', 'Arm 4: Dose-limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 or Later', 'Arms 3 and 4: Number of Participants with Adverse Events (AEs)', 'Arms 3 and 4: Number of Study Treatment Discontinuations Due to an Adverse Event (AE)']",,,,,18,Chile; Israel; Netherlands; South Korea; Spain; Taiwan; United States,"University of South Alabama, Mitchell Cancer Institute ( Site 0020) [Mobile, United States] | Florida Cancer Specialists ( Site 0002) [Sarasota, United States] | The West Clinic, P.C. ( Site 0021) [Germantown, United States] | FALP-UIDO ( Site 0502) [Santiago, Chile] | Bradfordhill-Clinical Area ( Site 0501) [Santiago, Chile] | Soroka Medical Center-Oncology ( Site 0012) [Beersheba, Israel] | Hadassah Ein Kerem Medical Center ( Site 0010) [Jerusalem, Israel] | The Chaim Sheba Medical Center - Oncology Institute ( Site 0001) [Ramat Gan, Israel] | Antoni van Leeuwenhoek Ziekenhuis ( Site 0003) [Amsterdam, Netherlands] | Erasmus MC ( Site 0031) [Rotterdam, Netherlands] | Seoul National University Hospital-Internal Medicine ( Site 0702) [Seoul, South Korea] | Severance Hospital, Yonsei University Health System-Medical oncology ( Site 0701) [Seoul, South Korea] | Hospital Universitario Quiron Madrid ( Site 0043) [Pozuelo de Alarcón, Spain] | Instituto Catalan de Oncologia - ICO ( Site 0044) [Barcelona, Spain] | Hospital Universitario Fundacion Jimenez Diaz ( Site 0041) [Madrid, Spain] | Centro Integral Oncologico Clara Campal START Madrid ( Site 0040) [Madrid, Spain] | National Taiwan University Hospital-Oncology ( Site 0801) [Taipei, Taiwan] | Koo Foundation Sun Yat-Sen Cancer Center ( Site 0802) [Taipei, Taiwan]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT03411161,S 81694 Plus Paclitaxel in Metastatic Breast Cancer,"Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate the Safety, Pharmacokinetic and Efficacy in Metastatic Breast Cancer",COMPLETED,PHASE1; PHASE2,Institut de Recherches Internationales Servier,2018-01-04,2020-06-08,2020-06-08,2018-01-26,2021-05-25,"['Incidence of DLTs (dose-limiting toxicities)', 'Safety and tolerability assessed by incidence of Adverse Events', 'Abnormalities in laboratory tests (haematology, blood biochemistry and urinalysis)', 'Abnormalities in physical examination and performance status (ECG) (mm/s)', 'Abnormalities in blood pressure (mmHg)', 'Abnormalities in heart rate (BPM (beat per minute))', 'Abnormalities in body temperature (C°degree celsius)', 'Abnormalities in respiration rate (cycles per minute)', 'Abnormalities in body weight (Kg)', 'Progression free survival (PFS) [based on Investigator review of the images according to RECIST 1.1]']","['The PK (pharmacokinetic) profile of S 81694 and paclitaxel plasma concentration : Area under the plasma concentration-time curve (AUC)', 'The PK profile of S 81694 and paclitaxel plasma concentration : Elimination half-life (T½)', 'The PK profile of S 81694 and paclitaxel plasma concentration : Maximum plasma concentration (Cmax)', 'The PK profile of S 81694 and paclitaxel plasma concentration : Minimum plasma concentration (Cmin)', 'Overall Response Rate (ORR) [ based on Investigator review of the images according to RECIST 1.1]', 'Incidence of treatment-emergent adverse events (AEs) graded according to NCI CTCAE v4.03']",,,,,6,Belgium; France; Japan; Netherlands,"Institut Jules Bordet Clinique Oncologie Médicale [Brussels, Belgium] | UZ Leuven Campus Gasthuisberg Dept. of General Medical [Leuven, Belgium] | Institut de Cancérologie de l'Ouest site Saint Herblain [Saint-Herblain, France] | Chiba cancer center Breast surgery [Chiba, Japan] | Osaka International Cancer Institute [Osaka, Japan] | Erasmus MC Section Clinical Pharmacology [Rotterdam, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,1,Phase 2
NCT03425773,Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care,"Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care",COMPLETED,PHASE1,"Cellid Co., Ltd.",2018-02-26,2019-05-13,2019-05-13,2018-02-08,2020-02-20,"['Evaluate Maximum tolerated dose(MTD) for phase 2 trial', 'Incidence of Serious Adverse Events assessed with CTCAE v4.03']","['Serum cytokine', 'HER2/neu specific antibody', 'NKT/NK cell assay', 'CD4/CD8 assay', 'Lymphocyte subset', 'Change of tumor burden']",,,,,1,South Korea,"Severance Hospital [Seoul, South Korea]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating a new treatment (BVAC-B) for patients with HER2/Neu positive gastric cancer, indicating it is a new medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03429101,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer,TERMINATED,PHASE1,"Spectrum Pharmaceuticals, Inc",2018-07-13,2019-04-17,2019-04-17,2018-02-12,2021-01-15,['Objective Response Rate (ORR)'],"['Disease Control Rate (DCR)', 'Progression-free Survival (PFS)']",,,,,2,United States,"Pacific Cancer Medical Center, Inc. [Anaheim, United States] | Los Angeles Hematology Oncology Medical Group [Glendale, United States]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Poziotinib, which is being studied in combination with T-DM1 for a specific patient population (HER2-positive breast cancer), indicating it is a new medicine being evaluated for efficacy in this context.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03430479,Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer,"Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer",COMPLETED,PHASE1; PHASE2,Kyoto Breast Cancer Research Network,2017-06-22,2018-11-30,2021-04-01,2018-02-13,2023-01-19,['Phase Ib : dose-limiting toxicity rate'],[],,,,,1,Japan,"Kyoto University Hospital [Kyoto, Japan]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves an anti PD-1 antibody, which is a new medicine being tested in combination with radiation therapy for a specific type of cancer (HER2-negative metastatic breast cancer).",OTHER,False,2021.0,4.0,0,Phase 2
NCT03448250,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,"Evaluation of a Web-based Psychological Intervention as add-on to Care as Usual in Breast Cancer Survivors: Effect on Immune Status, Inflammation and Psychometric Outcome",TERMINATED,,Technical University of Dortmund,2018-03-16,2021-09-30,2022-04-30,2018-02-28,2022-05-05,"['concentration of C-reactive protein (CRP)', 'circulating Interleukin (IL) 6', 'circulating Tumor necrosis factor (TNF)-α', 'stimulated IL-6', 'stimulated TNF-α']","['Plasma Concentrations of Cytokines', 'Concentration of secreted Cytokines after Phorbol-12-myristate-13-acetate (PMA) stimulation of peripheral blood mononuclear cells', 'Concentration of secreted Cytokines after Lipopolysaccharide (LPS) Stimulation of peripheral blood mononuclear cells', 'Circulating numbers of Lymphocytes, Monocytes, Granulocytes', 'Phenotypic analysis of T and NK cell subsets', 'Cortisol awakening response (CAR)', 'Determination of cancer-related fatigue using the Brief Fatigue Inventory Questionnaire', 'Determination of cancer-related emotional stress', 'Determination of depression', 'Determination of anxiety', 'Determination of fear of progression', 'Determination of usefulness of the program', 'Determination of Negative Effects']",,,,,2,Germany,"Technical University of Dortmund, Leibniz Research Centre for Working Environment and Human Factors [Dortmund, Germany] | University Medical Center Leipzig, Department of Medical Psychology and Medical Sociology, Section Psychosocial Oncology [Leipzig, Germany]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT03454451,CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers,"A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS",COMPLETED,PHASE1,"Corvus Pharmaceuticals, Inc.",2018-04-25,2022-12-28,2023-02-19,2018-03-06,2023-12-21,"['Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab.', 'Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab.', 'Identify the MDL(maximum dose level) of single agent CPI-006']","['Area under the curve (AUC) of CPI-006', 'Maximum serum concentration (Cmax) of CPI-006', 'Objective response rate per RECIST v.1.1 criteria of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab.']",,,,,27,Australia; United States,"Arizona Oncology [Tucson, United States] | City Of Hope [Duarte, United States] | UC San Francisco [San Francisco, United States] | Yale School of Medicine [New Haven, United States] | University of Miami [Miami, United States] | Northwestern University [Chicago, United States] | The University of Chicago [Chicago, United States] | The John Hopkins University [Baltimore, United States] | Dana Farber [Boston, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | NY Hematology [Albany, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | Carolina BioOncology Institute [Huntsville, United States] | Oncology Hematology Care [Cincinnati, United States] | University of Oklahoma - Stephenson Cancer Center [Oklahoma City, United States] | UPMC Hillman [Pittsburgh, United States] | Greenville [Greenville, United States] | Sarah Cannon Research Institute [Nashville, United States] | Mary Crowley Cancer Research [Dallas, United States] | Virginia Cancer [Fairfax, United States] | Froedtert Hospital & Medical College of Wisconsin [Milwaukee, United States] | Lifehouse [Camperdown, Australia] | St. Vincent's Hospital [Darlinghurst, Australia] | Westmead [Westmead, Australia] | Royal Brisbane [Herston, Australia] | Monash Hospital [Clayton, Australia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT03455270,"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer","A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",COMPLETED,PHASE1,"G1 Therapeutics, Inc.",2018-05-09,2022-09-29,2022-09-29,2018-03-06,2022-12-15,"['Dose Limiting Toxicity', 'Recommended Phase 2 dose', 'Number of Treatment Related Adverse Event, including Abnormal Laboratory Events']","['Tumor response based on RECIST, Version 1.1', 'Effect of food on bioavailability of G1T48', 'Pharmacokinetics of G1T48 and metabolites: Maximum Plasma Concentration (Cmax)', 'Pharmacokinetics of G1T48 and metabolites: Area under Curve - plasma concentration (AUC)', 'Pharmacokinetics of G1T48 and metabolites: Plasma: terminal half life (T1/2)', 'Pharmacokinetics of G1T48 and metabolites: Plasma - Volume of distribution', 'Pharmacokinetics of palbociclib: Plasma - Trough concentration']",,,,,15,Belgium; Bulgaria; Georgia; Moldova; Netherlands; Ukraine; United States,"Beverly Hills Cancer Center [Beverly Hills, United States] | Stanford Women Cancer Center [Stanford, United States] | Northwestern University - Feinberg School of Medicine [Chicago, United States] | University of North Carolina at Chapel Hill [Chapel Hill, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Sarah Cannon Research Institute at Tennessee Oncology [Nashville, United States] | Institut Jules Bordet [Brussels, Belgium] | UZ Leuven [Leuven, Belgium] | MHAT for Womens Health - Nadezhda OOD [Sofia, Bulgaria] | ARENSIA Exploratory Medicine LLC [Tbilisi, Georgia] | ARENSIA Exploratory Medicine Phase I Unit, The Institute of Oncology [Chisinau, Moldova] | VU University Medical Center [Amsterdam, Netherlands] | University Medical Center Groningen [Groningen, Netherlands] | Erasmus Medical Center [Rotterdam, Netherlands] | Spizhenko Clinic [Kiev, Ukraine]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03471663,A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer,"A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer",COMPLETED,PHASE1,"InventisBio Co., Ltd",2018-03-18,2023-10-18,2023-10-18,2018-03-20,2024-01-08,['Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria'],"['Maximum observed serum concentration (Cmax)', 'Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]', 'Time of maximum observed concentration (Tmax)', 'Objective response rate (ORR)', 'Progression free survival (PFS)']",,,,,15,China; United States,"Local Institution [Fresno, United States] | Local Institution [Aurora, United States] | Local Institution [New Haven, United States] | Local Institution [Boston, United States] | Local Institution [Eugene, United States] | Local Institution [Greenville, United States] | Local Institution [Nashville, United States] | Local Institution [Dallas, United States] | Local Institution [San Antonio, United States] | Local Institution [San Antonio, United States] | Local Institution [Tyler, United States] | Local Institution [Beijing, China] | Local Institution [Guangzhou, China] | Local Institution [Changsha, China] | Local Institution [Shenyang, China]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT03481998,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,A Phase IB/II to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer,COMPLETED,PHASE1; PHASE2,"Jiangsu HengRui Medicine Co., Ltd.",2018-03-22,2022-07-30,2022-07-30,2018-03-29,2023-11-21,['Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1'],"['Area under the plasma concentration versus time curve (AUC) of SHR6390', 'Peak Plasma Concentration (Cmax) of SHR6390', 'The time of SHR6390 to reach the maximum concentration (Tmax)', 'Half-time (t1/2) of SHR6390', 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1', 'Progression-free Survival (PFS) per RECIST 1.1', 'Disease Control Rate (DCR) per RECIST 1.1', 'Number of Participants With adverse events (AEs) and serious adverse events (SAEs)']",,,,,4,China,"Ha'erbin Tumor Hospital [Harbin, China] | Henan Cancer Hospital [Zhengzhou, China] | Sir Run Run Shaw Hospital of Zhejiang University [Hangzhou, China] | Cancer Hospital, Chinese Academy of Medical Sciences [Beijing, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT03504488,CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2),"A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)",COMPLETED,PHASE1; PHASE2,"BioAtla, Inc.",2018-06-27,2024-12-30,2024-12-30,2018-04-20,2025-01-15,"['Phase 1: Safety Profile', 'Phase 1: Safety Profile', 'Phase 1 and 2: Safety Profile', 'Phase 2: Confirmed Objective Response Rate (ORR)']","['Phase 1: Pharmacokinetics', 'Phase 1: Pharmacokinetics', 'Phase 1: Pharmacokinetics', 'Phase 1: Confirmed Objective Response Rate (ORR)', 'Phase 1: Immunogenicity', 'Phase 1 and 2: Duration of response (DOR)', 'Phase 1 and 2: Progression-free survival (PFS)', 'Phase 1 and 2: Best overall response (OR)', 'Phase 1 and 2: Disease control rate (DCR)', 'Phase 1 and 2: Time to response (TTR)', 'Phase 1 and 2: Overall survival (OS)', 'Phase 1 and 2: Tumor size']",,,,,59,Greece; Hong Kong; Poland; Spain; Taiwan; United States,"University of Arizona Cancer Center [Tucson, United States] | City of Hope - Duarte [Duarte, United States] | University of California, San Diego (UCSD) - Moores Cancer Center [La Jolla, United States] | California Research Institute [Los Angeles, United States] | USC Norris [Los Angeles, United States] | UC Irvine Medical Center - Chao Family Comprehensive Cancer Center [Orange, United States] | University of California San Francisco [San Francisco, United States] | American Institute of Research [Whittier, United States] | University of Colorado [Aurora, United States] | Sarah Cannon Research Institute at Health One [Denver, United States] | Florida Cancer Specialists & Research Institute [Fleming Island, United States] | Florida Cancer Specialists & Research Institute [Fort Myers, United States] | Memorial Cancer Institute (MCI) [Hollywood, United States] | Florida Cancer Specialist - North [St. Petersburg, United States] | Memorial Sloan-Kettering Cancer Center [Tampa, United States] | Moffitt Cancer Center [Tampa, United States] | Florida Cancer Specialists [West Palm Beach, United States] | Augusta University - Georgia Cancer Center [Augusta, United States] | Baptist Health Systems [Lexington, United States] | University of Kentucky [Lexington, United States] | Norton Cancer Institute, Brownsboro Hospital Campus [Louisville, United States] | Hematology/Oncology Clinic [Baton Rouge, United States] | Dana-Farber Cancer Institute [Boston, United States] | Comprehensive Cancer Care of Nevada [Las Vegas, United States] | OptumCare Cancer Care [Las Vegas, United States] | Roswell Park [Buffalo, United States] | NYU Langone Health [New York, United States] | Columbia University Medical Center [New York, United States] | FirstHealth Outpatient Cancer Center [Pinehurst, United States] | Wake Forest Baptist Health [Winston-Salem, United States] | The Christ Hospital [Cincinnati, United States] | Oregon Health & Science University [Portland, United States] | UPMC Cancer Center [Pittsburgh, United States] | Medical University of South Carolina- Hollings Cancer Center [Charleston, United States] | Sarah Cannon Research Institute [Nashville, United States] | Mary Crowley Cancer Research [Dallas, United States] | MD Anderson Cancer Center [Houston, United States] | University of Utah - Huntsman Cancer Institute [Salt Lake City, United States] | HENRY DUNANT Hospital Center, 4th Department of Medical Oncology and Clinical Trials Unit [Athens, Greece] | Metropolitan Hospital ""Perseus Healthcare Group SA"" 4th Oncology Department [Piraeus, Greece] | Bioclinic Thessaloniki, Οncology Department [Thessaloniki, Greece] | European Interbalkan Medical Center, Οncology Department [Thessaloniki, Greece] | Prince of Wales Hospital [Hong Kong, Hong Kong] | Queen Mary Hospital [Hong Kong, Hong Kong] | MED-Polonia, Sp. z o.o. (LLC) [Poznan, Poland] | Institute of Genetics and Immunology GENIM LCC in Lublin [Lublin, Poland] | Malgorzata Kozlik [Warsaw, Poland] | Polish Mother's Memorial Hospital-Research Institute [Lodz, Poland] | Beata Głogowska [Tomaszów Mazowiecki, Poland] | University Hospital Nuestra Senora de Valme [Seville, Spain] | Hospital de la Santa Creu i Sant Pau [Barcelona, Spain] | Hospital del Mar [Barcelona, Spain] | Anna Ramos Luna [Barcelona, Spain] | University Clinic of Navarra - Madrid [Madrid, Spain] | University Hospital 12 de Octubre [Madrid, Spain] | Kaohsiung Chang Gung Memorial Hospital [Kaohsiung City, Taiwan] | National Cheng Kung University Hospital [Tainan City, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan] | LinKou Chang Gung Memorial Hospital [Taoyuan, Taiwan]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a study of CAB-ROR2-ADC, which indicates it is a new medicine being tested for safety and efficacy in patients with various types of advanced solid tumors.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT03507543,The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors,"A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Impact Therapeutics, Inc.",2017-02-03,2020-09-24,2021-03-17,2018-04-25,2021-03-30,"['The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.', 'The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297.']","['Area Under Curve [AUClast, AUCINF and AUCtau]', 'Area Under Curve [AUClast, AUCINF and AUCtau]', 'Maximum plasma concentration (Cmax)', 'Maximum plasma concentration (Cmax)', 'Time at which Cmax occurred (Tmax)', 'Time at which Cmax occurred (Tmax)', 'Trough Concentrations (Ctrough)', 'Trough Concentrations (Ctrough)', 'Clearance (CL/F)', 'Clearance (CL/F)', 'Volume of distribution (Vd/F)', 'Volume of distribution (Vd/F)']",,,,,3,Australia,"Blacktown Hospital [Blacktown, Australia] | St George Private Hospital [Kogarah, Australia] | Nucleus Network [Melbourne, Australia]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03508011,A Study of IMP4297 in Patients With Advanced Solid Tumors,"A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Impact Therapeutics, Inc.",2017-08-23,2020-12-16,2020-12-16,2018-04-25,2021-03-30,"['The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.', 'The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297']","['Area Under Curve [AUClast, AUCINF]', 'Area Under Curve [AUClast, AUCINF]', 'Maximum plasma concentration (Cmax)', 'Maximum plasma concentration (Cmax)', 'Time at which Cmax occurred (Tmax)', 'Time at which Cmax occurred (Tmax)', 'Trough Concentrations (Ctrough)', 'Trough Concentrations (Ctrough)', 'Clearance (CL/F)', 'Clearance (CL/F)', 'Volume of distribution (Vd/F)', 'Volume of distribution (Vd/F)']",,,,,2,China,"Cancer Hospital Chinese Academy of Medical Sciences [Beijing, China] | Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03518606,Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours,A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour,COMPLETED,PHASE1; PHASE2,UNICANCER,2018-06-20,2022-04-01,2024-12-19,2018-05-08,2025-01-15,"['Maximum Tolerated Dose (MTD) and the phase II recommended dose (RP2D)', 'CBR-24week']",[],,,,,9,France,"Institut de Cancérologie de l'Ouest - Site Paul Papin [Angers, France] | Centre François Baclesse [Caen, France] | Centre Georges-François Leclerc [Dijon, France] | Institut Paoli-Calmettes [Marseille, France] | Centre Antoine Lacassagne [Nice, France] | Institut Curie [Paris, France] | Centre Eugène Marquis [Rennes, France] | Institut de Cancérologie de l'Ouest - Site René Gauducheau [Saint-Herblain, France] | Gustave Roussy [Villejuif, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2024.0,1.0,0,Phase 2
NCT03524170,"Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","RACHEL1: A Phase I Radiation and Checkpoint Blockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",COMPLETED,PHASE1,M.D. Anderson Cancer Center,2018-04-30,2022-02-10,2022-02-10,2018-05-14,2022-03-07,"['Recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer', 'Safety and tolerability in patients with metastatic HR+/HER2- breast cancer']","['Progression-free survival (PFS)', 'Overall survival (OS)', 'Immunologic/molecular response', 'Evaluation of the size of metastasis after treatment with M7824 with radiation (in-field) and non-irradiated (abscopal) sites']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT03535961,Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer,Phase II Single Arm Study of Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer,COMPLETED,PHASE2,Chinese Academy of Medical Sciences,2017-05-01,2019-05-01,2019-05-01,2018-05-24,2020-12-02,['objective response rate(ORR)'],"['disease control rate(DCR)', 'Progression free survival (PFS)', 'overall survival(OS)', 'Incidence of Treatment-Emergent Adverse Events']",,,,,1,China,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Apatinib, which is being tested in combination with Oral Etoposide for a specific indication (metastatic HER2 negative breast cancer), indicating it is a new medicine trial.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03538028,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,"A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies",COMPLETED,PHASE1,Incyte Biosciences International Sàrl,2018-06-18,2020-10-07,2020-10-07,2018-05-25,2020-10-30,['Number of treatment-emergent adverse events (TEAEs)'],"['Cmax of INCAGN02385', 'Tmax of INCAGN02385', 'Cmin of INCAGN02385', 'AUC0-t of INCAGN02385', 'Objective response rate (ORR) in participants with advanced or metastatic solid tumors', 'Disease control rate (DCR) in participants with advanced or metastatic solid tumors', 'Duration of response (DOR) in participants with advanced or metastatic solid tumors', 'Progression-free survival (PFS) in participants with advanced or metastatic solid tumors', 'ORR in participants with diffuse large B-cell lymphoma (DLBCL)', 'DOR in participants with DLBCL', 'PFS in participants with DLBCL']",,,,,4,United States,"The Angeles Clinic and Research Center [Los Angeles, United States] | Hackensack Medical Center [Hackensack, United States] | Carolina BioOncology Institute [Huntersville, United States] | Vanderbilt University Medical Center [Nashville, United States]",2018.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[""Duration of Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03549000,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,"A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.",TERMINATED,PHASE1,Novartis Pharmaceuticals,2018-07-18,2022-10-17,2022-10-17,2018-06-07,2024-12-13,['Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178'],"['Overall response rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Progression Free Survival (PFS)', 'Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.', 'Plasma concentration vs. time profiles for NIR178 and derived PK parameters', 'To assess the immunogenicity of NZV930 and PDR001']",,,,,10,Australia; Canada; Japan; Singapore; Spain; United Kingdom; United States,"H Lee Moffitt Cancer Center and Research Institute Inc [Tampa, United States] | University of Texas MD Anderson Cancer Center MD Anderson PSC [Houston, United States] | Novartis Investigative Site [Melbourne, Australia] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Chuo Ku, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Valencia, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Sutton, United Kingdom]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03554044,T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer,"A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast Cancer",COMPLETED,PHASE1,"University of California, San Francisco",2020-02-05,2023-12-31,2023-12-31,2018-06-12,2025-05-21,"['Number of patients with treatment-related toxicities by maximum observed grade', 'Maximum tolerated volume']","['Overall response rate (ORR)', 'Response duration']",,,,,1,United States,"University of California, San Francisco [San Francisco, United States]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating T-VEC, which is a new medicine, in combination with other therapies for a specific type of breast cancer.",OTHER,False,2023.0,2.0,0,Phase 1
NCT03559387,"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","A Randomized and Open-label Dose-finding, Ph. 2, Efficacy, Safety, and Pharmacokinetic Study of Once-per-cycle Prophylactic Injections of ANF-RHO™ Versus Pegfilgrastim (Neulasta®) in Non-metastatic Breast Cancer Patients at High-risk of Chemotherapy-induced Neutropenia",TERMINATED,PHASE2,Prolong Pharmaceuticals,2017-08-03,2018-04-18,2018-05-22,2018-06-18,2019-02-12,['Duration of neutropenia grade 1 or worse (absolute neutrophil count [ANC] ≤ 2.0 x 10^9/L) in the first cycle of chemotherapy (FE100C).'],"['Duration of neutropenia grade 1 or worse (absolute neutrophil count [ANC] ≤ 2.0 x 10^9/L) in the fourth cycle of chemotherapy (docetaxel).', 'Duration of severe neutropenia (ANC < 0.5 x 10^9/L) during the first chemotherapy cycle (21-day cycle FE100C)', 'Duration of severe neutropenia (ANC < 0.5 x 10^9/L) during the fourth chemotherapy cycle (21-day cycle docetaxel)', 'Incidence of severe neutropenia (ANC < 0.5 x 10^9/L) during all chemotherapy cycles', 'Incidence and duration of febrile neutropenia defined as peak temperature ≥38.5°C and ANC < 0.5 x 10^9/L, during all chemotherapy cycles', 'Incidence and duration of febrile neutropenia defined as peak temperature ≥38.0°C for two readings over two hours and ANC < 0.5 x 10^9/L, during all chemotherapy cycles', 'Incidence and duration of infection and infection-related events based on use of antibiotics during all chemotherapy cycles', 'Incidence and duration of infection and infection-related events based on the need for hospitalization during all chemotherapy cycles', 'Incidence and duration of moderate (ANC ≥ 50 x 10^9/L) leukocytosis during all chemotherapy cycles', 'Incidence and duration of severe (ANC ≥ 100 x 10^9/L) leukocytosis during all chemotherapy cycles', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Blood pressure', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Heart rate', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Respiratory rate', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Body Temperature', 'Incidence of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Duration of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Severity of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Site of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Measurement of Maximum Plasma Concentration (Cmax)', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Measurement of Time taken to reach the maximum concentration (Tmax)', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Measurement of half-life (T1/2)', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Area Under the Curve (AUC[0-t])', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Area Under the Curve (AUC[0-∞])', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Area Under the Curve (AUC[0-t]/AUC[0-∞])', 'Incidence of anti-drug antibodies to ANF-RHO and Neulasta']",,,,,8,France; Netherlands,"Hôpital Saint Louis - Center des Maladies du Sein [Paris, France] | Institut de cancérologie Jean Godinot [Reims, France] | Strasbourg Oncologie Libérale [Strasbourg, France] | CHU de Tours [Tours, France] | Erasmus Medical Center [Rotterdam, Netherlands] | Ikazia Ziekenhuis [Rotterdam, Netherlands] | Maasstad Ziekenhuis [Rotterdam, Netherlands] | Franciscus Gasthuis & Vlietland [Schiedam, Netherlands]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a new medicine (ANF-RHO™) against an existing treatment (Neulasta®) for a specific condition (chemotherapy-induced neutropenia), indicating it is a new medicine rather than an extension of indication.",INDUSTRY,False,2018.0,7.0,1,Phase 2
NCT03562832,Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP,"Phase II, Open Label Clinical Study to Investigate Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP",COMPLETED,PHASE2,Allarity Therapeutics,2018-06-20,2024-04-01,2024-08-01,2018-06-20,2025-01-23,['Anti-tumour efficacy after treatment with 600 mg 2X-121 as single oral agent in a 21-days cycle in mBC patients selected by the 2X-121 DRP'],"['Progression free survival (PFS) after administration of 2X-121 in patients with mBC', 'Duration of objective response after administration of 2X-121 in patients with mBC', 'Overall survival (OS) after administration of 2X-121 in patients with mBC', 'Performance status (ECOG)', 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0']",,,,,2,Denmark,"Herlev and Gentofte Hospital, Herlev Ringvej 75, DK-2730 Herlev [Herlev, Denmark] | Vejle Sygehus [Vejle, Denmark]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial investigates the anti-tumour effect and tolerability of a new PARP inhibitor (2X-121) in patients with metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT03565445,"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors","A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,"Astellas Pharma Global Development, Inc.",2018-07-02,2023-03-27,2023-03-27,2018-06-21,2024-11-01,"['Number of Participants with Dose Limiting Toxicities (DLTs)', 'Number of Participants with Adverse Events (AEs)', 'Number of Participants with Immune-related AEs', 'Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status', 'Pharmacokinetics (PK) of ASP1948 (Cycle 1): Area Under The Concentration-Time Curve From The Time Zero to The Last Measurable Concentration (AUClast)', 'PK of ASP1948 (Cycle 10): AUClast', 'PK of ASP1948 (Cycle 1): Area Under the Concentration-Time Curve From the Time of Dosing Extrapolated to Time Infinity (AUCinf)', 'PK of ASP1948 (Cycle 1): Percentage of AUCinf Due to Extrapolation From Time of The Last Measurable Concentration To Time Infinity (AUCinf %extrap)', 'PK of ASP1948 (Cycle 1): Area Under The Concentration-Time Curve From The Time of Dosing to The Start of Next Dosing Interval (AUCtau)', 'PK of ASP1948 (Cycle 1): Maximum Concentration (Cmax)', 'PK of ASP1948 (Cycle 10): Cmax', 'PK of ASP1948 (Cycle 10): Trough Concentration (Ctrough)', 'PK of ASP1948 (Cycle 1): Time of The Maximum Concentration (tmax)', 'PK of ASP1948 (Cycle 10): tmax', 'PK of ASP1948 (Cycle 10): AUCtau', 'PK of ASP1948 (Cycle 1): Terminal Elimination Half-Life ( t1/2)', 'PK of ASP1948 (Cycle 1): Time of Last Measurable Concentration (tlast)', 'PK of ASP1948 (Cycle 10): Terminal Elimination Half-Life ( t1/2)', 'PK of ASP1948 (Cycle 10): tlast', 'PK of ASP1948 (Cycle 1): Total Clearance (CL) after Intravenous Dosing', 'PK of ASP1948 (Cycle 10): CL after Intravenous Dosing', 'PK of ASP1948 (Cycle 1): Volume of Distribution During the Terminal Elimination Phase (Vz) After Intravenous Dosing', 'PK of ASP1948 (Cycle 10): Vz After Intravenous Dosing', 'PK of ASP1948 (Cycle 1): Apparent Volume of Distribution at Steady State (Vss) after Intravenous Dosing', 'PK of ASP1948 (Cycle 10): Vss After Intravenous Dosing']","['Objective Response Rate (ORR) as per RECIST V1.1', 'ORR as per iRECIST V1.1', 'Duration of Response (DOR) as per RECIST V1.1', 'DOR as per iRECIST', 'Persistence of response after discontinuation per RECIST V1.1', 'Persistence of response after discontinuation per iRECIST', 'Disease Control Rate (DCR) by RECIST 1.1', 'DCR by iRECIST']",,,,,42,Canada; Italy; Japan; Portugal; South Korea; Spain; Taiwan; United Kingdom; United States,"Yale Center for Clinical Investigation [New Haven, United States] | Norton Cancer Institute [Louisville, United States] | Cancer Center at Greater Baltimore Medical [Baltimore, United States] | University of Michigan Comprehensive Cancer Center [Ann Arbor, United States] | Washington University [St Louis, United States] | Oncology Hematology West P.C. dba Nebraska Cancer Specialists [Omaha, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | University of Oklahoma [Oklahoma City, United States] | UPMC- Hillman Cancer Center [Pittsburgh, United States] | University of South Carolina [Charleston, United States] | Sarah Cannon Research Institute - SCRI [Nashville, United States] | Henry-Joyce Cancer Center [Nashville, United States] | Mary Crowley Cancer Research Center [Dallas, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Virginia Cancer Care Specialist, PC [Fairfax, United States] | University of Washington-Seattle Cancer Care Alliance [Seattle, United States] | Site CA15002 [Edmonton, Canada] | Site CA15004 [Montreal, Canada] | Site IT39008 [Milan, Italy] | Site IT39006 [Modena, Italy] | Site JP81002 [Chiba, Japan] | Site JP81001 [Tokyo, Japan] | Site PT35104 [Porto, Portugal] | Site KR82001 [Seoul, South Korea] | Site KR82002 [Seoul, South Korea] | Site KR82003 [Seoul, South Korea] | Site KR82004 [Seoul, South Korea] | Site KR82005 [Seoul, South Korea] | Site KR82006 [Seoul, South Korea] | Site KR82007 [Seoul, South Korea] | Site ES34002 [Barcelona, Spain] | Site ES34006 [Barcelona, Spain] | Site ES34010 [Barcelona, Spain] | Site ES34014 [Barcelona, Spain] | Site ES34003 [Cataluna, Spain] | Site ES34004 [Cataluna, Spain] | Site ES34007 [Madrid, Spain] | Site ES34012 [Madrid, Spain] | Site TW88601 [Taipei, Taiwan] | Site TW88602 [Taipei, Taiwan] | Site GB44006 [Manchester, United Kingdom]",2018.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a study of ASP1948, which is a new drug targeting an immune modulatory receptor, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT03566485,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer,TERMINATED,PHASE1; PHASE2,Vanderbilt-Ingram Cancer Center,2018-07-10,2020-12-10,2020-12-10,2018-06-25,2021-08-11,"['Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)', 'Maximum Tolerated Dose (Phase I)', 'Recommended Phase II Dose (Phase I)', 'Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)']","['Clinical Benefit Rate (CBR) (Phase II)', 'Immune Related Response Criteria (irRC) (Phase II)', 'Progression-free Survival (PFS) (Phase II) in Days', 'Overall Survival (OS) (Phase II) in Days', 'Number of Adverse Events (Phase II)']","[{""type"":""PRIMARY"",""title"":""Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)"",""timeFrame"":""At 28 days"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""PRIMARY"",""title"":""Maximum Tolerated Dose (Phase I)"",""timeFrame"":""At 28 days"",""unit"":""mg"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""NA"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""PRIMARY"",""title"":""Recommended Phase II Dose (Phase I)"",""timeFrame"":""At 28 days"",""unit"":""mg"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""NA"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""PRIMARY"",""title"":""Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)"",""timeFrame"":""Up to 28 days after completion of study treatment, for a total of 2 years"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""NA"",""spread"":null,""lower"":""NA"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Clinical Benefit Rate (CBR) (Phase II)"",""timeFrame"":""At 6 months"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""NA"",""spread"":null,""lower"":""NA"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Immune Related Response Criteria (irRC) (Phase II)"",""timeFrame"":""Up to 28 days after completion of study treatment, for a total of 2 years"",""unit"":null,""paramType"":null,""dispersionType"":null,""groups"":[]},{""type"":""SECONDARY"",""title"":""Progression-free Survival (PFS) (Phase II) in Days"",""timeFrame"":""At 12 months"",""unit"":""days"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""56"",""spread"":null,""lower"":""51"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Overall Survival (OS) (Phase II) in Days"",""timeFrame"":""At 12 months"",""unit"":""days"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""161"",""spread"":null,""lower"":""136"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Number of Adverse Events (Phase II)"",""timeFrame"":""Up to 28 days after completion of study treatment, for a total of 2 years"",""unit"":""events"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""99"",""spread"":null,""lower"":null,""upper"":null}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""5""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""7""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""0""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""0""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""5""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""7""}]}],""dropWithdraws"":[{""type"":""Disease progression"",""reasons"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""5""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""4""}]},{""type"":""Clinical progression"",""reasons"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""0""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""1""}]},{""type"":""Toxicity"",""reasons"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""0""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""2""}]}]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""4"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""5"",""spread"":null},{""group"":""Total"",""value"":""9"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""1"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""5"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""7"",""spread"":null},{""group"":""Total"",""value"":""12"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""4"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""5"",""spread"":null},{""group"":""Total"",""value"":""9"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""1"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""4"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""5"",""spread"":null},{""group"":""Total"",""value"":""9"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""1"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""5"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""7"",""spread"":null},{""group"":""Total"",""value"":""12"",""spread"":null}]}]","[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""serious_affected"":2,""serious_at_risk"":5,""other_affected"":5,""other_at_risk"":5},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""serious_affected"":4,""serious_at_risk"":7,""other_affected"":7,""other_at_risk"":7}]",1,United States,"Vanderbilt-Ingram Cancer Center [Nashville, United States]",2018.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,1,1,1,0,1,0,1,5,0,0,1,0,,OTHER,True,2020.0,5.0,0,Phase 2
NCT03568656,Study to Evaluate CCS1477 in Advanced Tumours,"An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.",COMPLETED,PHASE1; PHASE2,CellCentric Ltd.,2018-07-23,2025-07-06,2025-07-06,2018-06-26,2025-08-08,"['Incidence of treatment-related adverse events', 'Laboratory assessments']","['PSA response', 'CTC response', 'Objective response rate (ORR)', 'Radiological progression-free survival (rPFS)', 'AUC of CCS1477', 'Cmax of CCS1477']",,,,,19,France; Netherlands; Spain; Sweden; United Kingdom; United States,"Dana-Farber Cancer Institute [Boston, United States] | Thomas Jefferson University, Sidney Kimmel Cancer Center [Philadelphia, United States] | Institute Bergonie [Bordeaux, France] | Hôpital Europeen Georges Pompidou [Paris, France] | Institute Gustave Roussy [Villejuif, France] | Netherlands Cancer Institute (NKI) [Amsterdam, Netherlands] | Hospital Vall d'Hebron, VHIO [Barcelona, Spain] | START CIOCC Hospital Universitario HM [Madrid, Spain] | Karolinska Institute [Stockholm, Sweden] | Belfast City Hospital [Belfast, United Kingdom] | Queen Elizabeth Hospital Cancer Centre [Birmingham, United Kingdom] | Cambridge University Hospital [Cambridge, United Kingdom] | Edinburgh Cancer Centre Western General Hospital [Edinburgh, United Kingdom] | The Beatson West of Scotland Cancer Centre [Glasgow, United Kingdom] | Leicester Royal Infirmary [Leicester, United Kingdom] | The Christie Hospital [Manchester, United Kingdom] | Freeman Hospital [Newcastle, United Kingdom] | University Hospital Southampton [Southampton, United Kingdom] | Royal Marsden Hospital [Sutton, United Kingdom]",2018.0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,1,Phase 2
NCT03579472,M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer,A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC),TERMINATED,PHASE1,M.D. Anderson Cancer Center,2018-05-30,2022-09-21,2022-09-21,2018-07-06,2022-10-31,"['Recommended phase II dose (RP2D)', 'Incidence of adverse events']",[],,,,,2,United States,"Lyndon Baines Johnson General Hospital [Houston, United States] | M D Anderson Cancer Center [Houston, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves M7824, which is a new medicine being tested in combination with Eribulin Mesylate for a specific type of cancer, indicating it is a new treatment approach.",OTHER,False,2022.0,3.0,0,Phase 1
NCT03596658,SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer,"Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of SHR9549 in Women With ER Positive HER2 Negative Advanced Breast Cancer",TERMINATED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2018-07-25,2019-10-14,2019-10-14,2018-07-24,2022-09-01,"['Dose Limited Toxicity (DLT)', 'Maximum Tolerated Dose (MTD)']","['Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC)', 'overall response rate (ORR)', 'progression free survival (PFS)', 'Incidence of Treatment-Emergent Adverse Events']",,,,,1,China,"The 307th Hospital of Military Chinese People's Liberation Army [Beijing, China]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03600090,Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,"Taizhou EOC Pharma Co., Ltd.",2018-10-16,2021-12-25,2021-12-25,2018-07-26,2022-03-31,['DLT'],"['PFS', 'Cmax', 'Tmax', 'AUC 0-inf', 'T1/2']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03602079,Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene,"A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies",COMPLETED,PHASE1; PHASE2,Klus Pharma Inc.,2018-07-16,2022-01-12,2022-01-12,2018-07-26,2023-08-03,['Phase I: Maximum Tolerated Dose'],"['Phase I: Number of patients with Dose Limiting Toxicities', 'Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.', 'Phase I: Number of participants who developed measurable anti-drug antibodies', 'Phase I Maximum observed serum or plasma concentration (Cmax).', 'Phase I Clearance (CL).', 'Phase I Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-∞]).', 'Phase I Terminal phase elimination half life (t½).', 'Phase I Volume of distribution at terminal phase (Vz).', 'Phase I Volume of distribution at steady state (Vss).']",,,,,10,United States,"Florida Cancer Specialists & Research Institute [Sarasota, United States] | Beth Israel Deaconess Medical Center Cancer Center [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Clinical Research Alliance, Inc. [Lake Success, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Providence Cancer Institute [Portland, United States] | Mary Crowley Cancer Research Centers - Medical City [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | South Texas Accelerated Research Therapeutics, LLC (START) [San Antonio, United States] | Virginia Cancer Specialist [Fairfax, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT03603197,BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer,"A Randomized, Double Blind and Placebo Controlled Multicenter Study Comparing BP-C1 and an Equal Looking Placebo in Metastatic Breast Cancer Patients. A Phase IIB Study",COMPLETED,PHASE2,Meabco A/S,2014-06-05,2016-08-30,2016-08-30,2018-07-27,2019-10-07,['Change (%) in the sum of diameters of target lesions'],"['Number of target lesions', 'Treatment response', 'Karnofsky Performance Status (KPS) score', 'Separate scores of the general questionnaire EORTC QLQ-C30', 'Separate scores of the specific questionnaire EORTC QLQ-BR23', 'Maximum Common Toxicity Criteria (CTC) score', 'Change in the Sum CTC score', 'Number of registered adverse events']",,,,,4,Thailand,"Udon Thani Cancer Hospital [Udon Thani, Thailand] | Siriraj Hospital, Mahidol University [Bangkok, Thailand] | Lampang Cancer Center [Lampang, Thailand] | Ubon Ratchanthani Cancer Hospital [Ubon Ratchathani, Thailand]",2014.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[""Target Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a study of BP-C1, which indicates it is being tested as a new treatment for metastatic breast cancer, suggesting it is a new medicine.",INDUSTRY,False,2016.0,9.0,0,Phase 2
NCT03619681,Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer,"A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer",COMPLETED,PHASE1,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2018-09-17,2022-06-30,2022-08-26,2018-08-08,2024-03-12,['The proportion of patients experiencing dose limiting toxicities.'],"['Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest.', 'Percentage of participants who experience laboratory abnormalities and/or adverse events as defined by CTCAE that are related to treatment', 'Maximum observed serum concentration (Cmax) of KN026.', 'Time of Maximum observed serum concentration (Tmax) of KN026.', 'Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) for KN026.', 'Serum Half-life (T-HALF) of KN026.', 'Serum clearance (CL) of KN026.', 'Volume of distribution at steady state (VSS) of KN026.', 'Frequency and titer of anti-KN026 antibody.', 'The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria.', 'Progression free survival according to RECIST 1.1 criteria.']",,,,,1,China,"Fudan University Shanghai Cancer Hospital [Shanghai, China]",2018.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03620201,M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer,A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC),COMPLETED,PHASE1,M.D. Anderson Cancer Center,2018-08-03,2024-10-18,2024-10-18,2018-08-08,2024-10-22,"['Change in tumor-infiltrating lymphocytes (TIL) percentage', 'Laboratory parameters', 'Eye symptoms (and signs if symptoms warranted additional evaluation)', 'Vital signs', 'Electrocardiogram parameters']",[],,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2018.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating M7824, which is a new treatment (Anti-PD-L1/TGF-Beta TRAP) for a specific type of breast cancer, indicating it is a new medicine.",OTHER,False,2024.0,1.0,0,Phase 1
NCT03629756,A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,COMPLETED,PHASE1,"Arcus Biosciences, Inc.",2018-07-24,2021-08-18,2021-09-03,2018-08-14,2024-05-24,"['Percentage of participants with Adverse Events', 'Percentage of participants who experience a Dose Limiting Toxicity']","['Etrumadenant Peak Serum Concentration: Cmax', 'Zimberelimab Peak Serum Concentration: Cmax', 'Etrumadenant Time of Peak Concentration: Tmax', 'Zimberelimab Time of Peak Concentration: Tmax', 'Percentage of participants with anti-drug antibodies to zimberelimab', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Duration of Response (DOR)', 'Percentage of Participants with Disease Control', 'Percentage of participants with Objective Response']",,,,,15,Australia; United States,"Scottsdale Healthcare Hospitals dba HonorHealth [Scottsdale, United States] | University of California, Los Angeles [Los Angeles, United States] | The Angeles Clinic and Research Institute [Los Angeles, United States] | Rocky Mountain Cancer Centers (Midtown) [Denver, United States] | University of Michigan [Ann Arbor, United States] | QUEST Research Institute [Royal Oak, United States] | Carolina BioOncology Institute [Huntersville, United States] | Prisma Health [Greenville, United States] | Texas Oncology, P.A. - Fort Worth Cancer Center [Fort Worth, United States] | Texas Oncology, P.A. - San Antonio Medical Center [San Antonio, United States] | Texas Oncology, P.A. - Tyler [Tyler, United States] | Medical Oncology Associates dba Summit Cancer Centers [Spokane, United States] | St. George Private Hospital [Kogarah, Australia] | Gallipoli Medical Research Foundation [Greenslopes, Australia] | Cabrini Health Limited [Malvern, Australia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03650348,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,"A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,"Pieris Pharmaceuticals, Inc.",2018-08-21,2022-08-11,2022-08-11,2018-08-28,2024-04-22,['Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab'],"['Overall response rate (ORR) per RECIST v1.1', 'Duration of response (DOR) per RECIST v1.1', 'Rate of complete response (CR) per RECIST v1.1', 'Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, and changes in clinical laboratory parameters', 'Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC)', 'Time to maximum dose concentration (Tmax)', 'Terminal half life (t1/2)', 'Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])']",,,,,8,United States,"USC Norris Comprehensive Cancer Center [Los Angeles, United States] | Hoag Memorial Hospital Presbyterian [Newport Beach, United States] | UCLA Health [Santa Monica, United States] | Ochsner Cancer Institute [New Orleans, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | The Ohio State University Comprehensive Cancer Center [Columbus, United States] | M.D. Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating PRS-343, which is a new medicine being tested in combination with atezolizumab for HER2-positive solid tumors, indicating it is a new medicine rather than an extension of indication.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03652077,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,"A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies",COMPLETED,PHASE1,Incyte Corporation,2018-09-24,2021-08-18,2021-08-18,2018-08-29,2021-11-15,"['Number of treatment-emergent adverse events', 'Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only)']","['Cmax of INCAGN02390', 'Tmax of INCAGN02390', 'Cmin of INCAGN02390', 'AUC0-t of INCAGN02390', 'Objective response rate', 'Duration of response', 'Disease control rate', 'Progression-free survival', 'Level of binding of INCAGN02390 to TIM-3', 'Immunogenicity of INCAGN02390']",,,,,4,United States,"The Angeles Clinical and Research Institute [Los Angeles, United States] | University of Mississippi [Jackson, United States] | Hackensack Medical Center [Hackensack, United States] | Carolina BioOncology [Huntsville, United States]",2018.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03654547,Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer,"A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers",COMPLETED,PHASE1,"TransThera Sciences (Nanjing), Inc.",2019-01-08,2023-01-31,2024-02-28,2018-08-31,2025-07-24,['Maximum Tolerated Dose (MTD) and/or Dose Limiting Toxicity (DLT)'],"['Dose Recommended for Dose Expansion (DRDE)', 'Optimal Biological Dose (OBD)', 'Number of Participants With Abnormal Laboratory Values', 'Number of Participants With Adverse Events That Are Related to Treatment', 'Peak Plasma Concentration (Cmax) of TT-00420', 'Time at which Cmax was first observed (Tmax) of TT-00420', 'Half-life (T1/2) of TT-00420', 'Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Response (DOR)', 'Progression Free Survival (PFS)', 'Overall Survival (OS)']",,,,,2,China; United States,"MD Anderson Cancer Center [Houston, United States] | Cancer Hopital Chinese Academy of Medical Sciences [Beijing, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is for TT-00420 (Tinengotinib), which is a new drug being tested in patients with advanced solid tumors and triple negative breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT03658967,Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE),"Phase 2, Double-Blind, Placebo-Controlled, Randomized Efficacy, Safety and Tolerability Study of Lymfactin in Combination With Surgical Lymph Node Transfer To Patients With Secondary Lymphedema Associated With the Treatment of Breast Cancer",COMPLETED,PHASE2,Herantis Pharma Plc.,2018-06-07,2019-12-16,2024-10-23,2018-09-06,2025-07-09,"['Measurement of the volume of the arms', 'Measurement of the lymphatic flow of the affected arm by quantitative lymphoscintigraphy (99Tc-nanocolloid clearance rate with calculation of transport index).', 'Questionnaire according to the Lymphedema Quality of Life Inventory (LQOLI)']","['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'CT scan of chest and abdomen', 'Lymfactin genome copy number in blood', 'Lymfactin genome copy number in wound secretion', 'Formation of anti-Lymfactin antibodies', 'Systemic concentration of vascular endothelial growth factor C (VEGF-C)']",,,,,5,Finland; Sweden,"Töölö Hospital, Department of Plastic Surgery [Helsinki, Finland] | Tampere University Hospital, Department of Plastic Surgery [Tampere, Finland] | Turku University Hospital, Department of Plastic Surgery [Turku, Finland] | Karolinska University Hospital, Department of Reconstructive Plastic Surgery [Stockholm, Sweden] | Uppsala University Hospital, Department of Plastic Surgery [Uppsala, Sweden]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on Lymfactin®, which is being tested for a specific condition (secondary lymphedema) and does not indicate an existing medicine being used for a new indication.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT03661424,BATs in Patients With Breast Cancer and Leptomeningeal Metastases,A Phase I Study of Anti-CD3 x Anti-Her2/Neu (Her2Bi) Armed Activated T Cells (ATC) in Patients With Breast Cancer Leptomeningeal Metastases,TERMINATED,PHASE1,University of Virginia,2019-02-26,2021-12-14,2021-12-14,2018-09-07,2022-12-20,"['Types of adverse events (AEs)', 'Frequency of adverse events (AEs)', 'Severity of adverse events (AEs)', 'Timing of onset of adverse events', 'Duration of adverse events', 'Relationship to study therapy of any adverse events or abnormalities of laboratory tests as determined by CTCAE v5.0 will be assessed based on protocol-defined relationships of definitely, probably, possibly, unlikely and unrelated to study therapy.', 'Number of participants achieving at least 80% of the planned HER2 BATs dose.']","['Immune shift: in vitro cytotoxicity assays and/or IFN-y EliSpots against breast cancer cell lines', 'Immune shift: Phenotyping of activating and regulatory immune cells', 'Immune shift: Measurement of cytokine patterns', 'Immune shift: Determination of anti-Her2 antibodies', 'Correlation of clinical and immune response characteristics to progression-free survival', 'Correlation of clinical and immune response characteristics to overall survival', 'Objective response rate (ORR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'MD Anderson Symptom Inventory for Spinal Tumors (MDASI - SP)', 'MD Anderson Symptom Inventory for Brain Tumors (MDASI- BT)']",,,,,1,United States,"University of Virginia [Charlottesville, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT03669497,Hypo-Fractionated Radiotherapy in Breast Cancer,Hypo-fractionated Radiotherapy Schedule of 26 GY in 5 Fractions With Simultaneous Integrated Boost (6 GY) in Advanced Incurable Breast Cancer: A Prospective Phase I/II Study (HYPORT-B).,COMPLETED,,Tata Medical Center,2018-01-02,2020-12-02,2021-09-06,2018-09-13,2023-12-22,['Toxicity (CTCAE v 4.03)'],['Response'],,,,,1,India,"Sanjoy Chatterjee [Kolkata, India]",2018.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2021.0,4.0,0,NA/Other
NCT03671330,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis.",COMPLETED,PHASE2,Novartis Pharmaceuticals,2018-08-29,2022-04-25,2025-05-09,2018-09-14,2025-05-28,['Progressive free survival (PFS) based on local assessment by RECIST 1.1 guideline'],"['Pharmacokinetic (PK) parameter: Cmax', 'PK parameter: Tmax', 'PK parameter: AUC024h', 'Overall Survival (OS)', 'Overall response rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Time To Response (TTR)', 'Duration of Response (DoR)', 'Time to deterioration of ECOG performance status from baseline']",,,,,24,China,"Novartis Investigative Site [Hefei, China] | Novartis Investigative Site [Beijing, China] | Novartis Investigative Site [Chongqing, China] | Novartis Investigative Site [Guangzhou, China] | Novartis Investigative Site [Shijiazhuang, China] | Novartis Investigative Site [Harbin, China] | Novartis Investigative Site [Changsha, China] | Novartis Investigative Site [Nanjing, China] | Novartis Investigative Site [Suzhou, China] | Novartis Investigative Site [Nanchang, China] | Novartis Investigative Site [Changchun, China] | Novartis Investigative Site [Shengyang, China] | Novartis Investigative Site [Shengyang, China] | Novartis Investigative Site [Xian, China] | Novartis Investigative Site [Chengdu, China] | Novartis Investigative Site [Kunming, China] | Novartis Investigative Site [Hangzhou, China] | Novartis Investigative Site [Hangzhou, China] | Novartis Investigative Site [Beijing, China] | Novartis Investigative Site [Fuzhou, China] | Novartis Investigative Site [Qingdao, China] | Novartis Investigative Site [Shanghai, China] | Novartis Investigative Site [Shanghai, China] | Novartis Investigative Site [Tianjin, China]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating the efficacy and safety of Ribociclib (LEE011), which indicates it is a new medicine being tested in a specific patient population (Chinese women with HR positive, HER2-negative, advanced breast cancer).",INDUSTRY,False,2025.0,0.0,0,Phase 2
NCT03674242,Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2),A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer,TERMINATED,PHASE2; PHASE3,ERYtech Pharma,2019-06-13,2022-03-31,2022-03-31,2018-09-17,2022-08-01,['Disease Control Rate (DCR)'],"['Disease Control Rate (DCR)', 'Objective response rate (ORR)', 'Progression-Free Survival (PFS)', 'Duration of Response (DoR)', 'Overall Survival (OS)', 'Incidence of treatment emergent adverse events as assessed by CTCAE v5.0', 'Clinical response assessed by F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging', 'Eryaspase induced immunogenecity', 'Biomarkers potentials in predicting eryaspase activity.', 'Pharmacokinetics of eryaspase', 'Pharmacodynamics of eryaspase']",,,,,16,Belgium; Hungary; Spain,"ZNA Middelheim [Antwerp, Belgium] | Institut Jules Bordet [Brussels, Belgium] | UZ Brussel [Brussels, Belgium] | Grand Hôpital de Charleroi asbl [Charleroi, Belgium] | Clinique Sainte-Elisabeth [Namur, Belgium] | Debreceni Egyetem - Klinikai Kozpont - Onkologiai Klinika [Debrecen, Hungary] | Bacs Kiskun Megyei Korhaz [Kecskemét, Hungary] | Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet [Szolnok, Hungary] | Complejo Hospitalario Universitario A Coruña [A Coruña, Spain] | Hospital Universitario Germans Trias i Pujol [Badalona, Spain] | Hospital Universitario Arnau Vilanova [Lleida, Spain] | Fundacion Jimenez Diaz [Madrid, Spain] | Hospital Clinico San Carlos [Madrid, Spain] | Hospital Universitario Quirón Madrid [Madrid, Spain] | Hospital Universitario Ramon y Cajal [Madrid, Spain] | Hospital Universitario Virgen del Rocio [Seville, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Eryaspase, which is being studied in combination with chemotherapy for a specific cancer type, indicating it is a new medicine being evaluated for efficacy in treating triple-negative breast cancer.",INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT03674567,Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab,Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer,COMPLETED,PHASE1; PHASE2,"RAPT Therapeutics, Inc.",2018-09-25,2024-12-31,2024-12-31,2018-09-17,2025-01-24,"['Safety and tolerability of FLX475 as a single agent and in combination with pembrolizumab measured by the incidence of adverse events, including dose-limiting toxicities and maximum tolerated dose', 'Overall response rate in subjects treated with FLX475 as a single agent and in combination with pembrolizumab']",[],,,,,35,Australia; Hong Kong; South Korea; Taiwan; Thailand; United States,"Banner MD Anderson Cancer Center [Gilbert, United States] | City of Hope [Duarte, United States] | University of California, Los Angeles JCCC Clinical Research Unit [Los Angeles, United States] | Yale Cancer Center [New Haven, United States] | Georgetown - Lombardi Comprehensive Cancer Center [Washington D.C., United States] | Comprehensive Hematology and Oncology, LLC [St. Petersburg, United States] | Moffitt Cancer Center [Tampa, United States] | Emory Winship Cancer Institute [Atlanta, United States] | University of Chicago [Chicago, United States] | University of Louisville Hospital/James Graham Brown Cancer Center [Louisville, United States] | Johns Hopkins University [Baltimore, United States] | Dana-Farber Cancer Institute [Boston, United States] | University of Michigan [Ann Arbor, United States] | Quantum Santa Fe [Santa Fe, United States] | New York Presbyterian Hospital-Columbia University Medical Center [New York, United States] | Carolina BioOncology Institute [Huntersville, United States] | Mary Crowley Cancer Research Center [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | University of Washington [Seattle, United States] | Austin Hospital [Heidelberg, Australia] | Linear Clinical Research Limited [Nedlands, Australia] | Queen Mary Hospital - Lymphoma [High West, Hong Kong] | Queen Mary Hospital [High West, Hong Kong] | Prince of Wales Hospital [Shatin, Hong Kong] | Chungbuk National University Hospital [Jungbuk, South Korea] | Seoul National University [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | National Cheng Kung University Hospital [Tainan City, Taiwan] | Chi Mei Meidcal Center [Tainan City, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan] | Taipei Veterans General Hospital [Taipei, Taiwan] | King Chulaongkorn Memorial Hospital [Bangkok, Thailand] | Ramathibodi Hospital [Bangkok, Thailand]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating FLX475, which is a new drug being tested for safety and efficacy in advanced cancer, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT03680560,Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers,"A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies",TERMINATED,PHASE1,"Cogent Biosciences, Inc.",2019-03-13,2020-03-12,2020-03-12,2018-09-21,2020-03-31,"['Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values', 'Determination of recommended phase 2 dose (RP2D) regimen']","['Anti-tumor activity as measured by overall response rate (ORR) per iRECIST', 'Anti-tumor activity as measured best overall response (BOR)', 'Anti-tumor activity as measured by duration of response (DOR)', 'Anti-tumor activity as measured by progression-free survival (PFS)', 'Anti-tumor activity as measured by overall survival (OS)', 'Assessment of persistence of ACTR as measured by flow cytometry', 'Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR)', 'Assessment of ACTR phenotype and function as measured by flow cytometry', 'Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration', 'Trastuzumab pharmacokinetics (PK)']",,,,,6,United States,"Yale Smilow Cancer Hospital [New Haven, United States] | Miami University Cancer Center [Miami, United States] | The Ohio State University [Columbus, United States] | Sarah Cannon Research Institute/Tennessee Oncology, PLLC [Nashville, United States] | Baylor Scott & White Medical Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03696771,Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer,"A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies",COMPLETED,PHASE1,Novartis Pharmaceuticals,2018-12-27,2020-10-19,2020-10-19,2018-10-05,2022-02-04,"['Incidence and severity of dose limiting toxicities (DLTs)', 'Number of participants with Adverse Events']","['Concentration versus time profiles for NJH395 and its catabolite', 'PK parameter (Cmax) for NJH395', 'Pharmacokinetic (PK) parameter (AUC) for NJH395', 'Incidence of anti-NJH395 antibodies and neutralizing antibodies to trastuzumab', 'Overall Response Rate', 'Clinical Benefit Rate (CBR)', 'Progression Free Survival (PFS)', 'Duration of Response (DOR)', 'Characterization of tumor-infiltrating lymphocytes by IHC']",,,,,4,Italy; Japan; South Korea; United States,"University of Texas MD Anderson Cancer Center [Houston, United States] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Seoul, South Korea]",2018.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03709082,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,"A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer",TERMINATED,PHASE1; PHASE2,University of Kansas Medical Center,2018-10-15,2020-03-12,2021-02-03,2018-10-17,2024-03-05,['Rate of Overall Response'],"['Proportion of participants with complete response (CR).', 'Proportion of participants with partial response (PR).', 'Proportion of participants with stable disease (SD).', 'Proportion of participants with Grade 3 or higher adverse event.', 'Number of patients with adverse events', 'Number of participants with a worsening Patient Reported Outcomes of Adverse Events (PRO-AE) score', 'Peak observed plasma concentration']",,,,,5,United States,"The University of Kansas Cancer Center, West Clinic [Kansas City, United States] | The University of Kansas Cancer Center, Westwood Campus [Kansas City, United States] | The University of Kansas Cancer Center, Overland Park Clinic [Overland Park, United States] | The University of Kansas Cancer Center, North Clinic [Kansas City, United States] | The University of Kansas Cancer Center, Lee's Summit Clinic [Lee's Summit, United States]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 2
NCT03719326,A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies,A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies,COMPLETED,PHASE1,"Arcus Biosciences, Inc.",2018-10-15,2021-07-01,2021-07-02,2018-10-25,2024-05-24,"['Incidence of Adverse Events (AEs)', 'Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase']","['Plasma concentration of etrumadenant', 'Plasma concentration of IPI-549', 'Percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR), as determined by Investigator according to Response Evaluation in Solid Tumors (RECIST) v 1.1', 'Percentage of participants with Disease Control (complete response, partial response, or stable disease) for > 6 months as determined by RECIST v1.1', 'Duration of Response as determined by the Investigator according to RECIST v1.1', 'Progression Free Survival (PFS) as determined by the Investigator according to RECIST v1.1', 'Overall Survival (OS) as determined by the Investigator according to RECIST v1.1', 'Percentage of etrumadenant target inhibition in peripheral blood', 'Immunophenotyping activity in select immune subsets for etrumadenant and IPI-549 in peripheral blood']",,,,,27,Australia; United States,"Scottsdale Healthcare Hospitals dba Honor Health Research Institute [Scottsdale, United States] | Arizona Clinical Research Center [Tucson, United States] | University of California, Los Angeles [Los Angeles, United States] | Rocky Mountain Cancer Centers (Aurora) [Aurora, United States] | Miami Cancer Institute at Baptist Health [Miami, United States] | Maryland Oncology Hematology, PA [Rockville, United States] | HealthPartners Institute Cancer Care Center [Saint Paul, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | Carolina BioOncology Institute [Huntersville, United States] | Willamette Valley Cancer Institute and Research Center [Eugene, United States] | Texas Oncology, P.A. - Austin (Midtown) [Austin, United States] | Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Texas Oncology, P.A. - Fort Worth Cancer Center [Fort Worth, United States] | Texas Oncology, P.A. - San Antonio Northeast [San Antonio, United States] | Texas Oncology, P.A. - San Antonio Medical Center [San Antonio, United States] | Texas Oncology, P.A. - Tyler [Tyler, United States] | Virginia Cancer Specialists, PC [Fairfax, United States] | Virginia Oncology Associates [Norfolk, United States] | Medical Oncology Associates dba Summit Cancer Centers [Spokane, United States] | MultiCare Regional Cancer Center [Tacoma, United States] | Chris O'Brien Lifehouse [Camperdown, Australia] | The Kinghorn Cancer Centre [Darlinghurst, Australia] | St. George Private Hospital [Kogarah, Australia] | Macquarie University [Macquarie, Australia] | Pindara Private Hospital [Benowa, Australia] | Peninsula & South Eastern Haematology and Oncology Group [Frankston, Australia] | Cabrini Hospital [Malvern, Australia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03726931,"FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET","FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET",COMPLETED,,"Amsterdam UMC, location VUmc",2018-11-13,2023-01-29,2023-01-29,2018-11-01,2023-05-03,"['Percentage of patients with a correctly changed treatment plan according to [18F]FES PET/CT compared to [18F]FDG PET/CT.', 'Percentage of metastatic lesions detected with [18F]FES PET/CT compared to [18F]FDG PET/CT.', 'Percentage of missed metastases with [18F]FES PET/CT compared to [18F]FDG PET/CT.', 'Percentage of correct treatment plans as well as diagnostic confidence after 6 months of follow-up based on the added information obtained with [18F]FES PET/CT compared to [18F]FDG PET/CT.']","['[18F]FES/[18F]FDG uptake related to size of the lesion', '[18F]FES/[18F]FDG uptake related to location of the lesion.', '[18F]FES/[18F]FDG uptake related to histological subtype.', '[18F]FES/[18F]FDG uptake related to grade.', '[18F]FES/[18F]FDG uptake related to ER expression level.', '[18F]FES/[18F]FDG uptake related to PR expression level.', '[18F]FES/[18F]FDG uptake related to HER2 expression level.', '[18F]FES/[18F]FDG uptake related to Ki67%/mitotic index.', '[18F]FES/[18F]FDG uptake related to intensity of ER staining.', '[18F]FES/[18F]FDG uptake related to intensity of tumor cell density.', '[18F]FES/[18F]FDG uptake related to intensity of microvessel density.', '[18F]FES/[18F]FDG uptake related to infiltration of lymphocytes.', '[18F]FES/[18F]FDG uptake related to amount of necrosis.', '[18F]FES/[18F]FDG uptake related to amount of stroma.', '[18F]FES/[18F]FDG uptake related to expression of glucose transporter-1 (GLUT1) in the primary tumor, lymph node and distant metastases.', 'Cut off value for [18F]FDG SUV max below which [18F]FES PET/CT adds information for staging.', 'Cut off value for [18F]FDG SUV peak below which [18F]FES PET/CT adds information for staging.', 'Cut off value for grade below which or above which [18F]FES PET/CT adds information for staging.', 'Cut off value for ER expression level below which or above which [18F]FES PET/CT adds information for staging.']",,,,,1,Netherlands,"VU University Medical Center [Amsterdam, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial text discusses the use of [18F]FES-PET as a new standard for staging breast cancer, indicating it is a new medicine or diagnostic method being evaluated.",OTHER,False,2023.0,2.0,0,NA/Other
NCT03739931,Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade",COMPLETED,PHASE1,"ModernaTX, Inc.",2018-11-27,2025-08-01,2025-08-01,2018-11-14,2025-08-15,"['Number of Participants with Dose Limiting Toxicities (DLTs)', 'Number of Participants with Adverse Events (AEs)', 'Arm B: Overall Response Rate (ORR): Percentage of Participants with Tumor Response (Partial or Complete) Based on Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) in Cutaneous Melanoma']","['ORR: Percentage of Participants with Tumor Response (Partial or Complete) Based on RECIST v1.1 and modified RECIST (iRECIST), and Cheson and Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) for Participants With Lymphoma', 'Pharmacokinetics: Maximum Observed Concentration (Cmax)']",,,,,24,Australia; Israel; United States,"UCSF Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | Providence St. John's Health Center [Santa Monica, United States] | University of Colorado Denver [Aurora, United States] | Yale Cancer Center [New Haven, United States] | Sarah Cannon Research Institute at Florida Cancer Specialists [Sarasota, United States] | The University of Chicago Medicine [Chicago, United States] | Massachusetts General Hospital [Boston, United States] | Cancer Center at Beth Israel Deaconess Medical Center [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States] | Henry Ford Hospital [Detroit, United States] | NYU Langone Medical Center [New York, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | James P. Wilmot Cancer Center [Rochester, United States] | The Cleveland Clinic Foundation [Cleveland, United States] | Oregon Health and Science University [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | One Clinical Research Perth [Nedlands, Australia] | Alfred Health [Melbourne, Australia] | Westmead Hospital [Westmead, Australia] | Melanoma Institute of Australia [Wollstonecraft, Australia] | Rambam Medical Center [Haifa, Israel] | Rabin Medical Center [Petah Tikva, Israel] | Chaim Sheba Medical Center [Ramat Gan, Israel] | Tel Aviv Sourasky Medical Center [Tel Aviv, Israel]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,1,Phase 1
NCT03742349,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,"A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer",TERMINATED,PHASE1,Novartis Pharmaceuticals,2019-01-31,2023-02-06,2023-02-06,2018-11-15,2025-05-18,"['Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety', 'Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety', 'Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)', 'Frequency of dose interuptions', 'Frequency of dose reductions', 'Dose intensities']","['Best overall response (BOR)', 'Progression free survival (PFS) per RECIST v1.1 and iRECIST', 'Presence of anti-spartalizumab antibodies', 'Presence of anti-LAG525 antibodies', 'Presence of anti-MCS110 antibodies', 'Presence of anti-canakinumab antibodies', 'Serum concentration of spartalizumab, LAG525, MCS110, canakinumab', 'Plasma concentration of NIR178, NJI675, capmatinib', 'PK parameter (Tmax) of spartalizumab', 'PK parameter (Cmax) of spartalizumab', 'PK parameter (AUC) of spartalizumab', 'PK parameter (Tmax) of LAG525', 'PK parameter (Cmax) of LAG525', 'PK parameter (AUC) of LAG525', 'PK parameter (Tmax) of NIR178', 'PK parameter (Cmax) of NIR178', 'PK parameter (AUC) of NIR178', 'PK parameter (Tmax) of capmatinib', 'PK parameter (Cmax) of capmatinib', 'PK parameter (AUC) of capmatinib', 'PK parameter (Tmax) of MCS110', 'PK parameter (Cmax) of MCS110', 'PK parameter (AUC) of MCS110', 'PK parameter (Tmax) of canakinumab', 'PK parameter (Cmax) of canakinumab', 'PK parameter (AUC) of canakinumab', 'Changes from baseline of PD markers in tumor tissue (TILs, CD8, PD-L1, LAG-3)']",,,,,13,Australia; Hong Kong; Israel; Italy; Japan; Netherlands; Singapore; Spain; United States,"Columbia University Medical Center- New York Presbyterian Columbia [New York, United States] | Sarah Cannon Research Institute Sarah Cannon Research [Nashville, United States] | Novartis Investigative Site [Westmead, Australia] | Novartis Investigative Site [Shatin, New Territories, Hong Kong] | Novartis Investigative Site [Tel Aviv, Israel] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Valencia, Spain]",2019.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The study involves a novel immunotherapy combination for treating triple negative breast cancer, indicating the development of a new medicine.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT03752723,Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),"A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC",COMPLETED,PHASE1; PHASE2,"Genexine, Inc.",2019-03-27,2023-05-11,2023-05-11,2018-11-26,2024-03-05,"['Incidence and nature of DLTs', 'Incidence, nature and severity of adverse events', 'Objective response rate (ORR)']",[],,,,,12,South Korea,"Seoul National University Bundang Hospital [Seongnam-si, South Korea] | Ajou Medical Center [Suwon, South Korea] | National Cancer Center [Goyang-si, South Korea] | Gachon University Gil Medical Center [Incheon, South Korea] | Asan Medical Center [Seoul, South Korea] | Ewha Womans University Mokdong Hospital [Seoul, South Korea] | Gangnam Severance Hospital [Seoul, South Korea] | Korea University Anam Hospital [Seoul, South Korea] | Korea University Guro Hospital [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | Seoul ST.Mary's Hospital [Seoul, South Korea] | Severance Hospital [Seoul, South Korea]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating GX-I7, which appears to be a new medicine in combination with Pembrolizumab for a specific patient population (refractory or relapsed TNBC).",INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT03763851,Cannabis Oil and Radiation Therapy for the Management of Pain,"Cannabis Oil and Radiation Therapy for the Management of Pain: Assessment of Safety and Efficacy in a Randomized, Double-blind Placebo-controlled Phase II/III Clinical Trial",TERMINATED,PHASE2,Tetra Bio-Pharma,2018-03-14,2018-11-30,2018-11-30,2018-12-04,2020-03-12,"['Cancer pain intensity assessed by Pain Intensity (PI) measurement a numerical rating scale', 'Cancer pain quality using the Brief Pain Inventory-SF (BPI-SF)']","['Impact of medical cannabis oil combined with radiation treatment on HRQoL as measured by the EQ-5D-5L', 'Functional status assessed by the Functional Assessment of Cancer Therapy for Prostate patients (FACT-P).', 'Fatigue burden assessed by the Brief Fatigue Inventory (BFI).', 'Cognitive status assessed by the Mini-Cog']",,,,,1,Canada,"Sante Cannabis [Montreal, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is investigating the use of cannabis oil, which is considered a new medicine, in combination with radiation therapy for managing cancer pain.",INDUSTRY,False,2018.0,7.0,0,Phase 2
NCT03775850,"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors","A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",COMPLETED,PHASE1,"Evelo Biosciences, Inc.",2018-12-19,2021-06-30,2021-10-31,2018-12-14,2023-03-24,"['Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0', 'Safety and tolerability of EDP1503 alone and in combination with pembrolizumab', 'Evidence of anti-tumor activity of EDP1503 based on ORR']","['Progression Free Survival', 'Overall Survival']",,,,,8,Canada; United States,"Highlands Oncology Group [Rogers, United States] | Florida Cancer Specialists [Sarasota, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Tennessee Oncology, PLLC [Chattanooga, United States] | Tennessee Oncology [Nashville, United States] | Centre de Recherche du CHUM [Montreal, Canada] | Jewish General Hospital [Montreal, Canada] | CHU de Québec - Université Laval [Québec, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03790423,18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer,Phase I: PET Imaging of Tissue Factor (TF) Expression in Patients With Primary and Metastastic Cancer Using 18F-ASIS.,COMPLETED,PHASE1,"Rigshospitalet, Denmark",2019-01-03,2019-11-18,2019-11-18,2018-12-31,2020-11-19,"['1.Biodistribution of the radiotracer 18F-ASIS estimated by PET', '2.Dosimetry of the radiotracer 18F-ASIS estimated by PET', '3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]']",['1.Quantitative uptake of the radiotracer 18F-ASIS in tumor tissue'],,,,,1,Denmark,"Rigshospitalet [Copenhagen, Denmark]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT03799523,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,COMPLETED,,The University of Texas Health Science Center at San Antonio,2019-01-16,2024-02-22,2024-02-22,2019-01-10,2024-08-09,['Position measurement from Port films.'],[],,,,,1,United States,"UT Health San Antonio Mays Cancer Center [San Antonio, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2024.0,1.0,0,NA/Other
NCT03816839,Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2),"A Phase 1 Study for the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy in Japanese Postmenopausal Women With Estrogen Receptor-Positive And Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (AMEERA-2)",TERMINATED,PHASE1,Sanofi,2019-03-25,2020-10-27,2024-12-26,2019-01-25,2025-07-07,['Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs)'],"['Safety: Adverse Events (AEs)', 'Assessment of Pharmacokinetic parameter of SAR439859: tlag', 'Assessment of Pharmacokinetic parameter of SAR439859: tmax', 'Assessment of Pharmacokinetic parameter of SAR439859: Cmax', 'Assessment of Pharmacokinetic parameter of SAR439859: AUC0-24h or AUC0-10h and/or AUC0-12h', 'Assessment of Pharmacokinetic parameter of SAR439859: Ctrough', 'Assessment of antitumor activity: Objective response rate (ORR)', 'Assessment of antitumor activity: Clinical benefit rate (CBR)', 'Assessment of antitumor activity: Duration of response', 'Assessment of antitumor activity: Non-progression rate']",,,,,3,Japan,"Investigational Site Number : 3920003 [Nagoya, Japan] | Investigational Site Number : 3920001 [Kashiwa-shi, Japan] | Investigational Site Number : 3920002 [Chuo-ku, Japan]",2019.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT03821233,A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers,A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers,COMPLETED,PHASE1,Zymeworks BC Inc.,2019-04-15,2024-09-27,2024-10-08,2019-01-29,2025-01-29,"['Incidence of dose-limiting toxicities (DLTs)', 'Incidence of adverse events', 'Incidence of lab abnormalities', 'Incidence of electrocardiogram (ECG) and left ventricular ejection fraction (LVEF) abnormalities', 'Incidence of dose reductions of ZW49']","['Serum concentrations of ZW49', 'Incidence of anti-drug antibodies (ADAs)', 'Objective response rate (ORR)', 'Disease control rate', 'Duration of response', 'Progression-free survival']",,,,,16,Australia; Canada; South Korea; United States,"City of Hope [Duarte, United States] | Moffitt Cancer Center [Tampa, United States] | University of Chicago Medicine [Chicago, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Fox Chase Cancer Center [Philadelphia, United States] | Sarah Cannon Research Institute [Nashville, United States] | NEXT Oncology [San Antonio, United States] | Virginia Cancer Specialists, PC [Fairfax, United States] | Flinders Medical Centre [Adelaide, Australia] | Princess Margaret Cancer Centre [Toronto, Canada] | Jewish General Hospital [Montreal, Canada] | Seoul National University Bundang Hospital [Seongnam-si, South Korea] | Korea University Anam Hospital [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea]",2019.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT03829436,TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers,"A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,Tempest Therapeutics,2019-03-20,2022-09-07,2022-09-07,2019-02-04,2023-07-03,"['Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.', 'Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab.', 'Identify the maximum tolerated dose']","['Assess pharmacokinetics: Maximum serum concentration (Cmax)', 'Assess pharmacokinetics: Area under the curve (AUC)', 'Objective response rate']",,,,,11,United States,"University of California - San Francisco [San Francisco, United States] | Miami Cancer Institute [Miami, United States] | Johns Hopkins University [Baltimore, United States] | University of Michigan Rogel Cancer Center [Ann Arbor, United States] | Columbia University Medical Center [New York, United States] | Carolina BioOncology Institute [Huntersville, United States] | Stephenson Cancer Center [Oklahoma City, United States] | University of Pennsylvania Perelman School of Medicine [Philadelphia, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | UPMC Hillman Cancer Center [Pittsburgh, United States] | Sarah Cannon Research Institute - TN [Nashville, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating TPST-1120, which is a new agent being tested both as a monotherapy and in combination with nivolumab, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03841110,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1),COMPLETED,PHASE1,Fate Therapeutics,2019-02-15,2022-11-15,2022-11-15,2019-02-15,2023-05-01,['The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.'],"['Objective-response rate (ORR)', 'Duration of FT500 persistence']",,,,,4,United States,"UCSD Moores Cancer Center [San Diego, United States] | University of Minnesota Masonic Cancer Center [Minneapolis, United States] | Hackensack University Medical Center/John Theurer Cancer Center [Hackensack, United States] | MD Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03854903,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696),COMPLETED,PHASE1,Georgetown University,2019-04-01,2023-11-01,2025-01-09,2019-02-26,2025-02-06,"['Toxicity of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors', 'Incidence of adverse events of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors', 'Grade of adverse events of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors', 'Maximum Tolerated Doses (MTD) of palbociclib and bosutinib when used in combination with fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors', 'Recommended Phase II Dose (RP2D) of palbociclib and bosutinib when used in combination with fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors']",[],,,,,1,United States,"Lombardi Comprehensive Cancer Center [Washington D.C., United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2025.0,0.0,0,Phase 1
NCT03872791,A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer,"A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer",COMPLETED,PHASE1; PHASE2,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2019-05-30,2022-08-16,2022-10-27,2019-03-13,2023-06-08,"['IRC assessed objective response', 'IRC assessed duration of response']","['PFS rate at 6 and 12 months', 'Frequency and severity of treatment emergent adverse events', 'Percentage of subjects with anti-drug antibodies']",,,,,12,China,"National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College [Beijing, China] | The First Affiliated Hospital of Xiamen University [Xiamen, China] | Sun Yat-sen Memorial Hospital, Sun Yat-sen University [Guangzhou, China] | Sun Yat-sen University Cancer Center [Guangzhou, China] | Harbin Medical University Cancer Hospital [Harbin, China] | Henan Cancer Hospital [Zhengzhou, China] | Hunan Cancer Hospital [Changsha, China] | Nantong Tumor Hospital [Nantong, China] | JiLin Cancer Hospital [Changchun, China] | Liaoning Cancer Hospital [Shenyang, China] | LiaoCheng People's Hospital [Liaocheng, China] | Zibo Municipal Hospital [Zibo, China]",2019.0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"[""Duration of Response"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating KN046, which is a new treatment being tested for triple-negative breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT03878823,Safety and Pharmacokinetics of ODM-209,"Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer",COMPLETED,PHASE1; PHASE2,"Orion Corporation, Orion Pharma",2019-04-17,2024-01-09,2024-01-09,2019-03-18,2024-02-01,['Maximum tolerated dose (MTD)'],[],,,,,4,Denmark; Finland; France,"Rigshospitalet, University Hospital of Copenhagen [Copenhagen, Denmark] | Helsinki University Central Hospital [Helsinki, Finland] | Tampere University Hospital [Tampere, Finland] | Institut Gustave Roussy [Villejuif, France]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a new medicine (ODM-209) being tested for safety and pharmacokinetics in specific cancer types, suggesting it is a novel treatment.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT03890744,ModraDoc006/r in Patients With Breast Cancer,"A Multicentre Phase IIa Study to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Patients With Recurrent or Metastatic HER-2 Negative Breast Cancer, Suitable for Treatment With a Taxane",COMPLETED,PHASE2,Modra Pharmaceuticals,2019-01-30,2020-02-13,2020-11-09,2019-03-26,2021-10-19,['The objective response rate (ORR)'],"['The number of CTCAE v.4.03 toxicities during treatment with ModraDoc006/r', 'The activity data on progression-free survival (PFS) of ModraDoc006/r']",,,,,4,Belgium; Denmark; Spain,"Institut Jules Bordet [Brussels, Belgium] | Centre Hospitalier Universitaire de Liège [Liège, Belgium] | Odense University Hospital [Odense, Denmark] | Hospital Quiron Pozuelo [Madrid, Spain]",2019.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating the efficacy and tolerability of ModraDoc006/r in a specific patient population, indicating it is a new medicine being tested for a specific condition (recurrent or metastatic HER-2 negative breast cancer).",INDUSTRY,False,2020.0,5.0,1,Phase 2
NCT03911453,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors in Response to the PARP Inhibitor Rucaparib,COMPLETED,EARLY_PHASE1,University of Arizona,2019-04-19,2021-07-16,2021-07-16,2019-04-11,2024-10-03,['Measurement of expression of PD-L1 by IHC via core biopsy.'],"['Measure change in expression of Ki67 by IHC after treatment with PARPi.', 'Measure and quantify change in number of tumor-infiltrating lymphocytes.', 'Measure levels of tumor PARylation in pre- and post-PARPi therapy by IHC.', 'Measure change in expression of programmed cell death-1 with ligand (PD-L1) pre- and post-PARPi therapy in circulating tumor cells (CTCs).', 'Measure cfDNA mutational expression for homologous recombination deficiency (HRD) and correlate with PD-L1 expression at baseline and change overtime.']",,,,,1,United States,"University of Arizona Cancer Center [Tucson, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating the effects of the PARP inhibitor Rucaparib, indicating it is a new medicine being tested for its impact on PD-L1 expression in a specific cancer type.",OTHER,False,2021.0,4.0,0,Phase 1
NCT03944499,Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.,"A Phase I,Multicenter,Open-label,Single-arm Study:A Dose-escalation Phase Evaluating FS1502 in Patients With HER2 Expressed Advanced Solid Tumors,and a Dose-expanded Phase in Patients With Local Advanced or Metastatic,HER2+ Breast Cancer",COMPLETED,PHASE1,Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,2019-10-11,2024-05-20,2024-08-12,2019-05-09,2025-09-15,"['DLT of first single dose of FS-1502.', 'MTD of single dose of FS-1502', 'Recommend Phase 2 Dose(RP2D) of single dose of FS-1502', 'Overall response rate (ORR) assessed by IRC']","['TEAE', 'SAE and AE that leading to treatment permanent discontinuation', 'Incidence of deaths and causes', 'Progression free survival (PFS)', 'Overall survival (OS)', '1-year overall survival (OS) rate', 'Duration of response (DoR)', 'Clinical benefit response (CBR)', 'Area under the serum concentration versus time curve (AUC)', 'Peak Serum Concentration (Cmax)', 'Time to maximum concentration (tmax)', 'Elimination half life (T1/2)', 'Clearance (Cl)', 'Anti-FS-1502 antibody']",,,,,12,China,"The First Affiliated Hospital of Bengbu Medical College [Bengbu, China] | Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College [Beijing, China] | Jilin Cancer Hospital [Jilin, China] | Sun Yat-sen University Cancer Prevention Center [Guangzhou, China] | Meizhou People's Hospital [Meizhou, China] | Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences [Shenzhen, China] | The Fourth Hospital of Hebei Medical University [Shijiazhuang, China] | Henan Cancer Hospital [Zhengzhou, China] | Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology [Wuhan, China] | Shandong Cancer Hospital [Jinan, China] | Tianjin Cancer Hospital [Tianjin, China] | Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University [Hangzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT03945604,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,"A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib and Fluzoparib in Subjects With Recurrent and Metastatic Triple Negative Breast Cancer",COMPLETED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2019-06-04,2021-02-09,2021-02-09,2019-05-10,2022-08-12,['Dose Limiting Toxicity (DLT)'],"['Adverse Events and Serious Adverse Events', 'Overall Response Rate (ORR)', 'Duration of response (DoR)', 'Disease Control Rate', 'Progression-Free-Survival', '12-months overall survival rate']",,,,,1,China,"Beijing Cancer Hosptial [Beijing, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves SHR-1210, which is identified as an Anti-PD-1 inhibitor, indicating it is a new medicine being tested in combination with other agents for a specific cancer type.",INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03950570,ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer,"A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors",COMPLETED,PHASE1; PHASE2,"Orinove, Inc.",2019-05-25,2023-01-30,2023-01-30,2019-05-15,2024-12-31,"['To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors: NCI CTCAEv5 Common Toxicity Criteria', 'To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer', 'To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study: NCI CTCAEv5 Common Toxicity Criteria', 'To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with Abraxane given intravenously at 100 mg/m2 once weekly for 3 weeks in the dose escalation and expansion stages of the study']","['To evaluate the peak concentrations (Cmax) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the time to peak concentrations (Tmax) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the area under the plasma concentration versus time curve (AUC) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the last time point with a quantifiable concentration (AUClast) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the plasma concentration end of a dosing interval (Ctau) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the average plasma concentration (Cav) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the minimum plasma concentrations (Cmin) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the elimination constant (λz) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the terminal half-life (T1/2) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the plasma clearance (CL/f) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.', 'To evaluate the volume of distribution (Vz/f) of ORIN1001 after oral administration as a single agent and in combination with Abraxane.']",,,,,20,United States,"Banner MD Anderson Cancer Center [Gilbert, United States] | University of Arizona Cancer Center [Tucson, United States] | UCLA Health Burbank Specialty Care [Burbank, United States] | UCLA Health Laguna Hills Cancer Care [Laguna Hills, United States] | University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center [Orange, United States] | University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC) - Oncology Center - Westwood [Westwood, Los Angeles, United States] | University of Colorado Anschutz Medical Campus [Denver, United States] | Highlands Ranch Hospital [Highlands Ranch, United States] | University of Colorado Lone Tree Medical Center [Lone Tree, United States] | University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center [Miami, United States] | Cancer Center of Kansas [Wichita, United States] | St Lukes Cancer Institute [Kansas City, United States] | Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)) [Buffalo, United States] | Northwell Health [New Hyde Park, United States] | Northwell Heath Cancer Institute [New Hyde Park, United States] | NYU Langone Health [New York, United States] | Gabrail Cancer Center [Canton, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | Sarah Cannon Research Institute [Nashville, United States] | Baylor College of Medicine Medical Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on ORIN1001, which is being tested as a new treatment for advanced solid tumors and relapsed refractory metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT03953833,B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer,"Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer",COMPLETED,PHASE1,"Shanghai Pharmaceuticals Holding Co., Ltd",2019-04-01,2023-01-13,2023-01-13,2019-05-17,2023-09-14,"['Maximum Tolerated Dose', 'Dose-Limiting Toxicity', 'Immunogenicity assessment', 'Titer of ADA positive sample', 'Pharmacokinetics measurement A', 'Pharmacokinetics measurement B', 'Pharmacokinetics measurement C', 'Pharmacokinetics measurement D', 'Pharmacokinetics measurement E', 'Pharmacokinetics measurement F', 'Pharmacokinetics measurement G', 'Therapeutic Efficacy A', 'Therapeutic Efficacy B', 'Therapeutic Efficacy C', 'Therapeutic Efficacy D']",[],,,,,1,China,"West China Hospital of Sichuan University [Chengdu, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT03955939,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy,COMPLETED,PHASE1,Eli Lilly and Company,2019-08-02,2020-05-14,2020-05-14,2019-05-20,2020-06-01,"['Number of Participants with Dose Reductions', 'Part II: Number of Participants with Dose Limiting Toxicities (DLTs)', 'Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)', 'Duration of Response (DoR)']","['Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR or SD With a Duration of At Least 6 Months', 'Progression-Free Survival (PFS)', 'Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668', 'PK: AUC of LY3295668 in Combination with Endocrine Therapy', 'PK: AUC of Endocrine Therapy in Combination with LY3295668', 'PK: AUC of Midazolam', 'PK: AUC of Midazolam in Combination with LY3295668']",,,,,7,Belgium; United States,"City of Hope National Medical Center [Duarte, United States] | Dana Farber Cancer Institute [Boston, United States] | South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States] | Cliniques Universitaires Saint-Luc [Brussels, Belgium] | Universitair Ziekenhuis Antwerpen [Edegem, Belgium] | Universitair Ziekenhuis Gent [Ghent, Belgium] | Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg [Leuven, Belgium]",2019.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on LY3295668 Erbumine, which is a new drug being tested in patients with metastatic breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03957096,A Safety Study of SGN-CD47M in Patients With Solid Tumors,A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors,TERMINATED,PHASE1,Seagen Inc.,2019-07-17,2020-09-14,2020-09-14,2019-05-21,2020-09-17,"['Number of patients with adverse events', 'Number of patients with laboratory abnormalities', 'Number of patients with dose-limiting toxicities (DLTs)']","['Objective response rate (ORR) per RECIST v1.1', 'ORR per iRECIST', 'Duration of objective response (DOR) per RECIST v1.1', 'DOR per iRECIST', 'Duration of complete response (CR) per RECIST v1.1', 'Duration of CR per iRECIST', 'Progression-free survival (PFS) per RECIST v1.1', 'PFS per iRECIST', 'Overall survival (OS)', 'Area under the concentration-time curve (AUC)', 'Maximum concentration (Cmax)', 'Time to Cmax (Tmax)', 'Trough concentration (Ctrough)', 'Incidence of antidrug antibodies (ADA)']",,,,,5,United States,"Case Western Reserve University / University Hospitals Cleveland Medical Center [Cleveland, United States] | Providence Portland Medical Center [Portland, United States] | Tennessee Oncology-Nashvilee/Sarah Cannon Research Institute [Nashville, United States] | MD Anderson Cancer Center / University of Texas [Houston, United States] | NEXT Oncology [San Antonio, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03970967,Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases,A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases,TERMINATED,,Alpha Tau Medical LTD.,2019-08-28,2023-11-30,2023-11-30,2019-06-03,2024-01-18,"['Tumor response to DaRT', 'Adverse Events']","['Change in tumor volume.', 'DaRT seeds placement', 'Change in quality of life: EORTC-QLQ-C30', 'Progression free survival', 'Pathological remissions.', 'Abscopal effects.', 'Change in quality of life: BR23', 'Abscopal effects']",,,,,1,Russia,"A. Tsyb Medical Radiological Research Center [Obninsk, Russia]",2019.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a new treatment method (Alpha Radiation Emitters Device) for a specific condition (newly diagnosed breast carcinoma with distant metastases), indicating it is a New Medicine.",INDUSTRY,False,2023.0,2.0,0,NA/Other
NCT03980093,The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,COMPLETED,,"University of Colorado, Boulder",2019-04-01,2020-08-31,2020-08-31,2019-06-10,2022-11-03,['Medication adherence assessed by electronic pillbox (Wisepill box)'],"['Self-reported medication adherence', 'Positive and negative emotional associations with taking anti-hormonal medication', 'Intentions to adhere to anti-hormonal medication in the next year and next several years', 'Medication nonpersistence assessed by electronic pillbox (Wisepill box)']",,,,,1,United States,"Rocky Mountain Cancer Centers [Greenwood Village, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03982004,Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,TERMINATED,PHASE1,Washington University School of Medicine,2020-09-14,2021-03-03,2021-03-03,2019-06-11,2021-06-21,['Safety and tolerability as measured by rate of treatment emergent grade 3 or higher toxicities'],"['Objective response rate (ORR) as measured by RECIST 1.1', 'Progression-free survival (PFS)', 'Change from baseline to week 3 in the number of tumor infiltrating lymphocytes after epicutaneous cryoimmunotherapy', 'Change from baseline to week 9 in the number of tumor infiltrating lymphocytes after epicutaenous cryoimmunotherapy plus pemrolizumab', 'Change from baseline to 18 weeks in the number of tumor cells', 'Change in quality of life as measured by the Dermatologic Quality of Life Index', 'Change in quality of life as measured by the Functional Assessment of Cancer Therapy (FACT)', 'Objective response rate as measured by measurement of 2 sentinel skin lesions', 'Objective response rate as measured by photography-based estimates of body surface area']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2020.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a new combination therapy (epicutaneous cryoimmunotherapy with pembrolizumab) for a specific condition (cutaneous metastatic breast cancer), indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT03983395,Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer,"A Phase 1/2, Open-Label, Dose-Escalation Study of ISB 1302 in Subjects With HER2-Positive Metastatic Breast Cancer",TERMINATED,PHASE1; PHASE2,Ichnos Sciences SA,2020-04-08,2020-07-24,2020-07-24,2019-06-12,2021-05-24,"['MTD: Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug (i.e. Cycle 1) in each cohort.', 'RP2D: Incidence and severity of AEs, AESI, and SAEs, including but not limited to laboratory values, PK and biomarkers.', 'Anti-tumor Activity of ISB 1302 administered Q1W (Part 2)']","['Incidence, nature, and intensity of AEs according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.', 'Antitumor activity of ISB 1302 administered Q1W (Part 1)', 'Additional preliminary anti-tumor clinical activity of ISB 1302 administered (Part 2)', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2) -Cmax', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2)-tmax', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2) -AUC0-tau', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2) - AUC0-t', 'Immunogenicity of ISB 1302 administered Q1W (Part 1 and Part 2)', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IL-2', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IL-6', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IL-10', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IFN-γ', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- TNF-α', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD3', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD4', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD8', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD25', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD69', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers - CD127', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include T cells', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include tumor microenvironment markers', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include apoptotic markers', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include Tumor Mutational Burden (TMB)', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include Epigenetic evaluation of Tregs', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include Epigenetic evaluation of T helper cells', 'Exploratory: Duration of treatment (Part 1 and Part 2)', 'Exploratory: Time to disease progression (Part 1 and Part 2)']",,,,,5,United States,"Ichnos Investigational Site 1 [Gilbert, United States] | Ichnos Investigational Site 5 [Los Angeles, United States] | Ichnos Investigational Site 4 [Louisville, United States] | Ichnos Investigational Site 2 [Detroit, United States] | Ichnos Investigational Site 3 [Philadelphia, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 2
NCT03985267,A New Mindfulness Intervention Called Mindfulness Based Swinging Technique (MBST) for Women With Breast Cancer,"Efficacy of Mindfulness Based Swinging Technique (MBST) for Improving Anxiety, Stress, Hopelessness and Self Efficacy Among Breast Cancer Patients in Treatment",COMPLETED,,University of Barcelona,2018-11-29,2021-08-01,2022-10-20,2019-06-13,2022-11-03,"['Evaluation of the immediate efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety', 'Evaluation of the immediate efficacy of the Mindfulness Based Swinging Technique (MBST) to increase self-efficacy', 'Evaluation of the immediate efficacy of the Mindfulness Based Swinging Technique (MBST) to increase hopefulness', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to increase self-efficacy', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to increase hopefulness', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety using the State Trait Anxiety Inventory.', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety using Emotion Thermometer.', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety using the Hospital Anxiety and Depression Scale.']","['Impact of education level on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of marital status on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of living arrangements on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of time for learning cancer diagnosis on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of having any metastasis on efficacy of the Mindfulness Based Swinging Technique (MBST)']",,,,,2,Turkey (Türkiye),"Ozel Oz Psikoloji Aile Danisma Merkezi (Oz Psychology Family Counselling Centre) [Izmir, Turkey (Türkiye)] | EgeMed Hospital [Aydin, Turkey (Türkiye)]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a new intervention (Mindfulness Based Swinging Technique) specifically designed for women with breast cancer, indicating it is a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03988556,Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis,Feasibility and Safety of CareMin650 in Cancer Patients at High Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis Due to the Administration of Radiotherapy: A Prospective Non-comparative Study,COMPLETED,,NeoMedLight,2019-07-04,2020-12-17,2020-12-17,2019-06-17,2021-04-30,"['Occurence of adverse events', 'Rate of discontinuation due to AEs']","['Skin lesions assessment - time of lesion occurrence', 'Skin lesions assessment - size of lesions', 'Skin lesions assessment - location', 'Skin lesions assessment - Grade', 'Skin lesions assessment - Time until resolution', 'Oral mucosa lesions assessment - time of lesion occurrence', 'Oral mucosa lesions assessment - size of lesions', 'Oral mucosa lesions assessment - location', 'Oral mucosa lesions assessment - Grade', 'Oral mucosa lesions assessment - Time until resolution']",,,,,5,France,"Institut de radiothérapie et radiochirurgie Hartmann [Levallois-Perret, France] | Centre Oscar Lambret [Lille, France] | Centre de Haute Energie [Nice, France] | Institut Curie [Paris, France] | Institut de Cancérologie Lucien Neuwirth [Saint-Priest-en-Jarez, France]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating the feasibility and safety of CareMin650, indicating it is a new medicine being tested for specific conditions (oral mucositis and radiation dermatitis) in cancer patients.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT03989037,A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer,"A Phase III, Randomized, Single-blind Study Comparing the Efficacy, Safety, and Immunogenicity of SIBP-01 and CN-Trastuzumab Combination With Docetaxel and Carboplatin in Patients With Early or Locally Advanced Her2 Positive Breast Cancer",COMPLETED,PHASE3,Shanghai Institute Of Biological Products,2019-06-27,2023-04-26,2023-04-26,2019-06-18,2023-12-27,['Total pathologic complete response (tpCR)'],"['Breast pathologic complete response (bpCR)', 'Proportion of patients with steady-state trough concentration (Ctrough, ss) > 20 μg/mL', 'PK Evaluation After Multi-Dose Administration']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2019.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[""Pathologic Complete Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves SIBP-01, which is a new medicine being tested in combination with CN-Trastuzumab for HER2 positive breast cancer.",INDUSTRY,False,2023.0,2.0,0,Phase 3
NCT03991260,99mTc-ADAPT6-based HER2 Imaging in Breast Cancer,SPECT Imaging of HER2 Expression in Breast Cancer Using Technetium-99m-labelled ADAPT6,COMPLETED,,Tomsk National Research Medical Center of the Russian Academy of Sciences,2019-06-05,2020-06-05,2020-09-05,2019-06-19,2021-04-01,"['Gamma camera-based whole-body 99mTc-ADAPT6 uptake value (%)', 'SPECT-based 99mTc-ADAPT6 uptake value in tumor lesions (kcounts)', 'SPECT-based 99mTc-ADAPT6 background uptake value (kcounts)', 'Tumor-to-background ratio (SPECT)']","['Safety attributable to 99mTc-ADAPT6 injections (physical findings)', 'Safety attributable to 99mTc-ADAPT6 injections (laboratory tests)', 'Safety attributable to 99mTc-ADAPT6 injections (incidence and severity of adverse events)', 'Safety attributable to 99mTc-ADAPT6 injections (concomitant medication)']",,,,,1,Russia,"TomskNRMC [Tomsk, Russia]",2019.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes the use of 99mTc-ADAPT6, which is a new imaging agent for assessing HER2 expression in breast cancer, indicating it is a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03997968,A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors,"A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors",COMPLETED,PHASE1; PHASE2,"Cyteir Therapeutics, Inc.",2019-10-09,2024-11-30,2024-12-20,2019-06-25,2024-12-24,"['Part A: Incidence of dose limiting toxicity', 'Part B: Objective response rate', 'Part C: Incidence of dose limiting toxicity', 'Part D: Incidence of dose limiting toxicity', 'Part E: Incidence of dose limiting toxicity']","['Part A: Incidence of adverse events and other safety measures', 'Part C: Incidence of adverse events and other safety measures', 'Part D: Incidence of adverse events and other safety measures', 'Part E: Incidence of adverse events and other safety measures', 'Part A: Assessment of pharmacokinetic parameters', 'Part C: Assessment of pharmacokinetic parameters', 'Part D: Assessment of pharmacokinetic parameters', 'Part E: Assessment of pharmacokinetic parameters', 'Part B: Assessment of pharmacokinetic parameters', 'Part A: Objective response rate', 'Part C: Objective response rate', 'Part D: Objective response rate', 'Part E: Objective response rate', 'Part B: Anti-tumor activity and by DOR', 'Part B: Anti-tumor activity by PFS', 'Part B: Anti-tumor activity by DCR', 'Part B: Anti-tumor activity by OS', 'Part B: Safety assessment']",,,,,16,United States,"University of California San Francisco [San Francisco, United States] | Stanford Comprehensive Cancer Center [Stanford, United States] | Sarah Cannon Research Institute at HealthONE [Denver, United States] | Florida Cancer Specialists and Research Institute [Sarasota, United States] | Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | University of Michigan [Ann Arbor, United States] | Mayo Clinic [Rochester, United States] | John Theurer Cancer Center at HUMC [Hackensack, United States] | NYU Langone Health [New York, United States] | Oklahoma University-Stephenson Cancer Center [Oklahoma City, United States] | Thomas Jefferson University, Sidney Kimmel Cancer Center [Philadelphia, United States] | Sarah Cannon Research Institute at Tennessee Oncology [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | University of Washington Seattle Cancer Center [Seattle, United States] | Medical College of Wisconsin [Milwaukee, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT04002284,Anlotinib in Metastatic HER2 Negative Breast Cancer,"The Efficacy and Safety of Anlotinib in Metastatic HER2 Negative Breast Cancer, a Single Arm Phase II Clinical Trial",COMPLETED,PHASE2,Peng Yuan,2018-07-12,2020-01-10,2020-03-15,2019-06-28,2020-07-29,['objective response rate(ORR)'],"['disease control rate(DCR)', 'Progression free survival (PFS)', 'overall survival(OS)', 'Safety and Tolerability']",,,,,1,China,"National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College [Beijing, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating Anlotinib, which is being tested for a specific indication (metastatic HER2 negative breast cancer) and does not appear to be an existing treatment for this condition, indicating it is a new medicine.",UNKNOWN,False,2020.0,5.0,0,Phase 2
NCT04024436,A Study of TAS-120 in Patients With Metastatic Breast Cancer,A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,COMPLETED,PHASE2,"Taiho Oncology, Inc.",2020-01-28,2023-05-31,2024-10-30,2019-07-18,2024-12-06,"['Objective Response Rate (ORR) - Cohorts 1, 2', 'Clinical Benefit Rate (CBR) - Cohort 3', '6-month Progression-free Survival (PFS) rate - Cohort 4']","['Complete Response (CR) - Cohort 3', 'Overall Response Rate (ORR) - Cohort 4', 'Clinical Benefit Rate (CBR) - Cohort 1,2, and 4', '6-month Progression-free Survival (PFS) rate - Cohorts 1-3', 'Progression-free Survival (PFS)', 'Duration of Response (DOR)', 'Overall Survival (OS)', 'Number of Adverse Events (AEs) Related to TAS-120 as a monotherapy and in combination with Fulvestrant', 'Number of Adverse Events (AEs) Related to Futibatinib as a monotherapy and in combination with Fulvestrant']",,,,,37,Canada; France; Italy; Portugal; Spain; United Kingdom; United States,"Mayo Clinic - AZ [Phoenix, United States] | USCF [San Francisco, United States] | Florida Cancer Specialists [Fort Myers, United States] | Mayo Clinic - FL [Jacksonville, United States] | Florida Cancer Specialists [St. Petersburg, United States] | Florida Cancer Specialists [Tallahassee, United States] | Moffitt Cancer Center [Tampa, United States] | Florida Cancer Specialists [West Palm Beach, United States] | Massachusetts General Hospital [Boston, United States] | BIDMC [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Mayo Clinic - MN [Rochester, United States] | HCA Midwest Health [Kansas City, United States] | Tennessee Oncology [Chattanooga, United States] | Tennessee Oncology [Nashville, United States] | UT Southwestern [Dallas, United States] | MD Anderson [Houston, United States] | Tom Baker Cancer Center [Calgary, Canada] | SunnyBrook Health Sciences [Toronto, Canada] | Institut Gustave Roussy [Villejuif, France] | Centre Leon Berard [Lyon, France] | AOU Policlinico - Vittorio Emanuele [Catania, Italy] | Istituto Europeo Di Oncologia - IEO [Milan, Italy] | AOU Modena Policlinico [Modena, Italy] | Ospedale E. Agnelli [Pinerolo, Italy] | Azienda Ospedaliero Universitaria Pisana [Pisa, Italy] | Istituto Nazionale Tumori Regina Elena [Roma, Italy] | Fondazione Policlinico Universitario Agostino Gemelli IRCCS [Roma, Italy] | Centro Hospitalar Universitario Lisboa Norte [Lisbon, Portugal] | Porto University [Porto, Portugal] | Instituto Portugues de Oncologia do Porto [Porto, Portugal] | Vall d'Hebron [Barcelona, Spain] | University Gregorio Marañon [Madrid, Spain] | START Madrid - CIOCC [Madrid, Spain] | HCA Healthcare UK [London, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom] | The Royal Marsden NHS Foundation Trust [Sutton, United Kingdom]",2020.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating TAS-120, which is a new drug being tested in patients with metastatic breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT04025216,A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers,"A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma",TERMINATED,PHASE1,"Kite, A Gilead Company",2019-10-10,2022-12-02,2022-12-02,2019-07-18,2024-01-24,"['Dose Escalation: Dose Identification of CART-TnMUC1', 'Cohort Expansion: Objective Response in solid tumors']","['Safety of CART-TnMUC1 in solid tumors and multiple myeloma', 'Tolerability of CART-TnMUC1 in solid tumors and multiple myeloma', 'Feasibility of CART-TnMUC1 in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Overall Survival (OS) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Progression Free Survival (PFS) in solid tumors', 'Preliminary anti-tumor efficacy of CART as assessed by Objective Response Rate (ORR) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Clinical Benefit Rate in solid tumors', 'Preliminary anti-tumor efficacy of CART as assessed by Duration of Response (DOR) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Time to Response (TTR) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Time to Progression (TTP) in multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Minimal Residual Disease (MRD) in multiple myeloma', 'Peripheral expansion and persistence of CART-TnMUC1 cells in solid tumors and multiple myeloma']",,,,,10,United States,"Mayo Clinic of Arizona [Phoenix, United States] | The Angeles Clinic and Research Institute [Los Angeles, United States] | Moffitt Cancer Center [Tampa, United States] | University of Chicago Medical Center [Chicago, United States] | Washington University School of Medicine [St Louis, United States] | Hospital of the University of Pennsylvania [Philadelphia, United States] | University of Pittsburgh Medical Center [Pittsburgh, United States] | Sarah Cannon Research Institute [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | University of Washington Medical Center [Seattle, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a first-in-human study of CART-TnMUC1, which indicates it is a new medicine being tested for advanced TnMUC1-positive solid tumors and multiple myeloma.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04042480,A Study of SGN-CD228A in Advanced Solid Tumors,A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors,TERMINATED,PHASE1,Seagen Inc.,2019-09-03,2023-03-09,2023-03-09,2019-08-02,2023-03-23,"['Number of participants with adverse events', 'Number of participants with laboratory abnormalities', 'Number of participants with dose limiting toxicities']","['Best response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'Best response per modified RECIST (mRECIST) (participants with pleural mesothelioma only)', 'Objective response rate (ORR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Duration of objective response (DOR)', 'Duration of complete response', 'Maximum concentration (Cmax) of antibody-conjugated monomethylauristatin E (acMMAE)', 'Cmax of free MMAE', 'Cmax of total antibody', 'Time to maximum concentration (Tmax) of acMMAE', 'Tmax of free MMAE', 'Tmax of total antibody', 'Area under the plasma concentration-time curve from time 0 to the last available [AUC (0-last)] of acMMAE', 'AUC(0-last) of free MMAE', 'AUC(0-last) of total antibody', 'Trough concentration (Ctrough) of acMMAE', 'Ctrough of free MMAE', 'Ctrough of total antibody', 'Incidence of anti-drug antibodies (ADA)']",,,,,14,France; Italy; Spain; United Kingdom; United States,"University of Alabama at Birmingham [Birmingham, United States] | The Angeles Clinic and Research Institute [Los Angeles, United States] | University of Chicago Medical Center [Chicago, United States] | Wake Forest Baptist Medical Center / Wake Forest University [Winston-Salem, United States] | Case Western Reserve University / University Hospitals Cleveland Medical Center [Cleveland, United States] | Oregon Health and Science University [Portland, United States] | University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center [Pittsburgh, United States] | Sanford Cancer Center [Sioux Falls, United States] | MD Anderson Cancer Center / University of Texas [Houston, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Institut Gustave Roussy [Villejuif, France] | Istituto Europeo di Oncologia [Milan, Italy] | Hospital Universitario Vall d'Hebron [Barcelona, Spain] | The Royal Marsden Hospital (Surrey) [Sutton, United Kingdom]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04060342,GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma,"A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors",TERMINATED,PHASE1,"GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",2019-08-13,2022-04-11,2022-04-11,2019-08-19,2022-08-18,"['Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs)', 'Phase 1 Dose Escalation - Regimens A, B, and C and Phase 1 Expansion - Regimen B: Incidence of adverse events (AEs)', 'Phase 1 Dose Escalation - Regimens A and B: Cmax of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: Ctrough of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: Tmax of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: t1/2 of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: AUC of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: CL/F of GB1275', 'Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)']","['Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: Cmax of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: Ctrough of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: Tmax of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: t1/2 of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: AUC of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: CL/F of GB1275', 'Phase 1 - Regimen C: Cmax of nab-paclitaxel and gemcitabine', 'Phase 1 - Regimen C: Tmax of nab-paclitaxel and gemcitabine)', 'Phase 1 - Regimen C: AUC of nab-paclitaxel and gemcitabine', 'Phase 2 - Basket Cohorts 1, 2, and 3: Duration of Response (DOR)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Time to Response (TTR)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Clinical Benefit Rate (CBR)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Progression Free Survival (PFS)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Time to Progression (TTP)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Overall Survival (OS)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Incidence of AEs', 'Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275']",,,,,8,United Kingdom; United States,"UCSF Medical Center at Mission Bay [San Francisco, United States] | University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) [Aurora, United States] | Washington University School of Medicine - Siteman Cancer Center [St Louis, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Duke University Medical Center [Durham, United States] | The Sarah Cannon Research Institute/Tennessee Oncology [Nashville, United States] | South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States] | The Royals Marsden NHS Foundation Trust [Sutton, United Kingdom]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is a Phase 1/2 study of GB1275, indicating it is a new medicine being tested for the first time in humans.",INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT04094519,A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,COMPLETED,PHASE1,"Astellas Pharma Global Development, Inc.",2020-01-27,2020-12-27,2020-12-27,2019-09-19,2024-11-20,"['Pharmacokinetics (PK) of Digoxin in combination with rosuvastatin in plasma: maximum concentration (Cmax)', 'Pharmacokinetics (PK) of Digoxin in combination with rosuvastatin in plasma: area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)', 'Pharmacokinetics (PK) of Digoxin in combination with rosuvastatin in plasma: area under the concentration time curve from the time of dosing extrapolated to time infinity (AUCinf)']","['Number of participants with Adverse Events (AEs)', 'Number of participants with laboratory value abnormalities and/or adverse events (AEs)', 'Number of participants with vital sign abnormalities and /or adverse events (AEs)', 'Number of participants with routine 12-lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)', 'Pharmacokinetics (PK) of enzalutamide and its metabolite (N-desmethyl) in plasma: maximum concentration (Cmax)', 'Pharmacokinetics (PK) of enzalutamide and its metabolite (N-desmethyl) in plasma: area under the concentration-time curve during a dosing interval, where tau (τ) is the length of the dosing interval (AUCtau)', 'Pharmacokinetics (PK) of enzalutamide and its metabolite (N-desmethyl) in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)']",,,,,1,Moldova,"Site MD37301 [Chisinau, Moldova]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04097756,A Phase I Study of LX-039 Tablets,"A Phase I Study of LX-039 Tablets in Postmenopausal Patients With ER+, HER2- Advanced Breast Cancer After Failure of Endocrine Therapy",COMPLETED,PHASE1,"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.",2020-01-07,2022-08-08,2023-02-07,2019-09-20,2023-05-01,"['To explore the tolerance of LX-039 in ER +, HER2 - patients with advanced breast cancer']","['The safety of LX-039 in ER +, HER2 - patients with advanced breast cancer', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'To explore the efficacy of LX-039 in ER +, HER2 - patients with advanced breast cancer according to Recist 1.1.', 'Comparison of changes in maximum uptake ability of FES(progression free survival) in breast cancer lesions before and after treatment with LX-039 by PET(positron emission tomography) scan (performed in some subjects)', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after a single dose of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039', 'PK profiles after continuous administration of LX-039']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04102618,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1),TERMINATED,EARLY_PHASE1,Oncolytics Biotech,2019-03-29,2022-04-20,2022-04-20,2019-09-25,2022-08-15,['To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.'],"['To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HR+/HER2-negative breast cancer.', 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HER2-positive breast cancer.', 'To identify biological changes, as defined by gene expression between posttreatment and pretreatment samples following pelareorep in combination with different therapies.', 'To describe the safety profile of the combination therapies']",,,,,14,Spain,"ICO Badalona [Badalona, Spain] | Hospital Clínic de Barcelona [Barcelona, Spain] | Hospital Quirón Dexeus [Barcelona, Spain] | Hospital Moisés Broggi [Esplugues de Llobregat, Spain] | Hospital Fuenlabrada [Madrid, Spain] | Hospital La Paz [Madrid, Spain] | Hospital Puerta de Hierro de Majadahonda [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Universitario Fundación Jiménez Díaz [Madrid, Spain] | Hospital Clínico Universitario Virgen Arrixaca [Murcia, Spain] | Hospital Universitario Virgen Macarena [Seville, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain] | Instituto Valenciano de Oncología [Valencia, Spain] | Hospital Clínico Lozano Blesa [Zaragoza, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating pelareorep, which is a new treatment being tested in combination with other therapies for early breast cancer, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04103853,"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer: an Open-label, Multi-center, Dose-escalating，Phase I/Ib Study.",COMPLETED,PHASE1,"Suzhou Kintor Pharmaceutical Inc,",2017-09-06,2019-05-22,2020-06-30,2019-09-26,2021-09-24,"['Dose-limiting Toxicity(DLT)', 'maximum tolerated dose (MTD)', 'Disease Control Rate(DCR)']","['maximum concentration (Cmax)', 'time that maximum concentration is observed (tmax)', 'area under the concentration time-curve from time zero to infinity (AUC0∞)', 'terminal elimination half life (t½)', 'drug clearance (CL)', 'apparent volume of distribution (Vd)', 'Number of participants with treatment-related adverse events as assessed by CTCAE V4.03']",,,,,7,China,"Beijing Cancer Hospital [Beijing, China] | Sun-Yat-sen University Cancer center [Guangzhou, China] | The Fourth Hospital of Hebei Medical University [Shijiazhuang, China] | Hunan Cancer Hospital [Changsha, China] | Jiangsu Province Hospital [Nanjing, China] | Ruijin Hospital, Shanghai Jiaotong University School of Medicine [Shanghai, China] | Tianjin Medical University Cancer Institute and Hospital [Tianjin, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04106167,"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy","Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",TERMINATED,,Fate Therapeutics,2019-06-11,2023-08-11,2023-08-11,2019-09-26,2023-09-21,['Overall Survival (OS) post-Infusion'],[],,,,,4,United States,"UCSD Moores Cancer Center [San Diego, United States] | University of Minnesota Masonic Cancer Center [Minneapolis, United States] | Hackensack University Medical Center [Hackensack, United States] | MD Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a study involving FT500 Cellular Immunotherapy, which suggests it is a new medicine being evaluated for its effects on overall survival.",INDUSTRY,False,2023.0,2.0,0,NA/Other
NCT04121286,A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China,"A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Allist Pharmaceuticals, Inc.",2020-07-14,2022-06-17,2022-06-17,2019-10-09,2025-05-20,"['Number of participants with dose limiting toxicities', 'Find Recommended Phase 2 Dose (RP2D) of JAB-3312']","['Number of participants with adverse events', 'Area under the curve', 'Cmax', 'Tmax', 'T1/2', 'Objective response rate ( ORR )', 'Duration of response ( DOR )']",,,,,5,China,"Cancer Hospital, Chinese Academy of Medical Sciences [Beijing, China] | Beijing Cancer Hospital [Beijing, China] | Peking Union Medical Collage Hospital [Beijing, China] | Peking University Third Hospital [Beijing, China] | Henan Provovential Cancer Hospital [Henan, China]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04125693,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,A Roll-over Study to Provide Continued Treatment With Rogaratinib in Participants Who Were Enrolled in Rogaratinib Studies,COMPLETED,PHASE2,Bayer,2019-10-30,2021-02-16,2021-02-16,2019-10-14,2022-04-01,"['Incidence of treatment-emergent adverse events (TEAEs)', 'Incidence of treatment-emergent serious adverse events (TESAEs)', 'Incidence of drug-related TEAEs', 'Incidence of drug-related TESAEs']",['Frequency of dose modifications'],,,,,1,Switzerland,"Kantonsspital St. Gallen [Sankt Gallen, Switzerland]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 2
NCT04132817,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,"A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast Cancer",COMPLETED,PHASE1,Bristol-Myers Squibb,2020-09-22,2022-08-15,2022-08-15,2019-10-21,2022-12-02,"['Incidence of Adverse Events (AEs)', 'Incidence of Serious Adverse Events (SAEs)', 'Incidence of AEs leading to dose and asset limiting toxicity (DALT)', 'Incidence of AEs leading to discontinuation', 'Incidence of laboratory abnormalities']","['Change from baseline in programmed cell death receptor-ligand 1 (PD-L1) by immunohistochemistry (IHC)', 'Objective Response Rate (ORR)', 'Median duration of response (mDOR)', 'Progression-free survival rate (PFSR)']",,,,,8,United States,"Local Institution [Los Angeles, United States] | Local Institution - 0003 [Sacramento, United States] | Local Institution - 0009 [Aurora, United States] | Local Institution - 0002 [St Louis, United States] | Local Institution - 0008 [New York, United States] | Local Institution [Pittsburgh, United States] | Local Institution [Dallas, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04134884,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,COMPLETED,PHASE1,Kathy Miller,2020-04-01,2024-01-30,2024-03-14,2019-10-22,2024-03-22,"['Safety of ASTX727 plus talazoparib using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0', 'Rate of dose limiting toxicity']","['Overall response rate', 'Clinical benefit response for triple negative disease subjects', 'Clinical benefit response for hormone receptor positive/ HER2 negative subjects', 'Progression free survival in all enrolled subjects']",,,,,2,United States,"Indiana University Melvin & Bren Simon Cancer Center [Indianapolis, United States] | Wake Forest Baptist Comprehensive Cancer Center [Winston-Salem, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2024.0,1.0,0,Phase 1
NCT04142892,Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer,A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer,COMPLETED,EARLY_PHASE1,SOLTI Breast Cancer Research Group,2020-11-06,2021-04-30,2021-04-30,2019-10-29,2022-04-01,['Complete Cell Cycle Arrest (CCCA)'],"['IHC of tumor expression', 'PAM50 (Prediction Analysis of Microarray 50) subtype change', 'antiproliferative effect', 'proliferation score', 'gene expression changes', 'molecular markers in blood', 'identification putative prognostic and predictive biomarkers', 'Adverse Events (AEs)']",,,,,4,Spain,"Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Clínic de Barcelona [Barcelona, Spain] | Hospital Universitari Arnau de Vilanova de Lleida [Lleida, Spain] | Hospital Universitario Sant Joan de Reus [Tarragona, Spain]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating Onapristone as a new treatment for a specific patient population (postmenopausal women with hormone receptor-positive and HER2-negative breast cancer), indicating it is a New Medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT04145323,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,COMPLETED,EARLY_PHASE1,"University of Wisconsin, Madison",2019-09-25,2019-12-19,2019-12-19,2019-10-30,2020-01-18,"['Comparison of Necrotic tissue area determined visually by the operating surgeon vs indocyanine Green (ICG) microangiography', 'Time to achieve the peak fluorescent signal from necrotic tissue using ICG', 'Percentage overlap of identified areas of necrosis determined by ICG and clinical standard of care']",[],,,,,1,United States,"University of Wisconsin [Madison, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT04147819,"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein","A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of Thorium-227 Labeled Antibody-chelator Conjugate BAY2701439, in Participants With Advanced HER2-expressing Tumors",COMPLETED,PHASE1,Bayer,2020-07-02,2023-08-21,2023-09-26,2019-11-01,2024-09-27,"['Dose escalation: Incidence of TEAEs including TESAEs', 'Dose escalation: Severity of TEAEs including TESAEs', 'Dose escalation: Frequency of DLTs at each dose level', 'Dose expansion: ORR by RECIST 1.1 based on Investigator review', 'Dose expansion: Frequency of TEAEs', 'Dose expansion: Severity of TEAEs']","['Dose escalation: Recommended dose level(s) of BAY2701439 for the dose expansion cohorts', 'Dose escalation: Recommended treatment schedule of BAY2701439 for the dose expansion cohorts', 'Dose expansion: Recommended dose for further clinical development of BAY2701439', 'Cmax of thorium-227', 'Cmax of radium-223', 'Cmax of total antibody', 'AUC(0-42 days) of thorium-227', 'AUC(0-42 days) of radium-223', 'AUC(0-42 days) of total antibody']",,,,,6,United Kingdom; United States,"Johns Hopkins Hospital/Health System [Baltimore, United States] | Washington University School of Medicine [St Louis, United States] | Memorial Sloan-Kettering Cancer Center [New York, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | Southampton General Hospital [Southampton, United Kingdom] | Royal Marsden NHS Trust (Surrey) [Sutton, United Kingdom]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a first-in-human study of a new drug (BAY2701439) targeting advanced cancer with HER2 expression, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04150731,16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer,16α-18F-fluor-17β-østradiol PET/CT Til Visualisering af østrogenreceptor-positive Levermetastaser Fra brystkræft,COMPLETED,PHASE1; PHASE2,University of Aarhus,2020-10-23,2022-10-25,2023-06-28,2019-11-05,2023-12-04,['Sensitivity of parametric FES-PET/CT'],"['Correlation of ER expression', 'Examination of the heterogeneity of ER expression in liver metastases', 'Examination of the heterogeneity of ER expression i metastases', 'Examination of the heterogeneity of ER expression', 'Correlation of tumor blood flow to ER+ cells']",,,,,1,Denmark,"Department of Nuclear Medicine & PET Centre, Aarhus University Hospital [Aarhus N, Denmark]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text discusses a specific imaging agent (16α-18F-fluor-17β-estradiol) used for visualizing estrogen receptor positive liver metastases, indicating it is a new medicine for diagnostic purposes.",OTHER,False,2023.0,2.0,0,Phase 2
NCT04168528,Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT,"Phase I/IIa Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of 68GaNOTA-Anti-MMR-VHH2, a New Radiopharmaceutical for in Vivo Imaging of Tumour-Associated Macrophages by Means of PET : UZBRU_VHH2_1",COMPLETED,PHASE1; PHASE2,Universitair Ziekenhuis Brussel,2019-11-05,2024-12-04,2024-12-04,2019-11-19,2024-12-11,"['Tolerability and safety of 68GaNOTA-Anti-MMR-VHH2: reported as type, frequency and severity (graded according to the CTCAEv5) (Part I).', 'Human biodistribution using blood sampling and PET/CT imaging: reported as relative uptake values per organ at 10, 90 and 150 minutes per individual subject and as a mean over all subjects (Part I).', 'Human dosimetry using PET/CT imaging data: radiation dose to individual organs and the equivalent dose for the whole body of each subject and as a mean over all subjects (Part I).', 'Tumor targeting potential using PET/CT and correlation to immunohistological MMR staining after resection: assessed using correlation coefficient (Part II).']",[],,,,,1,Belgium,"Uz Brussel [Brussels, Belgium]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2024.0,1.0,0,Phase 2
NCT04176757,A Study of ZN-c5 in Participants With Breast Cancer,"A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer",COMPLETED,PHASE1,Zeno Alpha Inc.,2020-01-03,2021-04-27,2021-05-25,2019-11-25,2022-08-01,['Corroborate the single agent Recommended Phase 2 Dose'],"['Dose-biomarker relationship', 'Dose-biomarker relationship', 'Dose-biomarker relationship']",,,,,10,Australia; Bosnia and Herzegovina; United States,"Site 3 [Tucson, United States] | Site 2 [New York, United States] | Site 4 [Nashville, United States] | Site 1 [Houston, United States] | Site 5 [Seattle, United States] | Site 11 [Liverpool, Australia] | Site 9 [Sydney, Australia] | Site 10 [Cairns, Australia] | Site 8 [Richmond, Australia] | Site 7 [Banja Luka, Bosnia and Herzegovina]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT04182516,Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors,A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors,TERMINATED,PHASE1,Nerviano Medical Sciences,2019-11-25,2023-03-31,2024-05-16,2019-12-02,2024-09-19,['Number of Participants with first-cycle dose limiting toxicity'],"['Number of participants with Adverse Events (AEs)', 'Maximum concentration (Cmax) of NMS-03305293 after single and multiple doses of drug', 'Time to observed Cmax (Tmax) of NMS-033052293 after single and multiple doses of drug', 'Area under the concentration-time curve to the last of measurable concentration (AUClast) of NMS-033052293 after single and repeated dose of drug.', 'Terminal elimination half-life (t1/2) of NMS-033052293 after single and multiple doses of drug.', 'Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-033052293 after multiple doses of drug.', 'Accumulation ratio (Rac) of NMS-033052293 after multiple doses of drug.', 'Oral plasma clearance (CL/F) of NMS-033052293 after multiple doses of drug.', 'Apparent volume of distribution (Vd/F) of NMS-033052293 after multiple doses of drug.', 'Renal clearance of NMS-033052293 after multiple doses of drug.', 'Objective tumor response (OR)', 'Progression Free Survival (PFS)', 'Time To Progression (TTP)', 'Time to PSA progression (for prostate cancer only)']",,,,,10,Bulgaria; China; Italy; United Kingdom; United States,"MD Anderson Cancer Center [Houston, United States] | MHAT - Dobrich AD (Department of medical oncology) [Dobrich, Bulgaria] | MHAT Sveta Sofia EOOD (Department of medical oncology) [Sofia, Bulgaria] | MHAT Women's Health - Nadezhda OOD (Clinic of medical oncology) [Sofia, Bulgaria] | Fudan University Shanghai Cancer Center [Shanghai, China] | TianJin Medical University Cancer Institute & Hospital [Tianjin, China] | Fondazione IRCCS Istituto Nazionale dei Tumori di Milano [Milan, Italy] | Istituto Oncologico Veneto IRCCS [Padua, Italy] | Centro Ricerche Cliniche di Verona Srl [Verona, Italy] | University College London Hospitals NHS Foundation Trust [London, United Kingdom]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04185311,"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted","A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deleted",TERMINATED,PHASE1,Jonsson Comprehensive Cancer Center,2019-07-10,2023-05-17,2023-05-17,2019-12-04,2023-08-15,['Incidence and severity of adverse events (AEs)'],['histopathological evaluation of changes of tumor for inflammatory infiltration and tumor necrosis'],,,,,1,United States,"UCLA / Jonsson Comprehensive Cancer Center [Los Angeles, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2023.0,2.0,0,Phase 1
NCT04187898,"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer","Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients With Breast-Cancer Receiving Docetaxel and Cyclophosphamide",COMPLETED,PHASE1,"Spectrum Pharmaceuticals, Inc",2020-03-11,2024-07-16,2024-08-16,2019-12-05,2024-09-19,['Time to Recovery of Absolute Neutrophil Count (ANC) From Nadir to ≥1.5×10^9/L in Cycle 1'],"['Duration of Grade 4 Neutropenia (DSN) in Cycle 1', 'Proportion of Patients With Grade 4 Neutropenia in Cycle 1', 'Incidence of Grade 3 Febrile Neutropenia (FN) in Cycle 1', 'Incidence of Neutropenic Complications, Including Hospitalization due to Neutropenia, FN, and use of Anti-infectives During Cycle 1', 'Expansion Phase: Time to Recovery of ANC From Nadir to ≥1.5×10^9/L in Cycles 2-4', 'Expansion Phase: DSN in Cycles 2-4', 'Expansion Phase: Proportion of Patients With Grade 4 Neutropenia in Cycles 2-4', 'Expansion Phase: Incidence of FN in Cycles 2-4', 'Expansion Phase: Incidence of Neutropenic Complications, Including Hospitalization due to Neutropenia, FN, and use of Anti-infectives During Cycles 2-4', 'Number of Patients With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety', 'Proportion of Patients Discontinuing Because of a TEAE']",,,,,8,United States,"ACRC/ Arizona Clinical Research Center [Tucson, United States] | Yuma Regional Medical Center Cancer Center [Yuma, United States] | Pacific Cancer Medical Center [Anaheim, United States] | City of Hope [Long Beach, United States] | BRCR Medical Center, Inc. [Plantation, United States] | Bond & Steele Clinic, P.A. [Winter Haven, United States] | SCL Health Research Institute, Inc. [Billings, United States] | Mercy Health Youngstown [Youngstown, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a new medicine, Eflapegrastim, in patients with breast cancer, indicating it is a new treatment being tested.",INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT04197999,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,"A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects",TERMINATED,PHASE1,GlycoMimetics Incorporated,2019-11-21,2021-08-25,2021-08-25,2019-12-13,2022-03-22,"['Occurrences of dose-limiting toxicities (DLT) including protocol-defined adverse events (AEs)/serious adverse events (SAEs), and/or laboratory abnormalities will be assessed in order to determine recommended phase II dose (Safety and Tolerability)']","['Area under the plasma concentration-time curve [AUC0-t and AUC0-∞] of GMI-1359', 'Maximum plasma concentration [Cmax] of GMI-1359', 'Time to reach maximum plasma concentration [tmax] of GMI-1359', 'Individual estimate of the terminal elimination rate constant [Λz] of GMI-1359', 'Half-life [t1/2] of GMI-1359', 'Total plasma clearance [CL] of GMI-1359', 'Apparent volume of distribution estimated at the terminal phase [Vz] of GMI-1359', 'Pre- and post-dose circulating tumor cells (CTC) enumeration to determine tumor cell mobilization [digital pathology assay]', 'Pre-and post-dose CD34+ cell quantification to determine mobilization into peripheral blood [standard flow cytometry]']",,,,,1,United States,"Duke University Medical Center [Durham, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on GMI-1359, which is being evaluated for safety and tolerability in a specific patient population (HR+ metastatic breast cancer), indicating it is a new medicine.",INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT04234113,Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors,A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors,TERMINATED,PHASE1,SOTIO Biotech AG,2019-06-13,2024-08-31,2024-11-27,2020-01-21,2025-01-08,"['Part A: Number of participants with dose-limiting toxicities (DLTs)', 'Part A1: Number of participants with DLTs', 'Part B: Number of participants with DLTs', 'Part B1: Number of participants with DLTs', 'Part A: Number of participants with AEs', 'Part A1: Number of participants with AEs', 'Part B: Number of participants with AEs', 'Part B1: Number of participants with AEs', 'Part D: Number of participants with AEs', 'Part A: Number of participants with serious AEs (SAEs)', 'Part A1: Number of participants with SAEs', 'Part B: Number of participants with SAEs', 'Part B1: Number of participants with SAEs', 'Part D: Number of participants with SAEs', 'Part A: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa', 'Part A1: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa', 'Part B: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa', 'Part B1: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa', 'Part D: Number of participants with AEs leading to premature discontinuation of nanrilkefusp alfa', 'Part A: Number of participants who died', 'Part A1: Number of participants who died', 'Part B: Number of participants who died', 'Part B1: Number of participants who died', 'Part D: Number of participants who died', 'Part A: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function)', 'Part A1: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function)', 'Part B: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function)', 'Part B1: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function)', 'Part D: Number of participants with nanrilkefusp alfa-related clinical laboratory test abnormalities (coagulation; hematology; clinical chemistry; urinalysis; thyroid and cardiac function)']","['Part A: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes)', 'Part A1: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes)', 'Part B: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes)', 'Part D: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 1 hour (+/-15 minutes)', 'Part A: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes)', 'Part A1: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes)', 'Part B: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes)', 'Part D: Nanrilkefusp alfa concentration profile, Cycle 1 Day 1, 4 hours (+/-15 minutes)', 'Part A: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1', 'Part A1: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1', 'Part B: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1', 'Part D: Overall activation levels of Ki-67+ CD8+ T cells on day 6 of cycle 1', 'Part A: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1', 'Part A1: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1', 'Part B: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1', 'Part D: Overall activation levels of Ki-67+ CD8+ CD45RO+ CD45RA- T cells on day 6 of cycle 1', 'Part A: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A1: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part B: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part D: Overall activation levels of Ki-67+ CD4+ T cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A1: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part B: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part D: Overall activation levels of Ki-67+ NK cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A1: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part B: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part D: Overall activation levels of Ki-67+ NKT cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A1: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part B: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part D: Overall activation levels of Ki-67+ Treg cells on day 6 of cycle 1 at 12 μg/kg nanrilkefusp alfa', 'Part A: Objective response rate (ORR)', 'Part A1: ORR', 'Part B: ORR', 'Part D: ORR', 'Part A: Duration of response (DoR)', 'Part A1: DoR', 'Part B: DoR', 'Part D: DoR', 'Part A: Clinical benefit rate (CBR)', 'Part A1: CBR', 'Part B: CBR', 'Part D: CBR', 'Part A: Progression-free survival (PFS)', 'Part A1: PFS', 'Part B: PFS', 'Part D: PFS', 'Part A: Number of participants with anti-drug antibodies (ADAs) at the end of treatment', 'Part A1: Number of participants with ADAs at the end of treatment', 'Part B: Number of participants with ADAs at the end of treatment', 'Part B1: Number of participants with ADAs at the end of treatment', 'Part D: Number of participants with ADAs at the end of treatment']",,,,,12,Czechia; France; Spain; United States,"Yale Cancer Center [New Haven, United States] | University of Pittsburgh [Pittsburgh, United States] | MD Anderson Cancer Center [Houston, United States] | Masarykův Onkologický Ústav Brno Klinika komplexní onkologické péče [Brno, Czechia] | Centre Léon Bérard [Lyon, France] | Hôpitaux Universitaires de Marseille Timone [Marseille, France] | Hopital Saint Louis [Paris, France] | Institut Gustave Roussy [Paris, France] | Institut de Cancerologie de L'Ouest [Saint-Herblain, France] | Institut Claudius Regaud [Toulouse, France] | Vall d'Hebron Institute of Oncology [Barcelona, Spain] | University Hospital Sanchinarro [Madrid, Spain]",2019.0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response"",""Duration of Response""]",3,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04246671,TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer,Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.,COMPLETED,PHASE1,Bavarian Nordic,2020-08-10,2024-02-17,2024-12-11,2020-01-29,2025-03-03,['Patients with Dose Limiting Toxicity (DLT)'],[],,,,,9,United States,"Mayo Clinic - Phoenix [Scottsdale, United States] | Providence Saint John's Health Center [Santa Monica, United States] | Mayo Clinic - Jacksonville [Jacksonville, United States] | H. Lee Moffitt Cancer Center [Tampa, United States] | Georgia Cancer Center Augusta University [Augusta, United States] | Massachusetts General Hospital [Boston, United States] | Mayo Clinic - Rochester [Rochester, United States] | Providence Cancer Institute [Portland, United States] | University of Washington [Seattle, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT04247126,"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors","A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors",COMPLETED,PHASE1,Syros Pharmaceuticals,2020-01-23,2023-01-31,2023-03-30,2020-01-29,2023-10-27,"['Groups 1 and 2: Dose-Limiting Toxicity of SY-5609', 'Groups 1 and 2: Number of Participants With Treatment Emergent Adverse Events', 'Groups 3 and 4 (Safety Lead-ins): Number of Participants With Dose-Limiting Toxicity', 'Groups 3 and 4 (Safety Lead-ins): Number of Participants With TEAEs', 'Groups 3 and 4 (Expansions): Progression Free Survival']","['Groups 1 and 2: Area Under The Concentration Versus Time Curve of SY-6509', 'Groups 1 and 2: Apparent Clearance of SY-5609', 'Groups 1 and 2: Apparent Volume of Distribution of SY-5609', 'Groups 1 and 2: Elimination Half-Life of SY-5609', 'Groups 1 and 2: Maximum Plasma Concentration (Cmax) of SY-5609', 'Groups 1 and 2: Time of Maximum Plasma Concentration (Tmax) of SY-5609', 'Groups 1 and 2: Minimum or Trough Plasma Concentration (Cmin) of SY-5609', 'Groups 1 and 2: Time of Minimum or Trough Plasma Concentration (Tmin) of SY-5609', 'Groups 3 and 4 (Safety Lead-ins): Progression Free Survival', 'Groups 3 and 4 (Safety Lead-ins): Objective Response Rate (ORR)', 'Groups 3 and 4 (Safety Lead-ins): Complete Response/Remission (CR) Rate', 'Groups 3 and 4 (Safety Lead-ins): Disease Control Rate', 'Groups 3 and 4 (Safety Lead-ins): Time to Response', 'Groups 3 and 4 (Safety Lead-ins): Duration of Response', 'Groups 3 and 4 (Expansions): Objective Response Rate', 'Groups 3 and 4 (Expansions): Complete Response Rate', 'Groups 3 and 4 (Expansions): Disease Control Rate', 'Groups 3 and 4 (Expansions): Time to Response', 'Groups 3 and 4 (Expansions): Duration of Response']",,,,,16,United States,"Banner MD Anderson Cancer Center [Gilbert, United States] | Cedars-Sinai Medical Center [Los Angeles, United States] | University of California Los Angeles [Los Angeles, United States] | Orlando Health Cancer Institute [Orlando, United States] | Emory University [Atlanta, United States] | The University of Iowa [Iowa City, United States] | Johns Hopkins University [Baltimore, United States] | Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | University of Michigan [Ann Arbor, United States] | START Midwest, LLC [Grand Rapids, United States] | Duke University [Durham, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Sidney Kimmel Cancer Center [Philadelphia, United States] | Sarah Cannon Research Institute - Tennessee Oncology [Nashville, United States] | South Texas Accelerated Research Theraputics (START), LLC [San Antonio, United States]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04252300,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants","Open Label, Fixed Sequences, One-way Cross-over Study to Determine the Effects of Multiple Doses BAY1817080 (150 mg) on the Pharmacokinetics of a 5 mg Dose Rosuvastatin in Healthy Participants",COMPLETED,PHASE1,Bayer,2020-03-02,2020-08-29,2020-12-07,2020-02-05,2021-03-11,"['Maximum plasma concentration of rosuvastatin without concomitant administration of BAY1817080 (Cmax)', 'Maximum plasma concentration of rosuvastatin after concomitant administration of BAY1817080 (Cmax1)', 'Area under the concentration-time curve of rosuvastatin without concomitant administration of BAY1817080 (AUC)', 'Area under the concentration-time curve of rosuvastatin after concomitant administration of BAY1817080 (AUC1)']","['Number of participants with treatment-emergent adverse events (TEAEs)', 'Severity of treatment-emergent adverse events']",,,,,1,United States,"Covance Clinical Research Unit, Inc. [Daytona Beach, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The study involves a new drug (BAY1817080) and its effects on the pharmacokinetics of an existing drug (rosuvastatin), indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04254107,A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer,A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies,TERMINATED,PHASE1,Seagen Inc.,2020-05-29,2023-12-01,2023-12-01,2020-02-05,2025-02-10,"['Number of participants with adverse events (AEs)', 'Number of participants with laboratory abnormalities by grade', 'Number of participants with a dose-limiting toxicity (DLT) at each dose level']","['Objective Response Rate (ORR)', 'Complete response (CR) rate', 'Duration of objective response', 'Duration of CR', 'Duration of progression-free survival', 'Duration of overall survival', 'Area under the concentration-time curve (AUC)', 'Time to maximum concentration (tmax)', 'Maximum concentration (Cmax)', 'Trough concentration (Ctrough)', 'Number of participants with antidrug antibodies (ADA)']",,,,,36,Canada; France; Italy; Spain; United Kingdom; United States,"University of Alabama at Birmingham [Birmingham, United States] | Arizona Oncology Associates, PC - HOPE [Tucson, United States] | City of Hope [Duarte, United States] | California Research Institute [Los Angeles, United States] | University of California, San Francisco | HDFCCC - Hematopoietic Malignancies [San Francisco, United States] | Yale Cancer Center [New Haven, United States] | Johns Hopkins Medical Center [Baltimore, United States] | Maryland Oncology Hematology, P.A. [Rockville, United States] | University of Michigan Comprehensive Cancer Center [Ann Arbor, United States] | Minnesota Oncology Hematology P.A. [Minneapolis, United States] | Mayo Clinic Rochester [Rochester, United States] | University of Mississippi Medical Center [Jackson, United States] | Weill Cornell Medicine [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Wake Forest Baptist Medical Center / Wake Forest University [Winston-Salem, United States] | University of Cincinnati Cancer Institute [Cincinnati, United States] | Providence Portland Medical Center [Portland, United States] | University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center [Pittsburgh, United States] | Vanderbilt University Medical Center [Nashville, United States] | Texas Oncology - Austin Midtown [Austin, United States] | Texas Oncology - Baylor Sammons Cancer Center [Dallas, United States] | MD Anderson Cancer Center / University of Texas [Houston, United States] | Texas Oncology - Northeast Texas [Tyler, United States] | Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care [Blacksburg, United States] | Virginia Cancer Specialists, PC [Fairfax, United States] | Carbone Cancer Center / University of Wisconsin [Madison, United States] | University of Alberta / Cross Cancer Institute [Edmonton, Canada] | University Health Network, Princess Margaret Hospital [Toronto, Canada] | Institut Gustave Roussy [Villejuif, France] | Istituto Europeo di Oncologia [Milan, Italy] | Policlinico Universitario Agostino Gemelli [Rome, Italy] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | L'Institut Catala d'Oncologia [L'Hospitalet de Llobregat, Spain] | HM Centro Integral Oncologico Clara Campal [Madrid, Spain] | Sarah Cannon Research Institute UK [London, United Kingdom] | The Royal Marsden Hospital (Surrey) [Sutton, United Kingdom]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04261218,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer","A Trial to Assess the Safety, Pharmacodynamic Effects, Pharmacokinetics and Efficacy of the MNK Inhibitor Tomivosertib (eFT508) in Combination With Paclitaxel, Following a Run-in Period of Tomivosertib Monotherapy, in Patients With Advanced Breast Cancer",COMPLETED,PHASE1,Translational Research in Oncology,2020-08-25,2022-07-04,2022-07-04,2020-02-07,2022-07-20,"['Number of Patients with Adverse Events (AEs)', 'Change from Baseline Pharmacodynamic Effects (PD) Following 14 Days of Tomivosertib Monotherapy']","['Overall Response Rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Pharmacokinetic Effects (PK)']",,,,,3,Canada,"Cross Cancer Institute [Edmonton, Canada] | British Columbia Cancer Vancouver [Vancouver, Canada] | Jewish General Hospital [Montreal, Canada]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing the safety and efficacy of Tomivosertib, which is identified as a MNK inhibitor, indicating it is a new medicine being tested in combination with an existing treatment (Paclitaxel) for advanced breast cancer.",OTHER,False,2022.0,3.0,0,Phase 1
NCT04277338,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3,SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Technetium-99m-labelled Designed Ankyrin Repeat Proteins HE3-G3 (99mTc-HE3-G3),COMPLETED,PHASE1,Tomsk National Research Medical Center of the Russian Academy of Sciences,2020-02-10,2021-02-10,2021-10-04,2020-02-20,2021-10-06,"['Gamma camera-based whole-body 99mTc-HE3-G3 uptake value (%)', 'SPECT-based 99mTc-HE3-G3 uptake value in tumor lesions (counts)', 'SPECT-based 99mTc-HE3-G3background uptake value (counts)', 'Tumor-to-background ratio (SPECT)']","['Safety attributable to 99mTc-HE3-G3 injections (physical findings)', 'Safety attributable to 99mTc-HE3-G3 injections (laboratory tests)', 'Safety attributable to 99mTc-HE3-G3 injections (incidence and severity of adverse events)', 'Safety attributable to 99mTc-HE3-G3 injections (concomitant medication)']",,,,,1,Russia,"TomskNRMC [Tomsk, Russia]",2020.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a new imaging agent (99mTc-HE3-G3) for assessing HER2 expression in breast cancer, indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT04278144,A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors,Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors,TERMINATED,PHASE1; PHASE2,"Bolt Biotherapeutics, Inc.",2020-02-24,2024-12-10,2025-02-14,2020-02-20,2025-09-15,"['Incidence of adverse events (AEs) and serious adverse events (SAEs)', 'Incidence and nature of dose-limiting toxicities (DLTs)', 'Incidence of potential-immune related toxicities', 'Maximum tolerable dose (MTD) or a tolerated dose below MTD', 'Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)']","['PK (Cmax) of BDC-1001', 'PK (Cmin) of BDC-1001', 'PK (AUC0-t) of BDC-1001', 'PK (AUC0-inf) of BDC-1001', 'PK (CL) of BDC-1001', 'PK (Vz) of BDC-1001', 'PK (t1/2) of BDC-1001', 'Objective response rate (ORR) using RECIST 1.1', 'Duration of response (DOR)', 'Disease control rate (DCR) of confirmed CR, PR, or stable disease (SD) lasting 4 or more weeks', 'Progression Free Survival (PFS)', 'Incidence of anti-BDC-1001 antibodies', 'Incidence of adverse events (AEs) and serious adverse events (SAEs)', 'Incidence of potential-immune related toxicities']",,,,,21,France; South Korea; Spain; United States,"Stanford University [Palo Alto, United States] | Georgetown University Medical Center [Washington D.C., United States] | The University of Chicago Medical Center [Chicago, United States] | Dana-Farber Cancer Institute [Boston, United States] | START Midwest [Grand Rapids, United States] | Memorial Sloan-Kettering Cancer Center [New York, United States] | Levine Cancer Institute [Charlotte, United States] | Stephenson Cancer Center [Oklahoma City, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Virginia Cancer Specialists [Fairfax, United States] | Institut Bergonie [Bordeaux, France] | Institut Paoli Calmettes [Marseille, France] | Institut Gustave Roussy [Villejuif, France] | Samsung Medical Center [Seoul, South Korea] | Seoul National University Bundang Hospital [Seongnam-si, South Korea] | Asan Medical Center [Seoul, South Korea] | Hospital del Mar [Barcelona, Spain] | Hospital Universitario Vall d'Hebron [Barcelona, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2025.0,0.0,1,Phase 2
NCT04293094,Study of AMG 650 in Adult Participants With Advanced Solid Tumors,"A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,"Volastra Therapeutics, Inc.",2020-03-11,2022-10-24,2023-02-15,2020-03-03,2023-08-24,"['Number of Participants with Dose Limiting Toxicities (DLTs)', 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'Number of Participants with Serious Adverse Events (SAEs)', 'Number of Participants with Treatment-related Adverse Events', 'Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurement', 'Number of Participants Who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECGs) Measurement', 'Number of Participants Who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests']","['Objective Response Rate (ORR)', 'Duration of Response (DOR)', 'Progression-free Survival (PFS)', 'Clinical Benefit Rate (CBR)', 'Time to Response (TTR)', 'Time to Progression (TTP)', 'Overall Survival (OS)', 'Maximum Plasma Concentration (Cmax) of AMG 650', 'Time to Maximum Plasma Concentration (Tmax) of AMG 650', 'Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for AMG 650']",,,,,22,Australia; Belgium; Canada; Italy; Japan; Spain; United States,"The Angeles Clinic and Research Institute, West Los Angeles Office [Los Angeles, United States] | Sarcoma Oncology Research Center LLC [Santa Monica, United States] | Indiana University [Indianapolis, United States] | Mayo Clinic [Rochester, United States] | Washington University [St Louis, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Laura and Isaac Perlmutter Cancer Center at New York University Langone [New York, United States] | Wake Forest University School of Medicine [Winston-Salem, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Oregon Health and Science University [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | Texas Oncology - Baylor [Dallas, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | The Queen Elizabeth Hospital [Woodville South, Australia] | Peter MacCallum Cancer Centre [Melbourne, Australia] | Universitair Ziekenhuis Leuven - Campus Gasthuisberg [Leuven, Belgium] | Cross Cancer Institute [Edmonton, Canada] | Princess Margaret Cancer Centre [Toronto, Canada] | IRCCS Istituto Europeo di Oncologia [Milan, Italy] | Aichi Cancer Center [Nagoya, Japan] | National Cancer Center Hospital East [Kashiwa-shi, Japan] | Hospital General Universitario Gregorio Marañon [Madrid, Spain]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The study evaluates AMG 650, which is a new drug being tested in participants with advanced solid tumors, indicating it is a New Medicine.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04319757,ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors,"A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",COMPLETED,PHASE1,"Acepodia Biotech, Inc.",2020-06-24,2024-07-15,2024-07-15,2020-03-24,2024-12-05,"['Adverse events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)', 'Phase Ib/II starting dose for ACE1702']","['Quantify NK cell persistence after administering ACE1702', 'Evaluate immune function after administering ACE1702']",,,,,3,Taiwan; United States,"Northwestern Univeristy [Chicago, United States] | MD Anderson Cancer Center [Houston, United States] | Taipei Veteran General Hospital [Taipei, Taiwan]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04320030,[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers,Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 PET/CT in Triple Negative Breast Cancers,COMPLETED,PHASE2,Institut Cancerologie de l'Ouest,2020-06-11,2021-07-21,2021-07-21,2020-03-24,2023-02-21,['Correlation between M1/M2 macrophage polarization and [18F]DPA-714 PET/CT binding'],"['Correlation between TSPO genotyping (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder) and [18F]DPA-714 PET/CT binding', 'Assess the value of early and late [18F]-DPA-714 PET/CT acquisitions', 'Evaluate the performance of the three types of imaging used in this study: [18F]-DPA-714 PET/CT (early and late), 18FDG PET/CT and diffusion-weighted breast MRI in the characterization of triple negative breast cancer', 'Perform tumor molecular subtyping', '[18F]-DPA-714 toxicity']",,,,,3,France,"APHP - Hôpital Tenon [Paris, France] | Institut de cancerologie de l'Ouest [Saint-Herblain, France] | CHU Bretonneau [Tours, France]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves the use of [18F]-DPA-714 PET/CT, which suggests it is being evaluated as a new imaging agent in the context of triple negative breast cancer, indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT04332653,NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors,An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors,COMPLETED,PHASE1; PHASE2,NeoImmuneTech,2020-06-10,2024-11-22,2025-01-13,2020-04-03,2025-07-25,"['Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7', 'Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7', 'Phase 2a: Preliminary Assessment of the Objective Response Rate (ORR) of NT-I7 in Combination with Pembrolizumab', 'Biomarker Cohort: Number of Tumor-Infiltrating Lymphocytes (TILs)', 'Biomarker Cohort: Distribution of Tumor-Infiltrating Lymphocytes (TILs)', 'Biomarker Cohort: Phenotype of Tumor-Infiltrating Lymphocytes (TILs)']","['Duration of Objective Response (DOR)', 'Disease Control Rate (DCR)', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Number of Participants Who Experience an Increase in Anti-Drug Antibodies (ADAs) to NT-I7', 'Biomarker Cohort: Objective Response Rate (ORR)', 'Incidence, Nature, and Severity of Adverse Events (AEs) graded according to National Cancer Institute Common Terminologies Criteria for Adverse Events (NCI CTCAE) v5.0']",,,,,8,United States,"Moffit Cancer Center [Tampa, United States] | Barbara Ann Karmanos Cancer Institute [Detroit, United States] | Washington University School of Medicine in St. Louis [St Louis, United States] | Duke University Medical Center [Durham, United States] | Fox Chase Cancer Center [Philadelphia, United States] | Sarah Cannon Research Institute [Nashville, United States] | Mary Crowley Cancer Research [Dallas, United States] | MD Anderson Cancer Center [Houston, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is investigating NT-I7 (Efineptakin Alfa), which is a new medicine being tested in combination with Pembrolizumab for advanced solid tumors. There is no indication that this is an extension of indication for an existing medicine.",INDUSTRY,False,2025.0,0.0,0,Phase 2
NCT04335006,"A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.","A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer.",TERMINATED,PHASE3,"Jiangsu HengRui Medicine Co., Ltd.",2020-07-14,2023-04-14,2023-04-14,2020-04-06,2023-05-06,['Progression-free Survival (PFS)'],"['Progression Free Survival (PFS)', 'Overall Survival (OS) in PD-L1 positive/ITT population', 'Objective response rate (ORR) in the PD-L1-positive/ITT population', 'Clinical benefit rate (CBR), defined as the proportion of patients with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1', 'Percentage of Participants with Adverse Events (AEs)', 'Serum concentration of SHR-1210 and plasma concentration of apatinib', 'Proportion of anti-SHR-1210 antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline']",,,,,1,China,"Sun Yat-sen Memorial Hospital, Sun Yat-sen University [Guangzhou, China]",2020.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Carelizumab, which is being tested in combination with other drugs for a specific type of cancer, indicating it is a new medicine being evaluated for efficacy in a new patient population.",INDUSTRY,False,2023.0,2.0,0,Phase 3
NCT04348916,"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",TERMINATED,PHASE1,"Oncorus, Inc.",2020-05-20,2023-05-31,2023-05-31,2020-04-16,2023-06-08,"['Percentage of Dose-Limiting Toxicities (DLTs)', 'Percentage of Adverse Events (AEs)', 'Percentage of Serious Adverse Events (SAEs)', 'Maximum Tolerated Dose (MTD) of ONCR-177', 'Recommended Phase 2 Dose (RP2D) of ONCR-177']","['Percentage of Objective Response Rate (ORR)', 'Durable Response Rate (DRR)', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Incidence and rate of detection of ONCR-177', 'Changes in the level of HSV-1 antibodies compared to baseline']",,,,,11,Canada; United States,"City of Hope [Duarte, United States] | Sarah Cannon Research Institute at HealthONE [Denver, United States] | Moffitt Cancer Center [Tampa, United States] | Emory University [Atlanta, United States] | Massachusetts General Hospital [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States] | Roswell Park Cancer Institute [Buffalo, United States] | The Ohio State University Wexner Medical Center James Cancer Hospital [Columbus, United States] | Sarah Cannon Research Institute - Tennessee Oncology [Nashville, United States] | The University of Texas at Austin [Austin, United States] | University Health Network, Princess Margaret Cancer Centre [Toronto, Canada]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is studying ONCR-177, which is described as an oncolytic herpes simplex virus for intratumoral injection, indicating it is a new medicine being tested for the treatment of advanced solid tumors.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04367090,Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer,"An Open, Single-arm and Multi-center Pharmacokinetic Study of Pyrotinib and Docetaxel Plus Trastuzumab in Patients With HER2 Positive Recurrent or Metastasis Breast Cancer.",COMPLETED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2020-05-28,2022-08-10,2023-05-24,2020-04-29,2023-09-18,"['Pharmacokinetic parameter: Cmax of pyrotinib and docetaxel', 'Pharmacokinetic parameter: AUC of pyrotinib and docetaxel']","['ORR', 'AEs+SAEs', 'λz', 'The incidence of≥3 grade diarrhea with different treatment']",,,,,1,China,"Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University [Guangzhou, China]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Pyrotinib, which is a new medicine being studied in combination with other drugs for a specific patient population (HER2 metastatic breast cancer).",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04382352,B002 in Patients With HER2-positive Breast Cancer,"Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.",COMPLETED,PHASE1,"Shanghai Pharmaceuticals Holding Co., Ltd",2019-05-28,2022-04-26,2022-04-26,2020-05-11,2023-03-24,"['Maximum Tolerated Dose (MTD)', 'Dose-Limiting Toxicity (DLT)']","['Tmax', 'Cmax', 'AUC', 'Anti-drug antibody (ADA)', 'Objective Remission Rate (ORR)']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes an experimental study on a new treatment (B002) for HER2-positive breast cancer, indicating it is a new medicine being tested for this specific condition.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04430842,"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S","A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma",COMPLETED,PHASE1,"Quadriga Biosciences, Inc.",2020-07-20,2022-09-21,2022-12-22,2020-06-12,2023-01-18,['Determination of maximum tolerated dose (MTD)'],"['Safety and tolerability assessed by adverse events and serious adverse events', 'Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC) of QBS10072S', 'Half-life of QBS10072S in plasma (t1/2)', 'Time to maximum concentration of QBS10072S in plasma (Tmax)']",,,,,2,Australia,"St George Private Hospital [Kogarah, Australia] | Sydney Southwest Private Hospital [Liverpool, Australia]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing a new drug (QBS10072S) in patients with specific types of cancer, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04440943,A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies,A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies,COMPLETED,PHASE1,Celldex Therapeutics,2020-08-04,2023-04-06,2023-04-06,2020-06-22,2023-06-18,['Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0'],"['Objective Response Rate', 'Clinical Benefit Rate', 'Duration of Response', 'Progression-free Survival', 'Overall Survival', 'Immunogenicity Evaluation', 'Pharmacokinetic Evaluation']",,,,,5,United States,"Northside Hospital [Atlanta, United States] | University of Chicago [Chicago, United States] | Oncology Hematology West, PC dba Nebraska Cancer Specialists [Omaha, United States] | Duke Cancer Center [Durham, United States] | Providence Portland Medical Center [Portland, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04441099,NBE-002 in Patients With Advanced Solid Tumors,"A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors",TERMINATED,PHASE1; PHASE2,NBE-Therapeutics AG,2020-06-19,2023-08-14,2023-08-14,2020-06-22,2023-09-07,"['Recommended Phase 2 Dose (RP2D) (Phase 1)', 'Anti-tumor Activity (Phase 2)']","['Incidence of Adverse Events (Safety and Tolerability)', 'Preliminary Anti-tumor Activity (Phase 1)', 'Concentrations of NBE-002', 'Concentrations of NBE-002-reactive antibodies']",,,,,3,United States,"Sarah Cannon Research Institute - TN Oncology [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT04464174,Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer,"A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients",COMPLETED,PHASE2,MedSIR,2020-10-08,2023-11-10,2023-11-10,2020-07-09,2024-07-26,"['Safety and tolerability of ipatasertib (GDC-0068) in combination with capecitabine, eribulin, or carboplatin plus gemcitabine; as incidence of Adverse Events as assessed by the investigator, with severity determined through the use of NCI-CTCAE v.4.03']","['Progression Free Survival (PFS)', 'Time to response (TTR)', 'Objective response rate (ORR)', 'Duration of Response (DoR)', 'Clinical Benefit Rate (CBR)', 'Overall Survival (OS)', 'Best percentage of change from baseline in the size of target tumor lesions']",,,,,14,Portugal; Spain,"Champalimaud Clinical Centre - Champalimaud Foundation [Lisbon, Portugal] | Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto) [Porto, Portugal] | Hospital Provincial de Castellón [Castellon, Spain] | Hospital Clínico Universitario Virgen de la Arrixaca [El Palmar, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Universitari Dexeus [Barcelona, Spain] | Hospital San Pedro de Alcántara [Cáceres, Spain] | Hospital Universitari Arnau de Vilanova [Lleida, Spain] | Hospital Quiron San Camilo- Ruber Juan Bravo [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital Universitario Virgen de la Victoria [Málaga, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain] | Hospital Arnau de Vilanova [Valencia, Spain] | Hospital Universitario Miguel Servet [Zaragoza, Spain]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating ipatasertib (GDC-0068), which is a new medicine being tested in combination with chemotherapy for a specific type of breast cancer.",OTHER,False,2023.0,2.0,1,Phase 2
NCT04481230,"Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer","Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer: Phase I Clinical Trial",COMPLETED,EARLY_PHASE1,Centre Jean Perrin,2020-11-12,2022-07-28,2022-09-19,2020-07-22,2024-10-01,"['determination of the recommended dose of 99mTc-NTP 15-5 to obtain the best tracer joints contrast on images without any toxicity', 'dose-limiting toxicity (DLT)']","['3D quantification analysis', 'Safety of 99mTc-NTP 15-5 (frequence of adverse events)', 'Biodistribution of 99mTc-NTP 15-5', 'Pharmacokinetics of 99mTc-NTP 15-5 by assessment of Area Under the Curve (AUC)', 'Pharmacokinetics of 99mTc-NTP 15-5 by assessment of Maximum Concentration (Cmax)', 'Pharmacokinetics of 99mTc-NTP 15-5 by assessment of the time take to reach Cmax (Tmax)', 'Urinary elimination of 99mTc-NTP 15-5', 'Dosimetry']",,,,,2,France,"Centre Jean Perrin [Clermont-Ferrand, France] | CHU Clermont-Ferrand [Clermont-Ferrand, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT04483505,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.","Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort",COMPLETED,PHASE1,Fundacion CRIS de Investigación para Vencer el Cáncer,2020-11-25,2023-04-04,2023-04-04,2020-07-23,2023-12-28,"['Recommended Phase 2 Dose', 'Incidence of Treatment-Emergent Adverse Event']","['Progression free survival', 'Pharmacokinetic interactions of fulvestrant and palbociclib over rogaratinib metabolism.', 'Pharmacodynamic markers levels of FGFR1 Blockade', 'Response rate']",,,,,8,Spain,"Institut Català d'oncologia - Hospital Duran I Reynals [L'Hospitalet de Llobregat, Spain] | Hospital Universitario de Fuenlabrada [Fuenlabrada, Spain] | Hospital Quirónsalud Madrid [Pozuelo de Alarcón, Spain] | Hospital Universitari Arnau de Vilanova de Lleida [Lleida, Spain] | Hospital Ramon y Cajal [Madrid, Spain] | Hospital Clinico San Carlos [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain]",2020.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Rogaratinib, which is being tested in combination with other drugs for a specific type of breast cancer, indicating it is a new medicine being evaluated for efficacy and safety.",OTHER,False,2023.0,2.0,0,Phase 1
NCT04496492,Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.,Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer.,COMPLETED,PHASE2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",2016-02-09,2016-02-09,2017-07-06,2020-08-03,2020-08-03,"['Changes in blood oxidant capacity', 'Changes in blood antioxidant capacity', 'Absolute and relative changes in peripheral blood mononuclear cells obtained before and after four weeks of tocotrienol treatment, as detected by 13-colors citofluorimetry analysis', ""Changes of immune-related miRNA levels in patients' serum samples obtained before and after four weeks of tocotrienol treatment, as determined by quantitative real-time PCR analysis"", 'Changes in immune response associated gene levels in preoperative tissue tumor biopsies and in surgical specimens, obtained before and after four weeks of tocotrienol treatment, respectively, as determined by gene expression profiling analysis', 'Changes in serum inflammatory cytokines and growth factor']","['Treatment-induced changes in proliferation/apoptosis, anti-inflammatory and anti-oxidant activity of breast cancer cell lines', 'Changes in expression of tumor proliferation, hormone receptors and HER2']",,,,,1,Italy,"Fondazione IRCCS Istituto Nazionale Tumori [Milan, Italy]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial investigates the use of tocotrienol, a compound derived from annatto, in breast cancer patients, indicating it is a new medicine being tested for a specific condition.",OTHER,False,2017.0,8.0,0,Phase 2
NCT04504669,First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours,"A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.",COMPLETED,PHASE1,AstraZeneca,2020-08-18,2024-10-07,2024-10-07,2020-08-07,2024-11-05,"['Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs', 'Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of Dose Limiting Toxicities (DLTs)', 'Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of vital signs and abnormal laboratory parameters', 'Incidence of AEs and SAEs related to AZD8701 as monotherapy and in combination with Durvalumab in disease specific expansions treated at the MTD/OBD/MFD', 'Objective Response Rate according to RECIST 1.1 by investigator assessment in disease specific expansions treated at the MTD/OB/MFD']","['Progression-free survival according to RECIST 1.1 by investigator assessment', 'Duration of Response according to RECIST 1.1 by investigator assessment', 'Disease Control Rate at 16 weeks according to RECIST 1.1 by investigator assessment', 'Time to Response according to RECIST 1.1 by investigator assessment', 'Best percentage change in tumour size according to RECIST 1.1 by investigator assessment', 'Overall Survival at 18 months', 'Maximum concentration (Cmax) of AZD8701 in plasma when administered as monotherapy and in combination with Durvalumab', 'Time to maximum concentration (tmax) of AZD8701 in plasma when administered as monotherapy and in combination with Durvalumab', 'Exposure to AZD8701 through measurement of area under the curve (AUC) in plasma when administered as monotherapy and in combination with Durvalumab', 'Maximum concentration (Cmax) of AZD8701 in urine when administered as monotherapy and in combination with Durvalumab', 'Time to maximum concentration (tmax) of AZD8701 in urine when administered as monotherapy and in combination with Durvalumab', 'Exposure to AZD8701 through measurement of area under the curve (AUC) in urine when administered as monotherapy and in combination with Durvalumab', 'Urine concentrations of AZD8701 to assess renal clearance when administered as monotherapy and in combination with Durvalumab', 'Maximum concentration (Cmax) of Durvalumab in serum when administered in combination with AZD8701', 'Minimum concentration (Cmin) of Durvalumab in serum when administered in combination with AZD8701', 'Change in FOXP3 mRNA expression']",,,,,13,Canada; France; Spain; United States,"Research Site [Baltimore, United States] | Research Site [St Louis, United States] | Research Site [Huntersville, United States] | Research Site [Franklin, United States] | Research Site [Houston, United States] | Research Site [Madison, United States] | Research Site [Toronto, Canada] | Research Site [Rennes, France] | Research Site [Villejuif, France] | Research Site [Barcelona, Spain] | Research Site [L'Hospitalet de Llobregat, Spain] | Research Site [Madrid, Spain] | Research Site [Madrid, Spain]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04505826,"A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer","A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer",COMPLETED,PHASE1; PHASE2,"Olema Pharmaceuticals, Inc.",2020-08-13,2024-07-30,2024-07-30,2020-08-10,2025-08-24,"['Dose Limiting Toxicities (DLT)', 'Characterize the incidence, nature and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250', 'Pharmacokinetics of OP-1250', 'Anti-tumor activity of OP-1250']",[],,,,,19,Australia; United States,"UCLA Hematology/Oncology [Los Angeles, United States] | University of Colorado [Aurora, United States] | University of Miami, Sylvester Comprehensive Cancer Center [Deerfield Beach, United States] | Advent Health [Orlando, United States] | Florida Cancer Center [Sarasota, United States] | Winship Cancer Institute of Emory University [Atlanta, United States] | Indiana University Melvin and Bren Simon Comprehensive Cancer Center [Indianapolis, United States] | Dana Farber Cancer Institute [Boston, United States] | Saint Luke's Hospital of Kansas City [Kansas City, United States] | Montefiore Medical Center [The Bronx, United States] | Cleveland Clinic Taussig Cancer Center [Cleveland, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | Providence Portland Medical Center [Portland, United States] | OHSU Knight Cancer Institute [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | Macquarie University [Sydney, Australia] | Westmead [Westmead, Australia] | ICON Cancer Centre [Auchenflower, Australia] | Cancer Research South Australia [Adelaide, Australia]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a Phase I study of OP-1250, indicating it is a new medicine being tested for the first time in humans for advanced and/or metastatic HR+, HER2- breast cancer.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT04509596,"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer","A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD1516 in Combination With Trastuzumab and Capecitabine, or DZD1516 in Combination With T-DM1, in Patients With Metastatic HER2 Positive (HER2+) Breast Cancer",COMPLETED,PHASE1,Dizal Pharmaceuticals,2020-09-21,2022-07-07,2022-07-07,2020-08-12,2025-04-01,"['Incidence of adverse events (AEs) and serious adverse events (SAEs)', 'Incidence of dose limiting toxicities (DLTs)', 'To define maximum tolerated dose (MTD) of DZD1516 if possible (Part A only)', 'To define Recommended Phase II Combination Dose (RP2CD) of DZD1516 in combination with trastuzumab and capecitabine (Part B only)', 'To define Recommended Phase II Combination Dose (RP2CD) of DZD1516 in combination with T-DM1 (Part C only)']","['Drug concentrations of DZD1516 and its metabolite DZ2678 in plasma, urine and CSF', 'Maximum plasma concentration (Cmax) of DZD1516 and its metabolite DZ2678', 'Area under the plasma concentration-time curve (AUC) of DZD1516 and its metabolite DZ2678', 'Plasma concentration of capecitabine and metabolites 5-FU (Part B only)', 'Plasma Cmax of capecitabine and 5-FU (Part B only)', 'Plasma AUC of capecitabine and 5-FU (Part B only)', 'Plasma concentration of DM1 (Part C only)', 'Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Response (DoR)', 'Progression free survival (PFS) (Part B and Part C on)', 'Overall survival (for patients with leptomeningeal metastasis in Part B and Part C only)']",,,,,3,China; United States,"UCLA Hematology/Oncology Parkside [Santa Monica, United States] | Zhejiang Cancer Hospital [Hangzhou, China] | Cancer Hospital, Fudan University [Shanghai, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT04514159,A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer,"A Phase 1b Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer",COMPLETED,PHASE1,Zeno Alpha Inc.,2020-11-12,2022-10-24,2022-10-24,2020-08-14,2023-02-01,['Incidence and severity of adverse events from ZN-c5 in combination with abemaciclib'],['Determine tumor responses to combination treatment'],,,,,5,Poland; United States,"Site 2 [Gilbert, United States] | Site 1 [Charleston, United States] | Site 6 [Grudziądz, Poland] | Site 4 [Krakow, Poland] | Site 5 [Lodz, Poland]",2020.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves ZN-c5, which appears to be a new medicine being tested in combination with Abemaciclib for a specific type of breast cancer.",INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT04541225,Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors,"Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",TERMINATED,PHASE1,Nuvation Bio Inc.,2020-12-08,2022-08-31,2022-08-31,2020-09-09,2023-07-14,['Phase 1 Dose Escalation: Safety and tolerability of NUV-422 to determine the recommended Phase 2 dose (RP2D)'],[],,,,,12,United States,"Arizona Oncology Associates [Tucson, United States] | Miami Cancer Institute [Miami, United States] | Dana-Farber Cancer Institute [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Carolina BioOncology Institute [Huntersville, United States] | Prisma Health Cancer Institute [Greenville, United States] | Texas Oncology P.A. Austin [Austin, United States] | Texas Oncology-Baylor Charles A. Sammons Cancer Center [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | Texas Oncology [Tyler, United States] | University of Utah Huntsman Cancer Institute [Salt Lake City, United States] | Virginia Cancer Specialists [Fairfax, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04541433,"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer","A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- Tumor Activity of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer",COMPLETED,PHASE1,AstraZeneca,2020-09-29,2022-07-29,2025-06-23,2020-09-09,2025-08-07,"['The number of subjects with dose-limiting toxicity, as defined in the protocol.', 'The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.']","['Objective Response Rate', 'Duration of Response', 'Clinical benefit rate at 24 weeks', 'Percentage Change in Tumour Size', 'Progression Free Survival', 'Maximum Observed Plasma Concentration (Cmax) of AZD9833', 'Time to observed Cmax (Tmax) for AZD9833']",,,,,3,Japan,"Research Site [Chūōku, Japan] | Research Site [Kashiwa, Japan] | Research Site [Kōtoku, Japan]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT04551885,FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,"A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,Fate Therapeutics,2020-09-07,2023-08-11,2023-08-11,2020-09-16,2023-09-21,"['Incidence of Dose-Limiting Toxicities (DLTs) Within Each Dose Level Cohort', 'Severity of DLTs Within Each Dose Level Cohort']","['Number of Participants with ≥1 Adverse Events (AE)', 'Investigator-Assessed Duration of Response (DOR)', 'Disease Control Rate (DCR)', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Determination of PK of FT516 in peripheral blood']",,,,,3,United States,"University of Minnesota Masonic Cancer Center [Minneapolis, United States] | Hackensack University Medical Center/John Theurer Cancer Center [Hackensack, United States] | MD Anderson Cancer Center [Houston, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04554056,Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF,"A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia",COMPLETED,PHASE2; PHASE3,"Mabwell (Shanghai) Bioscience Co., Ltd.",2020-09-21,2022-08-20,2022-11-05,2020-09-18,2022-12-02,['The primary objective of this study will be to evaluate the efficacy of MW05 pre-filled syringe as compared to PEG-rhG-CSF standard dosing (6 mg) in the first chemotherapy cycle.'],"['The duration of grade 4 neutropenia in cycle 2~4 assessed by ANC（ANC < 0.5 × 109/L）', 'The incidence of grade 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 0.5 × 109/L）', 'The incidence of grade 3 or 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）', 'The duration of grade 3 or 4 neutropenia In cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）', 'Incidence of febrile neutropenia (FN) (defined as ANC < 1.0×109/L; a single measurement of body temperature > 38.3°C or a temperature ≥ 38.0 °C sustained over 1 h)', 'The proportion of subjects rescued by short-acting G-CSF in cycle 1~4.']",,,,,1,China,"Fudan University Affiliated Cancer Hospital [Shanghai, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is comparing a new treatment (MW05) against an existing standard (PEG-rhG-CSF) for a specific condition (chemotherapy-induced neutropenia), indicating that MW05 is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT04580485,INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors,"A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors",COMPLETED,PHASE1,Incyte Corporation,2021-02-03,2024-01-22,2024-01-22,2020-10-08,2025-07-11,['Number of treatment-emergent adverse events (TEAE)'],"['Cmax of INCB106385 as a single agent or in combination with INCMGA00012', 'Tmax of INCB106385 as a single agent or in combination with INCMGA00012', 'Cmin of INCB106385 as a single agent or in combination with INCMGA00012', 'AUC of INCB106385 as a single agent or in combination with INCMGA00012', 'CL/F of INCB106385 as a single agent or in combination with INCMGA00012', 'Objective Response Rate (ORR)', 'Disease Control Rate', 'Duration Of Response (DOR)', 'Change in tumoral gene expression', 'Change in immune cell activation in tumors']",,,,,27,Belgium; France; Italy; Spain; United Kingdom; United States,"Cedars-Sinai Medical Center [West Hollywood, United States] | University of Maryland-Greenebaum Cancer Center [Baltimore, United States] | Dana Farber Cancer Institute [Boston, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Columbia University Medical Center [New York, United States] | University of Pittsburgh [Pittsburgh, United States] | Md Anderson Cancer Center [Houston, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Cliniques Universitaires Ucl Saint-Luc [Brussels, Belgium] | Universitaire Ziekenhuis Leuven - Gasthuisberg [Leuven, Belgium] | Institut Bergonie [Bordeaux, France] | Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole [Toulouse, France] | Institut Gustave Roussy [Villejuif, France] | A.O.U. Di Modena - Policlinico [Modena, Italy] | Istituto Nazionale Tumori Irccs Fondazione Pascale [Naples, Italy] | Irccs Istituto Clinico Humanitas [Rozzano, Italy] | Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) [Verona, Italy] | Hospital General Universitario Vall D Hebron [Barcelona, Spain] | Fundacion Jimenez Diaz University Hospital [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Centro Integral Oncologico Clara Campal [Madrid, Spain] | Clinica Universidad de Navarra (Cun) [Pamplona, Spain] | Cambridge University Hospitals Nhs Foundation Trust [Cambridge, United Kingdom] | University of Glasgow [Glasgow, United Kingdom] | Guys and St Thomas Nhs Foundation Trust [London, United Kingdom] | Imperial College Healthcare Nhs Trust - Hammersmith Hospital [London, United Kingdom] | The Christie Nhs Foundation Trust Uk [Manchester, United Kingdom]",2021.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[""Duration of Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04584112,"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer","A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer",COMPLETED,PHASE1,Hoffmann-La Roche,2020-09-28,2023-03-08,2023-03-08,2020-10-12,2023-03-15,"['Percentage of Participants With Adverse Events (Cohort B)', 'Confirmed Objective Response Rate ORR (Cohort A)']","['Percentage of Participants With Adverse Events (Cohort A)', 'Progression-free Survival (Cohort A)', 'Duration of Response (Cohort A)', 'Overall Survival (Cohort A)', 'Serum Concentrations of Tiragolumab', 'Serum Concentrations of Atezolizumab', 'Plasma Concentrations of Nab-paclitaxel (Cohort B)', 'Plasma Concentrations of Carboplatin (Cohort B)', 'Plasma Concentrations of Doxorubicin (Cohort B)', 'Plasma Concentrations of Cyclophosphamide (Cohort B)', 'Percentage of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab', 'Percentage of Participants With ADAs to Atezolizumab']",,,,,24,Australia; Brazil; Germany; Russia; South Korea; Spain; Taiwan; United States,"University of Alabama at Birmingham [Birmingham, United States] | Univ of Chicago [Chicago, United States] | Levine Cancer Institute [Charlotte, United States] | Magee-Woman's Hospital [Pittsburgh, United States] | Tennessee Onc., PLLC - SCRI [Nashville, United States] | Mater Hospital; Cancer Services [South Brisbane, Australia] | Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit [Bull Creek, Australia] | Hospital Sao Rafael - HSR [Salvador, Brazil] | Hospital Araujo Jorge; Departamento de Ginecologia E Mama [Goiânia, Brazil] | Hospital Sírio-Libanês [São Paulo, Brazil] | Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda [São Paulo, Brazil] | Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum [Essen, Germany] | Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg [Heidelberg, Germany] | Arkhangelsk Regional Clinical Oncology Dispensary [Arkhangelsk, Russia] | SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"" [Moskva, Russia] | Blokhin Cancer Research Center; Combined Treatment [Moskva, Russia] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia [Santiago de Compostela, Spain] | Hospital Universitario Virgen Macarena; Servicio de Oncologia [Seville, Spain] | Hospital Clínico Universitario de Valencia; Servicio de Oncología [Valencia, Spain] | China Medical University Hospital; Surgery [Taichung, Taiwan] | National Taiwan Uni Hospital; General Surgery [Taipei, Taiwan]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Tiragolumab, which is being studied in combination with other treatments for a specific cancer type, indicating it is a new medicine being evaluated for safety and efficacy.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04586335,Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.,"Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.",TERMINATED,PHASE1,"Haihe Biopharma Co., Ltd.",2020-09-28,2023-02-15,2023-02-15,2020-10-14,2024-03-21,"['Dose Limiting Toxicities (DLT)', 'Tumor objective response rate (ORR)']","['Number of participants with treatment-related adverse events as assessed by CTCAE v5.0', 'Disease control rate (DCR)', 'Pharmacokinetic measures - Plasma concentration time Area Under the Curve', 'Pharmacokinetic measures - Cmax', 'Pharmacokinetic measures - Tmax', 'Pharmacokinetic measures - CL/F', 'Pharmacokinetic measures - Vz/F', 'Pharmacokinetic measures - terminal half- life (t1/2)']",,,,,7,Australia; China; United States,"Yale Cancer Center [New Haven, United States] | UT Southwestern: Simmons Cancer Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States] | Scientia Cancer Centre [Sydney, Australia] | Integrated Oncology Network PTY LTD [Brisbane, Australia] | Monash Cancer Centre [Melbourne, Australia] | Fudan University - Pudong Medical Center [Shanghai, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves CYH33, which is identified as a new oral PI3K inhibitor being studied in combination with Olaparib, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04592484,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors","A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma",COMPLETED,PHASE1; PHASE2,Codiak BioSciences,2020-09-15,2022-08-03,2022-12-23,2020-10-19,2023-02-08,['To determine the safety and tolerability of ascending doses of CDK-002'],[],,,,,8,United Kingdom; United States,"Honor Health [Scottsdale, United States] | Columbia University/CUMC [New York, United States] | University of Pennsylvania [Philadelphia, United States] | NEXT Oncology [San Antonio, United States] | The Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital [Glasgow, United Kingdom] | Oxford University Hospitals NHS Trust [Headington, United Kingdom] | The Royal Marsden Hospital [London, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 2
NCT04629846,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.,"A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase III Clinical Study to Evaluate QL1209/Pertuzumab in Combination With Docetaxel in Patients With Early-Stage or Locally Advanced HER2-Positive and ER/PR-negative Breast Cancer.",COMPLETED,PHASE3,"Qilu Pharmaceutical Co., Ltd.",2020-11-23,2022-08-22,2023-10-24,2020-11-16,2024-04-19,['Total pathologic complete response (tpCR) rate'],"['Percentage of Participants With tpCR as Assessed by the Local Pathologist', 'Percentage of Participants With Breast Pathologic Complete Response (bpCR) assessed by the IRC', 'Percentage of Participants With bpCR as Assessed by the Local Pathologist', 'Percentage of Participants With an Objective Response']",,,,,2,China,"Fudan University Cancer Hospital [Shanghai, China] | Tianjin Medical University Cancer Institution & Hospital [Tianjin, China]",2020.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[""Pathologic Complete Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial evaluates the efficacy and safety of QL1209, which appears to be a new treatment in combination with existing therapies for a specific type of breast cancer.",INDUSTRY,False,2023.0,2.0,0,Phase 3
NCT04665921,A Study of SGN-STNV in Advanced Solid Tumors,A Phase 1 Study of SGN-STNV in Advanced Solid Tumors,TERMINATED,PHASE1,Seagen Inc.,2021-01-18,2024-03-01,2024-03-01,2020-12-14,2025-02-07,"['Incidence of adverse events (AEs)', 'Incidence of laboratory abnormalities', 'Incidence of dose limiting toxicities']","['Objective response rate (ORR) as assessed by the investigator per RECIST v1.1', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Duration of objective response (DOR)', 'Area under the concentration-time curve (AUC)', 'Time to maximum concentration (Tmax)', 'Maximum concentration (Cmax)', 'Trough concentration (Ctrough)', 'Incidence of antidrug antibodies (ADA)']",,,,,18,Canada; France; Italy; Spain; United Kingdom; United States,"The Angeles Clinic and Research Institute [Los Angeles, United States] | University of California, San Francisco | HDFCCC - Hematopoietic Malignancies [San Francisco, United States] | Shands Cancer Center / University of Florida [Gainesville, United States] | University of Miami [Miami, United States] | Beth Israel Deaconess Medical Center [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | South Texas Accelerated Research Therapeutics Midwest [Grand Rapids, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University Hospitals Cleveland Medical Center [Cleveland, United States] | Oregon Health and Science University [Portland, United States] | Magee Womens Hospital of UPMC [Pittsburgh, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | University of Ottawa / Ottawa General Hospital [Ottawa, Canada] | University Health Network, Princess Margaret Hospital [Toronto, Canada] | Institut Gustave Roussy [Villejuif, France] | Istituto Europeo di Oncologia [Milan, Italy] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | The Royal Marsden Hospital (Surrey) [Sutton, United Kingdom]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04682431,A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors,"A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,Ikena Oncology,2020-11-10,2023-08-25,2023-08-31,2020-12-23,2024-03-22,"['Incidence of Adverse Events (AE)', 'Dose Limiting Toxicity of PY159 (Part A only)']","['Measure PY159 concentration at the end of infusion (CEOI)', 'Measure PY159 maximum concentration (Cmax)', 'Measure PY159 concentration at the trough level (Ctrough)', 'Measure PY159 Area under the curve (AUC)0-t', 'Measure PY159 half-life (T1/2)', 'Measure PY159 Clearance (CL)', 'Measure PY159 Volume at Steady State (Vss)', 'Incidence of Anti-Drug Antibody (ADA) formation to PY159', 'Determining PY159 time to maximum concentration (Tmax)', 'Objective response rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Duration of response (DOR)']",,,,,17,United States,"USC Norris Cancer Center [Los Angeles, United States] | UCSF Mount Zion Cancer Center [San Francisco, United States] | UCLA Parkside Cancer Center [Santa Monica, United States] | University of Colorado [Aurora, United States] | Smilow Cancer Hospital at Yale New Haven [New Haven, United States] | Florida Cancer Specialists - Sarasota - SCRI [Sarasota, United States] | Indiana University [Indianapolis, United States] | Massachusetts General Hospital [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Rutgers Cancer Institute of New Jersey [New Brunswick, United States] | Case Western Reserve University [Cleveland, United States] | The University of Oklahoma [Norman, United States] | Oregon Health and Science University [Portland, United States] | Thomas Jefferson University [Philadelphia, United States] | Mary Crowley Cancer Center [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | Start South Texas Accelerated Research Therapeutic [San Antonio, United States]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04691375,A Study of PY314 in Subjects With Advanced Solid Tumors,"A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,Ikena Oncology,2020-10-29,2023-08-31,2023-09-22,2020-12-31,2024-03-22,"['Incidence of Adverse Events (AE)', '(Part A only) Dose Limiting Toxicity of PY314']","['Measure PY314 concentration at the end of infusion (CEOI)', 'Measure PY314 concentration at the trough level (Ctrough)', 'Determining PY314 time to maximum concentration (Tmax)', 'Measure PY314 Area under the curve (AUC)0-t', 'Measure PY314 half-life (T1/2)', 'Measure PY314 Clearance (CL)', 'Measure PY314 Volume at Steady State (Vss)', 'Measure PY314 maximum concentration (Cmax)', 'Incidence of Anti-Drug Antibody (ADA) formation to PY314', 'Objective response rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Duration of response (DOR)']",,,,,23,United States,"Mayo Clinic Scottsdale - PPDS [Phoenix, United States] | Honor Health Research Institute [Scottsdale, United States] | City of Hope - Comprehensive Cancer Center [Duarte, United States] | Stanford Hospital and Clinics [Palo Alto, United States] | UC San Diego Moores Cancer Center [San Diego, United States] | University of Colorado Hospital [Aurora, United States] | Mayo Clinic Jacksonville - PPDS [Jacksonville, United States] | H Lee Moffitt Cancer Center and Research Institute [Tampa, United States] | University of Chicago [Chicago, United States] | Massachusetts General Hospital [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Mayo Clinic - PPDS [Rochester, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | The Cleveland Clinic Foundation [Cleveland, United States] | University of Oklahoma Peggy and Charles Stephenson Cancer Center [Oklahoma City, United States] | OHSU Knight Cancer Institute Beaverton Clinic [Portland, United States] | Thomas Jefferson University [Philadelphia, United States] | Sarah Cannon Research Institute [Nashville, United States] | Vanderbilt Ingram Cancer Center [Nashville, United States] | Start South Texas Accelerated Research Therapeutics [San Antonio, United States] | NEXT Virginia [Fairfax, United States] | Wisconsin Institutes for Medical Research [Madison, United States]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating PY314, which is a new agent being tested in subjects with advanced solid tumors, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04703920,"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer","A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",COMPLETED,PHASE1,University of Michigan Rogel Cancer Center,2021-03-04,2024-12-01,2025-01-02,2021-01-11,2025-01-23,['Dose limiting toxicities (DLT) within the first two cycles of treatment'],"['Proportion of patients experiencing toxicities. Participants may continue to receive the investigational study therapy until disease progression or unacceptable toxicity.', 'Plasma concentrations of talazoparib at steady state', 'Plasma concentrations of belinostat at steady state', 'Number of patients with an objective response']",,,,,1,United States,"University of Michigan Rogel Cancer Center [Ann Arbor, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2025.0,0.0,0,Phase 1
NCT04712721,Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.,"Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.",TERMINATED,EARLY_PHASE1,Novartis Pharmaceuticals,2021-10-14,2024-06-18,2024-07-01,2021-01-15,2025-04-15,"['Time-activity curves (TACs) from 68Ga-FF58 PET/CT images', 'Standard Uptake Value (SUV) mean and max in lesions detected by PET scans', 'Tumor to Background Ratio (TBR) of lesions detected by PET scans']","['Number of Participants with Treatment Emergent Adverse Events', 'Percentage of lesions detected by conventional scans, PET scans, or both modalities', 'Lesion-level analyses of diagnostics by [68Ga]-FF58 compared with conventional imaging', 'Dosimetry Group: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of 68Ga-FF58', 'Dosimetry Group: Time of maximum observed drug concentration occurrence (Tmax) of 68Ga-FF58', 'Dosimetry Group: Observed maximum plasma concentration (Cmax) of 68Ga-FF58', 'Dosimetry Group: Terminal elimination half-life (T^1/2) of 68Ga-FF58', 'Dosimetry Group: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of 68Ga-FF58', 'Dosimetry Group: Total systemic clearance for intravenous administration (CL) of 68Ga-FF58', 'Dosimetry Group: Volume of distribution during the terminal phase following intravenous elimination (Vz) of 68Ga-FF58', 'Dosimetry Group: Urinary excretion of radioactivity expressed as a percentage of injected activity (%IA)', 'Dosimetry Group: Absorbed dose of 68Ga- FF58', 'Dosimetry Group: Effective whole-body dose of 68Ga- FF58']",,,,,2,France; Germany,"Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Essen, Germany]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT04714619,CB-103 Plus NSAI In Luminal Advanced Breast Cancer,CB-103 Plus NSAI In Luminal Advanced Breast Cancer: CAILA Study,TERMINATED,PHASE2,MedSIR,2021-05-06,2021-09-02,2022-04-26,2021-01-19,2023-12-19,['Progression-free survival (PFS)'],"['Safety and tolerability of CB-103 in combination with NSAI (anastrozole or letrozole)', 'Efficacy in terms of PFS of CB-103 in combination with NSAI in all patients and in sub.groups', 'Overall response rate (ORR)', 'Clinical benefit rate (CBR)', 'Clinical benefit rate (CBR)', 'Time to tumor response (TTR)', 'Duration of response (DoR)', 'Overall survival (OS)', 'Maximum tumor shrinkage (MTS)', 'Pharmacokinetics (PK), in terms of Cmax', 'PK, in terms of AUC', 'PK in terms of Vd/F', 'PK in terms of CL/F', 'Pharmacokinetics (PK), in terms of Tmax']",,,,,2,Spain,"Complejo Hospitalario de Jaen [Jaén, Spain] | Hospital Sant Joan de Reus [Reus, Spain]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves CB-103, which is being tested in combination with NSAI for luminal advanced breast cancer, indicating it is a new medicine being evaluated for efficacy and safety.",OTHER,False,2022.0,3.0,0,Phase 2
NCT04728035,Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Irinotecan Liposome Injection in Patients With Advanced Breast Cancer",COMPLETED,PHASE1,"CSPC Ouyi Pharmaceutical Co., Ltd.",2021-05-31,2023-06-05,2024-06-05,2021-01-28,2024-07-26,"['Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)', 'Dose limiting toxicity (DLT)', 'Maximum Tolerated Dose (MTD, if available)', 'Recommended Phase 2 Dose (RP2D)']","['Objective Response Rate (ORR)', 'Progression-Free Survival (PFS)', 'Disease Control Rate (DCR)', 'Duration of Response (DOR)', 'Overall survival (OS)', 'CNS objective response rate (CNS ORR)', 'CNS clinical benefit rate (CNS CBR)', 'The Area under the concentration-time curve from time zero to infinity (AUCinf)', 'The Maximum observed plasma concentration (Cmax)', 'The terminal elimination half-life (T1/2)', 'The time to maximum concentration (Tmax)', 'The Apparent volume of distribution (Vd)']",,,,,1,China,"Cancer Hosptial of CAMS [Beijing, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT04742959,Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",COMPLETED,PHASE1; PHASE2,"TransThera Sciences (Nanjing), Inc.",2021-03-14,2024-02-20,2024-02-20,2021-02-08,2024-04-26,"['Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment', 'Dose limiting toxicity (DLT)']","['Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Objective Response (DOR)', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Area under the curve (AUC0-∞)', 'Area under the curve (AUC0-t)', 'Maximum observed concentration (Cmax)', 'Half-life (T1/2)', 'Time to Maximum Concentration (Tmax)', 'Volume of Distribution (Vd)']",,,,,6,United States,"City of Hope [Duarte, United States] | The University of Chicago [Chicago, United States] | Rutgers Cancer Institute [New Brunswick, United States] | Gabrail Cancer Center Research [Canton, United States] | UT Southwestern Medical Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a study of TT-00420 (Tinengotinib) as a new treatment (monotherapy and combination therapy) for patients with advanced solid tumors, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT04746638,Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26,SPECT Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26 (99mTc- RM26) in Prostate Cancer and Breast Cancer Patients,COMPLETED,PHASE1,Tomsk National Research Medical Center of the Russian Academy of Sciences,2021-02-01,2022-05-19,2023-06-01,2021-02-10,2023-11-28,"['Gamma camera-based whole-body 99mTc-RM26 uptake value (%)', 'SPECT-based 99mTc-RM26 value in tumor lesions (counts)', 'SPECT-based 99mTc-RM26 uptake value (counts)', 'Tumor-to-background ratio (SPECT)']","['Safety attributable to 99mTc-RM26 injections (physical findings)', 'Safety attributable to 99mTc-RM26 injections (laboratory tests)', 'Safety attributable to 99mTc-RM26 injections (incidence and severity of adverse events)', 'Safety attributable to 99mTc-RM26 injections (concomitant medication)']",,,,,1,Russia,"TomskNRMC [Tomsk, Russia]",2021.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes the use of a labeled compound (99mTc-RM26) for molecular imaging in cancer patients, indicating it is a new medicine being evaluated for its safety and efficacy in a specific application.",OTHER,False,2023.0,2.0,0,Phase 1
NCT04752059,Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases,Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases,COMPLETED,PHASE2,Medical University of Vienna,2020-07-28,2023-05-01,2023-05-01,2021-02-12,2023-05-12,['Reponse rate of brain metastases to trastuzumab-deruxtecan'],"['Progression-free survival', 'Overall Survival', 'Safety of trastuzumab deruxtecan in patients with active brain metastases']",,,,,1,Austria,"AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology [Vienna, Austria]",2020.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating Trastuzumab-Deruxtecan (T-DX), which is a new medicine being tested in a specific patient population (HER2-positive breast cancer patients with brain metastases).",OTHER,False,2023.0,2.0,0,Phase 2
NCT04752267,18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases,Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain Tumors,COMPLETED,EARLY_PHASE1,University of Southern California,2021-02-15,2023-09-18,2023-09-18,2021-02-12,2024-05-24,"['Correlation between multiparametric magnetic resonance imaging (mpMRI) radiomics and dynamic fluorine F 18 (18F)-FAMU (FMAU) positron emission tomography (PET) kinetic analysis parameters', 'Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters']",[],,,,,1,United States,"USC / Norris Comprehensive Cancer Center [Los Angeles, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2023.0,2.0,0,Phase 1
NCT04771975,Connecting Breast Cancer Survivors for Exercise,Connecting Breast Cancer Survivors for Exercise: A Randomized Controlled Trial Phase I and II,COMPLETED,,Jenna Smith,2021-05-10,2021-12-30,2022-01-30,2021-02-25,2023-08-21,"['Phase 1 and Phase 2: Change in exercise volume', 'Phase 1 and Phase 2: Change in exercise volume', 'Phase 1 and Phase 2: Change in exercise volume']","['Phase 1 and Phase 2: Change in exercise volume', 'Phase 1: Change in social support', 'Phase 1: Change in health-related quality of life assessed by the Short-Form-12', 'Phase 1: Change in quality of life assessed by the EuroQol-5 Dimension-3 level (EQ-5D-3L)', 'Phase 1 and Phase 2: Cost of intervention arms', 'Phase 1: Use of health care resources', 'Phase 1 and Phase 2: Intervention adherence', 'Phase 2: Resistance Exercise Self-Efficacy', 'Phase 2: Physical Self', 'Phase 2: Body Functionality appreciation']",,,,,1,Canada,"University of Toronto [Toronto, Canada]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT04778982,Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer,"A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast Cancer",TERMINATED,,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2022-05-25,2023-03-15,2023-03-15,2021-03-03,2023-07-17,"['Dose limiting toxicity (DLT)', 'Objective response rate (ORR)']","['Duration of response (DOR)', 'Progression free survival (PFS) rates', 'Overall survival (OS)', 'Clinical benefit rate (CBR)']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves KN026, which is being evaluated for its efficacy in combination with other treatments for advanced breast cancer, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,NA/Other
NCT04789096,Tucatinib Together With Pembrolizumab and Trastuzumab,"A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer",TERMINATED,PHASE2,"Breast Cancer Trials, Australia and New Zealand",2023-03-07,2025-06-04,2025-06-04,2021-03-09,2025-06-06,['Objective Response Rate (ORR) in the PD-L1 positive cohort'],"['Objective response rate (ORR) in the PD-L1 negative/unknown cohort', 'Progression free survival (PFS) in each PD-L1 cohort', 'Duration of response (DoR) in each PD-L1 cohort', 'Clinical benefit rate (CBR) in each PD-L1 cohort', 'Overall survival (OS) in each PD-L1 cohort', 'Incidence of treatment-emergent adverse events [Safety]', 'Incidence of treatment-emergent adverse events [Tolerability of tucatinib]', 'Incidence of treatment-emergent adverse events [Tolerability of pembrolizumab]']",,,,,15,Australia,"Coffs Harbour Health Campus [Coffs Harbour, Australia] | Gosford Hospital [Gosford, Australia] | Nepean Cancer Care Centre [Kingswood, Australia] | Macquarie University [Macquarie Park, Australia] | Prince of Wales Hospital [Randwick, Australia] | Calvary Mater Newcastle [Waratah, Australia] | Westmead Hospital [Westmead, Australia] | Wollongong Hospital [Wollongong, Australia] | Sunshine Coast University Hospital [Birtinya, Australia] | Royal Adelaide Hospital [Adelaide, Australia] | Icon Cancer Centre Hobart [Hobart, Australia] | Austin Hospital [Heidelberg, Australia] | Peter MacCallum Cancer Centre [Parkville, Australia] | Epworth Richmond Hospital [Richmond, Australia] | Sunshine Hospital [St Albans, Australia]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Tucatinib, which is being studied in combination with Pembrolizumab and Trastuzumab for a specific patient population (pre-treated advanced HER2-positive breast cancer), indicating it is a new medicine being evaluated.",OTHER,False,2025.0,0.0,0,Phase 2
NCT04789668,Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases,Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases,COMPLETED,PHASE1; PHASE2,M.D. Anderson Cancer Center,2021-01-15,2023-12-08,2023-12-08,2021-03-09,2024-12-13,"['Clinical benefit rate', 'Incidence of intracranial and extracranial toxicities and dose-limiting toxicities (Phase I)', 'Recommended phase II dose (Phase I)', 'Time to intracranial progression (Phase II)', 'Overall survival (Phase II)']","['Intracranial progression', 'Time to extracranial progression', 'Best achieved extracranial objective response rate', 'Duration of response', 'Dose, duration and frequency of steroid use for symptomatic management']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2023.0,2.0,0,Phase 2
NCT04818632,AZD9833 China PK Study,"A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination With Palbociclib or Everolimus in Chinese Patients With Oestrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (mBC)",COMPLETED,PHASE1,AstraZeneca,2021-11-12,2023-09-07,2023-09-07,2021-03-26,2024-12-17,"['The number of subjects with dose-limiting toxicity, as defined in the protocol.', 'The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.', 'Plasma AZD9833 concentrations and derived PK parameters.']","['The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.', 'Plasma AZD9833 concentrations and derived PK parameters (for optional expansion cohorts Part B Cohorts 2 and 3 only). Everolimus (whole blood) concentrations and derived PK parameters (for optional expansion cohort Part B Cohort 3 only).', 'Objective Response Rate', 'Duration of Response', 'Clinical benefit rate at 24 weeks', 'Percentage Change in Tumour Size', 'Progression Free Survival']",,,,,4,China,"Research Site [Beijing, China] | Research Site [Chengdu, China] | Research Site [Shanghai, China] | Research Site [Wuhan, China]",2021.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating AZD9833, which is a new drug being tested in combination with other treatments for a specific type of breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04834778,A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD),"A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,"HiberCell, Inc.",2021-06-08,2023-12-07,2024-01-30,2021-04-08,2024-03-08,"['Determination of MTD of HC-5404-FU', 'Occurrence of dose-limiting toxicities (DLTs)', 'Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment related TEAEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0', 'Incidence of TEAEs leading to premature discontinuation', 'Incidence of significant laboratory abnormalities, based on hematology, serum chemistry, and urinalysis test results', 'Incidence of abnormalities observed in 12 lead ECG parameters', 'Incidence of abnormalities observed in vital signs measurements and physical examinations']","['Area under the plasma concentration versus time curve from time 0 until last measurable concentration (AUC0 last)', 'Area under the plasma concentration versus time curve from time 0 to 12 hours postdose (AUC0 12)', 'Area under the plasma concentration versus time curve from time 0 extrapolated to infinity (AUC0 ∞)', 'Area under the plasma concentration versus time curve over a dosing interval (AUC0 t)', 'Peak plasma concentration (Cmax)', 'Time of the maximum observed plasma concentration (tmax)', 'Apparent total clearance (CL/F) of plasma concentration', 'Apparent volume of distribution during the terminal phase (Vz/F) of plasma concentration', 'Apparent terminal elimination half life (t1/2) of plasma concentration', 'Accumulation ratio based on AUC0 t (ARAUC) of plasma concentration', 'Linearity ratio (LR) of plasma concentration', 'Overall response rate (ORR) to HC-5404-FU using iRECIST', 'Duration of response (DOR) to HC-5404-FU using iRECIST', 'Time to treatment failure (TTF)', 'Progression-free survival (PFS) using iRECIST', 'Overall response (OS) using iRECIST']",,,,,4,United States,"Karmanos Cancer Institute [Detroit, United States] | HealthPartners Cancer Care Center [Saint Paul, United States] | Baylor University Medical Center [Dallas, United States] | The University of Texas M.D. Anderson Cancer Center [Houston, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on a new drug, HC-5404-FU, being tested in subjects with advanced solid tumors, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT04836520,SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.,"Single-arm, Single-center, PhaseⅡ Clinical Study of SHR6390 Combined With Anastrozole for Preoperative Treatment of Hormone Receptor Positive and HER2 Negative Early or Locally Advanced Breast Cancer.",COMPLETED,PHASE2,Tianjin Medical University Cancer Institute and Hospital,2021-08-02,2023-02-28,2023-03-31,2021-04-08,2023-04-12,"['Changes in Ki67 scores', 'RCB (0-1) after surgery']","['Objective response rate (ORR) evaluated by the investigator', 'tpCR', 'Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v5.0 (CTCAE)']",,,,,1,China,"TianJin Medical University Cancer Institute and Hospital [Tianjin, China]",2021.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves SHR6390, which is being tested in combination with Anastrozole for a specific treatment of breast cancer, indicating it is a new medicine.",OTHER,False,2023.0,2.0,0,Phase 2
NCT04837677,A Study of PRT1419 in Patients With Advanced Solid Tumors,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,Prelude Therapeutics,2021-08-11,2023-02-06,2023-02-06,2021-04-08,2023-03-15,"['Dose limiting toxicities (DLT) of PRT1419', 'Maximally tolerated dose (MTD) and/or optimal biological dose (OBD)', 'Recommended phase 2 dose (RP2D) and schedule of PRT1419']","['Safety and tolerability of PRT1419: AEs, SAEs, CTCAE assessments', 'Pharmacokinetic profile of PRT1419: maximum observed plasma concentration', 'Anti-tumor activity of PRT1419: measurement of objective responses', 'Progression-free survival']",,,,,7,United States,"Sarah Cannon Research Institute at HealthONE [Denver, United States] | Florida Cancer Specialists [Lake Mary, United States] | Florida Cancer Specialists [Sarasota, United States] | University of Iowa Hospitals and Clinics [Iowa City, United States] | Thomas Jefferson University, Sidney Kimmel Cancer Center [Philadelphia, United States] | UPMC Hillman Cancer Center [Pittsburgh, United States] | Tennessee Oncology [Nashville, United States]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT04850625,Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine,"Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study",COMPLETED,,Fudan University,2020-01-15,2021-06-15,2021-06-15,2021-04-20,2022-07-05,['PFS'],['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0'],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2020.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Pyrotinib, which is a new medicine being tested in combination with Vinorelbine for a specific patient population (HER2-Positive Metastatic Breast Cancer).",OTHER,False,2021.0,4.0,0,NA/Other
NCT04852419,A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS,A PHASE 1B STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ZN-C5 IN CHINESE SUBJECTS WITH ADVANCED BREAST CANCER,COMPLETED,PHASE1,Zentera Therapeutics HK Limited,2021-05-31,2022-06-23,2022-06-23,2021-04-21,2022-08-11,"['Observed Dose Limited Toxicities (DLTs) in safety lead in phase', 'Incidence of treatment-emergent adverse events', 'Incidence of treatment-emergent adverse events']","['CBR (CR [+ PR] + SD ≥ 24 weeks).', 'bjective Response Rate (ORR)', 'Duration of Response (DOR)', 'Progression-Free Survival (PFS)']",,,,,1,China,"Fudan University Cancer Hospital [Shanghai, China]",2021.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing a new drug (ZN-C5) in a specific patient population (Chinese subjects with advanced breast cancer), indicating it is a New Medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04869943,Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer,"Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor",TERMINATED,PHASE3,Veru Inc.,2021-10-12,2024-01-09,2024-01-09,2021-05-03,2024-01-26,['To demonstrate the efficacy of Enobosarm in the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).'],['Objective Response Rate (ORR)'],,,,,54,Poland; Spain; Ukraine; United States,"Ironwood Cancer and Research Centers [Chandler, United States] | Banner Health/ Banner MD Anderson Cancer Center [Gilbert, United States] | The Oncology Insitute of Hope and Innovation [Glendale, United States] | Marin Cancer Care, Inc. [Greenbrae, United States] | California Research Institute (CRI) [Los Angeles, United States] | University of California San Francisco Comprehensive Cancer Center [San Francisco, United States] | Providence Medical Group [Santa Rosa, United States] | Rocky Mountain Cancer Centers [Denver, United States] | Morton Plant Hospital/ BayCare Health System, Inc [Clearwater, United States] | University of Miami- Sylvester Comprehensive Cancer Center [Miami, United States] | Miami Cancer Institute [Miami, United States] | Woodlands Medical Specialists, PA [Pensacola, United States] | Miami Cancer Institute, Plantation MCIP [Plantation, United States] | University Cancer & Blood Center [Athens, United States] | Blessing Corporate Services [Quincy, United States] | MBCCOP - LSU Health Sciences Center [Shreveport, United States] | Dana-Farber Cancer Institute Breast Oncology [Boston, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | Astera Cancer Care [East Brunswick, United States] | Inspira Medical Center Mullica Hill [Mullica Hill, United States] | Inspira Medical Center [Vineland, United States] | The Lindner Center for Research and Education at the Christ Hospital [Cincinnati, United States] | Magee-Women's Hospital [Pittsburgh, United States] | Tidelands Health [Murrells Inlet, United States] | Tennessee Cancer Specialists [Knoxville, United States] | Baptist Clinical Research Institute [Nashville, United States] | Texas Oncology Sammons Cancer Center [Dallas, United States] | Texas Oncology - Tyler [Tyler, United States] | Virginia Cancer Specialists [Fairfax, United States] | Virginia Oncology Associates [Norfolk, United States] | Oncology and Hematology Associates of Southwest Virginia, Inc. [Roanoke, United States] | MultiCare Institute for Research and Innovation [Puyallup, United States] | Cancer Care Northwest [Spokane, United States] | MultiCare Institute for Research and Innovation [Spokane, United States] | Wojewódzka Przychodnia Onkologiczna, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi [Lodz, Poland] | Instytut Centrum Zdrowia Matki Polki [Lodz, Poland] | Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli [Lublin, Poland] | Specjalistyczny Szpital Onkologiczny NU-MED [Maków Mazowiecki, Poland] | ""Oddział Onkologii Klinicznej i Chemioterapii Europejskie Centrum Zdrowia Otwock"" [Otwock, Poland] | Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy [Warsaw, Poland] | A Coruña University Hospital [A Coruña, Spain] | Hospital Universitari Dexeus [Barcelona, Spain] | Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO) [Barcelona, Spain] | Institut Catala d'Oncologia (ICO) [Barcelona, Spain] | Hospital Universitari Arnau de Vilanova de Lleida [Lleida, Spain] | Hospital Ruber Internacional [Madrid, Spain] | Hospital Universitario 12 de Octubre (H12O) [Madrid, Spain] | Hospital Universitario HM Sanchinarro [Madrid, Spain] | Hospital Clínico Universitario de Valencia (CHUV) [Valencia, Spain] | Municipal Institution ""Dnipropetrovsk City Multi-field Clinical Hospital #4"", Dnepropetrovsk state m [Dnipro, Ukraine] | State institution ""V.T. Zaycev Institute of general and urgent surgery of National academy medical sciences of Ukraine"" [Kharkiv, Ukraine] | Khmelnytsky Regional Antitumor Center, Department of Breast, Skin, Soft Tissues and Bones Tumorsa [Khmelnytskyi, Ukraine] | Kyiv City Clinical Oncology Center [Kyiv, Ukraine] | Odessa Regional Oncological Dispensary [Odesa, Ukraine]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial evaluates the efficacy of Enobosarm, which is a new treatment for a specific type of metastatic breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 3
NCT04906070,Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan,Study of the Safety and Efficacy of Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan,COMPLETED,,Hekabio,2019-05-25,2022-03-31,2022-05-27,2021-05-28,2022-06-03,['Tumor response to HB-001'],['Adverse Events'],,,,,4,Japan,"Tohoku University Hospital [Miyagi, Japan] | Kansai Medical University Hospital [Osaka, Japan] | National Cancer Center Hospital [Tokyo, Japan] | Tokyo Medical And Dental University Medical Hospital [Tokyo, Japan]",2019.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a new treatment (HB-001) using alpha-particle sources for recurrent malignant solid tumors, suggesting it is a new medicine rather than an extension of an existing indication.",INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT04916002,A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer,"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer",TERMINATED,PHASE2,Regeneron Pharmaceuticals,2021-11-30,2024-10-31,2024-10-31,2021-06-07,2024-11-08,"['Objective response rate (ORR) with vidutolimod in combination with cemiplimab in study participants with metastatic or advanced/unresectable CSCC, MCC, BCC, NSCLC,TNBC or OPSCC']","['Safety and tolerability of vidutolimod administered by IT injection in combination with cemiplimab in the study participants', 'Efficacy of vidutolimod in combination with cemiplimab in the study participants']",,,,,24,Australia; United States,"University of Alabama [Birmingham, United States] | City of Hope [Duarte, United States] | UC San Diego Moores Cancer Center [La Jolla, United States] | University of California [Los Angeles, United States] | GenesisCare USA [Jacksonville, United States] | Orlando Health Cancer Institute [Orlando, United States] | University of Iowa [Iowa City, United States] | Norton Cancer Institute [Louisville, United States] | VA Maryland Health Care System [Baltimore, United States] | Dana-Farber Cancer Institute [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Dartmouth Clinical Trial Office [Lebanon, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | East Carolina University [Greenville, United States] | Ohio State University [Columbus, United States] | OU Health Stephenson Cancer Center [Oklahoma City, United States] | University of Pittsburgh Medical Center [Pittsburgh, United States] | Oncology Consultants [Houston, United States] | University of Utah Huntsman Cancer Center [Salt Lake City, United States] | University of Washington [Seattle, United States] | St. Vincent's Hospital [Darlinghurst, Australia] | Princess Alexandra Hospital [Woolloongabba, Australia] | Peter MacCallum Cancer Centre (PMCC) and The Royal Melbourne Hospital [Melbourne, Australia] | Fiona Stanley Hospital [Murdoch, Australia]",2021.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Vidutolimod, which is being tested in combination with Cemiplimab for advanced or metastatic cancer, indicating it is a new medicine being evaluated for safety and efficacy.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT04927481,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer,"A Multicenter, Open-label, Single-arm, Phase II Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer",TERMINATED,PHASE2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",2021-06-11,2023-01-17,2023-01-17,2021-06-16,2024-02-23,['Objective response rate (ORR)'],"['Disease control rate (DCR)', 'Duration of response (DoR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Treatment emergent adverse events (TEAEs)']",,,,,29,China,"Anhui Provincial Hospical [Hefei, China] | Cancer Center Sun Yat-sen University [Guozhou, China] | Affiliated Hospital of Hebei University [Baoding, China] | The Fourth Hospital of Hebei Medical University [Shijiazhuang, China] | Tangshan People's Hospital [Tangshan, China] | Xingtai People's Hospital [Xingtai, China] | Harbin Medical University Cancer Hospital [Harbin, China] | Daqing People's Hospital [Daqing, China] | Cancer Hospital of Jiamusi City [Jiamusi, China] | The First Affiliated Hospital of Xinxiang Medical University [Xinxiang, China] | Cancer Hospital of Henan Province [Zhengzhou, China] | The First Affiliated Hospital of Zhengzhou University [Zhengzhou, China] | Henan Provincial People's Hospital [Zhenzhou, China] | Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology [Wuhan, China] | Zhongnan Hospital of Wuhan University [Wuhan, China] | Hubei Cancer Hospital [Wuhan, China] | Changsha Kexin Cancer Hospital [Changsha, China] | Yiyang Central Hospital [Yiyang, China] | The third Hospital of Nanchang [Nanchang, China] | The second hospital of Jinlin University [Changchun, China] | The second hospital of Dalian Medical University [Dalian, China] | The First Affiliated Hospital of Jinzhou Medical University [Jinzhou, China] | The First hospital of China Medical University [Shenyang, China] | Shanxi Provincial Cancer Hospital [Taiyuan, China] | Yuncheng Central Hospital [Yuncheng, China] | Sichuan Cancer Hospital & Institute [Chengdu, China] | The second people's hospital of neijiang [Neijiang, China] | Affiliated tumor Hospital of Xinjiang Medical University [Ürümqi, China] | The First Affiliated Hospital of Xinjiang Medical University [Ürümqi, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating a new formulation (liposome injection) of Mitoxantrone Hydrochloride for a specific patient population (advanced HER2 negative breast cancer), indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT04940026,"Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women","A Phase 1, Open-label, Single Center, One Period, One Sequence Study to Determine Absorption, Metabolism, and Excretion of a Single Oral Dose of Radiolabeled [14C]- SAR439859 and an Assessment of the Absolute Oral Bioavailability Using the Microdosing Technique in Healthy Post-menopausal Women",COMPLETED,PHASE1,Sanofi,2021-06-15,2021-08-19,2021-08-19,2021-06-25,2025-09-24,"['Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administration', 'Percentage of radioactive dose excreted in urine and feces after oral administration', 'Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administration', 'Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administration', 'Assessment of PK parameter: CL for SAR439859 after IV administration', 'Assessment of PK parameter: AUC ratios after IV administration', 'Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: AUC ratios after oral administration', 'Assessment of PK parameter: Cmax for M7 after IV and oral administration', 'Assessment of PK parameter: AUC for M7 after IV and oral administration', 'Assessment of PK parameter: t1/2z for M7 after IV and oral administration', 'Assessment of PK parameter: Rmet Cmax after IV and oral administration', 'Assessment of PK parameter: Rmet AUC after IV and oral administration', 'Absolute oral bioavailability of SAR439859', 'Relative bioavailability of SAR439859 after oral administration']",['Number of participants with adverse events'],,,,,1,United Kingdom,"Investigational Site Number 8260001 [Nottingham, United Kingdom]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT04942054,A Study in Patients With Advanced Breast Cancer,"A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients",TERMINATED,PHASE1,Sun Pharma Advanced Research Company Limited,2022-05-20,2023-02-28,2023-02-28,2021-06-28,2023-05-22,"['Incidence of dose limiting toxicities at each dose levels (Part 1 only)', 'Incidence and severity of adverse events with each dose level']","['evaluation of Cmax (Part 1 and Part 2)', 'evaluation of tmax (Part 1 and Part 2)', 'evaluation of AUC (Part 1 and Part 2)', 'tumour response']",,,,,6,India; United States,"Hoag Memorial Hospital Presbyterian [Newport Beach, United States] | The University of Chicago [Chicago, United States] | HealthCare Global Enterprises Ltd [Bangalore, India] | HCG Manavata cancer Centre [Nashik, India] | LMMF's Deenanath Mangeshkar Hospital & Research Centre [Pune, India] | Noble Hospital Pvt. Ltd., [Pune, India]",2022.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 1
NCT04982926,A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer,A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations,COMPLETED,PHASE1,"Taiho Oncology, Inc.",2021-09-16,2025-01-02,2025-03-24,2021-07-29,2025-08-01,"['Dose Escalation:Maximum Tolerated Dose (MTD)', 'Dose Expansion:Overall Response Rate']","['Dose Escalation: Overall Response Rate (ORR)', 'Dose Escalation:Pharmacokinetic (PK) Profile', 'Dose Expansion:Incidence of treatment-emergent Adverse Events (Safety and tolerability)', 'Dose Expansion:Duration of Response (DOR)', 'Dose Expansion:Disease Control Rate (DCR)', 'Dose Expansion:Progression Free Survival (PFS)', 'Dose Expansion:Pharmacokinetic profile of TAS2940']",,,,,3,France; United States,"Tennessee Oncology [Nashville, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | CLCC Gustave Roussy [Villejuif, France]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a Phase 1 study of TAS2940, indicating it is a new medicine being tested for the treatment of locally advanced or metastatic solid tumors.",INDUSTRY,False,2025.0,0.0,1,Phase 1
NCT04983238,Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial With a Single Arm run-in Period to Evaluate the Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985",COMPLETED,PHASE1; PHASE2,Byondis B.V.,2022-01-10,2023-04-19,2023-06-26,2021-07-30,2024-01-05,['Efficacy of BYON5667 eye drops by assessing the percentage of patients with SYD985-related ocular adverse events Grade >=1 at Day 63'],"['Ocular toxicity', 'Tolerability of BYON5667 eye drops by means of Eye Drop Tolerability questionnaire scores', 'National Eye Institute Visual Function Questionnaire (NEI VFQ-25) scores', 'SYD985-related ocular adverse events (AE)', 'Discontinuation due to SYD985-related ocular toxicity', 'Efficacy of SYD985 by assessing the objective response rate (ORR)', 'Efficacy of SYD985 by assessing the progression-free survival (PFS)', 'Efficacy of SYD985 by assessing the overall survival', 'Safety of SYD985 by assessing incidence and severity of treatment-emergent drug-related adverse events']",,,,,10,Belgium; France; Spain,"University Hospital Antwerp [Antwerp, Belgium] | UZ Leuven [Leuven, Belgium] | Institut Bergonié [Bordeaux, France] | Centre Oscar Lambret [Lille, France] | Hôpital Saint Louis [Paris, France] | Vall d' Hebron [Barcelona, Spain] | ICO I'Hospitalet - Hospital Duran i Reynals [L'Hospitalet de Llobregat, Spain] | Hospital Universitari Arnau de Vilanova [Lleida, Spain] | START Madrid HU Fundacion Jimenez Diaz [Madrid, Spain] | START Madrid HU HM Sanchinarro [Madrid, Spain]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial evaluates Sodium Thiosulfate (BYON5667) eye drops, which is a new medicine being tested for a specific indication (reducing ocular toxicity in cancer patients treated with SYD985).",INDUSTRY,False,2023.0,2.0,1,Phase 2
NCT04993040,A PK Study of Oraxol in Breast Cancer Patients,A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients,COMPLETED,PHASE1,"Athenex, Inc.",2019-04-22,2019-12-09,2020-12-09,2021-08-06,2021-08-06,"['Cmax', 'Cmin', 'Cavg', 'AUC0-t', 'AUC']","['Safety', 'Tumor response rate', 'Progression-free survival', 'Overall survival']",,,,,1,China,"Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University [Guangzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a study of Oraxol, which suggests it is a new medicine being evaluated for its pharmacokinetics in breast cancer patients.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT05001347,A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors,A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors,COMPLETED,PHASE2,I-Mab Biopharma US Limited,2021-11-02,2023-02-08,2023-02-08,2021-08-11,2023-10-12,['Objective Response Rate (ORR) in each Tumor Type'],"['Incidence of treatment emergent adverse events', 'Number of participants with laboratory value abnormalities', 'Number of participants with vital sign abnormalities', 'Number of participants with abnormal physical examination results', 'Objective Response Rate (ORR)', 'Duration of response (DOR)', 'Disease control rate (DCR)', 'Progression-free-survival (PFS)', 'Overall survival (OS)', 'Pharmacokinetic profiles of serum TJ004309 and atezolizumab', 'Pharmacokinetic (PK) parameters: Area under the curve (AUC0-T)', 'Assessment of PK parameter: Cmax', 'Assessment of PK parameter: tmax']",,,,,17,United States,"Arizona Oncology Associates [Tucson, United States] | Innovative Clinical Research Institute [Whittier, United States] | Medical Oncology Hematology Consultants, PA [Newark, United States] | Illinois Cancer Specialists [Arlington Heights, United States] | Women's Cancer Care [Covington, United States] | Maryland Oncology Hematology [Rockville, United States] | Laura and Isaac Perlmutter Cancer Center at NYU Langone [New York, United States] | Duke Cancer Center [Durham, United States] | Tri County Hematology and Oncology Associates [Massillon, United States] | Texas Oncology - Arlington North [Arlington, United States] | Texas Oncology - Austin Central [Austin, United States] | Texas Oncology - Bedford [Bedford, United States] | Texas Oncology - Forth Worth Cancer Center [Fort Worth, United States] | Texas Oncology - The Woodlands, Gynecologic Oncology [The Woodlands, United States] | Texas Oncology - Longview Cancer Center [Tyler, United States] | Virginia Cancer Specialists [Fairfax, United States] | Northwest Cancer Specialists [Vancouver, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves TJ004309, which is a new medicine being tested in combination with Atezolizumab for patients with ovarian cancer and selected solid tumors.",INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT05002868,"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors","A Multi-center, Open-label, Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,Rhizen Pharmaceuticals SA,2021-10-05,2024-04-25,2024-04-25,2021-08-12,2024-09-19,"['Maximum tolerated dose (MTD) of RP12146 in patients with locally advanced or metastatic solid tumors', 'Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE Criteria v5.0']","['Tmax', 'Cmax', 'AUC', 'Overall response rate (ORR)', 'Clinical benefit rate (CBR)', 'Progression free survival (PFS)']",,,,,6,Czechia; Poland,"Multiscan s.r.o. [Hořovice, Czechia] | SP ZOZ University Hospital in Krakow Oncology Clinic, 50 Kopernika Street [Krakow, Poland] | Klinika Onkologii ICZMP [Lodz, Poland] | Pratia Poznań Medical Center [Poznan, Poland] | Clinical Trials Site Nasz Lekarz [Torun, Poland] | Maria Skłodowska-Curie Memorial National Oncology Institute [Warsaw, Poland]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT05007106,MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005),"A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors",COMPLETED,PHASE2,Merck Sharp & Dohme LLC,2021-09-16,2025-08-05,2025-08-05,2021-08-16,2025-08-14,"['Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)', 'Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR', 'ORR per RECIST 1.1 as Assessed by Investigator in Participants with Selected Solid Tumors', 'PFS per RECIST 1.1 as Assessed by Investigator at 9 months', 'PFS per RECIST 1.1 as Assessed by Investigator at 12 months']","['Overall Survival (OS)', 'PFS per RECIST 1.1 as Assessed by Investigator', 'Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR', 'DOR per RECIST 1.1 as Assessed by Investigator', 'ORR per RECIST 1.1 as Assessed by Investigator', 'PFS per RECIST 1.1 as Assessed by Investigator in Participants with Cervical Cancer', 'Change from Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30)', 'Change from Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5)', 'Number of Participants Who Experienced One or More Adverse Events (AEs)', 'Number of Participants Who Discontinued Study Intervention Due to an AE']",,,,,73,Canada; Chile; Colombia; France; Germany; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,"Alaska Womens Cancer Care ( Site 1016) [Anchorage, United States] | City of Hope Comprehensive Cancer Center ( Site 1001) [Duarte, United States] | University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente [Orange, United States] | Karmanos Cancer Institute ( Site 1007) [Detroit, United States] | Memorial Sloan Kettering - Basking Ridge ( Site 1023) [Basking Ridge, United States] | Memorial Sloan Kettering - Monmouth ( Site 1022) [Middletown, United States] | Memorial Sloan Kettering - Bergen ( Site 1025) [Montvale, United States] | Memorial Sloan Kettering- Commack ( Site 1021) [Commack, United States] | Memorial Sloan Kettering - Westchester ( Site 1020) [Harrison, United States] | Memorial Sloan Kettering Cancer Center ( Site 1002) [New York, United States] | Memorial Sloan Kettering - Nassau ( Site 1026) [Uniondale, United States] | Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024) [Tulsa, United States] | Sanford Cancer Center-Gynecologic Oncology ( Site 1015) [Sioux Falls, United States] | Houston Methodist Hospital ( Site 1017) [Houston, United States] | Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051) [Kingston, Canada] | Princess Margaret Cancer Centre ( Site 1056) [Toronto, Canada] | FALP-UIDO ( Site 1401) [Santiago, Chile] | Oncovida ( Site 1405) [Santiago, Chile] | Bradfordhill-Clinical Area ( Site 1402) [Santiago, Chile] | James Lind Centro de Investigacion del Cancer ( Site 1404) [Temuco, Chile] | Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422) [Medellín, Colombia] | Clinica de la Costa S.A.S. ( Site 1421) [Barranquilla, Colombia] | Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425) [Bogotá, Colombia] | Oncologos del Occidente ( Site 1424) [Pereira, Colombia] | Fundación Cardiovascular de Colombia ( Site 1423) [Piedecuesta, Colombia] | CENTRE LEON BERARD-Medical oncology ( Site 1151) [Lyon, France] | Centre Georges François Leclerc ( Site 1155) [Dijon, France] | Institut Regional du Cancer Montpellier ( Site 1157) [Montpellier, France] | Gustave Roussy-medicine departement ( Site 1153) [Villejuif, France] | Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156) [Avignon, France] | Institut Curie ( Site 1152) [Paris, France] | Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180) [Heidelberg, Germany] | Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne [Tübingen, Germany] | Klinikum der Universität München Großhadern ( Site 1176) [München, Germany] | Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172) [Düsseldorf, Germany] | Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171) [Berlin, Germany] | Rambam Health Care Campus-Oncology ( Site 1141) [Haifa, Israel] | Hadassah Medical Center-Oncology ( Site 1142) [Jerusalem, Israel] | Sheba Medical Center-ONCOLOGY ( Site 1144) [Ramat Gan, Israel] | Sourasky Medical Center-Oncology ( Site 1143) [Tel Aviv, Israel] | Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136) [Rome, Italy] | Ospedale San Raffaele-Oncologia Medica ( Site 1135) [Milan, Italy] | Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138) [Rozzano, Italy] | Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( [Milan, Italy] | Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134) [Napoli, Italy] | Aichi Cancer Center Hospital ( Site 1324) [Nagoya, Japan] | National Cancer Center Hospital East ( Site 1321) [Kashiwa, Japan] | Osaka International Cancer Institute ( Site 1323) [Osaka, Japan] | National Cancer Center Hospital ( Site 1322) [Tokyo, Japan] | Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121) [Amsterdam, Netherlands] | Erasmus Medisch Centrum-Medical Oncology ( Site 1122) [Rotterdam, Netherlands] | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101 [Warsaw, Poland] | Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103) [Gdansk, Poland] | Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104) [Koszalin, Poland] | Seoul National University Hospital-Internal Medicine ( Site 1312) [Seoul, South Korea] | Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311) [Seoul, South Korea] | Asan Medical Center ( Site 1313) [Seoul, South Korea] | Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113) [Hospitalet, Spain] | HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117) [Pozuelo de Alarcón, Spain] | Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111) [Madrid, Spain] | Clinica Universidad de Navarra-Medical Oncology ( Site 1118) [Madrid, Spain] | HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114) [Seville, Spain] | NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302) [Tainan City, Taiwan] | National Taiwan University Hospital-Oncology ( Site 1301) [Taipei, Taiwan] | Mackay Memorial Hospital ( Site 1305) [Taipei, Taiwan] | Chang Gung Medical Foundation-Linkou Branch ( Site 1304) [Taoyuan District, Taiwan] | Istanbul Universitesi Cerrahpasa ( Site 1203) [Istanbul- Fatih, Turkey (Türkiye)] | Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201) [Adana, Turkey (Türkiye)] | Hacettepe Universitesi-oncology hospital ( Site 1209) [Ankara, Turkey (Türkiye)] | Ankara City Hospital-Medical Oncology ( Site 1202) [Ankara, Turkey (Türkiye)] | Trakya University-Medical Oncology ( Site 1207) [Edirne, Turkey (Türkiye)] | Acibadem Universitesi Atakent Hastanesi ( Site 1208) [Istanbul, Turkey (Türkiye)] | TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204) [Istanbul, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves MK-7684A, which is a co-formation of Vibostolimab and Pembrolizumab, indicating it is a new medicine being tested in participants with selected solid tumors.",INDUSTRY,False,2025.0,0.0,1,Phase 2
NCT05013554,Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors,"A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.",TERMINATED,PHASE1,Sanofi,2021-08-16,2024-01-15,2024-01-15,2021-08-19,2025-09-15,"['Part 1: Dose Escalation Determine the MTD/maximum administered dose (MAD) and RD(s) of SAR443216', 'Part 1: Dose Escalation: Safety of SAR443216', 'Part 2: Dose Expansion Objective response rate (ORR) of SAR443216 in all participants', 'Part 2: Dose Expansion Duration of response (DoR) of SAR443216 in all participants.']","['Part 1: Objective response rate (ORR) of SAR443216 in all participants', 'Part 1: Duration of response (DoR) of SAR443216 in all participants', 'Part 1 and Part 2: Progression Free Survival (PFS)', 'Part 2: Safety of SAR443216', 'Part 1 and Part 2: Pharmacokinetic Parameter: Cmax of SAR443216', 'Part 1 and Part 2: Pharmacokinetic Parameter: Ctrough of SAR443216', 'Part 1 and Part 2: Pharmacokinetic Parameter: t 1/2 of SAR443216', 'Part 1 and Part 2: Pharmacokinetic Parameter: AUC0-τ of SAR443216', 'Part 1 and Part 2: Evaluation of SAR443216 immunogenicity']",,,,,11,Belgium; France; South Korea; Spain; Taiwan; United States,"~University of Texas - MD Anderson Cancer Center Site Number : 8400002 [Houston, United States] | Investigational Site Number : 0560002 [Ghent, Belgium] | Investigational Site Number : 2500001 [Pierre-Bénite, France] | Investigational Site Number : 2500002 [Villejuif, France] | Investigational Site Number : 4100001 [Seoul, South Korea] | Investigational Site Number : 4100002 [Seoul, South Korea] | Investigational Site Number : 7240003 [Barcelona, Spain] | Investigational Site Number : 7240001 [Madrid, Spain] | Investigational Site Number : 7240002 [Madrid / Madrid, Spain] | Investigational Site Number : 1580001 [Taichung, Taiwan] | Investigational Site Number : 1580002 [Tainan City, Taiwan]",2021.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is a first-in-human study evaluating SAR443216, indicating it is a new medicine being tested for safety and efficacy in participants with specific solid tumors.",INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT05035407,"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",COMPLETED,PHASE1,National Cancer Institute (NCI),2022-03-08,2025-07-16,2025-07-16,2021-09-05,2025-09-03,['To determine the maximally tolerated dose of KK-LC-1 TCR T cells plus aldesleukin for the treatment of KK-LC-1 plus cancers.'],[],,,,,1,United States,"National Institutes of Health Clinical Center [Bethesda, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,NIH,False,2025.0,0.0,0,Phase 1
NCT05069935,FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,"A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,Fate Therapeutics,2021-10-15,2023-08-11,2023-08-11,2021-10-06,2023-09-21,"['Define the Recommended Phase 2 Dose (RP2D)', 'Incidence and Severity of Adverse Events (AEs)0']",[],,,,,4,United States,"Hackensack University Medical Center [Hackensack, United States] | Sarah Cannon [Nashville, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05070247,A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors,"An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors",TERMINATED,PHASE1; PHASE2,Takeda,2022-04-14,2025-01-06,2025-01-06,2021-10-07,2025-03-07,"['Dose Escalation: Number of Participants With Grade 3 or Higher TEAEs', 'Dose Escalation: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)', 'Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)', 'Dose Escalation: Number of Participants Reporting one or More Serious Adverse Event (SAEs)', 'Dose Escalation: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations', 'Dose Expansion: Overall Response Rate (ORR)']","['Dose Escalation and Dose Expansion: Cmax: Maximum Serum Concentration for TAK-500', 'Dose Escalation and Dose Expansion: Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAK-500', 'Dose Escalation and Dose Expansion: AUCt: Area Under the Serum Concentration-time Curve From Time 0 to Time t for TAK-500', 'Dose Escalation and Dose Expansion: AUCinf: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-500', 'Dose Escalation and Dose Expansion: t1/2: Terminal Disposition Phase Half-life for TAK-500', 'Dose Escalation and Dose Expansion: CL: Total Clearance After Intravenous Administration for TAK-500', 'Dose Escalation and Dose Expansion: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-500', 'Dose Escalation and Dose Expansion: Changes in Intratumoral Tumor Cell Infiltration', 'Dose Escalation and Dose Expansion: Number of Participants With Positive Anti-drug Antibody (ADA) and Acquired Immunogenicity', 'Dose Escalation: Overall Response Rate (ORR)', 'Dose Escalation and Dose Expansion: Disease Control Rate (DCR)', 'Dose Escalation and Dose Expansion: Duration of Response (DOR)', 'Dose Escalation and Dose Expansion: Time to Response (TTR)', 'Dose Expansion: Progression Free Survival (PFS)', 'Dose Expansion: Overall Survival (OS)', 'Dose Expansion: Number of Participants With Grade 3 or Higher TEAEs', 'Dose Expansion: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)', 'Dose Expansion: Number of Participants With Dose Limiting Toxicities (DLTs)', 'Dose Expansion: Number of Participants Reporting one or More Serious Adverse Event (SAEs)', 'Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations']",,,,,12,United States,"Univeristy of Alabama at Birmingham [Birmingham, United States] | City of Hope Comprehensive Cancer Center [Duarte, United States] | University of California San Diego [La Jolla, United States] | University of Colorado - Anschutz Medical Campus - PPDS [Aurora, United States] | Sarah Cannon Research Institute [Denver, United States] | Sylvester Comprehensive Cancer Center [Miami, United States] | Northwestern [Chicago, United States] | Dana Farber Cancer Institute [Boston, United States] | New York University [New York, United States] | Fox Chase Cancer Center [Philadelphia, United States] | Sarah Cannon Cancer Institute [Nashville, United States] | START South Texas Accelerated Research Therapeutics [San Antonio, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a study of TAK-500, which is identified as a 'Novel Stimulator of Interferon Genes Agonist', indicating it is a new medicine being evaluated for safety and efficacy in treating solid tumors.",INDUSTRY,False,2025.0,0.0,0,Phase 2
NCT05080842,A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer",TERMINATED,PHASE1,Accutar Biotechnology Inc,2021-11-12,2024-04-04,2024-04-04,2021-10-18,2025-02-13,"['Incidence of dose limiting toxicities (DLTs)', 'Incidence of treatment-emergent adverse events (TEAEs), and clinically significant grade 3 or higher laboratory abnormalities following administration of AC682']","['Objective response rate (ORR) as a measure of anti-tumor activity', 'Clinical benefit rate (CBR) as a measure of anti-tumor activity', 'Duration of response (DOR) as a measure of anti-tumor activity', 'Disease control rate (DCR) as a measure of anti-tumor activity', 'Progression free survival (PFS) as a measure of anti-tumor activity', 'Pharmacokinetic Analysis: area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(0-inf))', 'Pharmacokinetic Analysis: area under the concentration-time curve over the dosing interval (AUC(0-tau))', 'Pharmacokinetic Analysis: maximum plasma concentration (Cmax)', 'Pharmacokinetic Analysis: time to maximum plasma concentration (tmax)', 'Pharmacokinetic Analysis: terminal elimination half life (t1/2)']",,,,,5,United States,"Site 01 [Denver, United States] | Site 04 [Orlando, United States] | Site 02 [Sarasota, United States] | Site 03 [Nashville, United States] | Site 05 [Houston, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT05103826,A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,A Phase I Study to Evaluate Safety 、Tolerability 、 Pharmacokinetics and Efficacy of SHR6390 in Combination With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,TERMINATED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2021-10-25,2023-06-15,2023-06-15,2021-11-02,2023-08-15,"['(Safety Lead-in) dose limited toxicity (DLT) of SHR6390+famitinib in the first cycle', '(Safety Lead-in) Recommended Phase II Dose (RP2D) of SHR6390+famitinib']","['AEs+SAEs', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Cmax', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Tmax', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: t1/2', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: AUC', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: CL/F', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Vz/F', 'Evaluation of pharmacokinetic parameter of SHR6390+famitinib: Rac', 'Objective Response Rate (ORR)', 'Disease control rate (DCR)', 'Duration of response (DoR)']",,,,,1,China,"Harbin Medical University Cancer Hospital [Harbin, China]",2021.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05110170,Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®,"A Multicenter, Randomized, Open-Label Phase Ⅲ Trial to Compare Efficacy and Safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® in Patients With Breast Cancer",COMPLETED,PHASE3,Luye Pharma Group Ltd.,2020-10-15,2022-04-05,2022-06-24,2021-11-05,2023-05-16,['Non-inferiority of LY01005 compared with ZOLADEX®: the percentage of subjects with serum E2 maintaining at postmenopausal level (≤30 pg/mL) from Week 4 to Week 12 after the first dose.'],"['Incidence of adverse events (AE).', 'Changes in serum E2 level after administration.', 'Changes in serum LH level after administration.', 'Changes in serum FSH level after administration.', 'PK subgroup: changes in serum E2 level after administration to assess PD characteristic of LY01005.', 'PK subgroup: changes in serum LH level after administration to assess PD characteristic of LY01005.', 'PK subgroup: changes in serum FSH level after administration to assess PD characteristic of LY01005.', 'PK subgroup: changes in serum goserelin level after administration to assess PK characteristic of LY01005.']",,,,,1,China,"Zhejiang Cancer Hospital [Hangzhou, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating LY01005, which is a new formulation of goserelin acetate, indicating it is a new medicine being tested for efficacy and safety in patients with breast cancer.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT05134194,A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer,"A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician Choice Versus Treatment of Physician Choice for Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Systemic Chemotherapy Regimens for Advanced/Metastatic Setting",TERMINATED,PHASE3,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",2022-01-17,2022-01-17,2022-12-15,2021-11-24,2024-04-16,['Progression free survival (PFS)'],[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2022.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Camrelizumab, which is being studied in combination with chemotherapy for a specific cancer type, indicating it is a new medicine being evaluated for a new use.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT05159518,A Study of PRT2527 in Participants With Advanced Solid Tumors,"A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors",COMPLETED,PHASE1,Prelude Therapeutics,2022-02-14,2023-12-06,2023-12-06,2021-12-16,2023-12-11,"['Dose limiting toxicities (DLT) of PRT2527', 'Maximally tolerated dose (MTD) of PRT2527', 'Recommended phase 2 dose (RP2D) and schedule of PRT2527']","['Safety and tolerability of PRT2527: AEs, SAEs, CTCAE assessments', 'Pharmacokinetic profile of PRT2527: maximum observed plasma concentration', 'Anti-tumor activity of PRT2527: measurement of objective responses', 'Duration of response to PRT2527: Objective responses']",,,,,8,United States,"Sarah Cannon Research Institute at HealthONE [Denver, United States] | Investigational Drug Services, AdventHealth Celebration [Celebration, United States] | Florida Cancer Specialists [Sarasota, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Thomas Jefferson University, Sidney Kimmel Cancer Center [Philadelphia, United States] | Fox Chase Cancer Center [Philadelphia, United States] | Mary Crowley Cancer Research [Dallas, United States] | NEXT Virginia [Fairfax, United States]",2022.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05159778,Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA),"A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy",COMPLETED,PHASE2,"HiberCell, Inc.",2021-11-09,2023-03-22,2023-04-12,2021-12-16,2023-06-22,['Overall response rate (ORR)'],"['Median Progression Free Survival (mPFS)', 'PFS at 6, 9, 12, 18, and 24 months', 'Median Overall Survival (mOS)', 'OS rates at 6, 9, 12, 18, 24 months', 'Disease Control Rate (DCR)', 'Duration of Response (DoR)', 'Profile safety of Imprime PGG in combination with pembrolizumab', 'Correlate changes in immune cell activation markers in tumor samples and in peripheral blood immune cells with treatment outcome', 'Correlate PD-L1 status and changes in the tumor immune microenvironment with treatment outcome', 'Correlate levels of serum anti-β-glucan antibody (ABA) with treatment outcome', 'Correlate treatment outcome in select metastatic breast cancer subpopulations']",,,,,16,United States,"The University of Arizona Cancer Center - North Campus [Tucson, United States] | The University of Arizona Cancer Center [Tucson, United States] | University of Colorado at Denver [Denver, United States] | University of Miami and Clinics -Sylvester Comprehensive Cancer Center [Miami, United States] | Mt. Sinai (Miami) [Miami Beach, United States] | Moffitt Cancer Center [Tampa, United States] | Louisiana State University Health Sciences Center - New Orleans [New Orleans, United States] | HealthPartners Cancer Research Center [Saint Louis Park, United States] | St. Luke's Cancer Institute [Kansas City, United States] | St. Vincent - Frontier Cancer Center [Billings, United States] | University of New Mexico Comprehensive Cancer Center [Albuquerque, United States] | Columba University Medical Center [New York, United States] | Stony Brook University [Stony Brook, United States] | Thomas Jefferson University- Sidney Kimmel Cancer Center [Philadelphia, United States] | Baptist Clinical Research Institute [Memphis, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Imprime PGG, which is being tested in combination with pembrolizumab for a specific patient population with metastatic breast cancer, indicating it is a new medicine being evaluated for efficacy and safety.",INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT05176080,"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer","Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer",TERMINATED,PHASE1; PHASE2,Henan Cancer Hospital,2021-12-08,2024-07-03,2024-07-03,2022-01-04,2024-12-17,"['RP2D in phase Ib', 'ORR in phase II']","['ORR in phase Ib', 'PFS in phase Ib', 'PFS in phase II', 'AE']",,,,,1,China,"Henan Cancer Hospital [Zhengzhou, China]",2021.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Famitinib, which is being evaluated in combination with SHR6390 and endocrine therapy for a specific type of advanced breast cancer, indicating it is a new medicine being tested for efficacy and safety.",OTHER_GOV,False,2024.0,1.0,0,Phase 2
NCT05176860,Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy,Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy,COMPLETED,,"Varian, a Siemens Healthineers Company",2022-12-20,2023-07-30,2023-07-30,2022-01-04,2023-09-06,['CBCT Image Quality'],"['Dosimetry Calculations', 'Patient Experience']",,,,,1,Canada,"Nova Scotia Health (QEII) [Halifax, Canada]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,NA/Other
NCT05194072,A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors,A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors,TERMINATED,PHASE1,"Seagen, a wholly owned subsidiary of Pfizer",2022-01-12,2025-05-14,2025-05-14,2022-01-18,2025-09-16,"['Number of participants with adverse events (AEs)', 'Number of participants with laboratory abnormalities', 'Number of participants with dose limiting toxicities (DLTs)', 'Number of participants with dose limiting toxicities (DLTs) and overall safety by dose level']","['Confirmed objective response rate (ORR) by investigator assessment', 'Complete response rate (CRR)', 'Duration of response (DOR)', 'Progression-free survival (PFS)', 'Invasive disease-free survival (iDFS)', 'Pharmacokinetic (PK) parameter - Area under the curve (AUC)', 'PK parameter - Maximum concentration (Cmax)', 'PK parameter - Time to maximum concentration (Tmax)', 'PK parameter - Apparent terminal half-life (t1/2)', 'PK parameter - Trough concentration (Ctrough)', 'Incidence of antidrug antibodies (ADAs)']",,,,,27,Canada; Germany; Spain; United Kingdom; United States,"UCHealth Sue Anschutz-Rodgers Eye Center [Aurora, United States] | University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) [Aurora, United States] | University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) [Aurora, United States] | University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) [Aurora, United States] | Presbyterian/St Lukes Medical Center [Denver, United States] | AdventHealth Celebration Infusion Center [Celebration, United States] | AdventHealth Medical Group Oncology Research at Celebration [Celebration, United States] | Mayo Clinic Florida [Jacksonville, United States] | Florida Cancer Specialists [Orlando, United States] | Sarah Cannon Research Institute at Florida Cancer Specialists [Orlando, United States] | Northwestern Medical Group [Chicago, United States] | Northwestern Memorial Hospital [Chicago, United States] | Community Health Network, Inc. [Indianapolis, United States] | Community Health Network, Inc. [Indianapolis, United States] | Community Health Network, Inc. [Indianapolis, United States] | START Midwest [Grand Rapids, United States] | Sarah Cannon Research Institute - Pharmacy [Nashville, United States] | SCRI Oncology Partners [Nashville, United States] | The University of Texas M.D. Anderson Cancer Center [Houston, United States] | The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services [Houston, United States] | South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States] | START Mountain Region [West Valley City, United States] | The Ottawa Hospital Cancer Centre [Ottawa, Canada] | Hamato-Onkologische Phase 1 Unit der Charite/Charite Research Organisation [Berlin, Germany] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | START Madrid-Hospital Universitario HM Sanchinarro [Madrid, Spain] | Sarah Cannon Research Institute [London, United Kingdom]",2022.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,1,Phase 1
NCT05203497,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.,SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Technetium-99m-labelled Affibody Molecule-based Tracer 99mTc-ZHER2:41071.,COMPLETED,PHASE1,Tomsk National Research Medical Center of the Russian Academy of Sciences,2021-12-22,2023-03-01,2023-03-01,2022-01-24,2023-04-21,"['Gamma camera-based whole-body 99mTc-ZHER2:41071 uptake value (% per organ)', 'SPECT/CT-based 99mTc-ZHER2:41071 uptake value in tumor lesions (kcounts)/SUV', 'SPECT-based 99mTc-ZHER2:41071 background uptake value (kcounts)/SUV', 'Tumor-to-background ratio (SPECT)']","['Safety attributable to 99mTc-ZHER2:41071 injections (physical examination)', 'Safety attributable to 99mTc-ZHER2:41071 injections (vital signs)', 'Safety attributable to 99mTc-ZHER2:41071 injections (ECG )', 'Safety attributable to 99mTc-ZHER2:41071 injections (blood laboratory tests)', 'Safety attributable to 99mTc-ZHER2:41071 injections (urine laboratory tests)', 'Safety attributable to 99mTc-ZHER2:41071 injections (incidence and severity of adverse events)', 'Safety attributable 99mTc-ZHER2:41071 injections (concomitant medication)']",,,,,1,Russia,"TomskNRMC [Tomsk, Russia]",2021.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes the use of a new tracer (99mTc-ZHER2:41071) for molecular imaging of HER2 expression in breast cancer, indicating it is a new medicine.",OTHER,False,2023.0,2.0,0,Phase 1
NCT05219578,RTX-224 Monotherapy in Patients With Solid Tumors,A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors,TERMINATED,PHASE1; PHASE2,Rubius Therapeutics,2022-01-12,2022-11-30,2022-11-30,2022-02-02,2022-12-09,"['Safety Assessment by rate of Adverse Events (AEs)', 'Dose limiting toxicities (DLTs) of RTX-224']","['Pharmacodynamics (PD) of RTX-224', 'Pharmacokinetics (PK) of RTX-224', 'Pharmacokinetics (PK) of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224']",,,,,5,United States,"HonorHealth [Scottsdale, United States] | USC Norris Comprehensive Cancer Center [Los Angeles, United States] | University of California San Francisco Health [San Francisco, United States] | Sarah Cannon Research Institute [Nashville, United States] | Virginia Cancer Specialists [Fairfax, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT05227261,Early Detection of Five Common Cancers Using the ctDNA Analysing Test,Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA,COMPLETED,,Gene Solutions,2022-04-10,2023-04-10,2024-04-10,2022-02-07,2025-02-18,"['Positive predictive value, Negative predictive value of the blood ctDNA test in early detecting cancers', 'Sensitivity and specificity of the test in early detecting cancers']","['Positive predictive value of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests', 'Rate of cancer development in the high-risk group as compared to the moderate-risk population']",,,,,1,Vietnam,"Hanoi medical university [Hanoi, Vietnam]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,NA/Other
NCT05252390,NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,TERMINATED,PHASE1; PHASE2,Nuvation Bio Inc.,2022-03-29,2024-07-15,2024-07-15,2022-02-23,2025-03-12,"['Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D)', 'Phase 1b Dose Escalation, NUV-868 + Olaparib: Safety and tolerability of NUV-868 in combination with olaparib to determine the recommended Phase 2 combination dose (RP2cD)', 'Phase 1b Dose Escalation, NUV-868 + Olaparib: Pharmacokinetic (PK) profiles of NUV-868 and olaparib when administered in combination', 'Phase 1b Dose Escalation, NUV-868 + Enzalutamide: Safety and tolerability of NUV-868 in combination with enzalutamide to determine the RP2cD', 'Phase 1b Dose Escalation, NUV-868 + Enzalutamide: Pharmacokinetic (PK) profiles of NUV-868 and enzalutamide when administered in combination', 'Phase 2, NUV-868 + Olaparib: Change from Baseline in Tumor Imaging', 'Phase 2, NUV-868 + Olaparib: Change from Baseline in PSA measurements', 'Phase 2, NUV-868 + Enzalutamide in Enzalutamide-Naïve Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Time from First Dose to Disease Progression', 'Phase 2, NUV-868 + Enzalutamide in Enzalutamide-Resistant mCRPC: Response to Study Treatment', 'Phase 1b Food Effect Substudy: Effect of Food on the Pharmacokinetics (PK) of NUV-868']",[],,,,,22,Australia; United States,"The University of Arizona Cancer Center [Tucson, United States] | Ellison Institute of Technology [Los Angeles, United States] | Rocky Mountain Cancer Centers, LLP [Aurora, United States] | Rocky Mountain Cancer Centers, LLP [Lone Tree, United States] | H. Lee Moffitt Cancer Center [Tampa, United States] | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins [Baltimore, United States] | Massachusetts General Hospital [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Laura & Isaac Perlmutter Cancer Center - NYU Langone Health [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Carolina BioOncology Institute [Huntersville, United States] | Fox Chase Cancer Center [Philadelphia, United States] | Sarah Cannon Research Institute - Tennessee Oncology [Nashville, United States] | Mary Crowley Cancer Research [Dallas, United States] | Texas Oncology - Fort Worth Cancer Center [Fort Worth, United States] | NEXT Virginia [Fairfax, United States] | Virginia Oncology Associates [Norfolk, United States] | Macquarie University Hospital [North Ryde, Australia] | Calvary Mater Hospital Newcastle [Waratah, Australia] | Cabrini Hospital Malvern [Malvern, Australia] | Peter Maccallum Cancer Centre [Melbourne, Australia] | Linear Clinical Research [Nedlands, Australia]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT05253053,To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,"A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor",COMPLETED,PHASE1; PHASE2,"TransThera Sciences (Nanjing), Inc.",2022-04-13,2024-08-31,2024-08-31,2022-02-23,2025-06-12,"['Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment', 'Dose limiting toxicity (DLT)']","['Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Objective Response (DOR)', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Area under the curve (AUC0-∞)', 'Area under the curve (AUC0-t)', 'Maximum observed concentration (Cmax)', 'Half-life (T1/2)', 'Time to Maximum Concentration (Tmax)', 'Volume of Distribution']",,,,,9,China,"The First Affiliated Hospital of Wannan Medical College [Wuhu, China] | Henan Cancer Hospital [Zhengzhou, China] | Hunan Cancer Hospital [Changsha, China] | Nanjing Drum Tower Hospital [Nanjing, China] | Jilin Cancer Hospital [Changchun, China] | Shandong Cancer Hospital [Jinan, China] | Beijing Cancer Hospital [Beijing, China] | Peking University Third Hospital [Beijing, China] | Fudan Univisity Shanghai Cancer Center [Shanghai, China]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating TT-00420 (Tinengotinib) as a new treatment for patients with advanced solid tumors, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT05261269,A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer,A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer,COMPLETED,PHASE1,"Dantari, Inc.",2022-02-02,2023-09-13,2023-10-11,2022-03-02,2023-12-13,"['Incidence and nature of Dose Limiting Toxicities (DLTs)', 'Incidence, nature, and severity of adverse events graded according to NCI CTCAE v5.0', 'Total exposure (area under the curve) from time 0 to the last measurable concentration (AUC0-last)', 'Maximum observed plasma concentration (Cmax)', 'Minimum observed plasma concentration (Cmin through concentration)', 'Terminal half-life (t1/2)', 'Clearance rate', 'Volume of distribution']","['Objective response per RECIST v1.1, defined as the proportion of patients having a best overall response (BOR) of complete response (CR) or partial response (PR), as determined by Investigator review.', 'Progression-free survival per RECIST v1.1, defined as the time from randomization to documented disease progression or death from any cause, whichever occurs earlier as determined by Investigator review.', 'Disease control rate (DCR) per RECIST v1.1, defined as best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by Investigator review.', 'Clinical benefit rate (CBR) per RECIST v1.1, defined as the proportion of patients having a BOR of SD ≥ 6 months, PR or CR as determined by Investigator review.', 'Duration of response, defined as the time from first occurrence of a documented objective response until the time of disease progression, as determined by Investigator review with use of RECIST v1.1, or death from any cause during the study.']",,,,,9,United States,"UC San Diego Moores Cancer Center [La Jolla, United States] | UCLA - Parkside Cancer Center [Santa Monica, United States] | H Lee Moffitt Cancer Center and Research Institute [Tampa, United States] | University of Michigan [Ann Arbor, United States] | Saint Luke's Cancer Institute [Jackson, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | The University of Oklahoma Health Sciences Center [Oklahoma City, United States] | Magee Women's Hospital [Pittsburgh, United States] | Sarah Cannon Research Institute/Tennessee Oncology [Nashville, United States]",2022.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on a new drug (DAN-222) being tested for safety and pharmacology in patients with metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05274451,A Study to Investigate LYL797 in Adults With Solid Tumors,"A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies",TERMINATED,PHASE1,"Lyell Immunopharma, Inc.",2022-03-29,2024-11-27,2024-11-27,2022-03-10,2025-07-01,"['Evaluate incidence of dose-limiting toxicities (DLTs)', 'Evaluate incidence of treatment-emergent adverse events (TEAEs)', 'Evaluate severity of treatment-emergent adverse events (TEAEs)', 'Determine recommended Phase 2 Dose (RP2D)']","['Evaluate anti-tumor activity of LYL797 based on overall response rate (ORR) by RECIST, version 1.1', 'Evaluate duration of response (DOR)', 'Evaluate progression-free survival (PFS)', 'Evaluate overall survival (OS)', 'Evaluate maximum concentration of LYL797 (Cmax) of LYL797 in peripheral blood (PB) samples', 'Evaluate time to Cmax (Tmax) of LYL797 in peripheral blood (PB) samples', 'Evaluate area under the concentration-time curve (AUC) of LYL797 in the peripheral blood (PB)', 'Evaluate Persistence of LYL797 CAR T cells in peripheral blood samples']",,,,,18,United States,"Mayo Clinic [Scottsdale, United States] | University of California, Los Angeles [Santa Monica, United States] | Yale New Haven Hospital [New Haven, United States] | Georgetown University [Washington D.C., United States] | Mayo Clinic [Jacksonville, United States] | University of Miami [Miami, United States] | University of Chicago [Chicago, United States] | Karmanos Cancer Institute [Detroit, United States] | Mayo Clinic [Rochester, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Montefiore Medical Center [The Bronx, United States] | University of Oklahoma [Oklahoma City, United States] | Oregon Health and Science University Hospital [Portland, United States] | Sidney Kimmel Cancer Center, Jefferson University Hospital [Philadelphia, United States] | Sarah Cannon Research Institute and Tennessee Oncology [Nashville, United States] | MD Anderson Cancer Center [Houston, United States] | Fred Hutchinson Cancer Research Center [Seattle, United States] | Froedtert Hospital, Medical College of Wisconsin [Milwaukee, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT05283837,"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)","A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel Study to Evaluate the Efficacy and Safety of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) With Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Patients With HER2 Positive Metastatic Breast Cancer",COMPLETED,PHASE3,Zydus Lifesciences Limited,2022-09-26,2023-09-06,2023-09-06,2022-03-17,2024-07-18,['Compare Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at day 127 from baseline'],"['Area under the curve from the time of dosing to the last measurable concentration (AUC0-t)', 'The area under the serum concentration versus time curve from time zero to infinity (AUC0-inf)', 'maximum measured serum concentration observed after a single dose at cycle 1 (Cmax)', 'Time of the maximum measured serum concentration (Tmax)', 'serum trough concentration of ZRC-3277 (Pre-Dose)']",,,,,1,India,"Unique Hospital-Multispeciality & Resesarch Institute [Sūrat, India]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,The trial evaluates a new medicine (ZRC-3277) that is being compared to an existing treatment (Pertuzumab) for a specific patient population (HER2 Positive Metastatic Breast Cancer).,INDUSTRY,False,2023.0,2.0,0,Phase 3
NCT05363605,A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours,"A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours",TERMINATED,PHASE1; PHASE2,Fusion Pharmaceuticals Inc.,2022-04-20,2023-09-08,2023-09-08,2022-05-06,2023-12-19,"['Phase 1: Phase 1: Incidence of AEs to evaluate safety and tolerability of [225Ac]-FPI-1966, [111In]-FPI-1967, and vofatamab.', 'Phase 1: Maximum tolerated dose (MTD) of [225Ac]-FPI-1966', 'Phase 1: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)', 'Phase 1: Effect of pre-dose administration of vofatamab on the radiation dosimetry of [111In]-FPI-1967 and [225Ac]-FPI-1966.', 'Phase 2: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.']","['Phase 1 and 2: Anti-tumour activity of [225Ac]-FPI-1966 regimen measured by response per RECIST v1.1', 'Phase 1 and 2: Tumour uptake of [111In]-FPI-1967 by evaluating SPECT/CT and/or planar images', 'Phase 2: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)', 'Phase 1 and 2: Clearance for radioactivity and for the targeting antibody.', 'Phase 1 and 2: Area under the curve (AUC) for radioactivity and targeting antibody', 'Phase 1 and 2: Maximum concentration after dosing (Cmax) for radioactivity and targeting antibody.', 'Phase 1 and 2: Half-life for radioactivity and targeting antibody.', 'Phase 1: Changes in clearance for radioactivity and targeting antibody following pre-dose administration of vofatamab', 'Phase 1: Changes in AUC for radioactivity and targeting antibody following pre-dose administration of vofatamab.', 'Phase 1: Changes in Cmax for radioactivity and targeting antibody following pre-dose administration of vofatamab.', 'Phase 1: Changes in half-life for radioactivity and targeting antibody following pre-dose administration of vofatamab']",,,,,6,Australia; United States,"City of Hope [Duarte, United States] | University of California, San Francisco [San Francisco, United States] | University of Iowa Hospitals and Clinics [Iowa City, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | GC Murdoch [Murdoch, Australia] | St Vincent's Hospital [Melbourne, Australia]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,1,Phase 2
NCT05364255,"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833","A Phase I, Open-Label, Single-Dose, Single-Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 After Oral Administration in Healthy Post-Menopausal Female Subjects",COMPLETED,PHASE1,AstraZeneca,2022-05-10,2022-06-20,2022-06-20,2022-05-06,2024-06-21,"['The cumulative amount of AZD9833 excreted (CumAe)', 'The cumulative amount of AZD9833 excreted, expressed as a percentage of the radioactive dose administered (Cum%Ae)', 'Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry', 'Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry', 'Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry']","['The amount of total radioactivity eliminated in urine (Ae)', 'The amount of total radioactivity eliminated in urine expressed as a percentage of the radioactive dose administered (%Ae)', 'The cumulative amount of AZD9833 excreted in urine (CumAe)', 'The cumulative amount of AZD9833 excreted in urine, expressed as a percentage of the radioactive dose administered (Cum%Ae)', 'The amount of total radioactivity eliminated in faeces (Ae)', 'The amount of total radioactivity eliminated in faeces expressed as a percentage of the radioactive dose administered (%Ae)', 'The cumulative amount of AZD9833 excreted in faeces (CumAe)', 'The cumulative amount of AZD9833 excreted in faeces, expressed as a percentage of the radioactive dose administered (Cum%Ae)', 'Time to maximum concentration (tmax) for AZD9833 and total radioactivity', 'Maximum observed concentration (cmax) for AZD9833 and total radioactivity', 'Area under the curve from time 0 to the time of last measurable concentration for AZD9833 and total radioactivity (AUC0-t)', 'Area under the curve from time 0 extrapolated to infinity for AZD9833 and total radioactivity (AUC0-inf)', 'Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC%extr) and total radioactivity', 'Terminal elimination half-life for AZD9833 (t1/2) and total radioactivity', 'First order rate constant associated with the terminal (log-linear) portion of the curve for AZD9833 (λz) and total radioactivity', 'Total body clearance calculated after a single extravascular administration for AZD9833 (CL/F) and total radioactivity', 'Apparent volume of distribution based on the terminal phase for AZD9833 (Vz/F) and total radioactivity', 'Renal clearance for AZD9833 (CLr) and total radioactivity', 'Evaluation of whole blood:plasma concentration ratios for total radioactivity', ""Number of AE's experienced by subjects""]",,,,,1,United Kingdom,"Research Site [Ruddington, United Kingdom]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT05376527,Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact,Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact in Patients With Recurrent/Refractory Metastatic Breast Cancer With Single and Multiple Administration,COMPLETED,PHASE1,"""Oncostar"" LLC",2022-05-11,2025-02-27,2025-02-27,2022-05-17,2025-03-24,"['Frequency, nature, intensity and duration of adverse events related with the use of the study drug', 'Degree of severity, duration, reversibility of dose-limiting toxicity']",['Determination of virus concentrations in blood'],,,,,1,Russia,"N.N. Petrov National Medical Research Center of Oncology [Saint Petersburg, Russia]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a study of a new drug based on a recombinant virus for treating metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT05383170,A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers,"A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC) (CATALYST)",COMPLETED,PHASE1; PHASE2,Cytovation AS,2023-03-21,2024-09-23,2024-09-23,2022-05-20,2024-09-27,"['Incidence, frequency, and seriousness of TEAEs', 'Incidence of DLTs', 'ORR based on radiological assessment according to the RECIST v1.1']","['PFS', 'OS']",,,,,25,France; Italy; Netherlands; Spain; United States,"University of Alabama at Birmingham [Birmingham, United States] | City Of Hope [Duarte, United States] | Henry Ford Health System [Detroit, United States] | University of Pittsburgh Medical Center [Pittsburgh, United States] | Texas Oncology - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Houston Methodist [Houston, United States] | CHRU de Besançon [Besançon, France] | Institut Bergonie [Bordeaux, France] | CHU Lille [Lille, France] | Centre Leon Berard [Lyon, France] | AP-HM - Hôpital de la Timone [Marseille, France] | Institut Paoli Calmettes [Marseille, France] | Hôpital Saint Louis - AP-HP [Paris, France] | Institute Gustave Roussy [Villejuif, France] | Istituto Europeo di Oncologia [Milan, Italy] | Azienda Ospedaliero Universitaria Senese [Siena, Italy] | NKI/AvL [Amsterdam, Netherlands] | Maastricht UMC [Maastricht, Netherlands] | EMC [Rotterdam, Netherlands] | Vall d'Hebron (VHIO) [Barcelona, Spain] | Clinica Universidad de Navarra Madrid [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Universitario HM Sanchinarro [Madrid, Spain] | Clinica Universidad de Navarra Pamplona [Pamplona, Spain] | Hospital Universitario Virgen Macarena [Seville, Spain]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial evaluates CyPep-1, which appears to be a new treatment being tested in combination with Pembrolizumab for advanced or metastatic cancers, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT05384119,Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer,TERMINATED,PHASE1,"Tvardi Therapeutics, Incorporated",2023-01-09,2024-04-25,2024-04-25,2022-05-20,2025-02-21,"['Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)', 'Phase 1b: Number of Participants Who Experience an Adverse Event (AE)', 'Phase 1b: Number of Participants Who Experience a Serious Adverse Event (SAE)', 'Phase 2: Landmark Progression Free Sulrvival at 6 Months (PFS6)']","['Phase 1b: PFS6', 'Phase 1b and Phase 2: Clinical Benefit Rate (CBR)', 'Phase 1b and Phase 2: Overall Response Rate (ORR)', 'Phase 1b and Phase 2: Overall Response Rate (ORR)', 'Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of TTI-101', 'Phase 1b and Phase 2: Time of Maximum Observed Plasma Concentration (Tmax) of TTI-101', 'Phase 1b and Phase 2: Area Under the Plasma Concentration-time Curve from Time 0 to Time t (AUC[0-t]) of TTI-101', 'Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 1 (pY-STAT1) Positive Cells in Tumor Biopsy Samples', 'Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 3 (pY-STAT3) Positive Cells in Tumor Biopsy Samples', 'Phase 1b and Phase 2: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples', 'Phase 1b and Phase 2: Duration of Response (DoR) to Treatment', 'Phase 1b and Phase 2: Time to Tumor Progression (TTP)', 'Phase 1b and Phase 2: Best Overall Response (BOR)', 'Phase 2: Progression-free Survival (PFS)']",,,,,6,United States,"Holy Cross Health Fort Lauderdale - Holy Cross Hospital [Fort Lauderdale, United States] | Washington University School of Medicine Siteman Cancer Center [St Louis, United States] | Vanderbilt - Ingram Cancer Center [Nashville, United States] | Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Harold C. Simmons Comprehensive Cancer Center [Dallas, United States] | University of Texas MD Anderson Cancer Center [Houston, United States]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves TTI-101, which is a STAT3 inhibitor being tested in combination with existing therapies for a specific type of breast cancer, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT05388435,"Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients","A Phase 1/2, Open-Label, Multicenter, Dose-Finding Study of SKL27969 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Advanced Solid Tumors",TERMINATED,PHASE1; PHASE2,"SK Life Science, Inc.",2022-09-12,2024-03-01,2024-03-01,2022-05-24,2025-05-04,"['Part 1 (Dose Escalation Phase) - Numbers of participants with adverse events, dose interruptions and modifications', 'Part 1 (Dose Escalation Phase) - Number of participants with dose limiting toxicities', 'Part 1 (Dose Escalation Phase) - Number of participants with abnormal assessments', 'Part 2 (Dose Expansion Phase) - Number of participants with partial response data', 'Part 2 (Dose Expansion Phase) - Number of participants with progression-free survival', 'Part 2 (Dose Expansion Phase) - Number of participants with overall survival']","['Part 1 (Dose Escalation Phase) - Number of participants with partial response data', 'Part 2 (Dose Expansion Phase) - Number of participants with adverse events, dose interruptions and modifications', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 2 (Dose Expansion Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969', 'Part 1 (Dose Escalation Phase) - Pharmacokinetics of SKL27969']",,,,,4,United States,"City of Hope [Duarte, United States] | START Midwest [Grand Rapids, United States] | Carolina BioOncology Institute [Huntersville, United States] | MD Anderson Cancer Center [Houston, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating SKL27969, which is a new drug being tested in patients with advanced solid tumors, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT05390710,PhI to Solid Tumors and PhII to Locally Advanced or mTNBC,A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC,COMPLETED,PHASE1,Laekna Limited,2021-06-12,2023-12-11,2023-12-11,2022-05-25,2024-10-10,"['To evaluate the safety.', 'recommended Phase II dose (RP2D) of LAE005 and afuresertib and nab-paclitaxel as a combination treatment in patients with advanced solid tumours (including mTNBC)', 'To evaluate the tolerability.', 'To determine the maximum tolerated dose (MTD)']","['To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via DCR', 'To characterize the AUC0-t of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel.', 'To characterize the AUC0-inf of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel.', 'To characterize the Tmax of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel.', 'To characterize the T1/2 of LAE005 and afuresertib in patients receiving combination treatment of LAE005 and afuresertib and nab-paclitaxel.', 'To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via BOR', 'To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via DOR', 'To assess the preliminary anti-tumor activity of LAE005 and afuresertib and nab-paclitaxel via PFS']",,,,,5,China,"The first affiliated hopsital of bengbu medical college [Bengbu, China] | Cancer Hospital Chinese Academy of Medical Sciences [Beijing, China] | Sun Yat-sen Memorial Hospital [Guangzhou, China] | Sir RunRun Shaw Hospital Zhejiang University School of Medicine [Hangzhou, China] | Tianjin Medical University Cancer Institute & Hospital [Tianjin, China]",2021.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves LAE005, which is being evaluated in combination with other agents for advanced solid tumors, indicating it is a new medicine being tested for efficacy and safety.",INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05395052,FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors,"A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,Fate Therapeutics,2022-05-31,2023-08-11,2023-08-11,2022-05-27,2023-09-21,"['Determine the Recommended Phase 2 Dose (RP2D)', 'Number of Participants with ≥ Adverse Event (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0']",[],,,,,5,United States,"Honor Health Research Institute [Scottsdale, United States] | UCLA Division of Hematology-Oncology [Los Angeles, United States] | Hackensack University Medical Center - John Theurer Cancer Center [Hackensack, United States] | Carolina BioOncology Institute [Huntersville, United States] | NEXT Oncology [San Antonio, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05395117,"A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin","A Fixed Sequence, Open-label Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Probe), Rosuvastatin (OATP1B1/3, BCRP Probe), and Digoxin (P-gp Probe) in Healthy Participants",COMPLETED,PHASE1,AstraZeneca,2022-06-30,2022-09-12,2022-09-12,2022-05-27,2023-12-13,"['Area under the concentration-versus-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf)', 'Area under the concentration-versus-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast)', 'Maximum observed serum (peak) drug concentration [Cmax]']","['Time to reach peak or maximum observed concentration or response following drug administration (tmax)', 'Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz)', 'Partial area under the serum concentration time curve from time 0 to time 12 (AUC0-12h)', 'Maximum observed serum (peak) drug concentration [Cmax]', 'Time to reach peak or maximum observed concentration or response following drug administration (tmax)', 'Trough plasma exposure of AZD5462 (Ctrough)', 'Incidence of Adverse Events (AEs)']",,,,,1,United States,"Research Site [Brooklyn, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a study involving AZD5462, which suggests it is a new medicine being assessed for its pharmacokinetic interactions with other drugs.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT05435911,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil Compared to Propofol-based Total Intravenous Anesthesia in Patients Undergoing Breast Cancer Surgery: a Randomized Controlled Trial,COMPLETED,,Seoul National University Hospital,2022-08-02,2022-12-21,2022-12-21,2022-06-28,2023-01-13,['Time to eye opening (minute)'],"['Time to emergence (minutes)', 'Bispectral index score (Score)', 'Incidence of emergence agitation at operating room (n(%))', 'The modified Aldrete score (Score)', 'The modified Observers Assessment of Alertness/Sedation Scale (Score)', 'Postoperative Pain (score)', 'Postoperative opioid consumption (The number of analgesic use)', 'Postoperative nausea and vomiting (The incidence of PONV, n(%))', 'Postoperative quality of recovery (score)', 'Postoperative opioid consumption (The number of analgesic use)', 'Postoperative Pain (score)']",,,,,1,South Korea,"Department of Anesthesiology and Pain Medicine, Seoul National University Hospital [Seoul, South Korea]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial compares the effects of Remimazolam, which is a new medicine, against Flumazenil and Propofol in a specific surgical context.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05438303,"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers","A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran Etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers",COMPLETED,PHASE1,AstraZeneca,2022-06-13,2022-12-13,2022-12-13,2022-06-29,2023-01-12,"['Area under plasma concentration time curve from zero to infinity (AUCinf) of midazolam, omeprazole, total dabigatran, and celecoxib', 'Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) of midazolam, omeprazole, total dabigatran, and celecoxib', 'Maximum observed plasma concentration (Cmax) of midazolam, omeprazole, dabigatran etexilate and celecoxib']","['Number of participants with Adverse Events (AEs)', 'AUCinf for AZD9833 and free dabigatran', 'AUClast for AZD9833 and free dabigatran', 'Area under plasma concentration-time curve in the dose interval (AUCt) for AZD9833 and free dabigatran', 'Cmax for AZD9833 and free dabigatran', 'Time to reach maximum observed concentration (tmax) for AZD9833 and free dabigatran', 'Half-life associated with terminal slope of a semi-logarithmic concentration-time curve (t½λz) for AZD9833 and free dabigatran', 'Apparent total body clearance from plasma after extravascular administration (CL/F) for AZD9833 and free dabigatran', 'Apparent volume of distribution based on terminal phase (Vz/F) for AZD9833 and free dabigatran', 'tmax for midazolam, omeprazole, total dabigatran, and celecoxib', 't½λz for midazolam, omeprazole, total dabigatran, and celecoxib', 'CL/F for midazolam, omeprazole, total dabigatran, and celecoxib', 'Vz/F for midazolam, omeprazole, total dabigatran, and celecoxib', 'Area under the plasma concentration-curve from zero to 24 hours post dose (AUC0-24) for celecoxib']",,,,,2,United States,"Research Site [Long Beach, United States] | Research Site [Berlin, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT05454943,Remote Time-restricted EAting DeliverY,Proof-of-Concept of Time-Restricted Eating as a Novel Lifestyle Intervention for Breast Cancer Prevention,COMPLETED,,University of Toronto,2022-07-07,2023-09-20,2024-01-30,2022-07-12,2025-10-01,"['Adherence to TRE for the 16-week intervention', 'Hemoglobin A1c']","['HOMA-IR', 'Free-living glucose control', 'C-Reactive Protein', 'Lipid profile', 'Body weight', 'Waist circumference', 'Blood Pressure', '10-year cardiovascular disease risk', 'Metabolic syndrome (NCEP/ATP III criteria)', 'Metabolic syndrome z-score', 'Alanine Aminotransferase', 'TRE acceptability and appropriateness', 'TRE Adoption', 'Cost of intervention delivery', 'TRE Sustainability', 'TRE Adverse Events', 'Health-related quality of life', 'Sleep duration', 'Sedentary time', 'Physical activity']",,,,,1,Canada,"Remote Ontario-wide [Toronto, Canada]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2024.0,1.0,0,NA/Other
NCT05489679,A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer",TERMINATED,PHASE1,Accutar Biotechnology Inc,2022-10-01,2023-09-28,2023-09-28,2022-08-05,2024-01-25,"['Incidence of dose limiting toxicities (DLTs) from AC682 monotherapy', 'Incidence of treatment emergent adverse events(TEAEs) from AC682 monotherapy']","['To determine the PK of AC682 after a single dose or multiple doses:', 'To determine the PK of AC682 after a single dose or multiple doses:', 'To determine the PK of AC682 after a single dose or multiple doses:', 'To determine the PK of AC682 after a single dose or multiple doses:', 'To determine the PK of AC682 after a single dose or multiple doses:', 'To evaluate the preliminary anti-tumor activity of AC682:', 'To evaluate the preliminary anti-tumor activity of AC682:', 'To evaluate the preliminary anti-tumor activity of AC682:', 'To evaluate the preliminary anti-tumor activity of AC682:', 'To evaluate the preliminary anti-tumor activity of AC682:']",,,,,3,China,"Site 1001 [Beijing, China] | Site 1003 [Hangzhou, China] | Site 1002 [Tianjin, China]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05500508,Oral AMXT 1501 Dicaprate in Combination With IV DFMO,"A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer",TERMINATED,PHASE1; PHASE2,"Aminex Therapeutics, Inc.",2022-11-29,2024-12-12,2024-12-12,2022-08-15,2024-12-24,"['Determine DLTs and RP2Ds in AMXT 1501 in combination with IV DFMO', 'Determine safety and tolerability of AMXT1501 in combination with IV DFMO']","['Determine the PK using AUC of AMXT 1501 and IV DFMO', 'Determine the PK using Cmax of AMXT 1501 and IV DFMO', 'Characterize investigator defined response Overall Response Rate (ORR) using RECIST v1.1', 'Characterize investigator defined Duration of Response (DOR)', 'Characterize AMXT1501 and IV DFMO on the expression of immune related gene signatures']",,,,,7,Australia; United States,"Mayo Clinic - Arizona [Phoenix, United States] | Mayo Clinic - Florida [Jacksonville, United States] | Mayo Clinic - Minnesota [Rochester, United States] | Cincinnati Children's Hospital Medical Center [Cincinnati, United States] | MD Anderson Cancer Center [Houston, United States] | Fred Hutch Cancer Center - Seattle Cancer Care Alliance [Seattle, United States] | Kids Cancer Centre [Sydney, Australia]",2022.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[""Duration of Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a new drug (AMXT 1501 Dicaprate) being tested in combination with another drug (DFMO) for safety and efficacy in cancer patients, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT05501769,"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer","A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer",COMPLETED,PHASE1,"Arvinas Estrogen Receptor, Inc.",2022-09-08,2024-07-03,2025-08-25,2022-08-15,2025-09-26,"['Incidence of dose limiting toxicities of ARV-471 in combination with everolimus', 'Recommended Phase 2 Dose (RP2D) for ARV-471 in combination with everolimus', 'Number of participants with adverse events as a measure of safety and tolerability of ARV-471 in combination with everolimus', 'Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471 in combination with everolimus']","['Overall response rate (ORR) in participants', 'Clinical benefit rate (CBR) in participants.', 'Duration of response (DOR) in participants', 'Maximum plasma concentrations (Cmax) of ARV-471 and everolimus', 'Time to maximum plasma concentrations (Tmax) of ARV-471 and everolimus', 'Area under the concentration-time curve over 24 hours at steady state (AUC(0-24)) of ARV-471 and everolimus']",,,,,9,Spain; United States,"Clinical Trial Site [San Diego, United States] | Clinical Trial Site [Santa Monica, United States] | Clinical Trial Site [Washington D.C., United States] | Clinical Trial Site [Lake Mary, United States] | Clinical Trial Site [Ann Arbor, United States] | Clinical Trial Site [Nashville, United States] | Clinical Trial Site [Barcelona, Spain] | Clinical Trial Site [Madrid, Spain] | Clinical Trial Site [Valencia, Spain]",2022.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating ARV-471, which is a new medicine being tested in combination with Everolimus for a specific type of breast cancer.",INDUSTRY,False,2025.0,0.0,1,Phase 1
NCT05511844,Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors,"Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors",TERMINATED,PHASE1,"Orum Therapeutics USA, Inc.",2022-10-03,2025-06-02,2025-06-02,2022-08-23,2025-07-04,"['Determination of Maximum Tolerated Dose (MTD) and Expansion Dose Level (EDL) [Dose Escalation Only]', 'Incidence of Adverse Events (AEs)', 'Define the Objective Response Rate (ORR) of ORM-5029 based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [Dose Expansion Only]', 'Define the Duration of Response (DOR) of ORM-5029 based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [Dose Expansion Only]']","['Assess pharmacokinetic (PK) parameters including area under the concentration versus time curve from time 0 hours to the last quantifiable concentration (AUC0-last) and from time 0 hours to infinity (AUC0-inf)', 'Assess maximum plasma and serum drug concentration (Cmax)', 'Define time to Cmax (Tmax)', 'Access pharmacokinetic (PK) parameters including terminal rate consent and terminal elimination half-life (t1/2)', 'Define Clinical Benefit Rate (CBR) of ORM-5029 based on RECIST 1.1', 'Define Time to Response (TTR) of ORM-5029 based on RECIST 1.1', 'Define Duration of Response (DOR) of ORM-5029 based on RECIST 1.1 [Dose Escalation Only]', 'Assess Progression-free survival (PFS) of ORM-5029 based on RECIST 1.1', 'Assess overall survival (OS)', 'Incidence of anti-drug antibody (ADA) against ORM-5029']",,,,,11,United States,"University of Alabama Birmingham [Birmingham, United States] | University of California - Los Angeles [Los Angeles, United States] | Dana Farber Cancer Institute [Boston, United States] | Washington University [St Louis, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Weill Cornell Medicine-New York [New York, United States] | Sarah Cannon Research Institute at Tennessee Oncology [Nashville, United States] | MD Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States] | NEXT Oncology - Virginia Cancer Specialists [Fairfax, United States] | Fred Hutchinson Cancer Center [Seattle, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a Phase I study of ORM-5029, indicating it is a new medicine being tested in humans for HER2-expressing advanced solid tumors.",INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT05519059,Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer,"A Multicenter, Single-Arm, Open-Label Phase I Clinical Study of Pelareorep With Paclitaxel in Advanced or Metastatic Breast Cancer",COMPLETED,PHASE1,"Adlai Nortye Biopharma Co., Ltd.",2021-10-11,2022-09-29,2023-05-30,2022-08-29,2023-11-22,['Number of participants with Dose Limiting Toxicities (DLTs)'],"['Objective response rate (ORR)', 'Disease control rate (DCR)', 'Progression-free survival (PFS)', 'Duration of response (DOR)', 'Overall survival (OS)']",,,,,1,China,"Bethune First Hospital of Jilin University [Changchun, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05524454,Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy,Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy (CONFIGURE),COMPLETED,,"Varian, a Siemens Healthineers Company",2023-03-20,2023-08-18,2023-08-18,2022-09-01,2023-09-06,['Image quality'],"['Image suitability for radiation dose calculation', 'Qualitative assessment of novel CBCT images']",,,,,1,Netherlands,"Maastricht Radiation Oncology [Maastricht, Netherlands]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,NA/Other
NCT05538572,A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors,"A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,Prelude Therapeutics,2022-12-27,2024-06-26,2024-06-26,2022-09-14,2024-07-01,"['Dose limiting toxicity (DLT) of PRT3645', 'Safety and tolerability of PRT3645: AEs, CTCAE Assessments', 'Maximally tolerated dose (MTD)/Recommended phase 2 dose (RP2D) of PRT3645']","['Efficacy of PRT3645: Tumor assessment and responses', 'Pharmacokinetic profile of PRT3645: Minimum and maximum observed plasma concentration', 'Pharmacodynamic effect of PRT3645: Target engagement']",,,,,13,Singapore; United States,"Smilow Cancer Hospital Phase 1 Unit [New Haven, United States] | AdventHealth Medical Group Oncology Research at Celebration [Celebration, United States] | Miami Cancer Institute [Miami, United States] | Florida Cancer Specialists [Sarasota, United States] | Winship Cancer Institute, Emory University [Atlanta, United States] | Laura and Isaac Perlmutter Cancer Center/ NYU Langone Health [New York, United States] | Cleveland Clinic [Cleveland, United States] | Hospital of the University of Pennsylvania [Philadelphia, United States] | Thomas Jefferson University, Sidney Kimmel Cancer Center [Philadelphia, United States] | Tennessee Oncology, PLLC [Nashville, United States] | South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States] | NEXT Virginia [Fairfax, United States] | National Cancer Centre Singapore [Singapore, Singapore]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT05555251,BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors,"Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors",TERMINATED,PHASE1; PHASE2,BioInvent International AB,2022-07-28,2024-02-07,2024-02-07,2022-09-26,2024-12-16,"['Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumab', 'Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab.']","['Assessment of the pharmacokinetic (PK) profile of BI-1607 when administered every 3 weeks in combination with trastuzumab', 'Assessment of the immunogenicity of BI-1607 when administered in combination with trastuzumab', 'Assessment of the CD32b receptor occupancy (RO) of BI-1607 on B cells when administered in combination with trastuzumab', 'Assessment of the possible antitumor activity of BI-1607 in combination with trastuzumab']",,,,,6,Germany; Spain; United Kingdom,"Evang. Kliniken Essen-Mitte [Essen, Germany] | Krankenhaus Nordwest [Frankfurt, Germany] | Hospital Vall d'Hebron [Barcelona, Spain] | Complejo hospitalario Ruber Juan Bravo [Madrid, Spain] | Churchill Hospital [Oxford, United Kingdom] | Southampton General Hospital [Southampton, United Kingdom]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT05555706,Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer,A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE2; PHASE3,"Shanghai Jiaolian Drug Research and Development Co., Ltd",2022-12-06,2024-09-30,2024-09-30,2022-09-27,2025-04-15,"['Objective response rate (ORR)(phase Ⅱ)', 'Progression-free survival (PFS)(IRC) (phase Ⅲ)']","['Disease control rate (DCR)', 'Duration of remission (DOR)', 'Time to Response (TTR)', 'Overall Survival (OS)', 'Drug concentration in plasma', 'Incidence of Treatment-Emergent Adverse Events']",,,,,13,China,"Affiliated Cancer Hospital, Sun Yat-sen University [Guangzhou, China] | Guangxi Medical University Cancer Hospital [Nanning, China] | Hainan cancer Hospital [Haikou, China] | The First Affiliated Hospital of henan University of Science and Technoloy [Luoyang, China] | Xiangyang Central Hospital [Xiangyang, China] | The Central Hospital of Yongzhou [Yongzhou, China] | Huai'an First People's Hospital [Huai'an, China] | Sichuan Cancer Hospital [Chengdu, China] | The second people's hospital of neijiang [Neijiang, China] | Yunnan Cancer Hospital [Kunming, China] | Zhejiang Cancer Hospital [Hangzhou, China] | Peking University Cancer Hospital [Beijing, China] | Tianjin medical university cancer institute&hospital [Tianjin, China]",2022.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves the evaluation of B013, which is a new treatment being tested in combination with Nab-Paclitaxel for a specific type of breast cancer, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 3
NCT05576077,A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors,A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING),TERMINATED,PHASE1,"Turnstone Biologics, Corp.",2023-01-17,2025-02-04,2025-02-24,2022-10-12,2025-03-10,['Safety and tolerability'],"['Proportion of patients with a response (ORR)', 'Estimated Disease Control Rate (DCR)', 'Estimated Duration of Response (DoR)']",,,,,13,Canada; United States,"University of California Irvine [Irvine, United States] | Memorial Healthcare System [Hollywood, United States] | University of Miami [Miami, United States] | Orlando Health [Orlando, United States] | Moffitt Cancer Center [Tampa, United States] | University of Chicago [Chicago, United States] | Norton Cancer Institute [Louisville, United States] | Providence Cancer Institute [Portland, United States] | Allegheny Research Institute [Pittsburgh, United States] | MD Anderson Cancer Center [Houston, United States] | Medical College of Wisconsin [Milwaukee, United States] | Princess Margaret Cancer Centre [Toronto, Canada] | Montreal University Hospital Center [Montreal, Canada]",2023.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[""Duration of Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves TBio-4101, which is a new treatment being tested in combination with Pembrolizumab for advanced solid tumors, indicating it is a new medicine.",INDUSTRY,False,2025.0,0.0,1,Phase 1
NCT05578820,"Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid","An Open Multicenter Study of the Safety, Tolerability, and Pharmacokinetics of Different Doses of Stimotimagene Copolymerplasmid at Patients With Advanced-stage Solid Tumors With Cymeven® (Ganciclovir) Infusions",COMPLETED,PHASE1,Gene Surgery LLC,2022-01-01,2024-04-11,2024-04-11,2022-10-13,2024-07-01,"['Safety (Presence/absence of dose-limiting toxicities (DLTs))', 'Safety (Frequency and severity of adverse events (CTCAE classification))', 'Safety (Number of cases of early termination of participation in the study due to the development of Serious Adverse Events and Other Adverse Events associated with the study therapy)', ""Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' peripheral blood)"", ""Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine)""]",[],,,,,4,Russia,"GBUZ Moscow Clinical Scientific Center named after Loginov MHD [Moscow, Russia] | FSBI N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia [Moscow, Russia] | FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Health of Russia [Moscow, Russia] | National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation [Moscow, Russia]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial investigates a new treatment (Stimotimagene Copolymerplasmid) for patients with advanced-stage solid tumors, indicating it is a New Medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT05585034,"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors","A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors",COMPLETED,PHASE1,"Xencor, Inc.",2022-12-14,2025-05-20,2025-05-20,2022-10-18,2025-08-07,"['Incidence of treatment-emergent adverse events (TEAEs)', 'Incidence of dose-limiting toxicities (DLTs)']","['Measurement of Cmax', 'Measurement of AUCtau', 'Objective Response Rate', 'Progression-free Survival', 'Duration of Response']",,,,,12,United States,"UCLA Hematology/Oncology [Los Angeles, United States] | Sarah Cannon Research Institute at HealthONE [Denver, United States] | Florida Cancer Specialists [Sarasota, United States] | Winship Cancer Institute, Emory University [Atlanta, United States] | Northwestern Memorial Hospital [Chicago, United States] | Columbia University Irvine Medical Center [New York, United States] | University of Cincinnati Medical Center [Cincinnati, United States] | UPMC Hillman Cancer Center [Pittsburgh, United States] | Tennessee Oncology [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | Huntsman Cancer Institute, University of Utah [Salt Lake City, United States] | Froedtert Hospital & The Medical College of Wisconsin [Milwaukee, United States]",2022.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating XmAb®808, which is a new medicine being tested in combination with Pembrolizumab for advanced solid tumors.",INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT05614518,Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT,"A Randomized, Open-Label, Crossover, Controlled, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases of Malignant Tumors Compared With 99mTc⁃MDP-BS±SPECT",COMPLETED,PHASE3,"HTA Co., Ltd.",2021-03-29,2022-06-02,2022-06-02,2022-11-14,2022-11-14,['Assess the sensitivity and specificity of 18F-NaF-PET/CT compared with 99mTc-MDP-BS±SPECT based on subjects.'],"['Number of participants with adverse events as assessed by CTCAE v5.0.', 'Assess the positive and negative predictive value of 18F-NaF-PET/CT compared with 99mTc-MDP-BS±SPECT based on subjects.', 'Assess the sensitivity, specificity, positive and negative predictive value of 18F-NaF-PET/CT compared with 99mTc⁃MDP-BS±SPECT based on lesions.']",,,,,1,China,"Chinese Academy of Medical Sciences Peking Union Medical College Hospital [Beijing, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing the diagnostic performance and safety of 18F-NaF-PET/CT, which indicates it is a new medicine being evaluated for its effectiveness in a specific application (bone metastases).",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT05618613,Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer,"An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)",TERMINATED,PHASE1; PHASE2,Context Therapeutics Inc.,2022-12-02,2023-06-23,2023-06-23,2022-11-16,2025-05-09,"['Determine the recommended Phase 2 dose (RP2D) of the combination of onapristone and elacestrant (Phase 1).', 'Evaluate the efficacy of elacestrant in combination with onapristone in terms of objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 (Phase 2).']","['Characterize the AEs of elacestrant in combination with onapristone.', 'Characterize the serious adverse events (SAEs) of elacestrant in combination with onapristone.', 'Characterize the safety in terms of changes in clinical laboratory values of elacestrant in combination with onapristone.', 'Characterize the safety in terms of changes in vital sign measurements of elacestrant in combination with onapristone.', 'Characterize the safety in terms of changes in ECG parameters of elacestrant in combination with onapristone.', 'Evaluate the area under the plasma concentration-time curve over the dosing interval of elacestrant as well as onapristone and their metabolites (Phase 1).', 'Evaluate the maximum plasma concentration (Cmax) of elacestrant as well as onapristone and their metabolites (Phase 1).', 'Evaluate the time of the maximum observed plasma concentration (Tmax) of elacestrant as well as onapristone and their metabolites (Phase 1).', 'Evaluate the trough concentration of elacestrant as well as onapristone and their metabolites (Phase 1).', 'Evaluate duration of response.', 'Evaluate clinical benefit rate.', 'Evaluate progression-free survival.', 'Evaluate overall survival.']",,,,,3,United States,"Cancer Treatment Centers of America - Western Regional Medical Center [Phoenix, United States] | Cancer Treatment Centers of America - Midwestern Regional Center [Zion, United States] | Sarah Cannon Research Institute [Nashville, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 2
NCT05623488,CAR T Cells in Mesothelin-Expressing Breast Cancer,"Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer",TERMINATED,PHASE1,University of Pennsylvania,2023-02-06,2025-04-07,2025-04-07,2022-11-21,2025-08-12,"['Occurrence of treatment-limiting toxicities (TLTs)', 'Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0.']","['Proportion of manufacturing product that do not meet the release criteria.', 'Proportion of the products that meet the target dose.', 'Proportion of enrolled subjects that receive study treatment.', 'Proportion of eligible subjects that receive study treatment', 'Proportion of subjects for which standard of care treatment is not impacted due to CAR T cell related toxicity.', 'Kinetics of expansion and persistence of infused cells by flow cytometry.', 'Kinetics of expansion and persistence of infused cells by quantitative PCR.']",,,,,1,United States,"University of Pennsylvania [Philadelphia, United States]",2023.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves CAR T cells, which are a new type of therapy being tested in a specific cancer type (mesothelin-expressing breast cancer), indicating it is a new medicine.",OTHER,False,2025.0,0.0,0,Phase 1
NCT05629949,"A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer","A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer",COMPLETED,PHASE3,"Qilu Pharmaceutical Co., Ltd.",2020-04-29,2022-12-31,2023-04-13,2022-11-29,2024-04-23,['ORR at Week 24 by IRC'],"['ORR at Week 24 by Investigator', 'PFS up to 12 months', 'DoR', 'DCR', 'Overall survival at 12 months']",,,,,1,China,"Cancer Hospital,Chinese Academy of Medical Sciences [Beijing, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating QL1701, which appears to be a new treatment regimen in combination with Docetaxel for HER2-positive metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,Phase 3
NCT05650086,Novel Thermal Imaging Technique for Breast Screening,A Phase II Study to Evaluate Accuracy of ThermalytixTM in Detecting Breast Cancer,TERMINATED,,University of Arizona,2022-11-15,2023-06-30,2023-06-30,2022-12-14,2024-09-27,['Sensitivity and specificity of ThermalytixTM in detecting breast cancer'],"['Sensitivity and specificity of ThermalytixTM in assessing need for biopsy', 'Correlate normal screening mammogram results with ThermalytixTM results', 'Correlate diagnostic mammogram results with ThermalytixTM results', 'Correlate mammogram results with ThermalytixTM results in patients who underwent lumpectomy', 'Report patient experience with ThermalytixTM']",,,,,1,United States,"University of Arizona Cancer Center [Tucson, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2023.0,2.0,0,NA/Other
NCT05708144,NIR Fluorescent Molecular Probe for the Identification of Breast Tissue,Study of a Novel Near-infrared(NIR) Fluorescent Molecular Probe Targeting Trop-2 for the Identification of Benign and Malignant Breast Tissue,COMPLETED,,Xiang'an Hospital of Xiamen University,2023-02-17,2023-10-30,2023-10-30,2023-02-01,2024-01-02,"['Expression of the trop-2 in the tumor', 'Uptake of the dye by the tumor', 'False positive rates of ICG-SG']",['Incidence rates of all adverse events (AEs)'],,,,,1,China,"Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine [Xiamen, China]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2023.0,2.0,0,NA/Other
NCT05708573,Potential Drug Interaction Between ALXN2040 and Rosuvastatin,A Phase 1 Study to Evaluate the Potential Drug Interaction Between ALXN2040 and Rosuvastatin in Healthy Adult Participants,COMPLETED,PHASE1,"Alexion Pharmaceuticals, Inc.",2023-02-01,2023-03-23,2023-04-05,2023-02-01,2023-04-14,"['Maximum observed plasma drug concentration during a dosing interval (Cmax) of rosuvastatin', 'Area under the concentration-time curve from time zero to the time of the last observed/measured nonzero concentration (AUC0-last) of rosuvastatin', 'Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of rosuvastatin', 'Time to reach Cmax (tmax) of rosuvastatin', 'First-order rate constant of drug associated with the terminal portion of the curve (λz) of rosuvastatin', 'Percentage of AUC0-inf due to extrapolation from time of last quantifiable concentration to infinity (AUC%extrap) of rosuvastatin', 'Apparent volume of distribution during the terminal elimination phase after extravascular administration (Vd/F) of rosuvastatin', 'Apparent total plasma clearance after extravascular administration (CL/F) of rosuvastatin', 'Cmax of ALXN2040', 'tmax of ALXN2040', 'Area under the concentration-time curve from time zero to 8 hours postdose (AUC0-8) of ALXN2040']",['Number of participants with adverse events (AEs)'],,,,,1,United States,"Clinical Trial Site [Baltimore, United States]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2023.0,2.0,0,Phase 1
NCT05712889,Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer,"An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer",COMPLETED,PHASE1,"Vincerx Pharma, Inc.",2023-01-24,2024-10-10,2024-10-10,2023-02-06,2024-11-15,"['Incidence of DLT (Dose limit toxicity) of VIP236', 'Number of participants with adverse events as a measure safety and tolerability']","['Objective response rate (ORR), defined as the proportions of subjects who have a best overall response of partial response (PR) or complete response (CR) as determined by investigators using RECIST 1.1', 'Disease control rate (DCR) per RECIST v1.1, defined as best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by Investigator review.', 'Progression-free survival per RECIST v1.1, defined as the time from enrollment to documented disease progression or death from any cause, whichever occurs earlier as determined by Investigator review', 'Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP236', 'Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP236']",,,,,6,Australia; United States,"Honor Health [Scottsdale, United States] | NEXT Austin [Austin, United States] | NEXT Oncology San Antonio [San Antonio, United States] | Macquarie University [Macquarie Park, Australia] | ICON Brisbane [Brisbane, Australia] | ICON Adelaide [Adelaide, Australia]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,1,Phase 1
NCT05716295,A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors,"A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)",TERMINATED,PHASE1; PHASE2,"Medikine, Inc.",2023-02-08,2024-04-30,2024-04-30,2023-02-08,2024-05-08,"['Dose Limiting Toxicities (DLT)', 'Maximum tolerated dose (MTD)', 'Optimal biological dose (OBD)', 'Recommended dose (RD)', 'Adverse events (AE)']","['Objective Response Rate (ORR)', 'Duration of Response (DOR)', 'Time to Response (TTR)', 'Disease Control Rate (DCR)', 'Progression-Free Survival (PFS)', 'Overall Survival (OS)', 'Blood concentration of MDK-703', 'Time to achieve maximum blood concentration']",,,,,6,United States,"Sarah Cannon Research Institute (Florida Cancer Specialists) [Sarasota, United States] | Carolina BioOncology Institute [Huntersville, United States] | NEXT Oncology Austin [Austin, United States] | Mary Crowley Cancer Research [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | NEXT Oncology Virginia [Fairfax, United States]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a study of MDK-703, which is being tested as a new treatment for patients with advanced or metastatic solid tumors, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT05732428,"A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China","A PHASE 1, OPEN LABEL STUDY EVALUATING THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ARV-471 (PF-07850327) AS A SINGLE AGENT IN CHINESE PARTICIPANTS WITH ER+/HER2- ADVANCED BREAST CANCER",COMPLETED,PHASE1,Pfizer,2023-02-20,2024-03-29,2024-11-01,2023-02-17,2025-01-27,"['Single dose Cmax (Maximum plasma concentration)', 'Single dose AUCtau', 'Multiple dose Cmax', 'Multiple dose AUCtau']","['Objective Response Rate - Percentage of Participants With Objective Response', 'Percentage of Participants With Clinical Benefit', 'Duration of Objective Response (DOR)', 'Presence (rate) or absence of blood biomarkers', 'Number of Participants With Notable Electrocardiogram (ECG) Values', 'Number of Participants With Laboratory Abnormalities', 'Number of Participants With Clinically Significant Change From Baseline in Vital Signs', 'Number of Participants With Adverse Events (AEs) by type, frequency, severity (as graded by NCI CTCAE verision 5.0), timing, seriousness and relationship to study treatment', 'Single dose Tmax', 'Single dose AUClast', 'Single dose MRCmax', 'Single dose AUCinf', 'Single dose CL/F', 'Single dose Vz/F', 'Single dose t½', 'Multiple dose Tmax', 'Multiple dose Vz/F', 'Multiple dose MRCmax', 'Rac', 't½eff', 'Multiple dose CL/F', 'Multiple dose t½', 'Single dose MRAUCtau', 'Multiple dose AUClast', 'Multiple dose Cmin', 'Multiple dose Ctrough']",,,,,3,China,"Cancer Hospital Chinese Academy of Medical Science [Beijing, China] | Jilin Province Tumor Hospital [Changchun, China] | The First Affiliated Hospital of Xi'an Jiaotong University [Xi'an, China]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT05744375,Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab,"Phase II Trial of TRAstuzumab deruxtecaN in firSt-line Treatment of HER2-positive Locally advanCEd or Metastatic Breast caNcer (MBC) Patients Considered Resistant to Trastuzumab + Pertuzumab + Taxane Due to Early Relapse.""TRANSCENDER Study""",TERMINATED,PHASE2,Spanish Breast Cancer Research Group,2023-09-28,2025-07-17,2025-07-17,2023-02-27,2025-07-25,['Objective Response Rate (ORR)'],"['Progression-Free Survival (PFS)', 'Overall Survival (OS)', 'Time to treatment response (TTR)', 'Duration of response (DoR)', 'The Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment', 'Changes from baseline in the global health status score (GHS)', 'Time to deterioration (TTD) in quality of life (QoL)']",,,,,19,Spain,"Hospital Universitario de Jeréz De La Frontera [Cadiz, Spain] | Hospital Universitario de Jaén [Jaén, Spain] | Hospital Universitario Marqués de Valdecilla [Santander, Spain] | Hospital Universitario de Fuenlabrada [Fuenlabrada, Spain] | Hospital Universitario Puerta de Hierro de Majadahonda [Majadahonda, Spain] | Hospital Universitario Son Espases [Palma de Mallorca, Spain] | Hospital Galdakao-Usansolo [Galdakao, Spain] | Complejo Hospitalario Universitario A Coruña (CHUAC) [A Coruña, Spain] | Hospital San Juan de Alicante [Alicante, Spain] | Hospital Universitario de Badajoz [Badajoz, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Universitario San Pedro de Alcántara [Cáceres, Spain] | Hospital Universitario Clínico San Cecilio [Granada, Spain] | Hospital Universitario Arnau de Vilanova de Lleida [Lleida, Spain] | Hospital General Universitario Gregorio Marañón [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Universitario La Paz [Madrid, Spain] | Hospital Universitario Virgen del Rocío [Seville, Spain]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating Trastuzumab Deruxtecan, which is a new medicine being tested in a specific patient population (HER2-positive locally advanced/metastatic breast cancer patients resistant to previous treatments).",OTHER,False,2025.0,0.0,0,Phase 2
NCT05756166,"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer",Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer,TERMINATED,PHASE1; PHASE2,Roswell Park Cancer Institute,2024-02-16,2025-04-08,2025-06-19,2023-03-06,2025-06-24,['Incidence of adverse events'],"['Progression-free survival', 'Overall response rate', 'Overall survival', 'Disease control rate']",,,,,1,United States,"Roswell Park Cancer Institute [Buffalo, United States]",2024.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2025.0,0.0,0,Phase 2
NCT05759949,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,"A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors",COMPLETED,PHASE1,"Relay Therapeutics, Inc.",2023-03-29,2025-03-18,2025-04-11,2023-03-08,2025-05-16,"['Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of RLY-5836', 'Number of participants with any dose-limiting toxicity (DLT)', 'Number of participants with adverse events (AEs)', 'Number of participants with serious adverse events (SAEs)']","['PIK3CA genotype in blood and tumor tissue by next generation nucleic acid sequencing', 'PK of RLY-5836: area under the concentration-time curve (AUC)', 'PK of RLY-5836: maximum plasma concentration (Cmax)', 'PK of RLY-5836: time to maximum concentration (tmax)', 'PK of RLY-5836: half-life (t½)', 'PK of RLY-5836: clearance following oral dose (CL/F)', 'Changes in circulating markers of glucose metabolism: changes in circulating glucose', 'Changes in circulating markers of glucose metabolism: changes in circulating insulin', 'Changes in circulating markers of glucose metabolism: changes in circulating C-peptide', 'Changes in circulating markers of glucose metabolism: changes in circulating glycosylated hemoglobin [HbA1c]', 'Preliminary antitumor activity of RLY-5836: duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)', 'Preliminary antitumor activity of RLY-5836: disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)', 'Preliminary antitumor activity of RLY-5836: objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)']",,,,,7,United States,"Sarah Cannon Research Institute at Florida Cancer Specialists [Orlando, United States] | Community Cancer Center North [Indianapolis, United States] | Massachusetts General Hospital [Boston, United States] | Rutgers Cancer Institute of New Jersey [New Brunswick, United States] | Memorial Sloan Kettering Cancer Center-Main Campus [New York, United States] | Tennessee Oncology, PLLC [Nashville, United States] | Huntsman Cancer Institute, University of Utah [Salt Lake City, United States]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT05784597,A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors,A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Patients with Solid Tumors,COMPLETED,PHASE1,Philogen S.p.A.,2023-04-27,2024-10-21,2024-10-21,2023-03-27,2024-11-15,"['Safety (AE)', 'Cohort A: Dosimetry - Effective dose equivalent (mSv)', 'Cohort A: Dosimetry - Absorbed doses (mGy)']","['Biodistribution profile: SUVmax', 'Biodistribution profile: SUVmean', 'Biodistribution profile: SUVsd', 'PK', 'Excretion', 'Immunopathology staining', 'Lesion detection rate']",,,,,5,Italy,"Istituto Nazionale dei Tumori | Fondazione IRCCS [Milan, Italy] | Istituto Clinico Humanitas [Rozzano, Italy] | Azienda Ospedaliero Universitaria Pisana [Pisa, Italy] | IRCCS Istituto Romagnolo per lo Studio dei Tumori ""Dino Amadori"" [Meldola, Italy] | IRCCS San Raffaele [Milan, Italy]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT05812326,PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer,Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer,COMPLETED,PHASE1; PHASE2,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2019-05-17,2022-11-16,2022-11-16,2023-04-13,2023-04-13,"['Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v5.0', 'Incidence of treatment-emergent adverse events [safety and tolerability] of dose of PD-1 Knockout CAR-T cells will be assessed using CTCAE v5.0', 'Monitoring the numbers of circulating AJMUC1 after infusion will be evaluated.']","['Response rate will be assessed according to the revised RECIST guideline iRECIST', 'Overall Survival - OS (Measure the time from enrollment to death)', 'Progression free survival - PFS (Time from enrollment to date of first documented progression or date of death)', 'Median CAR-T cell persistence--Will be measured by quantitative RT-PCR']",,,,,1,China,"Sun Yat-sen Memorial Hospital of Sun Yat-sen University [Guangzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves PD-1 Knockout Anti-MUC1 CAR-T Cells, which indicates a new therapeutic approach for treating advanced breast cancer, suggesting it is a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT05839288,Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients,Pyrotinib Plus Trastuzumab and Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study,COMPLETED,,Fudan University,2022-11-01,2023-03-01,2023-04-01,2023-05-03,2023-05-03,['progression-free survival (PFS)'],['Adverse events'],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2022.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Pyrotinib, which is being evaluated in combination with Trastuzumab and chemotherapy for HER2+ metastatic breast cancer, indicating it is a new medicine being tested for a specific indication.",OTHER,False,2023.0,2.0,0,NA/Other
NCT05904730,Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations,Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment,COMPLETED,PHASE1,Lynkcell Europe,2023-07-11,2024-11-09,2024-12-26,2023-06-15,2024-12-30,"['Antitumor effect of axitinib (INLYTA) among patients with solid tumors with BRCA 1/2 mutations independent of HER2 expression, with progression after previous treatment, including radiotherapy']",[],,,,,2,Ukraine,"Trials TEAM [Dnipro, Ukraine] | Trials TEAM [Kyiv, Ukraine]",2023.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2024.0,1.0,0,Phase 1
NCT05923268,Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy,SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Technetium-99m-labelled Designed Ankyrin Repeat Proteins ([99mTc]Tc-G3-(G3S)3C),COMPLETED,,Tomsk National Research Medical Center of the Russian Academy of Sciences,2023-06-04,2024-06-15,2024-06-15,2023-06-28,2025-04-09,"['Gamma camera-based whole-body [99mTc]Tc-G3-(G3S)3C uptake value (%)', 'SPECT-based [99mTc]Tc-G3-(G3S)3C uptake value in tumor lesions (counts) [99mTc]Tc-G3-(G3S)3C uptake coinciding with tumor lesions will be assessed using single-photon emission computed tomography and measured in counts', 'SPECT-based [99mTc]Tc-G3-(G3S)3C background uptake value (counts)', 'Tumor-to-background ratio (SPECT)']","['Safety attributable to [99mTc]Tc-G3-(G3S)3C injections (vital signs) (% of cases with abnormal findings relative to baseline)', 'Safety attributable to [99mTc]Tc-G3-(G3S)3C injections (physical examination) (% of cases with abnormal findings relative to baseline)', 'Safety attributable to [99mTc]Tc-G3-(G3S)3C injections (laboratory tests) (% of cases with abnormal findings relative to baseline)', 'Safety attributable to [99mTc]Tc-G3-(G3S)3C injections (% of incidence and severity of adverse events)', 'Safety attributable to [99mTc]Tc-G3-(G3S)3C injections (ECG ) (% of cases with abnormal findings relative to baseline)', 'Safety attributable to [99mTc]Tc-G3-(G3S)3C injections (% concomitant medication)']",,,,,1,Russia,"Olga [Tomsk, Russia]",2023.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes the use of a new imaging agent, [99mTc]Tc-G3-(G3S)3C, for molecular imaging of HER2 expression in breast cancer, indicating it is a new medicine.",OTHER,False,2024.0,1.0,0,NA/Other
NCT05940298,Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8,SPECT Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 ([99mTc]Tc- DB8) in Prostate Cancer and Breast Cancer Patients,COMPLETED,PHASE1,Tomsk National Research Medical Center of the Russian Academy of Sciences,2023-07-03,2024-06-01,2024-12-31,2023-07-11,2025-04-09,"['Gamma camera-based whole-body [99mTc]Tc-DB8 uptake value (%)', 'SPECT-based [99mTc]Tc-DB8 value in tumor lesions (counts)', 'SPECT-based [99mTc]Tc-DB8 background uptake value (counts)', 'Tumor-to-background ratio (SPECT)']","['Safety attributable to [99mTc]Tc-DB8 injections (physical findings)', 'Safety attributable to [99mTc]Tc-DB8 injections (laboratory tests)', 'Safety attributable to [99mTc]Tc-DB8 injections (incidence of adverse events)', 'Safety attributable to [99mTc]Tc-DB8 injections (concomitant medication)']",,,,,1,Russia,"TomskNRMC [Tomsk, Russia]",2023.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes the use of a labeled compound, [99mTc]Tc-DB8, for molecular imaging in prostate and breast cancer patients, indicating it is a new medicine being evaluated for its safety and efficacy in these specific applications.",OTHER,False,2024.0,1.0,0,Phase 1
NCT05954143,Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,"Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan",TERMINATED,PHASE2,"Bolt Biotherapeutics, Inc.",2023-11-30,2024-09-20,2024-09-25,2023-07-20,2025-02-11,['Anti-tumor activity of BDC-1001 as a single agent and in combination with pertuzumab'],"['Anti-tumor activity of BDC-1001 as a single agent and in combination with pertuzumab', 'Anti-tumor activity of BDC-1001 as a single agent and in combination with pertuzumab', 'Anti-tumor activity of BDC-1001 as a single agent and in combination with pertuzumab', 'Anti-tumor activity of BDC-1001 as a single agent and in combination with pertuzumab', 'Incidence of treatment-emergent events with BDC-1001 as a single agent and in combination with pertuzumab', 'Incidence of treatment-emergent events with BDC-1001 as a single agent and in combination with pertuzumab', 'Exposure profile of BDC-1001 as a single agent and in combination with pertuzumab', 'Exposure profile of BDC-1001 as a single agent and in combination with pertuzumab', 'Immunogenicity of BDC-1001 as a single agent and in combination with pertuzumab']",,,,,4,Spain; United States,"City of Hope [Irvine, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Virginia Cancer Specialists [Arlington, United States] | Hospital Universitario 12 de Octubre [Madrid, Spain]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves BDC-1001, which is being tested as a new treatment for HER2-positive metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2024.0,1.0,1,Phase 2
NCT05963984,A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants,"An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)",COMPLETED,PHASE2,Carrick Therapeutics Limited,2023-12-14,2025-03-20,2025-08-28,2023-07-27,2025-09-29,['Clinical Benefit Response (CBR)'],"['Objective Response Rate (ORR)', 'Duration of Response (DOR)', 'Progression Free Survival (PFS)', 'Incidence and severity of adverse events (AEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0', 'Samuraciclib plasma exposure: Cmax', 'Samuraciclib plasma exposure: Ctrough', 'Fulvestrant plasma exposure: Ctrough']",,,,,32,Hungary; Mexico; Spain; Turkey (Türkiye); United States,"Ocala Oncology Center PL DBA Florida Cancer Affiliates [Ocala, United States] | Mfsmc-Hjwci [Baltimore, United States] | Saint Luke's Cancer Institute [Kansas City, United States] | Sidney Kimmel Cancer Center - Jefferson Health [Philadelphia, United States] | The Center for Cancer and Blood Disorders [Fort Worth, United States] | Semmelweis Egyetem [Budapest, Hungary] | Szent Borbala Korhaz [Tatabánya, Hungary] | Nograd Varmegyei Szent Lazar Korhaz [Salgótarján, Hungary] | Actualidad Basada en la Investigación del Cáncer [Guadalajara, Mexico] | Renati Innovation S.A.P.I de C.V [Guadalajara, Mexico] | Cryptex Investigación Clínica S.A. de C.V. [Cuauhtémoc, Mexico] | Soltmed SMO [Mexico City, Mexico] | Oaxaca Site Management Organization S.C. [Oaxaca City, Mexico] | Centro de Investigacion Clinica de Oaxaca [Oaxaca City, Mexico] | Hospital Infanta Cristina [Badajoz, Spain] | Parc de Salut Mar - Hospital del Mar [Barcelona, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Institut Català d'Oncologia - L'Hospitalet [L'Hospitalet de Llobregat, Spain] | Hospital Universitario Marqués de Valdecilla [Santander, Spain] | MD Anderson Cancer Center [Madrid, Spain] | Hospital Clinico San Carlos [Madrid, Spain] | Hospital Vithas Málaga [Málaga, Spain] | Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca [Salamanca, Spain] | Hospital Clinico de Valencia [Valencia, Spain] | Gulhane Egitim ve Arastirma Hastanesi [Ankara, Turkey (Türkiye)] | Gazi University [Ankara, Turkey (Türkiye)] | Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi [Ankara, Turkey (Türkiye)] | Hacettepe Universite Hastaneleri [Ankara, Turkey (Türkiye)] | Trakya University [Edirne, Turkey (Türkiye)] | Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi [Istanbul, Turkey (Türkiye)] | TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi [Istanbul, Turkey (Türkiye)] | I.E.U. Medical Point Hastanesi [Izmir, Turkey (Türkiye)]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Samuraciclib, which is being tested in combination with Fulvestrant for a specific cancer indication, indicating it is a new medicine.",INDUSTRY,False,2025.0,0.0,1,Phase 2
NCT05976620,Clinical Study of 18F-FAPI-RGD in Breast Tumors,Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin avβ3 (FAPI-RGD) in Breast Tumors,COMPLETED,,Sichuan Provincial People's Hospital,2023-06-20,2023-12-15,2024-02-20,2023-08-04,2024-07-15,['Correlation between clinical indicators and PET/CT results'],[],,,,,1,China,"Departments of Nuclear Medicine, Sichuan Provincial People's Hospital [Chengdu, China]",2023.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a clinical study involving a new imaging probe (18F-FAPI-RGD) targeting specific proteins in breast tumors, indicating it is a new medicine.",OTHER,False,2024.0,1.0,0,NA/Other
NCT06025058,Neopep-S-based EasyDew MD Regen Cream for Radiotherapy Subject After Breast Tumor Resection,Researcher-led Clinical Study to Evaluate the Effectiveness and Safety of the Application of Neopep-S-based Easy Dew MD Regen Cream in Patients Under Radiotherapy After Breast Tumor Resection,COMPLETED,,Eun-ji Kim,2022-11-11,2023-07-27,2023-07-28,2023-09-06,2023-09-06,['Transepidermal water loss'],"['Itching score', 'VSS', 'BREAST-Q Survey Assessment']",,,,,1,South Korea,"Ajou University Hospital [Gyeonggi-do, South Korea]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a clinical study evaluating a new cream (Neopep-S-based EasyDew MD Regen Cream) for a specific application in patients undergoing radiotherapy after breast tumor resection, indicating it is a new medicine.",INDUSTRY,False,2023.0,2.0,0,NA/Other
NCT06065059,Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors,"Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors",TERMINATED,PHASE1; PHASE2,"Tango Therapeutics, Inc.",2023-12-08,2024-05-22,2024-05-22,2023-10-03,2024-08-13,"['To determine dosing for TNG348 alone and in combination (Phase 1 only)', 'Measure anti-tumor activity using RECIST 1.1 (Phase 2 only)']","['Measure anti-tumor activity using RECIST 1.1 (Phase 1 only)', 'Characterize the safety and tolerability profile', 'Characterize the plasma PK profile', 'Characterize the plasma PK profile', 'Characterize the plasma PK profile', 'Characterize the plasma PK profile', 'Characterize olaparib concentrations when administered with TNG348', 'Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination']",,,,,7,United States,"HealthONE [Denver, United States] | Mid Florida Cancer Centers [Orange City, United States] | Florida Cancer Specialists [Sarasota, United States] | Dana Farber Cancer Institute [Boston, United States] | New York University Langone Health [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States]",2023.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT06107790,"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer","Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer",COMPLETED,PHASE3,Zhejiang Hisun Pharmaceutical Co. Ltd.,2018-05-16,2022-01-28,2022-01-28,2023-10-30,2023-10-30,['ORR'],"['DCR', 'PFS', 'OS', 'Vital signs', 'Vital signs', 'Vital signs', 'Vital signs', 'physical examination,', 'ADAs', 'Ctrough', 'ECOG physical condition', 'left ventricular ejection fraction (LVEF),', 'adverse events (AE)']",,,,,1,China,"Jiangsu Province People's Hospital (First Affiliated Hospital of Nanjing Medical University) [Nanjing, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves HS022, which appears to be a new treatment being compared to an existing drug (Trastuzumab) in a specific patient population (HER2-positive breast cancer), indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT06168227,"A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer","A Multicenter and Real-world Analysis of Clinical Outcomes and Safety of the Novel Recombinant Humanized Anti-HER2 Therapeutic Antibody RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer",COMPLETED,,The First Affiliated Hospital with Nanjing Medical University,2021-10-01,2023-06-30,2023-09-30,2023-12-13,2023-12-13,"['Progression Free Survival (PFS)', 'Objective Response Rate (ORR)']","['The Number of Participants Who Experienced Adverse Events (AE)', 'Overall Survival (OS)']",,,,,1,China,"Jiangsu Provincial People's Hospital [Nanjing, China]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2023.0,2.0,0,NA/Other
NCT06171789,PRO1107 in Patients With Advanced Solid Tumors,A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors,TERMINATED,PHASE1; PHASE2,Genmab,2024-01-29,2025-08-18,2025-08-18,2023-12-15,2025-09-15,"['Number of Participants with Adverse Events', 'Number of Participants with Dose Limiting Toxicities (DLTs)']","['Objective Response Rate', 'Disease Control Rate', 'Progression-free Survival', 'Duration of Objective Response', 'Pharmacokinetic Parameter Area Under the Curve (AUC) for GEN1107', 'Pharmacokinetic Parameter Maximum Concentration (Cmax) for GEN1107', 'Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for GEN1107', 'Pharmacokinetic Parameter Apparent Terminal Half-life (t1/2) for GEN1107', 'Pharmacokinetic Parameter Trough Concentration (Ctrough) for GEN1107', 'Number of Participants with Anti-drug Antibodies (ADAs)', 'Cancer Antigen 125 (CA-125) Response per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer']",,,,,7,China; United States,"HonorHealth Research Institute [Scottsdale, United States] | Florida Cancer Specialists [Sarasota, United States] | Massachusetts General Hospital [Boston, United States] | SCRI Oncology Partners [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | START Mountain Cancer Center [Salt Lake City, United States] | Institution of Hunan Cancer Hospital [Changsha, China]",2024.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,1,Phase 2
NCT06257758,A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors,A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors,TERMINATED,PHASE1; PHASE2,Valerio Therapeutics,2024-01-10,2025-01-01,2025-01-01,2024-02-14,2025-03-17,"['Phase 1: Dose Limiting Toxicities', 'Phase 2: Objective Response Rate (ORR)']","['Phase 1: Assess the pharmacokinetics (PK) of VIO-01', 'Phase 1: Assess the pharmacokinetics (PK) of VIO-01', 'Phase 1: Assess the pharmacokinetics (PK) of VIO-01', 'Phase 2: Duration of response (DOR)']",,,,,3,United States,"Florida Cancer Specialists & Research Institute [Lake Mary, United States] | Stephenson Cancer Center - University of Oklahoma [Oklahoma City, United States] | Next Oncology [San Antonio, United States]",2024.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,0,Phase 2
NCT06264921,A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors,"A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors",TERMINATED,PHASE1,"NiKang Therapeutics, Inc.",2024-02-23,2025-04-07,2025-04-16,2024-02-20,2025-09-25,"['Number of Participants with Dose Limiting Toxicity (DLT) events', 'Objective Response Rate (ORR)']","['Progression-free survival (PFS)', 'Duration of Response (DOR)', 'Disease control rate', 'Overall Survival (OS)', 'Time to Response (TTR)', 'Number of Participants with Adverse Events', 'Maximum observed plasma concentration (Cmax) of NKT3447', 'Time to maximum observed plasma concentration of NKT3447 (Tmax)', 'Observed trough concentration of NKT3447 (Ctrough)', 'Area under the plasma concentration-time curve (AUC0-t) of NKT3447', 'Apparent clearance (CL/F)', 'Apparent volume of distribution (V/F)', 'Half-life (t1/2)', 'Accumulation ratio (AR)']",,,,,8,United States,"University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | Sarah Cannon Research Institute at HealthONE [Denver, United States] | AdventHealth Cancer Institute [Celebration, United States] | Augusta University Georgia Cancer Center [Augusta, United States] | Norton Cancer Institute - Broadway [Louisville, United States] | The Gabrail Pharmacology Phase 1 Research Center [Canton, United States] | Texas Oncology-Austin Midtown NEXT Oncology [Austin, United States] | START Mountain Region [West Valley City, United States]",2024.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT06290466,Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects,"A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Design to Evaluate the Pharmacokinetics and Effects on QT Interval of a Single Oral Dose of FCN-437c Capsule in Healthy Subjects.",COMPLETED,PHASE1,"Ahon Pharmaceutical Co., Ltd.",2022-11-11,2023-02-08,2023-02-08,2024-03-04,2024-03-04,['ΔΔQTcF'],"['adverse events', 'Physical examination', 'Axillary temperature', 'blood pressure', 'pulse', 'Ecg monitoring and electrocardiogram', 'laboratory examination', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters', 'Plasma concentration and pharmacokinetic parameters']",,,,,1,China,"Peking University Third Hospital [Beijing, China]",2022.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2023.0,2.0,0,Phase 1
NCT06299163,NM32-2668 in Adult Patients With Selected Advanced Solid Tumors,A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors,TERMINATED,PHASE1,Numab Therapeutics AG,2024-05-01,2025-04-18,2025-04-18,2024-03-07,2025-07-23,"['Incidence of Dose Limiting Toxicities (DLTs)', 'Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0 / ASTCT (for Cytokine Release Syndrome [CRS])', 'Frequency of dose interruptions/reductions', 'Duration of dose interruptions/reductions']","['Assessment of the maximum observed serum concentration (Cmax)', 'Assessment of the the minimum observed serum concentration (Cmin)', 'Time from dosing at which maximum observed serum concentration is apparent (Tmax)', 'Assessment of the terminal phase (apparent elimination) rate constant (λz)', 'Assessment of the elimination half-life (t½)', 'Assessment of the area under the serum concentration-time curve extrapolated from the last quantifiable concentration to infinity (AUC[0-infinity])', 'Assessment of the area under serum concentration-time curve over dosing interval (AUCtau)', 'Assessment of clearance (CL) of NM32-2668 in serum', 'Assessment of the volume of distribution (Vd) of NM32-2668 in serum', 'Assessment of accumulation ratios of Cmax (ARcmax) of NM32-2668 in serum', 'Assessment of accumulation ratios of Cmin (ARcmin) of NM32-2668 in serum', 'Assessment of accumulation ratios of AUC (ARauc) of NM32-2668 in serum', 'Frequency of specific anti-drug antibodies (ADAs) to NM32-2668', 'Concentration of specific ADAs to NM32-2668', 'Incidence of specific ADAs by category to NM32-2668', 'Best Overall Response (BOR) according to RECIST 1.1', 'Overall Response Rate (ORR) according to RECIST 1.1', 'Disease Control Rate (DCR) according to RECIST 1.1', 'Progression-free Survival (PFS) according to RECIST 1.1', 'Time to Response (TTR) according to RECIST 1.1', 'Duration of Response (DOR) according to RECIST 1.1', 'Overall Survival (OS)']",,,,,11,United States,"University of Alabama at Birmingham [Birmingham, United States] | USC Norris Comprehensive Cancer Center [Los Angeles, United States] | The University of Chicago Medical Center (UCMC) [Chicago, United States] | Duke University [Durham, United States] | Cleveland Clinic [Cleveland, United States] | University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center [Pittsburgh, United States] | Lifespan Cancer Institute at Rhode Island Hospital [Providence, United States] | Medical University of South Carolina (MUSC) [Charleston, United States] | Vanderbilt University Medical Center [Nashville, United States] | Mary Crowley Cancer Research [Dallas, United States] | Froedtert Hospital and the Medical College of Wisconsin [Milwaukee, United States]",2024.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2025.0,0.0,0,Phase 1
NCT06305702,Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer,Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer,COMPLETED,,Liaoning Cancer Hospital & Institute,2022-07-01,2023-12-31,2024-01-31,2024-03-12,2024-03-12,['Progression Free Survival(PFS)'],"['objective response rate (ORR)', 'Adverse events (AEs)']",,,,,1,China,"Liaoning Cancer Hospital &Institue [Shenyang, China]",2022.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Progression-Free Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial text indicates a study of Inetetamab, which suggests it is a new medicine being evaluated for HER2-positive metastatic breast cancer.",OTHER,False,2024.0,1.0,0,NA/Other
NCT06355024,Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer,a Pilot Study to Explore the Efficacy of Inosine Reversing Chemo Resistance in Triple Negative Breast Cancer,COMPLETED,PHASE2,Fudan University,2024-05-11,2025-01-01,2025-01-01,2024-04-09,2025-07-18,['Objective Response Rate (ORR)'],"['Disease Control Rate (DCR)', 'Progression Free Survival (PFS)', 'Biomarker analysis1', 'Safety and treatment-related AEs']",,,,,1,China,"breast cancer institute of Fudan University Cancer Hospital [Shanghai, China]",2024.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a pilot study exploring the efficacy of inosine in a new context (reversing chemo resistance in triple negative breast cancer), suggesting it is being tested as a new medicine.",OTHER,False,2025.0,0.0,0,Phase 2
NCT06390241,Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer,Avidination for Radionuclide THerapy (A.R.THE.) in Nonpalpable Breast Cancer,TERMINATED,PHASE1,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,2024-06-19,2025-01-30,2025-01-30,2024-04-30,2025-02-03,"['Safety of avidin-biotin-Dota-90Y', 'Safety of avidin-biotin-Dota-90Y', 'Anti-tumor activity of avidin-biotin-Dota-90Y']","['Dose-response', 'Biodistribution']",,,,,1,Italy,"IRCCS Istituto ROmagnolo per lo Studio dei Tumori ""Dino Amadori""-IRST S.r.l. [Meldola, Italy]",2024.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a new treatment approach (Avidination for Radionuclide Therapy) for a specific condition (Nonpalpable Breast Cancer), indicating it is a new medicine.",OTHER,False,2025.0,0.0,0,Phase 1
NCT06677957,A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants,"A Phase I, Open-Label, Two-Period, One-Sequence, Crossover Study in Healthy Subjects to Evaluate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein (Digoxin) and Breast Cancer Resistance Protein (Rosuvastatin)",COMPLETED,PHASE1,"Genentech, Inc.",2024-11-06,2024-12-30,2024-12-30,2024-11-07,2025-01-03,"['Maximum Observed Plasma Concentration (Cmax) of Digoxin and Rosuvastatin', 'Area Under the Plasma Concentration-Time Curve from Hour 0 to the Last Measurable Concentration (AUC0-t) of Digoxin and Rosuvastatin', 'Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Digoxin and Rosuvastatin', 'Time to Cmax (Tmax) of Digoxin and Rosuvastatin']",['Percentage of Participants with Adverse Events (AEs)'],,,,,1,United States,"Daytona Beach Clinical Rsch Unit [Daytona Beach, United States]",2024.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2024.0,1.0,0,Phase 1
NCT07166367,Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer,"A Phase II Single Arm Trial to Assess the Efficacy of ASLAN001 Plus Capecitabine in Previously Irradiated, Progressing Central Nervous System (CNS) Metastases for HER2 Positive Breast Cancer Patients",TERMINATED,PHASE2,"National Cancer Centre, Singapore",2016-08-11,2020-01-14,2020-01-14,2025-09-10,2025-09-10,['CNS objective response rate (ORR) based on RANO-BM criteria'],"['Safety/toxicity', 'Clinical benefit rate', 'Progression free survival', 'Overall survival']",,,,,1,Singapore,"National Cancer Centre Singapore [Singapore, Singapore]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves ASLAN001, which is being assessed for a specific indication (CNS metastases in HER2+ breast cancer), indicating it is a new medicine being tested for a new application.",OTHER,False,2020.0,5.0,0,Phase 2
